azathioprine has been researched along with Recrudescence in 673 studies
Azathioprine: An immunosuppressive agent used in combination with cyclophosphamide and hydroxychloroquine in the treatment of rheumatoid arthritis. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), this substance has been listed as a known carcinogen. (Merck Index, 11th ed)
azathioprine : A thiopurine that is 6-mercaptopurine in which the mercapto hydrogen is replaced by a 1-methyl-4-nitroimidazol-5-yl group. It is a prodrug for mercaptopurine and is used as an immunosuppressant, prescribed for the treatment of inflammatory conditions and after organ transplantation and also for treatment of Crohn's didease and MS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Randomised controlled trial adding azathioprine to steroid treatment for leprosy reactions." | 9.24 | AZALEP a randomized controlled trial of azathioprine to treat leprosy nerve damage and Type 1 reactions in India: Main findings. ( Darlong, J; Govindharaj, P; John, AS; Kurian, R; Lockwood, DN; Sundarrao, P, 2017) |
| " This study was undertaken to determine whether the addition of azathioprine (AZA) to glucocorticoids could achieve a higher sustained remission rate of newly diagnosed nonsevere eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA), microscopic polyangiitis (MPA), or polyarteritis nodosa (PAN)." | 9.24 | Adding Azathioprine to Remission-Induction Glucocorticoids for Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss), Microscopic Polyangiitis, or Polyarteritis Nodosa Without Poor Prognosis Factors: A Randomized, Controlled Trial. ( Agard, C; Baron, G; Bienvenu, B; Bourgarit, A; Cohen, P; Crestani, B; Delbrel, X; Diot, E; Geffray, L; Godmer, P; Groh, M; Guillevin, L; Le Guern, V; Le Jeunne, C; Lifermann, F; Limal, N; Liozon, E; Mékinian, A; Mouthon, L; Néel, A; Pagnoux, C; Papo, T; Puéchal, X; Quémeneur, T; Ravaud, P; Ruivard, M; Ruppert, AM; Sailler, L; Saraux, JL; Terrier, B, 2017) |
| "To compare the efficacy of tacrolimus (TAC) and mycophenolate mofetil (MMF) for the initial therapy of lupus nephritis (LN)." | 9.22 | Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomised controlled trial and long-term follow-up. ( Mok, CC; Ng, WL; Siu, YP; To, CH; Tong, KH; Yim, CW; Ying, KY, 2016) |
| "Cytoplasmic anti-neutrophil cytoplasmic antibody (C-ANCA) positivity at remission has been associated with an increased relapse rate in patients with proteinase 3 anti-neutrophil cytoplasmic antibody-associated vasculitis (PR3-AAV) after a switch to azathioprine maintenance therapy." | 9.22 | Extended versus standard azathioprine maintenance therapy in newly diagnosed proteinase-3 anti-neutrophil cytoplasmic antibody-associated vasculitis patients who remain cytoplasmic anti-neutrophil cytoplasmic antibody-positive after induction of remission ( Broekroelofs, J; de Joode, AA; DeSevaux, RG; Kallenberg, CG; Sanders, JS; Stegeman, CA; Tervaert, JW; van Paassen, P; Voskuyl, AE, 2016) |
| "To evaluate long-term effects of 2-year treatment with interferon beta combined with low-dose azathioprine and prednisone in multiple sclerosis." | 9.16 | Interferon, azathioprine and corticosteroids in multiple sclerosis: 6-year follow-up of the ASA cohort. ( Dolezal, O; Havrdova, E; Horakova, D; Kalincik, T; Krasensky, J; Seidl, Z; Vaneckova, M, 2012) |
| "To investigate the safety and efficacy of oral methylprednisolone combined with azathioprine sodium or mycophenolate mofetil for the treatment of bullous pemphigoid." | 9.12 | A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of bullous pemphigoid. ( Beissert, S; Böhm, M; Bonsmann, G; Frieling, U; Gollnick, H; Hunzelmann, N; Junghans, V; Luger, TA; Meurer, M; Pillekamp, H; Ruzicka, T; Rzany, B; Stadler, R; Sticherling, M; Werfel, T; Zillikens, D, 2007) |
| "To analyze disease-free survival in patients with antineutrophil cytoplasmic antibody (ANCA)-associated small-vessel vasculitis (AAV) treated with cyclophosphamide only or switched to azathioprine after 3 months of full remission while taking cyclophosphamide." | 9.11 | Positive classic antineutrophil cytoplasmic antibody (C-ANCA) titer at switch to azathioprine therapy associated with relapse in proteinase 3-related vasculitis. ( Boomsma, MM; Slot, MC; Stegeman, CA; Tervaert, JW, 2004) |
| " In a multicenter, prospectively randomized study we compared efficacy and side effects of a dexamethasone-cyclophosphamide (D/C) pulse therapy with a methylprednisolone-azathioprine (M/A) therapy in 22 patients with newly diagnosed pemphigus vulgaris and pemphigus foliaceus." | 9.11 | Intravenous dexamethasone-cyclophosphamide pulse therapy in comparison with oral methylprednisolone-azathioprine therapy in patients with pemphigus: results of a multicenter prospectively randomized study. ( Bröcker, EB; Haustein, UF; Linse, R; Rose, E; Wever, S; Zilliken, D, 2005) |
| "To evaluate, in a prospective, open-label study, the influence of antibiotics and azathioprine on the clinical outcome of perianal fistulas in patients with Crohn's disease." | 9.10 | Antibiotics and azathioprine for the treatment of perianal fistulas in Crohn's disease. ( Dejaco, C; Harrer, M; Miehsler, W; Reinisch, W; Vogelsang, H; Waldhoer, T, 2003) |
| "Our aim was to report the clinical experience with combination treatment using tacrolimus and either azathioprine (AZA) or 6-mercaptopurine (6MP) in patients with Crohn's disease (CD) perianal fistulae." | 9.09 | Combination therapy with oral tacrolimus (FK506) and azathioprine or 6-mercaptopurine for treatment-refractory Crohn's disease perianal fistulae. ( Lowry, PW; Sandborn, WJ; Tremaine, WJ; Weaver, AL, 1999) |
| "Seven patients who had an initial attack of nephrotic syndrome in childhood and had frequent relapses even after cyclophosphamide therapy were given a 2-year course of azathioprine." | 9.09 | Efficacy of long-term azathioprine for relapsing nephrotic syndrome. ( Hiraoka, M; Hori, C; Mayumi, M; Momoi, T; Ohshima, Y; Seo, A; Tsukahara, H, 2000) |
| "In most patients with autoimmune hepatitis, remission can be maintained with prednisolone, usually in combination with azathioprine, but the majority of patients have a relapse when treatment is stopped and therefore require long-term therapy." | 9.08 | Azathioprine for long-term maintenance of remission in autoimmune hepatitis. ( Johnson, PJ; McFarlane, IG; Williams, R, 1995) |
| "Seven newly diagnosed patients with Devic's neuromyelitis optica were treated with long-term prednisone and azathioprine, and were followed every 2 months for at least 18 months." | 9.08 | Devic's neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine. ( Ahmed, W; Dencoff, JE; Mandler, RN, 1998) |
| "We randomized 59 patients with relapsing-remitting multiple sclerosis to receive azathioprine (AZA) 3." | 9.07 | The efficacy of azathioprine in relapsing-remitting multiple sclerosis. ( Bailly, RC; Beatty, WW; Goodkin, DE; Hertsgaard, D; Teetzen, ML, 1991) |
| "This study aimed to perform a meta-analysis of the efficacy and safety of azathioprine (AZA) for neuromyelitis optica spectrum disorders (NMOSD), considering the potential predictive factors related to patient response to AZA in this disease." | 9.05 | Efficacy and safety of azathioprine for neuromyelitis optica spectrum disorders: A meta-analysis of real-world studies. ( Chen, C; Cui, Y; Dong, X; Li, M; Luo, D; Ma, L; Tian, X; Wei, R; Zhang, E; Zhou, Y, 2020) |
| "A case of acute pancreatitis induced by azathioprine presented in a 22-year-old patient with Crohn's disease is reported." | 8.80 | [Acute azathioprine-induced pancreatitis in a female patient with Crohn's disease]. ( Caro-Paton, A; Fernández, P; González, JM; Goyeneche, ML; Martín, MA; Remacha, B; Sánchez, G; Velicia, MR, 1999) |
| "The efficacy of azathioprine in the treatment of multiple sclerosis was assessed by meta-analysis of the results of all published blind, randomised, controlled trials." | 8.78 | Overview of azathioprine treatment in multiple sclerosis. ( Ellison, GW; Ghezzi, A; Goodkin, DE; Hughes, RA; McPherson, K; Mertin, J; Milanese, C; Yudkin, PL, 1991) |
| "This study aimed to evaluate the efficacy and safety of mycophenolate mofetil (MMF) or tacrolimus (TAC) compared with azathioprine (AZA) as maintenance therapy for active lupus nephritis (ALN)." | 8.12 | Mycophenolate mofetil or tacrolimus compared with azathioprine in long-term maintenance treatment for active lupus nephritis. ( Chen, N; Chen, X; Li, X; Ren, H; Shen, P; Xie, J; Xing, P; Zhang, Q; Zhang, W, 2022) |
| "Azathioprine is a common first-line therapy for neuromyelitis optica spectrum disorder (NMOSD)." | 8.02 | Long-term safety of azathioprine for treatment of neuromyelitis optica spectrum disorders. ( Apóstolos-Pereira, SL; Callegaro, D; Gomes, ABAGR; Pitombeira, MS; Sato, DK, 2021) |
| "To research and compare the efficacy and tolerability of mycophenolate mofetil (MMF) and azathioprine (AZA) in neuromyelitis optica (NMO) and NMO spectrum disorder (NMOSD)." | 7.85 | Comparisons of the efficacy and tolerability of mycophenolate mofetil and azathioprine as treatments for neuromyelitis optica and neuromyelitis optica spectrum disorder. ( Chen, H; Feng, H; Lian, Z; Liu, J; Miao, X; Qiu, W; Shi, Z; Wang, J; Zhang, Q; Zhou, H, 2017) |
| "Azathioprine (AZA) is commonly used in myasthenia gravis (MG)." | 7.83 | Remission And relapse of myasthenia gravis on long-term azathioprine: An ambispective study. ( Behari, M; Goyal, V; Gupta, A; Shukla, G; Srivastava, AK, 2016) |
| "To compare the efficacy and tolerability of azathioprine (AZA), mycophenolate mofetil (MMF), and cyclophosphamide (CTX) in patients with neuromyelitis optica spectrum disorder (NMOSD)." | 7.83 | Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and cyclophosphamide among patients with neuromyelitis optica spectrum disorder: A prospective cohort study. ( Cui, LY; Fei, YY; Qiao, L; Ren, HT; Wang, Q; Xu, Y; Zhang, Y; Zhao, Y, 2016) |
| "We investigated the efficacy of azathioprine (AZA) plus long-term low dose corticosteroids in Chinese patients with neuromyelitis optica (NMO) and neuromyelitis optica spectrum disorders (NMOSD) at the Center for Demyelinating Diseases, South China." | 7.81 | Azathioprine plus corticosteroid treatment in Chinese patients with neuromyelitis optica. ( Dai, Y; Hu, X; Kermode, AG; Li, C; Li, R; Lu, Z; Qiu, W; Wang, J; Wang, Y; Zhong, X, 2015) |
| "Azathioprine (AZA) is a common immunosuppressive drug used for relapse prevention in neuromyelitis optica (NMO)." | 7.80 | Long-term efficacy, tolerability and retention rate of azathioprine in 103 aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder patients: a multicentre retrospective observational study from the UK. ( Brown, R; Elsone, L; Goh, YY; Jacob, A; Jacob, S; Kitley, J; Leite, MI; Luppe, S; Lythgoe, D; McNeillis, B; Moss, K; Mutch, K; Palace, J; Robertson, N, 2014) |
| "To evaluate the efficacy, tolerability, optimal dosing, and monitoring of azathioprine in patients with neuromyelitis optica (NMO)." | 7.77 | Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica. ( Costanzi, C; Lucchinetti, CF; Mandrekar, J; Matiello, M; McKeon, A; Pittock, SJ; Thapa, P; Weinshenker, BG, 2011) |
| "To evaluate the efficacy and safety of prednisone as monotherapy and in combination with the three most popular adjuvant agents - azathioprine, cyclosporine (ciclosporin), and cyclophosphamide - in the treatment of pemphigus vulgaris." | 7.74 | Efficacy and safety of cyclophosphamide, azathioprine, and cyclosporine (ciclosporin) as adjuvant drugs in pemphigus vulgaris. ( Blaszczyk, M; Cwikla, J; Kolacinska-Strasz, Z; Labecka, H; Natorska, U; Olszewska, M; Sulej, J, 2007) |
| "To evaluate the long-term efficacy and tolerance of tacrolimus for the treatment of uveitis." | 7.74 | Long-term efficacy and tolerance of tacrolimus for the treatment of uveitis. ( Dick, AD; Hogan, AC; Lee, RW; McAvoy, CE, 2007) |
| "The efficacy of isoniazid (INAH) prophylaxis against tuberculosis (TB) in patients taking corticosteroid remains controversial." | 7.73 | Tuberculosis in systemic lupus erythematosus in an endemic area and the role of isoniazid prophylaxis during corticosteroid therapy. ( Chan, TM; Lau, CS; Lo, Y; Mok, MY; Wong, WS, 2005) |
| "Azathioprine is commonly used as a second-line immunosuppressive agent in the management of patients with retinal vasculitis." | 7.70 | The role of azathioprine in the management of retinal vasculitis. ( Graham, EM; Greenwood, AJ; Stanford, MR, 1998) |
| "Of the 19 patients treated with azathioprine for recurrent ileitis, 15 could be reevaluated by endoscopy or radiological examination." | 7.69 | Healing of severe recurrent ileitis with azathioprine therapy in patients with Crohn's disease. ( D'Haens, G; Geboes, K; Penninckx, F; Ponette, E; Rutgeerts, P, 1997) |
| "Azathioprine is an established immunosuppressive agent in the treatment of myasthenia gravis." | 7.69 | [Myasthenic crisis caused by azathioprine-induced fever]. ( George, A; Nau, R; Tumani, H, 1997) |
| "The combination of cyclosporine, azathioprine and low-dose prednisolone leads to marked improvement of perianal fistulas in Crohn's disease." | 7.69 | Combination of cyclosporine, azathioprine and prednisolone for perianal fistulas in Crohn's disease. ( Aichbichler, B; Fickert, P; Hinterleitner, TA; Krejs, GJ; Petritsch, W; Ranner, G, 1997) |
| "Azathioprine (AZA) has a slight but consistent effect on clinical outcome in multiple sclerosis (MS), but very few data are available on magnetic resonance imaging (MRI) changes." | 7.69 | Lesion load quantification in serial MR of early relapsing multiple sclerosis patients in azathioprine treatment. A retrospective study. ( Cavazzuti, M; Mavilla, L; Merelli, E; Tassone, G, 1997) |
| "Twenty-four patients with myasthenia gravis were treated with azathioprine." | 7.67 | Azathioprine in the treatment of myasthenia gravis. ( Cornblath, DR; Lisak, RP; Parry, GJ; Schatz, NJ; Witte, AS, 1984) |
| "In a prospective long-term study, thirty-seven patients with severe generalized pemphigus vulgaris were treated with a combined corticosteroid-azathioprine regimen." | 7.67 | Azathioprine in the treatment of pemphigus vulgaris. A long-term follow-up. ( Aberer, W; Stingl, G; Wolff, K; Wolff-Schreiner, EC, 1987) |
| "Thirteen adult patients with nephrotic syndrome resistant to corticosteroid administration were treated with azathioprine daily for four years." | 7.67 | Effect of long-term azathioprine administration in adults with minimal-change glomerulonephritis and nephrotic syndrome resistant to corticosteroids. ( Cade, R; Campbell, K; Croker, B; Mars, D; Peterson, J; Privette, M; Thompson, R, 1986) |
| "Effects of azathioprine, 150 mg per day on average, were studied in 213 patients with multiple sclerosis." | 7.66 | [Study of 213 cases of multiple sclerosis treated with azathioprine from 1967- to 1982]. ( Aimard, G; Confavreux, C; Devic, M; Guillot, M; Ventre, JJ, 1983) |
| "A controlled trial of azathioprine treatment of steroid-responsive frequent-relapsing nephrotic syndrome of childhood failed to show a therapeutic effect on the stability of remission after withdrawal of corticosteroid treatment." | 7.65 | Controlled trial of azathioprine in treatment of steroid-responsive nephrotic syndrome of childhood. ( Barratt, TM; Cameron, JS; Chantler, C; Counahan, R; Ogg, CS; Soothill, JF, 1977) |
| "Nineteen patients with multiple sclerosis were treated with azathioprine for two years." | 7.65 | Long-term treatment of multiple sclerosis with azathioprine. ( Liversedge, LA; Swinburn, WR, 1973) |
| " The dosage was further reduced by adding methotrexate at 7." | 7.01 | Relapsing autoimmune inner ear disease with significant response to methotrexate and azathioprine combination therapy: A case report and mini literature review. ( Huang, KH; Lin, CD; Lin, HC; Wu, PC, 2023) |
| "We evaluated the endoscopic recurrence (Rutgeerts score) at the sixth month after ICR in all included patients." | 6.84 | Endoscopic Recurrence 6 Months After Ileocecal Resection in Children With Crohn Disease Treated With Azathioprine. ( Bronsky, J; Copova, I; Hradsky, O; Pos, L; Rouskova, B; Skaba, R; Zarubova, K, 2017) |
| "Pemphigus is an autoimmune blistering mucocutaneous disorder." | 6.79 | Assessment of the therapeutic benefit of oral prednisolone and common adjuvant therapy in stage II of randomized controlled trial study for management of pemphigus vulgaris. ( Chams-Davatchi, C; Daneshpazhooh, M; Esmaili, N; Karimi, A; Mortazavi, H; Toosi, S; Valikhani, M, 2014) |
| "Hepatitis C virus (HCV) recurrence in HCV+ liver transplant recipients is almost inevitable and may be promoted by immunosuppression." | 6.71 | Double-blind comparison of hepatitis C histological recurrence Rate in HCV+ Liver transplant recipients given basiliximab + steroids or basiliximab + placebo, in addition to cyclosporine and azathioprine. ( Agnes, S; Burra, P; Callea, F; De Carlis, L; Fassati, LR; Ferrara, R; Filipponi, F; Grazi, GL; Pisati, R; Risaliti, A; Rossi, M; Salizzoni, M; Valente, U, 2004) |
| "Maintenance therapy for lupus nephritis (LN) remains controversial." | 6.61 | Maintenance therapy for lupus nephritis with mycophenolate mofetil or azathioprine. A meta-analysis . ( Deng, J; Luo, L; Xie, H; Zhu, L, 2019) |
| "The prednisolone was gradually tapered by 5 mg every 2-wk, but oral azathioprine at 50 mg was added after symptoms recurred at tapered dose of 10 mg." | 6.53 | Efficacy of additional treatment with azathioprine in a patient with prednisolone-dependent gastric sarcoidosis. ( Andoh, A; Bamba, S; Ban, H; Inatomi, O; Kushima, R; Murata, M; Sugimoto, M; Yokota, Y, 2016) |
| "Azathioprine (AZA) is an empirical attack -preventive immunotherapies drug to prevent the relapse of NMOSD, and tocilizumab (TCZ) has been also reported reduce the activity of NMOSD." | 5.91 | A comparison of the efficacy of tocilizumab versus azathioprine for neuromyelitis optica spectrum disorder: A study protocol for systematic review and meta-analysis. ( Bian, J; Huang, Y; Ji, W; Tang, Q; Wang, Y; Yao, M, 2023) |
| "However, the cumulative ESRD-free survival rate was lower in patients who received TAC after AZA than in those who received AZA alone (P = ." | 5.62 | Efficacy of tacrolimus as maintenance therapy after cyclophosphamide for treating antineutrophil cytoplasmic antibody-associated vasculitis. ( Ahn, SS; Lee, LE; Lee, SW; Park, YB; Pyo, JY; Song, JJ, 2021) |
| "Drug-induced acute pancreatitis (DIAP) is an often-neglected entity where the disorder is the consequence of the toxic effects of various agents applied to treat potentially life-threatening conditions, such as inflammatory bowel disease." | 5.56 | Recurrent acute pancreatitis induced by 5-ASA and azathioprine in ulcerative colitis. ( Bajor, J; Faluhelyi, N; Hegyi, P; Hegyi, PJ; Németh, BC; Szakács, Z, 2020) |
| "Rituximab is effective in treating pemphigus both as the first-line treatment and as an add-on treatment for refractory disease." | 5.56 | Maintenance therapy with azathioprine prolonged duration of remission for pemphigus patients who received rituximab as first-line or add-on therapy. ( Cho, YT; Chu, CY; Huang, YM; Wang, LF, 2020) |
| "Amantadine was given orally (200 mg/d) for 3 months." | 5.33 | Amantadine monotherapy is ineffective in the treatment of hepatitis C virus recurrence in the post-liver transplantation setting. ( Angelico, M; Anselmo, A; D'Andria, D; de Liguori Carino, N; de'Liguori Carino, N; Ielpo, B; Manzia, T; Muzi, F; Orlando, G; Sabato Ceraldi, S; Tariciotti, L; Tisone, G, 2005) |
| " In this case, once the dosage of oral prednisone was increased and methotrexate was added to the therapeutic scheme, inflammation was controlled within 1 month." | 5.33 | Combination of azathioprine and corticosteroids in the treatment of serpiginous choroiditis. ( Burnier, MN; Deschênes, J; Ozdal, PC; Vianna, RN, 2006) |
| "Azathioprine was then considered as an alternative treatment." | 5.27 | Azathioprine. An alternative treatment for recurrent idiopathic retroperitoneal fibrosis. ( Cogan, E; Fastrez, R, 1985) |
| "Laboratory examination revealed acute disseminated intravascular coagulation and lactacidaemia." | 5.25 | [Lactacidaemia and disseminated intravascular coagulation associated with phenformin medication (author's transl)]. ( Dienstl, F; Holzknecht, F; Hörtnagl, H; Kunz, F; Lederer, B, 1975) |
| "Randomised controlled trial adding azathioprine to steroid treatment for leprosy reactions." | 5.24 | AZALEP a randomized controlled trial of azathioprine to treat leprosy nerve damage and Type 1 reactions in India: Main findings. ( Darlong, J; Govindharaj, P; John, AS; Kurian, R; Lockwood, DN; Sundarrao, P, 2017) |
| " This study was undertaken to determine whether the addition of azathioprine (AZA) to glucocorticoids could achieve a higher sustained remission rate of newly diagnosed nonsevere eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA), microscopic polyangiitis (MPA), or polyarteritis nodosa (PAN)." | 5.24 | Adding Azathioprine to Remission-Induction Glucocorticoids for Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss), Microscopic Polyangiitis, or Polyarteritis Nodosa Without Poor Prognosis Factors: A Randomized, Controlled Trial. ( Agard, C; Baron, G; Bienvenu, B; Bourgarit, A; Cohen, P; Crestani, B; Delbrel, X; Diot, E; Geffray, L; Godmer, P; Groh, M; Guillevin, L; Le Guern, V; Le Jeunne, C; Lifermann, F; Limal, N; Liozon, E; Mékinian, A; Mouthon, L; Néel, A; Pagnoux, C; Papo, T; Puéchal, X; Quémeneur, T; Ravaud, P; Ruivard, M; Ruppert, AM; Sailler, L; Saraux, JL; Terrier, B, 2017) |
| "To compare the efficacy of tacrolimus (TAC) and mycophenolate mofetil (MMF) for the initial therapy of lupus nephritis (LN)." | 5.22 | Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomised controlled trial and long-term follow-up. ( Mok, CC; Ng, WL; Siu, YP; To, CH; Tong, KH; Yim, CW; Ying, KY, 2016) |
| "Cytoplasmic anti-neutrophil cytoplasmic antibody (C-ANCA) positivity at remission has been associated with an increased relapse rate in patients with proteinase 3 anti-neutrophil cytoplasmic antibody-associated vasculitis (PR3-AAV) after a switch to azathioprine maintenance therapy." | 5.22 | Extended versus standard azathioprine maintenance therapy in newly diagnosed proteinase-3 anti-neutrophil cytoplasmic antibody-associated vasculitis patients who remain cytoplasmic anti-neutrophil cytoplasmic antibody-positive after induction of remission ( Broekroelofs, J; de Joode, AA; DeSevaux, RG; Kallenberg, CG; Sanders, JS; Stegeman, CA; Tervaert, JW; van Paassen, P; Voskuyl, AE, 2016) |
| "To evaluate long-term effects of 2-year treatment with interferon beta combined with low-dose azathioprine and prednisone in multiple sclerosis." | 5.16 | Interferon, azathioprine and corticosteroids in multiple sclerosis: 6-year follow-up of the ASA cohort. ( Dolezal, O; Havrdova, E; Horakova, D; Kalincik, T; Krasensky, J; Seidl, Z; Vaneckova, M, 2012) |
| "To assess the efficacy of systemic corticosteroids (CS) alone as first-line treatment in patients with Churg-Strauss syndrome (CSS) without poor-prognosis factors, as defined by the Five-Factors Score (FFS), and to compare the efficacy and safety of oral azathioprine (AZA) versus intravenous pulse cyclophosphamide (CYC) as adjuvant immunosuppressive therapy for treatment failure or relapse." | 5.13 | Treatment of Churg-Strauss syndrome without poor-prognosis factors: a multicenter, prospective, randomized, open-label study of seventy-two patients. ( Arène, JP; Cohen, P; Cordier, JF; Delaval, P; Guillevin, L; Lauque, D; Letellier, P; Mahr, A; Pagnoux, C; Puéchal, X; Ribi, C, 2008) |
| "To investigate the safety and efficacy of oral methylprednisolone combined with azathioprine sodium or mycophenolate mofetil for the treatment of bullous pemphigoid." | 5.12 | A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of bullous pemphigoid. ( Beissert, S; Böhm, M; Bonsmann, G; Frieling, U; Gollnick, H; Hunzelmann, N; Junghans, V; Luger, TA; Meurer, M; Pillekamp, H; Ruzicka, T; Rzany, B; Stadler, R; Sticherling, M; Werfel, T; Zillikens, D, 2007) |
| "For patients with proliferative lupus nephritis, short-term therapy with intravenous cyclophosphamide followed by maintenance therapy with mycophenolate mofetil or azathioprine appears to be more efficacious and safer than long-term therapy with intravenous cyclophosphamide." | 5.11 | Sequential therapies for proliferative lupus nephritis. ( Contreras, G; Leclercq, B; Lenz, O; O'Nan, P; Pardo, V; Roth, D; Tozman, E, 2004) |
| "To analyze disease-free survival in patients with antineutrophil cytoplasmic antibody (ANCA)-associated small-vessel vasculitis (AAV) treated with cyclophosphamide only or switched to azathioprine after 3 months of full remission while taking cyclophosphamide." | 5.11 | Positive classic antineutrophil cytoplasmic antibody (C-ANCA) titer at switch to azathioprine therapy associated with relapse in proteinase 3-related vasculitis. ( Boomsma, MM; Slot, MC; Stegeman, CA; Tervaert, JW, 2004) |
| "Mycophenolate mofetil (MMF) and the sequential use of cyclophosphamide followed by azathioprine (CTX-AZA) demonstrate similar short-term efficacy in the treatment of diffuse proliferative lupus nephritis (DPLN), but MMF is associated with less drug toxicity." | 5.11 | Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. ( Chan, TM; Li, FK; Mok, MY; Tang, CS; Tse, KC, 2005) |
| " In a multicenter, prospectively randomized study we compared efficacy and side effects of a dexamethasone-cyclophosphamide (D/C) pulse therapy with a methylprednisolone-azathioprine (M/A) therapy in 22 patients with newly diagnosed pemphigus vulgaris and pemphigus foliaceus." | 5.11 | Intravenous dexamethasone-cyclophosphamide pulse therapy in comparison with oral methylprednisolone-azathioprine therapy in patients with pemphigus: results of a multicenter prospectively randomized study. ( Bröcker, EB; Haustein, UF; Linse, R; Rose, E; Wever, S; Zilliken, D, 2005) |
| " We investigated whether exposure to cyclophosphamide in patients with generalized vasculitis could be reduced by substitution of azathioprine at remission." | 5.10 | A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. ( Andrassy, K; Bacon, P; Dadoniené, J; de Groot, K; Ekstrand, A; Gaskin, G; Gregorini, G; Gross, W; Hagen, EC; Jayne, D; Mirapeix, E; Pettersson, E; Pusey, C; Rasmussen, N; Siegert, C; Sinico, A; Tervaert, JW; Tesar, V; Westman, K, 2003) |
| "To evaluate, in a prospective, open-label study, the influence of antibiotics and azathioprine on the clinical outcome of perianal fistulas in patients with Crohn's disease." | 5.10 | Antibiotics and azathioprine for the treatment of perianal fistulas in Crohn's disease. ( Dejaco, C; Harrer, M; Miehsler, W; Reinisch, W; Vogelsang, H; Waldhoer, T, 2003) |
| "Our aim was to report the clinical experience with combination treatment using tacrolimus and either azathioprine (AZA) or 6-mercaptopurine (6MP) in patients with Crohn's disease (CD) perianal fistulae." | 5.09 | Combination therapy with oral tacrolimus (FK506) and azathioprine or 6-mercaptopurine for treatment-refractory Crohn's disease perianal fistulae. ( Lowry, PW; Sandborn, WJ; Tremaine, WJ; Weaver, AL, 1999) |
| "Seven patients who had an initial attack of nephrotic syndrome in childhood and had frequent relapses even after cyclophosphamide therapy were given a 2-year course of azathioprine." | 5.09 | Efficacy of long-term azathioprine for relapsing nephrotic syndrome. ( Hiraoka, M; Hori, C; Mayumi, M; Momoi, T; Ohshima, Y; Seo, A; Tsukahara, H, 2000) |
| "In 42 patients with diffuse proliferative lupus nephritis we compared the efficacy and side effects of a regimen of prednisolone and mycophenolate mofetil given for 12 months with those of a regimen of prednisolone and cyclophosphamide given for 6 months, followed by prednisolone and azathioprine for 6 months." | 5.09 | Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. ( Chan, KW; Chan, TM; Fang, GX; Ji, YL; Lai, KN; Lau, CS; Li, FK; Tang, CS; Tong, MK; Wong, AK; Wong, RW, 2000) |
| " In this open study, we compared the renal outcome of two historical cohorts of patients with diffuse proliferative lupus nephritis (World Health Organization classes IVa and IVb) treated with either intravenous (IV) pulse CYC (group A; n = 22) or sequential oral CYC followed by azathioprine (AZA; group B; n = 21) and followed up prospectively." | 5.09 | Treatment of diffuse proliferative lupus glomerulonephritis: a comparison of two cyclophosphamide-containing regimens. ( Au, TC; Chan, KW; Ho, CT; Kwan, TH; Lau, CS; Mok, CC; Siu, YP; Wong, RW, 2001) |
| "Patients with pemphigus vulgaris may occasionally present the highly active, widespread form of the disease, and/or maybe resistant to conventional oral steroid therapy, and/or manifest significant side effects from the prolonged use of high oral prednisone dosage." | 5.08 | Steroid-pulse therapy in pemphigus vulgaris long term follow-up. ( Chaidemenos, GC; Chryssomallis, F; Dimitriades, A; Karakatsanis, G; Panagiotides, D, 1995) |
| "In most patients with autoimmune hepatitis, remission can be maintained with prednisolone, usually in combination with azathioprine, but the majority of patients have a relapse when treatment is stopped and therefore require long-term therapy." | 5.08 | Azathioprine for long-term maintenance of remission in autoimmune hepatitis. ( Johnson, PJ; McFarlane, IG; Williams, R, 1995) |
| "Seven newly diagnosed patients with Devic's neuromyelitis optica were treated with long-term prednisone and azathioprine, and were followed every 2 months for at least 18 months." | 5.08 | Devic's neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine. ( Ahmed, W; Dencoff, JE; Mandler, RN, 1998) |
| "We randomized 59 patients with relapsing-remitting multiple sclerosis to receive azathioprine (AZA) 3." | 5.07 | The efficacy of azathioprine in relapsing-remitting multiple sclerosis. ( Bailly, RC; Beatty, WW; Goodkin, DE; Hertsgaard, D; Teetzen, ML, 1991) |
| "This study aimed to perform a meta-analysis of the efficacy and safety of azathioprine (AZA) for neuromyelitis optica spectrum disorders (NMOSD), considering the potential predictive factors related to patient response to AZA in this disease." | 5.05 | Efficacy and safety of azathioprine for neuromyelitis optica spectrum disorders: A meta-analysis of real-world studies. ( Chen, C; Cui, Y; Dong, X; Li, M; Luo, D; Ma, L; Tian, X; Wei, R; Zhang, E; Zhou, Y, 2020) |
| "A case of acute pancreatitis induced by azathioprine presented in a 22-year-old patient with Crohn's disease is reported." | 4.80 | [Acute azathioprine-induced pancreatitis in a female patient with Crohn's disease]. ( Caro-Paton, A; Fernández, P; González, JM; Goyeneche, ML; Martín, MA; Remacha, B; Sánchez, G; Velicia, MR, 1999) |
| "The efficacies of corticosteroids and azathioprine (part 1) and of cyclophosphamide, immune globulin, cyclosporine, interferons, copolymer 1, and cladribine (part 2) in patients with multiple sclerosis (MS) are reviewed." | 4.79 | Immunotherapy in multiple sclerosis, Part 1. ( Becker, CC; Fleming, JO; Gidal, BE, 1995) |
| "The efficacy of azathioprine in the treatment of multiple sclerosis was assessed by meta-analysis of the results of all published blind, randomised, controlled trials." | 4.78 | Overview of azathioprine treatment in multiple sclerosis. ( Ellison, GW; Ghezzi, A; Goodkin, DE; Hughes, RA; McPherson, K; Mertin, J; Milanese, C; Yudkin, PL, 1991) |
| "A VKH disease patient, well controlled on azathioprine therapy, presented a uveitis relapse eleven days after the first vaccination for COVID-19." | 4.12 | Vogt-Koyanagi-Harada Relapse after COVID-19 Vaccination. ( Accorinti, M; Manni, P; Saturno, MC, 2022) |
| "This study aimed to evaluate the efficacy and safety of mycophenolate mofetil (MMF) or tacrolimus (TAC) compared with azathioprine (AZA) as maintenance therapy for active lupus nephritis (ALN)." | 4.12 | Mycophenolate mofetil or tacrolimus compared with azathioprine in long-term maintenance treatment for active lupus nephritis. ( Chen, N; Chen, X; Li, X; Ren, H; Shen, P; Xie, J; Xing, P; Zhang, Q; Zhang, W, 2022) |
| "A morning standard dose of 250 mcg tetracosactide (Synacthen test) was given in 25 consecutive patients (13 rheumatoid arthritis, 2 psoriatic arthritis, 5 systemic lupus erythematosus, 2 dermatomyositis, 1 systemic sclerosis, 2 temporal arteritis) at the time of relapse upon small reductions (1-2 mg daily) of low prednisolone dose (<7." | 4.12 | Impaired adrenal cortex reserve in patients with rheumatic and musculoskeletal diseases who relapse upon tapering of low glucocorticoid dose. ( Filippa, MG; Panopoulos, S; Sfikakis, PP; Spanos, E; Spanos, G; Tektonidou, MG; Yavropoulou, MP, 2022) |
| "Azathioprine is a common first-line therapy for neuromyelitis optica spectrum disorder (NMOSD)." | 4.02 | Long-term safety of azathioprine for treatment of neuromyelitis optica spectrum disorders. ( Apóstolos-Pereira, SL; Callegaro, D; Gomes, ABAGR; Pitombeira, MS; Sato, DK, 2021) |
| "Methotrexate seems to be efficient in the treatment of idiopathic granulomatous mastitis and provides drug-free remission." | 3.96 | Treatment of idiopathic granulomatous mastitis and factors related with disease recurrence ( Çinar, M; Çolak, S; Tekgöz, E; Yilmaz, S, 2020) |
| "To research and compare the efficacy and tolerability of mycophenolate mofetil (MMF) and azathioprine (AZA) in neuromyelitis optica (NMO) and NMO spectrum disorder (NMOSD)." | 3.85 | Comparisons of the efficacy and tolerability of mycophenolate mofetil and azathioprine as treatments for neuromyelitis optica and neuromyelitis optica spectrum disorder. ( Chen, H; Feng, H; Lian, Z; Liu, J; Miao, X; Qiu, W; Shi, Z; Wang, J; Zhang, Q; Zhou, H, 2017) |
| "Azathioprine (AZA) and mycophenolate mofetil (MMF) are the most commonly used first-line therapies for patients with neuromyelitis optica spectrum disorders (NMOSD)." | 3.85 | Predictors of response to first-line immunosuppressive therapy in neuromyelitis optica spectrum disorders. ( Hyun, JW; Joo, J; Joung, A; Kim, HJ; Kim, SH; Park, EY, 2017) |
| "Azathioprine (AZA) is commonly used in myasthenia gravis (MG)." | 3.83 | Remission And relapse of myasthenia gravis on long-term azathioprine: An ambispective study. ( Behari, M; Goyal, V; Gupta, A; Shukla, G; Srivastava, AK, 2016) |
| "To compare the efficacy and tolerability of azathioprine (AZA), mycophenolate mofetil (MMF), and cyclophosphamide (CTX) in patients with neuromyelitis optica spectrum disorder (NMOSD)." | 3.83 | Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and cyclophosphamide among patients with neuromyelitis optica spectrum disorder: A prospective cohort study. ( Cui, LY; Fei, YY; Qiao, L; Ren, HT; Wang, Q; Xu, Y; Zhang, Y; Zhao, Y, 2016) |
| "To compare the efficacy and tolerability of azathioprine, cyclophosphamide, mycophenolate, and rituximab in patients with neuromyelitis optica." | 3.81 | Analysis of the treatment of neuromyelitis optica. ( Balcer, L; Dahodwala, N; Galetta, S; Markowitz, C; Pruitt, A; Torres, J, 2015) |
| "We investigated the efficacy of azathioprine (AZA) plus long-term low dose corticosteroids in Chinese patients with neuromyelitis optica (NMO) and neuromyelitis optica spectrum disorders (NMOSD) at the Center for Demyelinating Diseases, South China." | 3.81 | Azathioprine plus corticosteroid treatment in Chinese patients with neuromyelitis optica. ( Dai, Y; Hu, X; Kermode, AG; Li, C; Li, R; Lu, Z; Qiu, W; Wang, J; Wang, Y; Zhong, X, 2015) |
| "In patients with juvenile dermatomyositis, treatment with intravenous immunoglobulin and cyclosporine A were more frequent as compared to adult patients." | 3.81 | [Clinical features of patients with juvenile and adult dermatomyositis]. ( Dankó, K; Farkas, F; Nagy-Vince, M; Szalmás, O, 2015) |
| "Azathioprine (AZA) is a common immunosuppressive drug used for relapse prevention in neuromyelitis optica (NMO)." | 3.80 | Long-term efficacy, tolerability and retention rate of azathioprine in 103 aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder patients: a multicentre retrospective observational study from the UK. ( Brown, R; Elsone, L; Goh, YY; Jacob, A; Jacob, S; Kitley, J; Leite, MI; Luppe, S; Lythgoe, D; McNeillis, B; Moss, K; Mutch, K; Palace, J; Robertson, N, 2014) |
| " Combined immunosuppressive therapy with prednisone and cyclophosphamide might be needed to treat recurrent thrombosis due to Behçet disease." | 3.80 | Recurrent right atrial thrombosis due to Behçet disease. ( Fukuda, K; Kuno, T; Kuwana, M; Murata, M; Ono, T; Satoh, T; Tamura, Y, 2014) |
| "To evaluate the efficacy, tolerability, optimal dosing, and monitoring of azathioprine in patients with neuromyelitis optica (NMO)." | 3.77 | Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica. ( Costanzi, C; Lucchinetti, CF; Mandrekar, J; Matiello, M; McKeon, A; Pittock, SJ; Thapa, P; Weinshenker, BG, 2011) |
| "Although azathioprine usually is reserved for inflammatory bowel disease that proves difficult to control, routine early use has recently been advocated for children with Crohn disease." | 3.74 | Predicting the need for azathioprine at first presentation in children with inflammatory bowel disease. ( Davies, P; Mossop, H; Murphy, MS, 2008) |
| "To evaluate the efficacy and safety of prednisone as monotherapy and in combination with the three most popular adjuvant agents - azathioprine, cyclosporine (ciclosporin), and cyclophosphamide - in the treatment of pemphigus vulgaris." | 3.74 | Efficacy and safety of cyclophosphamide, azathioprine, and cyclosporine (ciclosporin) as adjuvant drugs in pemphigus vulgaris. ( Blaszczyk, M; Cwikla, J; Kolacinska-Strasz, Z; Labecka, H; Natorska, U; Olszewska, M; Sulej, J, 2007) |
| "To evaluate the long-term efficacy and tolerance of tacrolimus for the treatment of uveitis." | 3.74 | Long-term efficacy and tolerance of tacrolimus for the treatment of uveitis. ( Dick, AD; Hogan, AC; Lee, RW; McAvoy, CE, 2007) |
| "The efficacy of isoniazid (INAH) prophylaxis against tuberculosis (TB) in patients taking corticosteroid remains controversial." | 3.73 | Tuberculosis in systemic lupus erythematosus in an endemic area and the role of isoniazid prophylaxis during corticosteroid therapy. ( Chan, TM; Lau, CS; Lo, Y; Mok, MY; Wong, WS, 2005) |
| " Renewed remission was obtained with additional infliximab, and was maintained with azathioprine for 12 months before the patient again presented with symmetrical polyarthritis." | 3.73 | [Symmetric polyarthritis in a patient with Churg-Strauss syndrome]. ( Aries, PM; Reinhold-Keller, E, 2005) |
| "A retrospective review of 30 patients with recurrent idiopathic neuroretinitis identified 7 who received ongoing immunosuppression with prednisone and/or azathioprine for whom adequate follow-up information was available." | 3.72 | Idiopathic recurrent neuroretinitis: effects of long-term immunosuppression. ( Kawasaki, A; Purvin, V; Ranson, N, 2003) |
| "The clinical courses were reviewed of six consecutive patients (12 eyes) with vision-threatening, steroid-dependent/resistant serpiginous choroiditis treated with a combination of immunosuppressive agents including azathioprine, cyclosporine, and cyclophosphamide." | 3.71 | Long-term immunosuppressive treatment of serpiginous choroiditis. ( Akpek, EK; Baltatzis, S; Foster, CS; Yang, J, 2001) |
| "Azathioprine is commonly used as a second-line immunosuppressive agent in the management of patients with retinal vasculitis." | 3.70 | The role of azathioprine in the management of retinal vasculitis. ( Graham, EM; Greenwood, AJ; Stanford, MR, 1998) |
| " The patients who achieved a complete remission with medical treatment, who had no history of intestinal perforation, and who received azathioprine after operation showed better clinical courses." | 3.70 | Long-term clinical course and prognostic factors in intestinal Behçet's disease. ( Cha, SD; Choi, IJ; Jung, HC; Kim, CY; Kim, JS; Park, JG; Song, IS, 2000) |
| "Of the 19 patients treated with azathioprine for recurrent ileitis, 15 could be reevaluated by endoscopy or radiological examination." | 3.69 | Healing of severe recurrent ileitis with azathioprine therapy in patients with Crohn's disease. ( D'Haens, G; Geboes, K; Penninckx, F; Ponette, E; Rutgeerts, P, 1997) |
| "This paper describes 108 consecutively treated patients receiving 109 cadaveric (CD) and living donor (LD) renal allografts using a protocol of quadruple sequential immunosuppression with a rabbit anti-human thymocyte IgG (Thymoglobuline), azathioprine, tapering corticosteroids, and delayed introduction of cyclosporine A." | 3.69 | Sequential biological immunosuppression. Induction therapy with rabbit antithymocyte globulin. ( Flemming, C; Guttmann, RD, 1997) |
| "Azathioprine is an established immunosuppressive agent in the treatment of myasthenia gravis." | 3.69 | [Myasthenic crisis caused by azathioprine-induced fever]. ( George, A; Nau, R; Tumani, H, 1997) |
| "The combination of cyclosporine, azathioprine and low-dose prednisolone leads to marked improvement of perianal fistulas in Crohn's disease." | 3.69 | Combination of cyclosporine, azathioprine and prednisolone for perianal fistulas in Crohn's disease. ( Aichbichler, B; Fickert, P; Hinterleitner, TA; Krejs, GJ; Petritsch, W; Ranner, G, 1997) |
| "Azathioprine (AZA) has a slight but consistent effect on clinical outcome in multiple sclerosis (MS), but very few data are available on magnetic resonance imaging (MRI) changes." | 3.69 | Lesion load quantification in serial MR of early relapsing multiple sclerosis patients in azathioprine treatment. A retrospective study. ( Cavazzuti, M; Mavilla, L; Merelli, E; Tassone, G, 1997) |
| " We are evaluating a new antiviral agent, ganciclovir 9-[1,3-dihydroxy-2-2 propoxymethyl] guanine (DHPG), used in solid-organ transplant recipients who developed life-threatening cytomegalovirus infections." | 3.68 | Diagnosis and treatment of cytomegalovirus disease in transplant patients based on gastrointestinal tract manifestations. ( Dunn, DL; Fasola, CG; Kramer, MA; Loeffler, CM; Matas, AJ; Mayoral, JL; Najarian, JS; Orrom, WJ, 1991) |
| "Twenty-four patients with myasthenia gravis were treated with azathioprine." | 3.67 | Azathioprine in the treatment of myasthenia gravis. ( Cornblath, DR; Lisak, RP; Parry, GJ; Schatz, NJ; Witte, AS, 1984) |
| "In a selected group of 69 patients with myasthenia gravis treated with prednisone, the factors were studied that might have influenced the reoccurrence or exacerbation of clinical signs after initial improvement in two-thirds of the patients." | 3.67 | Factors influencing the relapse risk at steroid dose reduction in myasthenia gravis. ( Oosterhuis, HJ; Scherpbier, HJ, 1987) |
| "In a prospective long-term study, thirty-seven patients with severe generalized pemphigus vulgaris were treated with a combined corticosteroid-azathioprine regimen." | 3.67 | Azathioprine in the treatment of pemphigus vulgaris. A long-term follow-up. ( Aberer, W; Stingl, G; Wolff, K; Wolff-Schreiner, EC, 1987) |
| "Thirteen adult patients with nephrotic syndrome resistant to corticosteroid administration were treated with azathioprine daily for four years." | 3.67 | Effect of long-term azathioprine administration in adults with minimal-change glomerulonephritis and nephrotic syndrome resistant to corticosteroids. ( Cade, R; Campbell, K; Croker, B; Mars, D; Peterson, J; Privette, M; Thompson, R, 1986) |
| "Effects of azathioprine, 150 mg per day on average, were studied in 213 patients with multiple sclerosis." | 3.66 | [Study of 213 cases of multiple sclerosis treated with azathioprine from 1967- to 1982]. ( Aimard, G; Confavreux, C; Devic, M; Guillot, M; Ventre, JJ, 1983) |
| "A controlled trial of azathioprine treatment of steroid-responsive frequent-relapsing nephrotic syndrome of childhood failed to show a therapeutic effect on the stability of remission after withdrawal of corticosteroid treatment." | 3.65 | Controlled trial of azathioprine in treatment of steroid-responsive nephrotic syndrome of childhood. ( Barratt, TM; Cameron, JS; Chantler, C; Counahan, R; Ogg, CS; Soothill, JF, 1977) |
| " In a comparison of these children with SLE, with and without AN, with a group of patients with nephrosis treated with corticosteroids and a group with glomerulonephritis treated with azathioprine, AN was related to the duration of daily steroid therapy rather than the total duration of steroid treatment; this was not true for azathioprine." | 3.65 | A vascular necrosis of the femoral head in childhood systemic lupus erythematosus. ( Drummond, KN; Hurley, RM; Patriquin, H; Steinberg, RH, 1974) |
| "Nineteen patients with multiple sclerosis were treated with azathioprine for two years." | 3.65 | Long-term treatment of multiple sclerosis with azathioprine. ( Liversedge, LA; Swinburn, WR, 1973) |
| "Adult patients with Crohn's disease in steroid-free clinical remission for more than 6 months, on combination therapy of infliximab and immunosuppressant therapy for at least 8 months were randomly assigned (1:1:1) to either continue combination therapy (combination group), discontinue infliximab (infliximab withdrawal group), or discontinue immunosuppressant therapy (immunosuppressant withdrawal group)." | 3.30 | Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial. ( Almer, S; Baert, F; Ben-Horin, S; Bossuyt, P; Bouhnik, Y; Colombel, JF; D'Haens, G; Ding, N; Fumery, M; Gilletta, C; Hertervig, E; Irving, P; Laharie, D; Lamb, CA; Louis, E; Nachury, M; Picon, L; Pollok, R; Resche-Rigon, M; Satsangi, J; Siegmund, B; Viennot, S; Vuitton, L, 2023) |
| "Relapses are associated with increased exposure to immunosuppressive medications, the accrual of damage and increased morbidity and mortality." | 3.30 | Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: an international randomised controlled trial. ( Al-Jayyousi, R; Andrews, J; Bond, S; Bruchfeld, A; Camilleri, B; Carette, S; Cheung, CK; Derebail, V; Doulton, T; Ferraro, A; Forbess, L; Fujimoto, S; Furuta, S; Gewurz-Singer, O; Harper, L; Ito-Ihara, T; Jayne, D; Jones, RB; Khalidi, N; Klocke, R; Koening, C; Komagata, Y; Langford, C; Lanyon, P; Luqmani, R; McAlear, C; Merkel, PA; Moreland, LW; Mynard, K; Nachman, P; Nodale, M; Pagnoux, C; Peh, CA; Pusey, C; Ranganathan, D; Rhee, RL; Smith, RM; Specks, U; Spiera, R; Sreih, AG; Tesar, V; Walters, G; Wroe, C, 2023) |
| "Recurrent pericarditis is a common and troublesome complication that affects 15%-30% of patients with a previous episode of pericarditis." | 3.01 | New Developments in the Management of Recurrent Pericarditis. ( Andreis, A; Collini, V; De Biasio, M; Franchin, L; Imazio, M; Mardigyan, V, 2023) |
| " The dosage was further reduced by adding methotrexate at 7." | 3.01 | Relapsing autoimmune inner ear disease with significant response to methotrexate and azathioprine combination therapy: A case report and mini literature review. ( Huang, KH; Lin, CD; Lin, HC; Wu, PC, 2023) |
| "Curcumin has anti-inflammatory properties and induces endoscopic remission in patients with ulcerative colitis." | 2.94 | Oral Curcumin No More Effective Than Placebo in Preventing Recurrence of Crohn's Disease After Surgery in a Randomized Controlled Trial. ( Bommelaer, G; Buisson, A; Fumery, M; Goutte, M; Hebuterne, X; Laharie, D; Nachury, M; Nancey, S; Pereira, B; Peyrin-Biroulet, L; Richard, D; Roblin, X, 2020) |
| "Clinical failure was defined for Crohn's disease (CD) as a Harvey-Bradshaw index ≥5 associated with a faecal calprotectin level >250 µg/g stool and for UC as a Mayo score >5 with endoscopic subscore >1 or as the occurrence of adverse events requiring to stop treatment." | 2.94 | Addition of azathioprine to the switch of anti-TNF in patients with IBD in clinical relapse with undetectable anti-TNF trough levels and antidrug antibodies: a prospective randomised trial. ( Berger, AE; Boschetti, G; Del Tedesco, E; Duru, G; Flourie, B; Nancey, S; Paul, S; Peyrin-Biroulet, L; Phelip, JM; Roblin, X; Vedrines, P; Williet, N, 2020) |
| "Early prediction of postoperative recurrence (POR) remains a major concern in Crohn's disease (CD)." | 2.94 | Variation of faecal calprotectin level within the first three months after bowel resection is predictive of endoscopic postoperative recurrence in Crohn's disease. ( Bommelaer, G; Boube, M; Buisson, A; Fumery, M; Hebuterne, X; Laharie, D; Minet-Quinard, R; Nancey, S; Pariente, B; Pereira, B; Peyrin-Biroulet, L; Roblin, X, 2020) |
| "The recurrence of Crohn's Disease after ileo-colonic resection is a crucial issue." | 2.94 | Azathioprine for prevention of clinical recurrence in Crohn's disease patients with severe endoscopic recurrence: an IG-IBD randomized double-blind trial. ( Angelucci, E; Annese, V; Aratari, A; Biancone, L; Bossa, F; Cappello, M; Castiglione, F; Cottone, M; Di Mitri, R; Giunta, M; Kohn, A; Macaluso, FS; Mocciaro, F; Onali, S; Orlando, A; Papi, C; Renna, S; Rispo, A; Scimeca, D; Scribano, ML; Testa, A; Ventimiglia, M, 2020) |
| "In APPRECIA trial, Crohn's disease (CD) patients undergoing intestinal resection were randomized to postoperative adalimumab (ADA) or azathioprine (AZA)." | 2.90 | Quality of life during one year of postoperative prophylactic drug therapy after intestinal resection in Crohn's patients: Results of the APPRECIA trial. ( Alba, C; Barrio, J; Bermejo, F; Calvet, X; Castro, L; Ceballos, D; Domènech, E; Echarri, A; Esteve, M; Gisbert, JP; Guardiola, J; Hinojosa, J; Iglesias, E; López-Sanromán, A; Marín-Jiménez, I; Márquez-Mosquera, L; Martín-Arranz, MD; Martínez-Montiel, P; Mínguez, M; Nos, P; Pons, V; Rimola, J; Ruiz, VV; Taxonera, C; Vera-Mendoza, I, 2019) |
| "We evaluated the endoscopic recurrence (Rutgeerts score) at the sixth month after ICR in all included patients." | 2.84 | Endoscopic Recurrence 6 Months After Ileocecal Resection in Children With Crohn Disease Treated With Azathioprine. ( Bronsky, J; Copova, I; Hradsky, O; Pos, L; Rouskova, B; Skaba, R; Zarubova, K, 2017) |
| " In this study, 681 patients were recorded safety data of RTX therapy, 23% (156 patients) had adverse events, and 0." | 2.82 | A meta-analysis on efficacy and safety of rituximab for neuromyelitis optica spectrum disorders. ( Dong, GY; Meng, YH; Xiao, XJ, 2022) |
| "Many patients with quiescent Crohn's disease are maintained on long-term treatment with azathioprine (AZA), but controlled data are limited." | 2.80 | Withdrawal of long-term maintenance treatment with azathioprine tends to increase relapse risk in patients with Crohn's disease. ( Högenauer, C; Novacek, G; Öfferlbauer-Ernst, A; Petritsch, W; Primas, C; Reinisch, W; Teml, A; Vogelsang, H; Wenzl, HH, 2015) |
| "There were no differences between treatment groups in relapses at 6, 12, or 18 months." | 2.80 | Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement. ( Brunetta, P; Ding, L; Fervenza, FC; Fessler, BJ; Geetha, D; Hoffman, GS; Ikle, D; Jepson, B; Kallenberg, CG; Langford, CA; Merkel, PA; Seo, P; Specks, U; Spiera, R; St Clair, EW; Stone, JH; Tchao, NK, 2015) |
| "The primary endpoint was clinical recurrence, and the secondary endpoint was endoscopic recurrence." | 2.80 | Tripterygium wilfordii Hook. f. versus azathioprine for prevention of postoperative recurrence in patients with Crohn's disease: a randomized clinical trial. ( Cao, L; Gong, J; Gu, L; Guo, Z; Li, J; Li, N; Li, Y; Zhang, W; Zhu, W; Zuo, L, 2015) |
| "Most patients with Crohn's disease need an intestinal resection, but a majority will subsequently experience disease recurrence and require further surgery." | 2.80 | Crohn's disease management after intestinal resection: a randomised trial. ( Andrews, JM; Bampton, PA; Bell, SJ; Brown, SJ; Connell, WR; De Cruz, P; Debinski, H; Desmond, PV; Elliott, PR; Florin, TH; Gearry, RB; Gibson, PR; Gorelik, A; Hamilton, AL; Johnston, MJ; Kamm, MA; Krejany, EO; Kronborg, I; Lawrance, IC; Leong, RW; Liew, D; Macrae, FA; Prideaux, L; Radford-Smith, G; Ritchie, KJ; Selby, W; Sparrow, M; Woods, R, 2015) |
| "A prednisone increase led to remission in 35 patients (80%)." | 2.80 | Outcomes of nonsevere relapses in antineutrophil cytoplasmic antibody-associated vasculitis treated with glucocorticoids. ( Brunetta, P; Ding, L; Fervenza, FC; Hoffman, GS; Iklé, D; Kallenberg, CG; Langford, CA; Lim, N; Merkel, PA; Miloslavsky, EM; Monach, PA; Seo, P; Specks, U; Spiera, R; St Clair, EW; Stone, JH; Tchao, NK; Villareal, M, 2015) |
| "Endoscopic recurrence (Rutgeerts score i2-i4) occurred in 33 of 73 (45%) thiopurine vs." | 2.80 | Efficacy of thiopurines and adalimumab in preventing Crohn's disease recurrence in high-risk patients - a POCER study analysis. ( Andrews, JM; Bampton, PA; Bell, SJ; Brown, SJ; Connell, WR; De Cruz, P; Debinski, H; Desmond, PV; Elliott, PR; Florin, TH; Gearry, RB; Gibson, PR; Gorelik, A; Hamilton, AL; Jakobovits, S; Johnston, MJ; Kamm, MA; Krejany, EO; Kronborg, I; Lawrance, IC; Leong, RW; Liew, D; Macrae, FA; Prideaux, L; Radford-Smith, G; Ritchie, KJ; Selby, W; Woods, R, 2015) |
| "Factors associated with HCV recurrence were evaluated." | 2.79 | Reduced fibrosis in recurrent HCV with tacrolimus, azathioprine and steroids versus tacrolimus: randomised trial long term outcomes. ( Burroughs, AK; Cholongitas, E; Corbani, A; Davidson, B; Davidson, J; Dhillon, AP; Hayes, P; Luong, T; Manousou, P; McCormick, PA; O'Beirne, J; Patch, D; Rodríguez-Perálvarez, M; Rolles, K; Samonakis, D; Thorburn, D; Tsochatzis, E, 2014) |
| "Prednisone was tapered to discontinuation after 5." | 2.79 | Rituximab for the treatment of relapses in antineutrophil cytoplasmic antibody-associated vasculitis. ( Allen, NB; Brunetta, P; Ding, L; Fervenza, FC; Geetha, D; Hoffman, GS; Iklé, D; Jepson, B; Kallenberg, CG; Keogh, K; Kissin, EY; Langford, CA; Merkel, PA; Miloslavsky, EM; Monach, PA; Peikert, T; Seo, P; Specks, U; Spiera, R; St Clair, EW; Stegeman, C; Stone, JH; Tchao, NK; Villarreal, M; Viviano, L; Ytterberg, SR, 2014) |
| "Pemphigus is an autoimmune blistering mucocutaneous disorder." | 2.79 | Assessment of the therapeutic benefit of oral prednisolone and common adjuvant therapy in stage II of randomized controlled trial study for management of pemphigus vulgaris. ( Chams-Davatchi, C; Daneshpazhooh, M; Esmaili, N; Karimi, A; Mortazavi, H; Toosi, S; Valikhani, M, 2014) |
| "Patients with subocclusive Crohn's disease (CD) who received azathioprine (AZA) therapy had lower re-hospitalization rates due to all causes and for surgical management of CD compared to those treated with mesalazine during a 3-year period." | 2.79 | Azathioprine is more effective than mesalazine at preventing recurrent bowel obstruction in patients with ileocecal Crohn's disease. ( Castro, AC; Chebli, JM; Chebli, LA; da Rocha Ribeiro, TC; de Lima Pace, FH; de Oliveira Zanini, KA; de Souza, GS; do Valle Pinheiro, B; Furtado, MC; Gaburri, PD; Machado de Oliveira, J; Pinto, AL; Ribeiro, LC; Vidigal, FM; Zanini, A, 2014) |
| "There was statistical difference in the recurrence interval and the yearly average recurrence times between the test group and the control group (P < 0." | 2.78 | [Effects of shugan jianpi gusui recipe on multiple sclerosis recurrence: a primary report]. ( Li, T; Mao, WQ; Zhang, XJ; Zhou, YQ, 2013) |
| "A fall in proteinuria was recorded in both groups during treatment, but it rose significantly in Aza group (1." | 2.76 | Cyclosporine versus azathioprine therapy in high-risk idiopathic membranous nephropathy patients: A 3-year prospective study. ( Basta-Jovanovic, G; Jovanovic, D; Marinkovic, J; Naumovic, R; Pavlovic, S; Stosovic, M, 2011) |
| "The decrease in ulcerative colitis disease activity index (UCDAI) scores of 50% or more was higher in the VSL#3 group than in the placebo group (63." | 2.75 | Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. ( Annese, V; Brandimarte, G; D'Amico, T; Danese, S; Di Giulio, E; Di Rosa, S; Elisei, W; Forti, G; Gasbarrini, A; Giglio, A; Giorgetti, GM; Hassan, C; Imeneo, M; Larussa, T; Luzza, F; Modeo, ME; Morini, S; Papa, A; Pistoia, MA; Rodino', S; Sacca', N; Sebkova, L; Tursi, A, 2010) |
| "Azathioprine (AZA) withdrawal in Crohn's disease after long-term remission under treatment is controversial." | 2.74 | Azathioprine withdrawal in patients with Crohn's disease maintained on prolonged remission: a high risk of relapse. ( Bouhnik, Y; Colombel, JF; Cosnes, J; Duclos, B; Lemann, M; Lerebours, E; Mary, JY; Soule, JC; Treton, X, 2009) |
| "Patients with Crohn's disease who underwent an ileocolic resection were randomized to side-to-side anastomosis or end-to-end anastomosis." | 2.74 | Recurrence of Crohn's disease after ileocolic resection is not affected by anastomotic type: results of a multicenter, randomized, controlled trial. ( McKenzie, M; McLeod, RS; Parkes, R; Ross, S; Wolff, BG, 2009) |
| "Mitoxantrone was approved by the French health authority (AFSAPPS) in October 2003 to treat patients with aggressive multiple sclerosis (MS)." | 2.73 | Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients. ( Chaperon, J; Coustans, M; Edan, G; Le Page, E; Leray, E; Morrissey, SP; Taurin, G, 2008) |
| "To investigate whether patients kept in remission by azathioprine treatment for >2 years benefit from further treatment, and to explore dose-response relationship." | 2.71 | Randomized controlled azathioprine withdrawal after more than two years treatment in Crohn's disease: increased relapse rate the following year. ( Dahlerup, JF; Fallingborg, J; Grønbaek, K; Munck, LK; Nørregaard, P; Vilien, M, 2004) |
| "Hepatitis C virus (HCV) recurrence in HCV+ liver transplant recipients is almost inevitable and may be promoted by immunosuppression." | 2.71 | Double-blind comparison of hepatitis C histological recurrence Rate in HCV+ Liver transplant recipients given basiliximab + steroids or basiliximab + placebo, in addition to cyclosporine and azathioprine. ( Agnes, S; Burra, P; Callea, F; De Carlis, L; Fassati, LR; Ferrara, R; Filipponi, F; Grazi, GL; Pisati, R; Risaliti, A; Rossi, M; Salizzoni, M; Valente, U, 2004) |
| "Azathioprine maintenance treatment in ulcerative colitis is beneficial for at least two years if patients have achieved remission while taking the drug." | 2.67 | Randomised controlled trial of azathioprine withdrawal in ulcerative colitis. ( Axon, AT; Foster, PN; Hawkey, CJ; Hawthorne, AB; Lennard-Jones, JE; Logan, RF; Scott, BB; Swarbrick, ET, 1992) |
| "Microscopic colitis is a common cause of chronic watery diarrhea with a great impact on patient quality of life." | 2.66 | Treatment of microscopic colitis: the role of budesonide and new alternatives for refractory patients. ( Casanova, MJ; Gisbert, JP; Rojo, E, 2020) |
| "Pericarditis is the most common form of pericardial disease and may be associated with significant morbidity and mortality." | 2.66 | Managing acute and recurrent idiopathic pericarditis. ( Cornelio, CK; Epperson, TM; Schwier, NC, 2020) |
| "Azathioprine was used as a maintenance treatment." | 2.66 | Recurrent myelitis and asymptomatic hypophysitis in IgG4-related disease: case-based review. ( Anagnostouli, M; Andreadou, E; Boutzios, G; Evangelopoulos, ME; Fragoulis, GE; Kilidireas, C; Koutsis, G; Stefanis, L; Toulas, P; Tzanetakos, D; Tzartos, J; Vakrakou, AG; Velonakis, G, 2020) |
| "About half of patients with Crohn's disease (CD) require surgery within 10 years of diagnosis." | 2.66 | Colonoscopy-guided therapy for the prevention of post-operative recurrence of Crohn's disease. ( Bravo-Soto, GA; Candia, R; Hernandez, C; Monrroy, H; Nguyen, GC, 2020) |
| "A standard clinical grading system, the Crohn's Disease Activity Index (CDAI) was developed to allow uniform decentralized clinical evaluation and decision-making throughout the 5 yr of the study." | 2.65 | National Cooperative Crohn's Disease Study: study design and conduct of the study. ( Becktel, JM; Best, WR; Kern, F; Lenk, LF; Singleton, JW; Summers, RW; Winship, DH, 1979) |
| "The response of active and quiescent Crohn's disease to prednisone, sulfasalazine, or azathioprine has been studied in 569 patients in a placebo-controlled, randomized, multicenter cooperative trial." | 2.65 | National Cooperative Crohn's Disease Study: results of drug treatment. ( Becktel, JM; Best, WR; Kern, F; Sessions, JT; Singleton, JW; Summers, RW; Switz, DM, 1979) |
| "51 patients with Crohn's disease who were in good health while taking azathiprine, 2 mg/kg body-weight/day, for at least six months were allocated either to a group in which azathioprine was continued or to one in which a control tablet was substituted." | 2.64 | Double-blind withdrawal trial of azathioprine as maintenance treatment for Crohn's disease. ( Bown, RL; Dawson, AM; Lennard-Jones, JE; O'Donoghue, DP; Powell-Tuck, J, 1978) |
| " The mean reduction in steriod dosage in the azathioprine group at the end of the trial (-15." | 2.64 | A controlled trial of azathioprine in Crohn's disease. ( Kirsner, JB; Levin, B; Rosenberg, JL; Wall, AJ, 1975) |
| "Autoimmune hepatitis is a corticosteroid-responsive liver disease arising consequent to immunogenetic and environmental risk factors." | 2.61 | Grand round: Autoimmune hepatitis. ( Gleeson, D; Heneghan, M; Hirschfield, GM; Hubscher, SG; Trivedi, PJ, 2019) |
| "Initial treatment of autoimmune hepatitis (AIH) with prednisolone ± azathioprine is based on randomised controlled trials." | 2.61 | Stopping immunosuppressive treatment in autoimmune hepatitis (AIH): Is it justified (and in whom and when)? ( Gleeson, D; Harrison, L, 2019) |
| "Maintenance therapy for lupus nephritis (LN) remains controversial." | 2.61 | Maintenance therapy for lupus nephritis with mycophenolate mofetil or azathioprine. A meta-analysis . ( Deng, J; Luo, L; Xie, H; Zhu, L, 2019) |
| " Long-term follow-up trials focused on gonadal toxicity and limitation of maximum dosage of cyclophosphamide should been carried out." | 2.61 | Efficacy and acceptability of immunosuppressive agents for pediatric frequently-relapsing and steroid-dependent nephrotic syndrome: A network meta-analysis of randomized controlled trials. ( Li, Q; Li, S; Tan, L; Wan, J; Yang, H; Zou, Q, 2019) |
| "Azathioprine may increase disease relapse as maintenance therapy compared with MMF." | 2.58 | Immunosuppressive treatment for proliferative lupus nephritis. ( Craig, JC; Flanc, RS; Henderson, L; Masson, P; Palmer, SC; Roberts, MA; Singh-Grewal, D; Strippoli, GF; Tong, A; Tunnicliffe, DJ; Webster, AC, 2018) |
| "Azathioprine was associated with more than half of patients becoming recurrence free; however, many patients required a restart of corticosteroids due to recurrence." | 2.55 | Treatment of Adults with Idiopathic Recurrent Pericarditis: Novel Use of Immunotherapy. ( Davies, ML; Hale, GM; Schwier, NC, 2017) |
| "Recurrent pericarditis is one of the most common and troublesome complications after an episode of pericarditis, and affects 20-50% of patients treated for pericarditis." | 2.53 | Recurrent pericarditis: new and emerging therapeutic options. ( Brucato, A; Gaita, F; Imazio, M; Lazaros, G, 2016) |
| "Recurrent pericarditis is one of the most troublesome complications of pericarditis occurring in about one third of patients with a previous attack of pericarditis." | 2.53 | Recurrent Pericarditis: Modern Approach in 2016. ( Adler, Y; Charron, P; Imazio, M, 2016) |
| "The prednisolone was gradually tapered by 5 mg every 2-wk, but oral azathioprine at 50 mg was added after symptoms recurred at tapered dose of 10 mg." | 2.53 | Efficacy of additional treatment with azathioprine in a patient with prednisolone-dependent gastric sarcoidosis. ( Andoh, A; Bamba, S; Ban, H; Inatomi, O; Kushima, R; Murata, M; Sugimoto, M; Yokota, Y, 2016) |
| "Autoimmune hepatitis is a chronic immune-mediated liver injury, frequently associated with progression to end-stage liver disease if untreated." | 2.52 | Autoimmune hepatitis: an approach to disease understanding and management. ( Adams, DH; Corrigan, M; Hirschfield, GM; Oo, YH, 2015) |
| " TB risk was higher when anti-TNF agents were combined with methotrexate or azathioprine as compared with either controls (24/4241 versus 0/4673; OR 54; 95% CI 5." | 2.50 | Higher risk of tuberculosis reactivation when anti-TNF is combined with immunosuppressive agents: a systematic review of randomized controlled trials. ( Armuzzi, A; Bruzzese, V; Diamanti, AP; Gatta, L; Hassan, C; Laganà, B; Lorenzetti, R; Migliore, A; Ridola, L; Zullo, A, 2014) |
| "Immunoglobulin G4 (IgG4)-associated autoimmune hepatitis (AIH) was recognized as a new disease entity; however, IgG4-associated de novo AIH after the liver transplantation had not been reported yet." | 2.49 | Immunoglobulin G4-associated de novo autoimmune hepatitis after liver transplantation for chronic hepatitis B- and C-related cirrhosis and hepatocellular carcinoma: a case report with literature review. ( Jia, JD; Rakhda, MI; Wang, TI; Zhao, XY, 2013) |
| "Azathioprine is an efficient maintenance treatment of IBD, able to maintain a complete clinical and anatomical remission in about one third of patients." | 2.49 | Is there still a room for azathioprine monotherapy in inflammatory bowel disease? ( Bourrier, A; Cosnes, J; Seksik, P, 2013) |
| "Three patients had recurrence at 12, 24 and 72 months, respectively, and 15 patients required emergency surgery." | 2.49 | Retroperitoneal fibrosis: single-centre experience from 1992 to 2010, current status of knowledge and review of the international literature. ( Álvarez Fernández, F; Flores Herrero, Á; García Betancourth, N; Gómez García, I; Gómez Rodríguez, A; Labra González, R; Romero Molina, M; Rubio Hidalgo, E; Sampietro Crespo, A; Sánchez Castaño, A, 2013) |
| "There is no difference in HCV recurrence between tacrolimus and cyclosporine regimens, but tacrolimus increases graft and patient survival in HCV transplanted patients." | 2.48 | Immunosuppression and HCV recurrence after liver transplantation. ( Burroughs, AK; Germani, G; Samonakis, DN, 2012) |
| "Crohn's disease is a chronic, progressive disabling condition ultimately leading to stricturing and/or penetrating complications." | 2.46 | [Postoperative recurrence of Crohn's disease, and its prevention]. ( Lakatos, L; Lakatos, PL, 2010) |
| "Autoimmune hepatitis is a chronic inflammatory disease of the liver with a dismal prognosis when left untreated." | 2.46 | Autoimmune hepatitis. ( Strassburg, CP, 2010) |
| "Acquired hemophilia A (AH) is a rare and serious acquired bleeding disorder where prompt and correct diagnosis is crucial, and immune suppression is often required for factor VIII (FVIII) autoantibody eradication." | 2.45 | Twelve years of experience of acquired hemophilia A: trials and tribulations in South Australia. ( Al-Qunfoidi, R; Coghlan, D; Duncan, E; Jaksic, W; Lloyd, J; McRae, S; Singhal, D; Szabo, F; Tay, L, 2009) |
| "Most common and suggestive features of Wegener's granulomatosis are upper (sinusitis, crusting rhinitis, saddle nose deformity, otitis media) and lower (excavated lung nodules, alveolar hemorrhage) respiratory tract, and kidney involvements." | 2.44 | [Wegener's granulomatosis and microscopic polyangiitis]. ( Pagnoux, C, 2008) |
| "Microscopic polyangiitis is a systemic necrotizing vasculitis of small vessels." | 2.44 | [Microscopic polyangiitis]. ( Guillevin, L; Guilpain, P; Pagnoux, C, 2007) |
| "In the past, recommendations for the treatment of Wegener's granulomatosis were primarily based on findings reported from open-label clinical trials." | 2.43 | Advances in the therapy of Wegener's granulomatosis. ( Gross, WL; Hellmich, B; Lamprecht, P, 2006) |
| "Ulcerative colitis is a chronic inflammatory bowel disease." | 2.42 | [Management of ulcerative colitis]. ( Kullak-Ublick, GA; Rammert, Ch, 2003) |
| "Ulcerative colitis is characterized by chronic inflammation of the colon." | 2.42 | Ulcerative colitis: conservative management and long-term effects. ( Fölsch, UR; Kühbacher, T; Schreiber, S, 2004) |
| "It describes the treatment of ulcerative colitis according to the different groups of patients and the degree of activity." | 2.41 | [Conservative therapy of inflammatory bowel diseases]. ( Nagy, F, 2002) |
| " Oral controlled-release budesonide has demonstrated comparable efficacy to prednisolone with less risk for adverse effects, although many questions remain regarding the long-term use of this agent." | 2.41 | Conventional treatment of Crohn's disease: objectives and outcomes. ( Rutgeerts, PJ, 2001) |
| "Treatment of thrombotic thrombocytopenic purpura (TTP) with plasma exchange has reduced mortality rates from 90% in untreated cases to less than 20%." | 2.41 | Frequently relapsing thrombotic thrombocytopenic purpura treated with cytotoxic immunosuppressive therapy. ( Allan, DS; Clark, WF; Kovacs, MJ, 2001) |
| "Autoimmune hepatitis has a global distribution and affects all ages." | 2.41 | Current concepts in the diagnosis, pathogenesis, and treatment of autoimmune hepatitis. ( Al-Khalidi, JA; Czaja, AJ, 2001) |
| "In view of a high recurrence rate of Crohn's disease after surgical resection prophylaxis is desirable." | 2.39 | [Crohn disease: prevention and drug therapy]. ( Andus, T; Gross, V; Schölmerich, J, 1995) |
| " Since there was no activity of the mixed connective tissue disease the methylprednisolone dosage was reduced and the administration of azathioprine was ceased." | 2.39 | [Chronic recurrent subileus due to Strongyloides stercoralis infection under immunosuppressive therapy]. ( Back, W; Birck, R; Braun, C; Gottstein, T; Gretz, N; Manegold, BC; Rohmeiss, P; Strauch, M, 1996) |
| "Crohn's disease is a chronic inflammatory intestinal disorder characterized in most patients by repeated episodes of diminished and exacerbated symptoms." | 2.38 | Maintenance of symptomatic remission in patients with Crohn's disease. ( Stark, ME; Tremaine, WJ, 1993) |
| "Of a total 44 patients with Crohn's disease, 10 patients with 9 internal and 15 external fistulae, some of which were recurrent, were analyzed at the Department of Surgery, Yokohama City University between 1973 and 1988." | 2.38 | The medical, nutritional and surgical treatment of fistulae in Crohn's disease. ( Fukushima, T; Sugita, A; Takemura, H; Tsuchiya, S; Yamazaki, Y, 1990) |
| "The modern medical and surgical treatment of ulcerative colitis has been detailed." | 2.35 | The management of ulcerative colitis. ( Watkinson, G, 1976) |
| "Crohn's disease is a perplexing disease with a high rate of morbidity and complications." | 2.35 | The protean manifestations of Crohn's disease. ( Farmer, RG, 1975) |
| "Clinical relapse was defined as necessity of re-induction of remission." | 1.91 | Prediction of thiopurine failure in pediatric Crohn's disease: pediatric IBD Porto group of ESPGHAN. ( Bronsky, J; de Meij, T; Dias, JA; Escher, JC; Hradsky, O; Kolacek, S; Kolho, KL; Kulich, M; Lerchova, T; Melek, J; Schwarz, J; Serban, DE; Sładek, M; Van Biervliet, S; Veres, G; Winther, K, 2023) |
| "A 35-year-old patient with Crohn's disease in clinical remission on azathioprine 150 mg daily and infliximab 5 mg/kg every 8 weeks was used for base-case analysis." | 1.91 | Azathioprine Withdrawal Is Cost-Effective in Patients with Crohn's Disease in Remission on Infliximab and Azathioprine. ( Almario, CV; Melmed, GY; Spiegel, BMR; Syal, G, 2023) |
| "Azathioprine (AZA) is an empirical attack -preventive immunotherapies drug to prevent the relapse of NMOSD, and tocilizumab (TCZ) has been also reported reduce the activity of NMOSD." | 1.91 | A comparison of the efficacy of tocilizumab versus azathioprine for neuromyelitis optica spectrum disorder: A study protocol for systematic review and meta-analysis. ( Bian, J; Huang, Y; Ji, W; Tang, Q; Wang, Y; Yao, M, 2023) |
| "Mortality rates for autoimmune hepatitis (AIH) vary." | 1.91 | Long-term Outcome of Autoimmune Hepatitis: Consecutive Patient Cohort and Data on the Second Twenty Years. ( Dhaliwal, H; Dube, A; Gleeson, D; Harrison, L; Hoeroldt, B; Wadland, E, 2023) |
| " Nine patients experienced adverse events from MMF, with lymphopenia and infection observed in 8." | 1.72 | The efficacy and safety of mycophenolate mofetil in Thai neuromyelitis optica spectrum disorder patients. ( Jitprapaikulsan, J; Pathomrattanapiban, C; Prayoonwiwat, N; Rattanathamsakul, N; Siritho, S; Tisavipat, N, 2022) |
| "Among these, 218 (ulcerative colitis (UC) = 179; Crohn's disease (CD) = 39) patients were in clinical remission and were continued on mesalamine." | 1.72 | Relapse rates after withdrawal of thiopurines in patients with inflammatory bowel disease. ( Ahuja, V; Das, P; Golla, R; Kante, B; Kedia, S; Kumar, P; Makharia, G; Mundhra, SK; Ranjan, MK; Sahni, P; Sharma, R; Vuyyuru, SK, 2022) |
| "Myelitis was the most common attack type throughout the disease course (51." | 1.72 | The description of neuromyelitis optica spectrum disorder: Patient registry in Yangtze River Delta area of China. ( Chang, X; Dong, Q; Huang, W; Li, W; Li, X; Lu, C; Lu, J; Quan, C; Tan, H; Wang, L; Wang, M; Xia, J; ZhangBao, J; Zhao, C; Zhou, L, 2022) |
| "Rituximab treatment for pemphigus has only recently been introduced to the Israeli health basket." | 1.62 | Treatment of Pemphigus Vulgaris and Foliaceus with Adjuvant Rituximab Compared to Immunosuppression Alone: Real-Life Experience. ( Hodak, E; Leshem, YA; Levi, A; Mimouni, D; Snast, I; Spitzer, L, 2021) |
| "LON was not observed in minimal change disease or focal segmental glomerulosclerosis." | 1.62 | Incidence, Clinical Features, and Outcomes of Late-Onset Neutropenia From Rituximab for Autoimmune Disease. ( Cortazar, FB; Huizenga, NR; Laliberte, K; Niles, JL; Rhee, EP; Rosenthal, JM; Wallace, ZS; Zonozi, R, 2021) |
| "Relapse was defined as requiring another antirheumatic/immunosuppressive drug or more than dose of 10 mg/d of prednisolone." | 1.62 | Comparison of relapse rates in Behçet's disease with venous involvement on different doses of azathioprine therapy, a retrospective observational study. ( Alpay-Kanitez, N; Bes, C; Celik, S; Cemal Icacan, O; Girgin, S; Omma, A; Yurumez, S, 2021) |
| "Preventing postoperative recurrence (POR) is a major concern in Crohn's disease (CD)." | 1.62 | Ustekinumab is more effective than azathioprine to prevent endoscopic postoperative recurrence in Crohn's disease. ( Bommelaer, G; Buisson, A; Fumery, M; Hebuterne, X; Laharie, D; Manlay, L; Nancey, S; Pariente, B; Pereira, B; Peyrin-Biroulet, L; Roblin, X; Rubin, DT; Vuitton, L, 2021) |
| "However, the cumulative ESRD-free survival rate was lower in patients who received TAC after AZA than in those who received AZA alone (P = ." | 1.62 | Efficacy of tacrolimus as maintenance therapy after cyclophosphamide for treating antineutrophil cytoplasmic antibody-associated vasculitis. ( Ahn, SS; Lee, LE; Lee, SW; Park, YB; Pyo, JY; Song, JJ, 2021) |
| "Lower extremity deep vein thrombosis (LEDVT) is a serious complication of Behçet's syndrome." | 1.56 | Clinical course of acute deep vein thrombosis of the legs in Behçet's syndrome. ( Cetinkaya, F; Hamuryudan, V; Hatemi, G; Melikoglu, M; Ozguler, Y; Seyahi, E; Tascilar, K; Ugurlu, S; Yazici, H, 2020) |
| " The administration of intratympanic infliximab is an effective and safe technique." | 1.56 | Intratympanic infliximab is a safe and effective rescue therapy for refractory immune-mediated hearing loss. ( García-Fernández, A; Mata-Castro, N; Sanz-López, L; Varillas-Delgado, D, 2020) |
| "Aquaporin-4-IgG positive (AQP4-IgG+) Neuromyelitis Optica Spectrum Disorder (NMOSD) is an uncommon central nervous system autoimmune disorder." | 1.56 | Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorder. ( Al-Harbi, T; Alroughani, R; Altintas, A; Bergamaschi, R; Boz, C; Butzkueven, H; Csepany, T; Eichau, S; Ferraro, D; Fragoso, Y; Grand'Maison, F; Granella, F; Havrdova, EK; Hor, JY; Izquierdo, G; Kalincik, T; Karabudak, R; Kister, I; Kunchok, A; Laureys, G; Lechner-Scott, J; Lugaresi, A; Malpas, C; Marriott, M; McCombe, P; Nytrova, P; Olascoaga, J; Onofrj, M; Oreja-Guevara, C; Ozakbas, S; Patti, F; Pucci, E; Simo, M; Singhal, B; Sola, P; Soysal, A; Terzi, M; Trojano, M; Turkoglu, R; Vucic, S; Yamout, B, 2020) |
| "Patients with IgG4-related disease (IgG4-RD) typically respond well to initial glucocorticoid therapy, but always relapse with tapered or maintenance dosage of steroid." | 1.56 | Relapse predictors and serologically unstable condition of IgG4-related disease: a large Chinese cohort. ( Chen, D; Gao, J; Li, ZG; Liu, Y; Shen, D; Wang, K; Wang, Y; Wang, Z; Xia, C; Yang, F; Yu, G; Zeng, Q; Zhang, S; Zhu, L, 2020) |
| " The routine clinical use of thiopurines has, however, been questioned due to a number of potential adverse effects." | 1.56 | Safety of Thiopurine Use in Paediatric Gastrointestinal Disease. ( Benninga, MA; Broekaert, I; Dolinsek, J; Mas, E; Miele, E; Orel, R; Pienar, C; Ribes-Koninckx, C; Thapar, N; Thomassen, RA; Thomson, M; Tzivinikos, C, 2020) |
| "Drug-induced acute pancreatitis (DIAP) is an often-neglected entity where the disorder is the consequence of the toxic effects of various agents applied to treat potentially life-threatening conditions, such as inflammatory bowel disease." | 1.56 | Recurrent acute pancreatitis induced by 5-ASA and azathioprine in ulcerative colitis. ( Bajor, J; Faluhelyi, N; Hegyi, P; Hegyi, PJ; Németh, BC; Szakács, Z, 2020) |
| "Rituximab is effective in treating pemphigus both as the first-line treatment and as an add-on treatment for refractory disease." | 1.56 | Maintenance therapy with azathioprine prolonged duration of remission for pemphigus patients who received rituximab as first-line or add-on therapy. ( Cho, YT; Chu, CY; Huang, YM; Wang, LF, 2020) |
| "Arterial ischemic stroke is rare in childhood." | 1.51 | Recurrent arterial ischemic stroke with good response to mycophenolate mofetil. ( Dehoorne, J; Herregods, N; Mondelaers, V; Van Coster, R; Van Driessche, B; Verhelst, H; Verloo, P, 2019) |
| "CASE REPORT A 57-year-old man with pemphigus vulgaris was treated with steroids, non-steroidal anti-inflammatory drugs (NSAIDS), and azathioprine." | 1.51 | Recurrent Asymptomatic Sigmoid Diverticular Perforation in a Patient with Pemphigus Vulgaris on Immunosuppressive Therapy: A Case Report. ( Abboud, R; El Masri, A; Emmanuel, N; Fawaz, M; Haidar Ahmad, H; Hashem, M; Hussein, R; Nicolas, G; Rabah, H; Saliba, C; Sleiman, A, 2019) |
| "To investigate the effectiveness, visual outcome, and prognostic factors of Vogt-Koyanagi-Harada (VKH) disease treatment with a reduced dose of corticosteroids combined with immunosuppressive agents." | 1.48 | Novel treatment regimen of Vogt-Koyanagi-Harada disease with a reduced dose of corticosteroids combined with immunosuppressive agents. ( Du, L; Kijlstra, A; Liang, L; Qi, J; Wang, C; Wu, L; Yang, P; Ye, Z; Zhou, Q, 2018) |
| "Patients with endoscopic recurrence detected by either ileocolonoscopy or CE received pharmacologic therapy with azathioprine or infliximab." | 1.48 | Impact of capsule endoscopy on prevention of postoperative recurrence of Crohn's disease. ( Ai, XY; Bai, Y; Chen, ZY; Feng, XC; Han, ZM; Li, AM; Li, MS; Liu, SD; Qiao, WG; Wan, TM; Xu, ZM; Zhang, J; Zhi, FC, 2018) |
| "However, disease relapse is common in long-term follow-up, despite a successful initial treatment response." | 1.48 | Relapse rate and predictors of relapse in a large single center cohort of type 1 autoimmune pancreatitis: long-term follow-up results after steroid therapy with short-duration maintenance treatment. ( Cho, DH; Jun, JH; Kim, MH; Lee, HW; Lee, SK; Lee, SS; Moon, SH; Nam, K; Park, DH; Seo, DW; Song, TJ, 2018) |
| "Despite advances in understanding and treatment of autoimmune hepatitis, important unmet clinical needs remain in both adult and paediatric patient populations." | 1.48 | Unmet needs and new models for future trials in autoimmune hepatitis. ( Jones, D; Manns, MP; Terracciano, L; Torbenson, M; Vierling, JM, 2018) |
| "Azathioprine can prevent postoperative recurrences in Crohn's disease." | 1.48 | Immediate prophylactic vs endoscopic or symptomatic-driven azathioprine treatment to prevent surgical recurrence after intestinal resection for Crohn's disease. ( Cai, X; Cao, L; Gong, J; Guo, Z; Li, Y; Liu, R; Wang, Z; Zhu, W, 2018) |
| "Original diagnoses were neuromyelitis optica spectrum disorder (44 patients [43." | 1.48 | Disease Course and Treatment Responses in Children With Relapsing Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease. ( Anlar, B; Baumann, M; Ciccarelli, O; Deiva, K; Forsyth, R; Ganelin-Cohen, E; Hacohen, Y; Hemingway, C; Hennes, EM; Hintzen, R; Jurynczyk, M; Kalser, J; Konuskan, B; Lechner, C; Leite, MI; Lim, M; Marignier, R; Maurey, H; Neuteboom, R; Palace, J; Poulat, AL; Rostásy, K; Wassmer, E; Wong, YY; Wright, S, 2018) |
| " During the follow-up, adverse events occurred in 6 patients." | 1.48 | Efficacy and safety of long-term thiopurine maintenance treatment for ulcerative colitis in Turkey: A single-center experience. ( Ecevit, Ç; Erdemir, G; Hekimci, H; Karakoyun, M; Kıran Taşçı, E; Özgenç, F, 2018) |
| " The primary outcome measure was achievement of disease remission (Pediatric Vasculitis Activity Score [PVAS] of 0) at 12 months with a corticosteroid dosage of <0." | 1.46 | Early Outcomes in Children With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. ( Benseler, SM; Cabral, DA; Charuvanij, S; Dancey, P; Eberhard, BA; Elder, ME; Foell, D; Hersh, AO; Huber, AM; Klein-Gitelman, M; Kostik, MM; Lawson, EF; Lee, T; Li, SC; Lubieniecka, JM; Luqmani, RA; Moorthy, LN; Morishita, KA; Nielsen, SM; Ristic, G; Shenoi, S; Toth, MB; Twilt, M; Yeung, RSM, 2017) |
| "191 attacks occurred during any of the treatments (annual relapse rate=0." | 1.46 | Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response. ( Aktas, O; Angstwurm, K; Berthele, A; Borisow, N; Faiss, J; Fischer, K; Friede, T; Gahlen, A; Geis, C; Hartung, HP; Havla, J; Hellwig, K; Hemmer, B; Hofstadt-van Oy, U; Jarius, S; Kleinschnitz, C; Kleiter, I; Krumbholz, M; Kümpfel, T; Lauda, F; Linker, RA; Marziniak, M; Mayer, C; Neuhaus, O; Pache, F; Paul, F; Ringelstein, M; Ruprecht, K; Schuster, S; Schwab, M; Stangel, M; Stellmann, JP; Then Bergh, F; Trebst, C; Tumani, H; Wildemann, B; Young, KL; Zeltner, L; Zettl, U; Ziemann, U, 2017) |
| "To examine the disease flare rate in lupus nephritis (LN), focusing on renal flares, and the factors associated with relapse risk in recent years." | 1.46 | Longterm Data on Disease Flares in Patients with Proliferative Lupus Nephritis in Recent Years. ( Chan, GCW; Chan, TM; Kwan, LPY; Ma, MKM; Mok, MMY; Tang, C; Yap, DYH, 2017) |
| "Beyond available guidelines, therapy of autoimmune hepatitis (AIH) shows wide variation among physicians." | 1.46 | Treatment Response and Outcome with Two Different Prednisolone Regimens in Autoimmune Hepatitis. ( Efe, C; Kav, T; Ozaslan, E; Purnak, T; Wahlin, S, 2017) |
| "16." | 1.46 | Autoimmune acute liver failure and seronegative autoimmune liver disease in children: Are they different from classical disease? ( Jain, V; Kathuria, R; Krishnani, N; Kumari, N; Poddar, U; Sarma, MS; Srivastava, A; Yachha, SK, 2017) |
| "Even following transplantation, recurrence of PSC is seen in approximately one quarter of patients and leads to high rates of graft failure." | 1.46 | Efficacy of oral vancomycin in recurrent primary sclerosing cholangitis following liver transplantation. ( Gow, P; Hey, P; Johnson, P; Lokan, J, 2017) |
| "We report a rare case of Takayasu's arteritis with isolated pulmonary artery stenosis in the presence of active hepatitis B and latent Mycobacterium tuberculosis infection in a middle-aged Asian woman who initially presented with severe dyspnea on exertion and recurrent syncope, occasional burning chest pains, and fatigue." | 1.46 | Takayasu's Arteritis with Isolated Pulmonary Artery Involvement in a Middle-Aged Asian Woman with Hepatitis B and Latent Tuberculosis Infection. ( Franzen, D; Greutmann, M; Kolios, A; Liebscher, F; Pfammatter, T, 2017) |
| "Postoperative recurrence of Crohn's disease is common." | 1.46 | Cost-utility Analysis: Thiopurines Plus Endoscopy-guided Biological Step-up Therapy is the Optimal Management of Postoperative Crohn's Disease. ( Candia, R; Naimark, D; Nguyen, GC; Sander, B, 2017) |
| "Clinical remission was defined as Crohn's Disease Activity Index (CDAI) < 150 and endoscopic remission as CDAI < 150 + absence of mucosal lesions + no signs of active inflammation on ileocolonoscopy." | 1.43 | Remission maintained by monotherapy after biological + immunosuppressive combination for Crohn's disease in clinical practice. ( Ampuero, J; Castro-Fernández, M; Guerrero-Jiménez, P; Millán-Lorenzo, M; Rojas-Feria, M; Romero-Gómez, M, 2016) |
| "Twenty-two patients with ulcerative colitis in clinical relapse and 7 control subjects referred for colonoscopy were enrolled." | 1.43 | Confocal laser endomicroscopy in ulcerative colitis: a longitudinal study of endomicroscopic changes and response to medical therapy (with videos). ( Brynskov, J; Ciocalteu, A; Hendel, J; Karstensen, JG; Klausen, P; Klausen, TW; Riis, LB; Săftoiu, A; Vilmann, P, 2016) |
| "The prednisolone was used for remission induction in 37 patients; 86." | 1.43 | Autoimmune hepatitis and long-term disease course in children in Turkey, a single-center experience. ( Aydogdu, S; Ecevit, CO; Karakoyun, M; Kilicoglu, E; Ozgenc, F; Yagci, RV, 2016) |
| "Azathioprine is a DMARD that has been reported to be effective in HSP nephritis and in adult cutaneous leukocytoclastic vasculitis, a condition with cutaneous histology similar to HSP." | 1.43 | Azathioprine therapy for steroid-resistant Henoch-Schönlein purpura: a report of 6 cases. ( Baszis, KW; Fotis, L; Moore, TL; Pepmueller, PH; Tuttle, PV; White, AJ, 2016) |
| "Acute-onset CIDP resembles Guillain-Barre syndrome (GBS), a rapidly progressive disorder, and follows a chronic course." | 1.43 | Acute-onset chronic inflammatory demyelinating polyneuropathy in hantavirus and hepatitis B virus coinfection: A case report. ( Choi, EH; Lim, JY; Lim, YH, 2016) |
| "The postoperative recurrence rate was lower in patients who received postoperative thiopurines (P = 0." | 1.42 | Postoperative Effects of Thiopurines in Patients with Intestinal Behçet's Disease. ( Cheon, JH; Hong, SP; Kim, TI; Kim, WH; Lee, HJ; Lee, HW; Park, SJ, 2015) |
| "The management of patients with ulcerative colitis who are dependent on corticosteroid for control of symptoms, or refractory to corticosteroids or standard immunosuppressive therapy, is challenging." | 1.42 | New Zealand Society of Gastroenterology Guidelines for the Management of Refractory Ulcerative Colitis. ( Day, AS; Eliadou, E; Gearry, RB; Inns, SJ; Rowbotham, DS; Schultz, M; Thompson-Fawcett, MW; Walmsley, R, 2015) |
| "Thiopurines prevent Crohn's disease (CD) endoscopic recurrence (ER) at least in 50% of patients 1 year after surgery." | 1.40 | Addition of mesalazine for subclinical post-surgical endoscopic recurrence of Crohn's disease despite preventive thiopurine therapy: A case-control study. ( Bernal, I; Boix, J; Cabré, E; Domènech, E; Lorenzo-Zúñiga, V; Mañosa, M; Marín, L; Moreno, V; Zabana, Y, 2014) |
| "Azathioprine was started within the first month in 33/52 patients; 26/52 received a second EEN course." | 1.40 | Repeated exclusive enteral nutrition in the treatment of paediatric Crohn's disease: predictors of efficacy and outcome. ( Bufler, P; Frivolt, K; Koletzko, S; Schatz, SB; Schwarzer, A; Schwerd, T; Werkstetter, KJ, 2014) |
| "Infliximab withdrawal in patients with Crohn's disease on concomitant antimetabolite therapy is considered to be superior if obtained after a maintenance therapy period compared to induction alone." | 1.40 | Infliximab as a bridge to remission maintained by antimetabolite therapy in Crohn's disease: A retrospective study. ( Amiot, A; Bastuji-Garin, S; Belhassan, M; Chauvin, A; Delchier, JC; Le Baleur, Y; Le Thuaut, A; Mesli, F, 2014) |
| " Variation in thiopurine dosing and metabolite measurement was found among practitioners." | 1.40 | Routine use of thiopurines in maintaining remission in pediatric Crohn's disease. ( Baldassano, RN; Boyle, BM; Colletti, RB; Crandall, WV; Kappelman, MD; Milov, DE, 2014) |
| "The cumulative risk of first recurrence after 1, 5 and 7 years was 40%, 63%, and 66% in CD patients and 51%, 75%, and 79% in UC patients, respectively." | 1.40 | Hospitalisation, surgical and medical recurrence rates in inflammatory bowel disease 2003-2011—a Danish population-based cohort study. ( Andersson, M; Bendtsen, F; Bengtsson, BG; Blixt, T; Jess, T; Munkholm, P; Prosberg, MV; Vester-Andersen, MK; Vind, I, 2014) |
| "While clinical relapse is noted frequently following drug withdrawal, there are few published data on predictive factors." | 1.40 | Thiopurine withdrawal during sustained clinical remission in inflammatory bowel disease: relapse and recapture rates, with predictive factors in 237 patients. ( Ahmad, T; Al-Hilou, H; Arnott, ID; Cummings, JR; Dattani, R; Felwick, R; Gambles, CJ; Gaya, DR; Harris, R; Irving, PM; Kalla, R; Kennedy, NA; Lamb, CA; Lees, CW; Lindsay, JO; Lobo, AJ; Mansfield, J; Marriott, S; Musy, R; Nayee, H; Parkes, M; Reynolds, S; Satsangi, J; Senanayake, SM; Smith, M; Warner, B, 2014) |
| "Current treatment strategies in autoimmune hepatitis (AIH) include long-term treatment with corticosteroids and/or azathioprine." | 1.39 | Relapse is almost universal after withdrawal of immunosuppressive medication in patients with autoimmune hepatitis in remission. ( Beuers, U; Bouma, G; Brouwer, JT; Coenraad, MJ; de Man, RA; den Ouden, JW; Drenth, JP; Guichelaar, MM; Koek, GH; Mulder, CJ; van Buuren, HR; van Erpecum, KJ; van Gerven, NM; van Hoek, B; van Nieuwkerk, KM; Verdonk, RC; Verwer, BJ; Witte, BI, 2013) |
| "A total of 82 Crohn's disease patients who received their first course of azathioprine or 6-mercaptopurine treatment at Severance Hospital between June 1996 and July 2007 were recruited to the study." | 1.38 | Outcome predictors for thiopurine maintenance therapy in patients with Crohn's disease. ( Cheon, JH; Hong, SP; Kim, TI; Kim, WH; Park, JJ, 2012) |
| "Among 33 cases, 25 were diagnosed as Wegener granulomatosis (WG), seven as microscopic polyangitis (MPA) and one as Churg-Strauss syndrome (SCS)." | 1.38 | Clinical features and outcomes of ANCA-associated renal vasculitis. ( Brunet, P; Burtey, S; Dussol, B; Seck, SM, 2012) |
| "While causes of pancreatitis have been extensively analyzed, different series reported different causes." | 1.38 | Acute and recurrent pancreatitis in children: exploring etiological factors. ( De Cunto, A; Martelossi, S; Minen, F; Ventura, A, 2012) |
| "Treatment with prednisone and azathioprine, plus, in three children, cyclosporine, resulted in complete remission in eight, partial remission in six, and failure in two." | 1.37 | Giant cell hepatitis with autoimmune hemolytic anemia in early childhood: long-term outcome in 16 children. ( Bernard, O; Choulot, JJ; Fabre, M; Gori, L; Jacquemin, E; Maggiore, G; Pacifico, L; Resti, M; Sciveres, M, 2011) |
| "Characteristics of childhood-onset Crohn's disease in Hungary are similar to those obtained in other European countries." | 1.37 | [To grow up with Crohn's disease]. ( Kovács, J; Lorincz, M; Nagy, A; Szabó, A, 2011) |
| "The probability of AIP recurrence was assessed by using Kaplan-Meier curves and the unadjusted Cox model." | 1.37 | Autoimmune pancreatitis: pancreatic and extrapancreatic MR imaging-MR cholangiopancreatography findings at diagnosis, after steroid therapy, and at recurrence. ( Bonatti, M; Frulloni, L; Graziani, R; Manfredi, R; Mantovani, W; Pozzi Mucelli, R, 2011) |
| "Regarding recurrence, case 1 recurred 4 months after surgery and again 14 months after discontinuing prednisone; case 2 relapsed 16 months after receiving high-dose methylprednisolone pulse therapy; and case 3 recurred during the period of prednisone dose reduction." | 1.37 | Recurrent autoimmune hypophysitis successfully treated with glucocorticoids plus azathioprine: a report of three cases. ( Ba, JM; Dou, JT; Du, J; Gu, WJ; Guo, QH; Lu, JM; Lu, ZH; Mu, YM; Wang, XL; Yang, GQ, 2011) |
| " Dose intensification to weekly dosing was needed in 16." | 1.37 | [Predictors of efficacy, mucosal healing and dose intensification during the first year of adalimumab therapy in patients with luminal and fistulizing Crohn's disease. National data from Hungary]. ( Banai, J; Bartha, Z; Farkas, K; Gasztonyi, B; Golovics, PA; Horváth, G; Kiss, LS; Lakatos, L; Lakatos, PL; Lovász, BD; Miheller, P; Molnár, T; Nagy, F; Palatka, K; Papp, M; Salamon, A; Szamosi, T; Szathmári, M; Szenes, M; Tóth, GT; Tulassay, Z; Végh, Z; Veres, G; Vincze, A, 2011) |
| "Even with proper immunosuppressive treatment, SLE can relapse." | 1.37 | Lupus relapse presented as frosted branch retinal angiitis: case report. ( Arellanes-Garcia, L; Cornejo-Ballesteros, H; Hernandez-Da Mota, SE; Melgoza-del-Angel, C; Recillas-Gispert, C; Sanchez-Gonzalez, R; Teran-Estrada, L, 2011) |
| "A total of 20 IBD (14 Crohn's disease, 6 ulcerative colitis) HIV infected patients and 40 matched control seronegative IBD patients (2 controls per case) were compared regarding relapse of their disease." | 1.36 | Course of inflammatory bowel disease in patients infected with human immunodeficiency virus. ( Baraboutis, IG; Georgiadis, D; Georgiou, O; Karamanolis, DG; Papastamopoulos, V; Rodias, M; Skoutelis, A; Viazis, N; Vlachogiannakos, J, 2010) |
| "Surgical recurrence occurred in 151/326 (46." | 1.36 | The impact of thiopurines on the risk of surgical recurrence in patients with Crohn's disease after first intestinal surgery. ( Dejaco, C; Gratzer, C; Herkner, H; Ho, E; Lissner, D; Miehsler, W; Novacek, G; Papay, P; Reinisch, W; Riss, S; Vogelsang, H, 2010) |
| "During the follow-up period, cumulative recurrence rates for intestinal BD were 24." | 1.36 | Response rates to medical treatments and long-term clinical outcomes of nonsurgical patients with intestinal Behçet disease. ( Cheon, JH; Chung, MJ; Kim, NK; Kim, SU; Kim, TI; Kim, WH; Park, JJ, 2010) |
| " Infliximab failure was defined by: (i) disease flare requiring shortening of the dosing interval or increasing the infliximab dose to 10 mg/kg, or switching to adalimumab; (ii) acute or delayed hypersensitivity reactions leading to infliximab discontinuation; or (iii) CD-related surgery." | 1.36 | Predictors of infliximab failure after azathioprine withdrawal in Crohn's disease treated with combination therapy. ( Bigard, MA; Chevaux, JB; Fay, R; Oussalah, A; Peyrin-Biroulet, L; Sandborn, WJ, 2010) |
| "Azathioprine was stopped and antibiotics started." | 1.36 | Gastric ulcers and swollen kidneys: a rare diagnosis complicating Crohn's disease. ( Lal, S; Ormerod, C; Sarkar, S; White, D; Woodcock, B, 2010) |
| "Refractory Wegener's granulomatosis with involvement of the eyes, upper and lower respiratory tracts, and kidneys." | 1.35 | Maintaining remission in a patient with vasculitis. ( Flossmann, O; Jayne, DR, 2008) |
| "Recurrent glomerulonephritis is a major problem in kidney transplantation but the role of immunosuppression in preventing this complication is not known." | 1.35 | Impact of immunosuppressive medication on the risk of renal allograft failure due to recurrent glomerulonephritis. ( Knoll, GA; Mulay, AV; van Walraven, C, 2009) |
| "Extraintestinal manifestations of Crohn's disease such as erythema nodosum and pyoderma gangrenosum are well recognized and appreciated." | 1.35 | Clinical spectrum of vulva metastatic Crohn's disease. ( Buchman, AL; Collyer, J; Leu, S; Mirowski, GW; Schlosser, B; Smidt, A; Stika, CS; Sun, PK; Vanagunas, A, 2009) |
| "At the time of recurrence, four patients were on maintenance dose (5-10 mg/day) of oral corticosteroid while the remaining three were off treatment." | 1.35 | Posterior segment recurrences in Vogt-Koyanagi-Harada disease. ( Gupta, A; Gupta, V; Sachdev, N; Singh, R, 2008) |
| "Limbic encephalitis is typically characterised by a sub-acute onset of disorientation, amnesia and seizures, but the clinical spectrum is not yet fully defined and the syndrome could be under-diagnosed." | 1.35 | Hypothermia in VGKC antibody-associated limbic encephalitis. ( Clover, L; Grubneac, A; Irani, SR; Jacob, S; Rajabally, YA; Vincent, A; Walters, RJ; Yazaki, M, 2008) |
| "To investigate the occurrence of adverse events and efficacy of azathioprine with or without mesalazine." | 1.35 | Should azathioprine and 5-aminosalicylates be coprescribed in inflammatory bowel disease?: an audit of adverse events and outcome. ( Edwards, CM; Probert, CS; Shah, JA, 2008) |
| "Eighteen patients (11 ulcerative colitis, 6 Crohn's disease, 1 indeterminate colitis), mean age 28." | 1.35 | Relapses of inflammatory bowel disease during pregnancy: in-hospital management and birth outcomes. ( Kane, SV; Kornbluth, AA; Murphy, SJ; Present, DH; Reddy, D, 2008) |
| "Seventy patients with pemphigus vulgaris, treated with a uniform protocol, were enrolled." | 1.35 | Impact of smoking on pemphigus. ( Chams-Davatchi, C; Esmaili, N; Farahani, F; Ghandi, N; Hallaji, Z; Kavusi, S; Lajevardi, V; Valikhani, M, 2008) |
| "Posterior scleritis is an unusual disease that may cause serious ocular inflammation and potentially blinding consequences." | 1.34 | Isolated bilateral posterior scleritis after eye trauma. ( Ramirez-Ortiz, MA; Vasquez-Resendis, A, 2007) |
| "Amantadine was given orally (200 mg/d) for 3 months." | 1.33 | Amantadine monotherapy is ineffective in the treatment of hepatitis C virus recurrence in the post-liver transplantation setting. ( Angelico, M; Anselmo, A; D'Andria, D; de Liguori Carino, N; de'Liguori Carino, N; Ielpo, B; Manzia, T; Muzi, F; Orlando, G; Sabato Ceraldi, S; Tariciotti, L; Tisone, G, 2005) |
| "We present 4 patients with CIDP who required respiratory assistance and mechanical ventilation." | 1.33 | Chronic inflammatory demyelinating polyneuropathy and respiratory failure. ( Henderson, RD; Sandroni, P; Wijdicks, EF, 2005) |
| "The need for immunosuppression in autoimmune hepatitis is established." | 1.33 | Early treatment response predicts the need for liver transplantation in autoimmune hepatitis. ( Adams, P; Ghent, C; Marotta, P; Tan, P, 2005) |
| " Records were reviewed for the dosage of immunosuppression, rate of relapse, steroid side effects, current status of liver function tests and evidence for cirrhosis and its complications." | 1.33 | Autoimmune hepatitis type 1: safety and efficacy of prolonged medical therapy. ( Boyer, JL; Seela, S; Sheela, H, 2005) |
| "Azathioprine is an important steroid sparing agent in the management of patients with inflammatory bowel disease." | 1.33 | Re-introduction of azathioprine in previously intolerant patients. ( Green, CJ; Mee, AS, 2006) |
| "Retroperitoneal fibrosis is a severe disease that affects the ureters, causing renal insufficiency in three-quarters of patients." | 1.33 | Long-term outcome of idiopathic retroperitoneal fibrosis treated with surgical and/or medical approaches. ( Banfi, G; Gallelli, B; Messa, P; Moroni, G; Ponticelli, C; Sandri, S, 2006) |
| " In this case, once the dosage of oral prednisone was increased and methotrexate was added to the therapeutic scheme, inflammation was controlled within 1 month." | 1.33 | Combination of azathioprine and corticosteroids in the treatment of serpiginous choroiditis. ( Burnier, MN; Deschênes, J; Ozdal, PC; Vianna, RN, 2006) |
| "Azathioprine was introduced early following the diagnosis (range, 1-35 days)." | 1.33 | Azathioprine monotherapy for maintenance of remission in pediatric patients with autoimmune hepatitis. ( Banerjee, S; Bishop, WP; Rahhal, R, 2006) |
| "Recurrence of Crohn's disease (CD) after surgery is common." | 1.33 | Azathioprine as a postoperative prophylaxis reduces symptoms in aggressive Crohn's disease. ( Almer, S; Andersson, P; Bodemar, G; Myrelid, P; Olaison, G; Svärm, S, 2006) |
| "Although the prognosis of type 1 autoimmune hepatitis is generally good with immunosuppressive treatment, the disease progresses in some patients despite the treatment." | 1.33 | Persistent elevation of serum alanine aminotransferase levels leads to poor survival and hepatocellular carcinoma development in type 1 autoimmune hepatitis. ( Ikeda, H; Iwasaki, Y; Kobashi, H; Makino, Y; Miyake, Y; Okamaoto, R; Sakaguchi, K; Shiratori, Y; Takaguchi, K; Terada, R, 2006) |
| "Hypersensitivity pneumonitis was suspected." | 1.33 | Recurrent episodes of dermatomyositis-associated pneumonitis masquerading as hypersensitivity pneumonitis. ( Marik, PE; Vahid, B, 2006) |
| "The morphological substrate of Crohn's disease in the Hydro-MRI images is reliably detected." | 1.32 | [Follow up of Crohn's disease under therapy with hydro-MRI]. ( Encke, J; Erb, G; Flosdorff, P; Ganten, M; Grüber-Hoffmann, B; Hansmann, J, 2003) |
| "Relapse of type 1 autoimmune hepatitis after drug withdrawal may relate to incomplete histological improvement during corticosteroid therapy and/or persistence of pathogenic mechanisms." | 1.32 | Histological features associated with relapse after corticosteroid withdrawal in type 1 autoimmune hepatitis. ( Carpenter, HA; Czaja, AJ, 2003) |
| "An open prospective study was made on Crohn's disease patients treated with TG." | 1.32 | Tioguanine in patients with Crohn's disease intolerant or resistant to azathioprine/mercaptopurine. ( Belaiche, J; Boitard, J; Bonaz, B; Cadiot, G; Coffin, B; Colombel, JF; Cortot, A; Flourié, B; Lémann, M; Marteau, P; Metman, EH, 2003) |
| "Standard therapy of Wegener's granulomatosis is prednisolone in combination with cyclophosphamide." | 1.32 | [Treatment of patients with Wegener's granulomatosis or ANCA-associated vasculitis]. ( Stegeman, CA; Tervaert, JW, 2003) |
| "Twenty-three consecutive patients (14 male/9 female, universal colitis 14/23) entered a 3-month course of NEORAL (initially dosed at 5 mg/kg/day) because of steroid-refractoriness (14 cases) and steroid-dependence (9 cases)." | 1.32 | Long-term efficacy of oral microemulsion cyclosporin for refractory ulcerative colitis. ( Actis, GC; Fadda, M; Lagget, M; Morino, F; Palmo, A; Pinna-Pintor, M; Rizzetto, M, 2004) |
| "Forty-seven patients with secondary progressive multiple sclerosis and seven others with primary progressive received monthly infusions of cyclophosphamide (750mg/m2) and methylprednisolone (500mg)." | 1.32 | [Treatment of progressive multiple sclerosis with monthly pulsed cyclophosphamide-methylprednisolone: predictive factors of treatment response]. ( Bourg, V; Chanalet, S; Chatel, M; Delmont, E; Lebrun, C; Soriani, MH, 2004) |
| "The diagnoses were juvenile oligoarthritis (n = 6, including two with extended disease), systemic arthritis (n = 2), juvenile spondyloarthropathy (n = 1), and juvenile dermatomyositis (n = 1)." | 1.32 | Joint lavage for treating recurrent knee involvement in patients with juvenile idiopathic arthritis. ( Job-Deslandre, C; Kahan, A; Sornay-Soares, C, 2004) |
| "Azathioprine (AZA) was given as maintenance therapy in 117 patients (75%)." | 1.32 | Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis. ( Lau, CS; Lee, KW; Leung, CY; Mok, CC; Ng, WL; Tang, S; Wong, RW; Ying, KY, 2004) |
| "Clinical recurrence rate at 3 years was significantly lower in the IS group than in the control group (3/12, 25% vs 6/10, 60%; P < 0." | 1.32 | Could immunosuppressive drugs reduce recurrence rate after second resection for Crohn disease? ( Alves, A; Bouhnik, Y; Joly, F; Lavergne-Slove, A; Panis, Y; Pocard, M; Valleur, P, 2004) |
| " Complications of high AZA dosing make dose escalation potentially problematic." | 1.32 | Utility of azathioprine metabolite measurements in post-transplant recurrent autoimmune and immune-mediated hepatitis. ( Emre, SH; Rumbo, C; Shneider, BL, 2004) |
| "Data from all patients with Crohn's disease whose diagnosis had been performed before 1st January 1978 were analyzed." | 1.32 | Crohn's disease over 20 years after diagnosis in a referral population. ( Beaugerie, L; Bouhnik, Y; Cosnes, J; Etienney, I; Gendre, JP; Lémann, M; Matuchansky, C; Modigliani, R; Rambaud, JC, 2004) |
| "A 26-year-old male with acute lymphoblastic leukemia (ALL) in its second complete remission received an unrelated bone marrow transplantation (UBMT) following cyclophosphamide plus total body irradiation conditioning." | 1.31 | A successful second unrelated BMT (UBMT) from a different unrelated donor to treat ALL that relapsed after the initial UBMT. ( Nakaseko, C; Nishimura, M; Saito, Y; Uehara, T; Yokota, A, 2002) |
| "The active stage and the recurrences were treated by oral and periocular cortico steroids; and two patients were supplemented with oral azathioprine." | 1.31 | Macular serpiginous choroiditis. ( Rawoof, A; Sahu, DK; Sujatha, B, 2002) |
| "The recurrence of immunoglobulin A nephropathy (IgAN) after renal transplantation has been described in 40% to 50% of cases." | 1.31 | An unusual recurrence of crescentic nephritis after renal transplantation for IgA nephropathy. ( Benabdallah, L; Bruneel, MF; Carron, PL; Kreis, H; Morelon, E; Noël, LH; Peraldi, MN; Rerolle, JP, 2002) |
| "Two months later, he developed axillary lymph node tuberculosis caused by Mycobacterium tuberculosis." | 1.31 | Reactivation of tuberculosis after conversion from azathioprine to mycophenolate mofetil 16 years after renal transplantation. ( Budde, K; Neumayer, HH; Schötschel, R; Waiser, J, 2000) |
| "Since relapses are frequent, these patients should be evaluated frequently." | 1.31 | Wegener granulomatosis in children and young adults. A case study of ten patients. ( Gothefors, L; Malmer, B; Müller Wiefel, DE; Nilsson, K; Stegmayr, BG; Sundelin, B, 2000) |
| "Meningococcal meningitis is itself uncommon, with a morbidity of approximately 1." | 1.31 | [Secondary immunologically-caused myocarditis, pericarditis and exudative pleuritis due to meningococcal meningitis]. ( Berwing, K; Damaschke, HJ; Stange, K, 2001) |
| "The most frequently seen posttransplant neoplasms were squamous carcinoma of skin, basal cell carcinoma (BCC), posttransplant lymphoproliferative disease (PTLD) and gastro-intestinal (GI) cancer." | 1.31 | One thousand renal transplants at Belfast City Hospital: post-graft neoplasia 1968-1999, comparing azathioprine only with cyclosporin-based regimes in a single centre. ( Douglas, JF; McGeown, MG; Middleton, D, 2000) |
| "Probabilities of clinical recurrence according to the Kaplan-Meier method were 9, 16 and 28% at 1, 2 and 3 years, respectively." | 1.31 | Azathioprine for prevention of postoperative recurrence in Crohn's disease: a retrospective study. ( Allez, M; Bouhnik, Y; Cuillerier, E; Lémann, M; Modigliani, R; Rambaud, JC, 2001) |
| "This study evaluated the effects of azathioprine in combination with low-dose prednisolone in the management of patients with intractable autoimmune hepatitis." | 1.31 | Therapeutic effects of azathioprine in combination with low-dose prednisolone in patients with intractable autoimmune hepatitis type 1. ( Fujiwara, A; Miyake, Y; Miyashita, M; Nishimura, M; Sakaguchi, K; Takenami, T; Terao, M; Tsuji, T, 2001) |
| "Azathioprine is effective treatment for ulcerative colitis and Crohn's disease." | 1.31 | The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. ( Fraser, AG; Jewell, DP; Orchard, TR, 2002) |
| "There were 11 biopsy-proven recurrences (1 man, 10 women) of AIH after OLT." | 1.31 | Incidence and recurrence of autoimmune/alloimmune hepatitis in liver transplant recipients. ( Crippin, JS; Fasola, CG; Gogel, B; Goldstein, RM; Gonwa, TA; Hoover, TC; Jung, G; Klintmalm, GB; Levy, MF; Marubashi, S; Molmenti, EP; Molmenti, H; Murray, NG; Netto, GJ; Sanchez, EQ; Smith, DM, 2002) |
| "We also compare this atypical sclerosing cholangitis (group I) to typical sclerosing cholangitis (group II) and to autoimmune hepatitis with (group III) and without (group IV) cholestasis." | 1.30 | An atypical presentation for primary sclerosing cholangitis. ( Gomez, DA; Luketic, VA; Sanyal, AJ; Shiffman, ML, 1997) |
| " No proteinuria was observed after total dosage of immunosuppressants was increased." | 1.30 | [A case of recurrent IgA nephropathy following renal transplantation under tacrolimus (FK506)]. ( Hatori, M; Honda, M; Ichimaru, N; Imai, E; Kokado, Y; Kyo, M; Matsumiya, K; Miyamoto, M; Nonomura, N; Okuyama, A; Takahara, S; Takao, T; Yokoyama, K, 1997) |
| "Azathioprine was used in addition to steroid therapy at a dosage of 2 mg/kg." | 1.30 | Azathioprine in steroid-resistant and steroid-dependent ulcerative colitis. ( Ardizzone, S; Bianchi Porro, G; Bollani, S; Imbesi, V; Molteni, F; Molteni, P, 1997) |
| "Latent Trypanosoma cruzi infection may be reactivated in immunosuppressed individuals, with unusual clinical patterns, such as meningoencephalitis, pseudo neoplastic lesions in the central nervous system, and myocarditis with numerous parasites in the heart muscle." | 1.30 | Influence of treatment with immunosuppressive drugs in mice chronically infected with Trypanosoma cruzi. ( Andrade, SG; Andrade, ZA; Carneiro Filho, A; de Lima, ES; de Souza, AJ, 1997) |
| "Prednisolone dosage was reduced and cyclosporin (350 mg/d) substituted for azathioprine." | 1.30 | [Late manifestation of a fatal Behçet's disease with cardiac involvement and lethal outcome]. ( Bocker, T; Görnig, M; Kaatz, M; Wollina, U; Zouboulis, CC, 1998) |
| "In this study 7 patients with severe ulcerative colitis and 4 patients with active Crohn's disease unresponsive to prednisone were treated with high dose intravenous cyclosporine." | 1.30 | [Cyclosporin A therapy in steroid-refractory patients with chronic inflammatory bowel diseases]. ( Dejaco, C; Gangl, A; Gasché, C; Moser, G; Novacek, G; Reinisch, W; Tillinger, W; Vogelsang, H, 1998) |
| "Thirty children operated on for Crohn's disease (CD) were reviewed (1975-1994)." | 1.30 | Postoperative outcome of Crohn's disease in 30 children. ( Aigrain, Y; Besnard, M; Cézard, JP; Debrun, A; Delagausie, P; Faure, C; Ferkdadji, L; Jaby, O; Mougenot, JF; Navarro, J; Peuchmaur, M, 1998) |
| "Relapses are frequent after treatment withdrawal." | 1.30 | [Treatment of myasthenia: role of corticoids and immunosuppressive agents]. ( Gajdos, P, 1999) |
| "Cyclic neutropenia is a rare hematologic disorder of unknown origin." | 1.30 | [Recurrent episodes of ulcerative gingivostomatitis associated with cyclic neutropenia]. ( Djawari, J; Sucker, C, 1999) |
| "Discontinuation of 6MP, while Crohn's disease is in remission, leads to higher relapse rates and continuation of 6MP reduces the likelihood of relapse." | 1.30 | Optimum duration of treatment with 6-mercaptopurine for Crohn's disease. ( Gleim, GW; Kim, PS; Korelitz, BI; Zlatanic, J, 1999) |
| "Recurrence was observed in 2 cases." | 1.30 | [Herpetic superinfection of pemphigus: 6 cases]. ( Azzouzi, S; el Ouazzani, T; Lakhdar, H; Sqalli, S; Zouhair, K, 1999) |
| "Detection of the chronic myelogenous leukemia (CML)-related marker, the bcr/abl m-RNA transcript, in blood or bone marrow of patients with CML in hematologic remission after allogeneic bone marrow transplantation (allo-BMT) may be associated with the presence of minimal residual disease but does not uniformly predict hematologic relapse." | 1.29 | Case report of spontaneous remission of cytogenetic relapse of chronic myelogenous leukemia suggestive of progression to blast crisis after allogeneic bone marrow transplantation. ( Agaliotis, DP; Elfenbein, GJ; Moscinski, LC; Papenhausen, PR, 1995) |
| "We report an unusual case of MCTD with recurrent optic neuropathy and transverse myelopathy suggestive of a relapsing-remitting demyelinating disorder." | 1.29 | Mixed connective tissue disease: recurrent episodes of optic neuropathy and transverse myelopathy. Successful treatment with plasmapheresis. ( Baum, K; Flechtner, KM, 1994) |
| "The pattern of relapses is described in a consecutive series of 150 patients with vasculitis." | 1.29 | Necrotizing vasculitis--relapse despite cytotoxic therapy. ( Adu, D; Bacon, PA; Emery, P; Gordon, M; Greaves, I; Luqmani, RA; Michael, J; Richards, N, 1993) |
| "Nine patients (11 eyes) with ocular cicatricial pemphigoid were treated with systemic azathioprine and a syngeneic nasal mucosa transplant from the inferior turbinate." | 1.29 | [Syngeneic transplantation of nasal mucosa and azathioprine medication for therapy of cicatricial ocular mucous membrane pemphigoid. Study of 9 patients with 11 eyes]. ( Bialasiewicz, AA; Busse, H; Förster, W; Grewe, S; Hüttenbrink, KB; Radig, H, 1994) |
| "Pharyngeal dysphagia can be the only clinical manifestation of polymyositis, usually a systemic disease." | 1.29 | [Pharyngeal dysphagia and polymyositis]. ( Bernades, P; Chemtob, A; Lévy, H; Lévy, P; Malka, D; Ponsot, P, 1993) |
| "Two patients with recurrent Crohn's disease in the reservoir after ileoanal anastomosis were treated with azathioprine for 18 and 24 months, respectively." | 1.29 | Treatment of Crohn's disease recurrence after ileoanal anastomosis by azathioprine. ( Berrebi, W; Bruhl, AL; Chaussade, S; Couturier, D; Hautefeuille, P; Pariente, A; Valleur, P, 1993) |
| "Recurrent erythema multiforme is an uncommon disorder." | 1.29 | Recurrent erythema multiforme: clinical features and treatment in a large series of patients. ( Leigh, IM; Schofield, JK; Tatnall, FM, 1993) |
| " After our early experience with group 1, we attempted to use a lower cyclosporine dosage in group 2." | 1.29 | Heart transplantation for chronic Chagas' heart disease. ( Amato-Neto, V; Bacal, F; Bellotti, G; Bocchi, EA; Fiorelli, A; Higuchi, ML; Jatene, AD; Mocelin, AO; Pileggi, F; Stolf, NA; Uip, D, 1996) |
| "In the second patient, Crohn's disease was less severe and remission occurred without treatment." | 1.29 | [Crohn's disease and pregnancy. Two case reports]. ( Abboud, P; Messing, B; Napoléone, C; Quéreux, C; Wahl, P; Zeitoun, P, 1996) |
| "Bullous pemphigoid is a clinically heterogeneous disease although little is known of the factors affecting its course and outcome." | 1.28 | Lack of predictive factors for the clinical course of bullous pemphigoid. ( Venning, VA; Wojnarowska, F, 1992) |
| "Ocular cicatricial pemphigoid (OCP) is a chronic, progressive, autoimmune disease that scars mucus membranes and may lead to blindness." | 1.28 | Remission and recurrence after withdrawal of therapy for ocular cicatricial pemphigoid. ( Foster, CS; Neumann, R; Tauber, J, 1991) |
| "Biopsies then taken revealed recurrence of myocarditis in the transplanted heart." | 1.28 | Response of recurrent giant cell myocarditis in a transplanted heart to intensive immunosuppression. ( Kong, G; Madden, B; Mitchell, A; Pomerance, A; Spyrou, N; Yacoub, M, 1991) |
| "To evaluate the rate of recurrence of focal segmental glomerulosclerosis (FSGS) in renal transplant patients treated with cyclosporine, we reviewed the outcome of 25 renal Tx performed in 24 patients who had FSGS as their original renal disease." | 1.28 | The recurrence of focal segmental glomerulosclerosis in kidney transplant patients treated with cyclosporine. ( Banfi, G; Colturi, C; Montagnino, G; Ponticelli, C, 1990) |
| "Primary biliary cirrhosis is characterized by chronic inflammation and necrosis of the intrahepatic bile ducts and by chronic cholestasis." | 1.27 | NIH conference: Primary biliary cirrhosis: a model autoimmune disease. ( Hoofnagle, JH; James, SP; Jones, EA; Strober, W, 1983) |
| "Features typical of chronic active hepatitis were observed on examination of the liver biopsy, and both the clinical and histological pictures were unlike those of other possible causes of liver dysfunction, such as chronic rejection, cyclosporine hepatotoxicity, and non-A non-B chronic hepatitis." | 1.27 | Recurrence of autoimmune chronic active hepatitis following orthotopic liver grafting. ( Calne, R; Neuberger, J; Portmann, B; Williams, R, 1984) |
| "Two cases of patients with relapsing polyradiculoneuropathy with high protein level in cerebrospinal fluid are reported." | 1.27 | [Recurrent polyradiculoneuritis: report of 2 cases]. ( Callegaro, D; de Assis, JL; Marchiori, PE; Scaff, M; Zambon, AA, 1983) |
| "Eighteen patients with Wegener's granulomatosis with renal involvement have been studied." | 1.27 | Wegener's granulomatosis: observations on 18 patients with severe renal disease. ( Bowley, N; Evans, DJ; Lockwood, CM; Peters, DK; Pinching, AJ; Pussell, BA; Rees, AJ; Sweny, P, 1983) |
| " Effectiveness of treatment was graded according to resolution of lesions, return to normal of abnormal laboratory findings, or the ability to lower the dosage of a second therapeutic agent (usually a corticosteroid)." | 1.27 | Cutaneous leukocytoclastic vasculitis: clinical experience in 44 patients. ( af Ekenstam, E; Callen, JP, 1987) |
| "Treatment with prednisone and azathioprine improved the liver condition in 16 of the 18 patients given treatment." | 1.27 | Liver disease associated with anti-liver-kidney microsome antibody in children. ( Alagille, D; Alvarez, F; Bernard, O; Hadchouel, M; Hadchouel, P; Homberg, JC; Maggiore, G; Odièvre, M, 1986) |
| "Fourteen patients with systemic lupus erythematosus had splenectomies done between 1960 and 1982 for treatment of severe thrombocytopenia." | 1.27 | Splenectomy does not cure the thrombocytopenia of systemic lupus erythematosus. ( Greipp, PR; Hall, S; McCormick, JL; McKenna, CH; Michet, CJ, 1985) |
| "Azathioprine was then considered as an alternative treatment." | 1.27 | Azathioprine. An alternative treatment for recurrent idiopathic retroperitoneal fibrosis. ( Cogan, E; Fastrez, R, 1985) |
| "After four years he had a recurrence of his disease while being maintained on azathiorpine." | 1.26 | Recurrence of Wegener's granulomatosis after kidney transplantation. Successful re-induction of remission with cyclophosphamide. ( Fauci, AS; Jaffe, BF; Monaco, AP; Steinman, TI; Wolff, SM, 1980) |
| "Nineteen of 160 children developed varicella between eight days and 6." | 1.26 | Varicella in children with renal transplants. ( Balfour, HH; Feldhoff, CM; Mauer, SM; Najarian, JS; Simmons, RL, 1981) |
| "Subsequent courses of treatment after relapse were equally effective in again inducing remission, but the probability of another relapse increased after each successive therapy and was 86% after three treatments." | 1.26 | Clinical features and prognosis of severe chronic active liver disease (CALD) after corticosteroid-induced remission. ( Ammon, HV; Czaja, AJ; Summerskill, WH, 1980) |
| "Anti-acetylcholine receptor antibody titres have been monitored in the sera of 19 myasthenic patients treated with plasma exchange combined with a three month period of immunosuppressive therapy." | 1.26 | Anti-acetylcholine receptor antibody titres in the sera of myasthenia patients treated with plasma exchange combined with immunosuppressive therapy. ( Behan, PO; Carter, B; Harrison, R; Lunt, GG; Simpson, JA, 1980) |
| "No patient showed recurrence of disease during treatment with cytotoxic agents." | 1.26 | Cyclophosphamide therapy of severe systemic necrotizing vasculitis. ( Fauci, AS; Haynes, BF; Katz, P; Wolff, SM, 1979) |
| "Recurrent Crohn's disease and that characterized by small bowel obstruction each displayed a characteristic appearance." | 1.26 | Radiographic findings of the National Cooperative Crohn's Disease Study. ( Caruthers, SB; Goldberg, HI; Nelson, JA; Singleton, JW, 1979) |
| "Twenty-one patients with myasthenia gravis underwent a course of plasma exchange combined with immunosuppressive therapy." | 1.26 | Plasma-exchange combined with immunosuppressive therapy in myasthenia gravis. ( Allan, TL; Behan, PO; Burnett, AK; Haase, G; Shakir, RA; Simpson, JA, 1979) |
| "Neurologic complications of systemic lupus erythematosus (SLE) are common, but chorea is rare." | 1.25 | Clinical features of chorea associated with systemic lupus erythematosus. ( Lusins, JO; Szilagyi, PA, 1975) |
| "Laboratory examination revealed acute disseminated intravascular coagulation and lactacidaemia." | 1.25 | [Lactacidaemia and disseminated intravascular coagulation associated with phenformin medication (author's transl)]. ( Dienstl, F; Holzknecht, F; Hörtnagl, H; Kunz, F; Lederer, B, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 134 (19.91) | 18.7374 |
| 1990's | 109 (16.20) | 18.2507 |
| 2000's | 158 (23.48) | 29.6817 |
| 2010's | 203 (30.16) | 24.3611 |
| 2020's | 69 (10.25) | 2.80 |
| Authors | Studies |
|---|---|
| Jeong, TJ | 1 |
| Kim, ES | 2 |
| Kwon, Y | 1 |
| Kim, S | 2 |
| Seo, SW | 1 |
| Choe, YH | 2 |
| Kim, MJ | 2 |
| Accorinti, M | 1 |
| Saturno, MC | 1 |
| Manni, P | 1 |
| Zhang, Q | 2 |
| Xing, P | 1 |
| Ren, H | 1 |
| Chen, X | 1 |
| Xie, J | 1 |
| Zhang, W | 2 |
| Shen, P | 1 |
| Li, X | 2 |
| Chen, N | 2 |
| Pathomrattanapiban, C | 1 |
| Tisavipat, N | 1 |
| Jitprapaikulsan, J | 1 |
| Prayoonwiwat, N | 1 |
| Rattanathamsakul, N | 1 |
| Siritho, S | 1 |
| Yavropoulou, MP | 1 |
| Filippa, MG | 1 |
| Panopoulos, S | 2 |
| Spanos, E | 1 |
| Spanos, G | 1 |
| Tektonidou, MG | 1 |
| Sfikakis, PP | 2 |
| Jourde-Chiche, N | 1 |
| Costedoat-Chalumeau, N | 1 |
| Baumstarck, K | 1 |
| Loundou, A | 1 |
| Bouillet, L | 1 |
| Burtey, S | 2 |
| Caudwell, V | 1 |
| Chiche, L | 1 |
| Couzi, L | 1 |
| Daniel, L | 1 |
| Deligny, C | 1 |
| Dussol, B | 2 |
| Faguer, S | 1 |
| Gobert, P | 2 |
| Gondran, G | 1 |
| Huart, A | 1 |
| Hummel, A | 1 |
| Kalbacher, E | 1 |
| Karras, A | 2 |
| Lambert, M | 1 |
| Le Guern, V | 2 |
| Lebourg, L | 1 |
| Loubière, S | 1 |
| Maillard-Lefebvre, H | 1 |
| Maurier, F | 2 |
| Pha, M | 1 |
| Queyrel, V | 1 |
| Remy, P | 1 |
| Sarrot-Reynauld, F | 1 |
| Verhelst, D | 1 |
| Hachulla, E | 2 |
| Amoura, Z | 1 |
| Daugas, E | 2 |
| Ranjan, MK | 1 |
| Vuyyuru, SK | 1 |
| Kante, B | 1 |
| Kumar, P | 2 |
| Mundhra, SK | 1 |
| Golla, R | 1 |
| Sharma, R | 1 |
| Sahni, P | 1 |
| Das, P | 1 |
| Makharia, G | 1 |
| Kedia, S | 1 |
| Ahuja, V | 1 |
| Huang, W | 1 |
| Tan, H | 1 |
| Xia, J | 1 |
| Li, W | 1 |
| ZhangBao, J | 1 |
| Chang, X | 1 |
| Wang, L | 1 |
| Wang, M | 1 |
| Zhao, C | 1 |
| Lu, J | 2 |
| Lu, C | 1 |
| Dong, Q | 1 |
| Zhou, L | 1 |
| Quan, C | 1 |
| Wang, X | 1 |
| Kong, L | 1 |
| Zhao, Z | 1 |
| Shi, Z | 2 |
| Chen, H | 2 |
| Lang, Y | 1 |
| Lin, X | 1 |
| Du, Q | 1 |
| Zhou, H | 2 |
| Lerchova, T | 1 |
| Hradsky, O | 3 |
| Kulich, M | 1 |
| Veres, G | 2 |
| Dias, JA | 1 |
| Sładek, M | 1 |
| Kolacek, S | 1 |
| Van Biervliet, S | 1 |
| Melek, J | 1 |
| Serban, DE | 1 |
| Winther, K | 1 |
| de Meij, T | 1 |
| Schwarz, J | 1 |
| Kolho, KL | 1 |
| Escher, JC | 1 |
| Bronsky, J | 3 |
| Dong, GY | 1 |
| Meng, YH | 1 |
| Xiao, XJ | 1 |
| Watanabe, R | 2 |
| Oshima, M | 1 |
| Nishioka, N | 1 |
| Sada, KE | 2 |
| Nagasaka, K | 1 |
| Akiyama, M | 1 |
| Ando, T | 1 |
| Higuchi, T | 1 |
| Inoue, Y | 1 |
| Kida, T | 1 |
| Mutoh, T | 1 |
| Nakabayashi, A | 1 |
| Onishi, A | 1 |
| Sakai, R | 1 |
| Waki, D | 1 |
| Yamada, Y | 1 |
| Yajima, N | 1 |
| Tamura, N | 1 |
| Kaname, S | 1 |
| Harigai, M | 2 |
| Nista, EC | 1 |
| De Lucia, SS | 1 |
| Manilla, V | 1 |
| Schepis, T | 1 |
| Pellegrino, A | 1 |
| Ojetti, V | 1 |
| Pignataro, G | 1 |
| Zileri Dal Verme, L | 1 |
| Franceschi, F | 1 |
| Gasbarrini, A | 2 |
| Candelli, M | 1 |
| Pizzolato Umeton, R | 3 |
| Waltz, M | 3 |
| Aaen, GS | 3 |
| Benson, L | 3 |
| Gorman, M | 3 |
| Goyal, M | 3 |
| Graves, JS | 3 |
| Harris, Y | 3 |
| Krupp, L | 3 |
| Lotze, TE | 3 |
| Shukla, NM | 3 |
| Mar, S | 3 |
| Ness, J | 3 |
| Rensel, M | 3 |
| Schreiner, T | 3 |
| Tillema, JM | 3 |
| Roalstad, S | 3 |
| Rodriguez, M | 3 |
| Rose, J | 3 |
| Waubant, E | 3 |
| Weinstock-Guttman, B | 3 |
| Casper, C | 3 |
| Chitnis, T | 3 |
| Syal, G | 2 |
| Melmed, GY | 2 |
| Almario, CV | 2 |
| Spiegel, BMR | 2 |
| Louis, E | 1 |
| Resche-Rigon, M | 1 |
| Laharie, D | 4 |
| Satsangi, J | 2 |
| Ding, N | 1 |
| Siegmund, B | 1 |
| D'Haens, G | 5 |
| Picon, L | 2 |
| Bossuyt, P | 1 |
| Vuitton, L | 2 |
| Irving, P | 1 |
| Viennot, S | 1 |
| Lamb, CA | 2 |
| Pollok, R | 1 |
| Baert, F | 2 |
| Nachury, M | 2 |
| Fumery, M | 4 |
| Gilletta, C | 1 |
| Almer, S | 2 |
| Ben-Horin, S | 2 |
| Bouhnik, Y | 7 |
| Colombel, JF | 6 |
| Hertervig, E | 1 |
| Tang, Q | 1 |
| Yao, M | 1 |
| Huang, Y | 1 |
| Bian, J | 1 |
| Wang, Y | 3 |
| Ji, W | 1 |
| Yin, Z | 1 |
| Qiu, Y | 2 |
| Duan, A | 1 |
| Fang, T | 1 |
| Chen, Z | 1 |
| Wu, J | 1 |
| Wang, Z | 4 |
| Chen, G | 1 |
| Smith, RM | 2 |
| Jones, RB | 3 |
| Specks, U | 7 |
| Bond, S | 1 |
| Nodale, M | 1 |
| Al-Jayyousi, R | 1 |
| Andrews, J | 1 |
| Bruchfeld, A | 2 |
| Camilleri, B | 1 |
| Carette, S | 1 |
| Cheung, CK | 1 |
| Derebail, V | 1 |
| Doulton, T | 1 |
| Ferraro, A | 1 |
| Forbess, L | 1 |
| Fujimoto, S | 2 |
| Furuta, S | 2 |
| Gewurz-Singer, O | 1 |
| Harper, L | 3 |
| Ito-Ihara, T | 1 |
| Khalidi, N | 1 |
| Klocke, R | 1 |
| Koening, C | 1 |
| Komagata, Y | 1 |
| Langford, C | 1 |
| Lanyon, P | 2 |
| Luqmani, R | 1 |
| McAlear, C | 1 |
| Moreland, LW | 1 |
| Mynard, K | 2 |
| Nachman, P | 1 |
| Pagnoux, C | 8 |
| Peh, CA | 2 |
| Pusey, C | 2 |
| Ranganathan, D | 1 |
| Rhee, RL | 1 |
| Spiera, R | 5 |
| Sreih, AG | 1 |
| Tesar, V | 4 |
| Walters, G | 2 |
| Wroe, C | 1 |
| Jayne, D | 3 |
| Merkel, PA | 8 |
| Imazio, M | 3 |
| Mardigyan, V | 1 |
| Andreis, A | 1 |
| Franchin, L | 1 |
| De Biasio, M | 1 |
| Collini, V | 1 |
| Dresser, L | 1 |
| Chaar, WA | 1 |
| Reder, AT | 2 |
| Abuaf, AF | 1 |
| Cipriani, VP | 1 |
| Javed, A | 1 |
| Lermi, N | 1 |
| Ekin, A | 1 |
| Ocak, T | 1 |
| Bozkurt, ZY | 1 |
| Ötegeçeli, MA | 1 |
| Yağız, B | 1 |
| Coşkun, BN | 1 |
| Pehlivan, Y | 1 |
| Dalkılıç, E | 1 |
| Huang, KH | 1 |
| Lin, HC | 1 |
| Lin, CD | 1 |
| Wu, PC | 1 |
| Allam, MM | 1 |
| El-Zawawy, HT | 1 |
| Kader Okda, AA | 1 |
| Ali Alshaikh, A | 1 |
| Ghazy, RM | 1 |
| Harrison, L | 2 |
| Hoeroldt, B | 1 |
| Dhaliwal, H | 1 |
| Wadland, E | 1 |
| Dube, A | 1 |
| Gleeson, D | 4 |
| Pisetsky, DS | 1 |
| Jiang, N | 1 |
| Jin, S | 1 |
| Yu, C | 1 |
| Zhao, J | 1 |
| Wang, Q | 2 |
| Tian, X | 2 |
| Li, M | 2 |
| Zeng, X | 1 |
| Bommelaer, G | 3 |
| Nancey, S | 5 |
| Hebuterne, X | 3 |
| Roblin, X | 6 |
| Peyrin-Biroulet, L | 7 |
| Richard, D | 1 |
| Pereira, B | 3 |
| Goutte, M | 1 |
| Buisson, A | 3 |
| Gueutier, A | 1 |
| Leducq, S | 1 |
| Joly, A | 1 |
| Vaillant, L | 1 |
| Samimi, M | 1 |
| Ozguler, Y | 1 |
| Hatemi, G | 1 |
| Cetinkaya, F | 1 |
| Tascilar, K | 1 |
| Hamuryudan, V | 1 |
| Ugurlu, S | 1 |
| Seyahi, E | 1 |
| Yazici, H | 1 |
| Melikoglu, M | 1 |
| Omar, D | 1 |
| Chen, Y | 1 |
| Cong, Y | 1 |
| Dong, L | 1 |
| Zen, M | 1 |
| Saccon, F | 1 |
| Gatto, M | 1 |
| Montesso, G | 1 |
| Larosa, M | 1 |
| Benvenuti, F | 1 |
| Iaccarino, L | 1 |
| Doria, A | 1 |
| Mata-Castro, N | 1 |
| Sanz-López, L | 1 |
| Varillas-Delgado, D | 1 |
| García-Fernández, A | 1 |
| Kunchok, A | 1 |
| Malpas, C | 1 |
| Nytrova, P | 1 |
| Havrdova, EK | 1 |
| Alroughani, R | 1 |
| Terzi, M | 1 |
| Yamout, B | 1 |
| Hor, JY | 1 |
| Karabudak, R | 1 |
| Boz, C | 1 |
| Ozakbas, S | 1 |
| Olascoaga, J | 1 |
| Simo, M | 1 |
| Granella, F | 1 |
| Patti, F | 1 |
| McCombe, P | 1 |
| Csepany, T | 1 |
| Singhal, B | 1 |
| Bergamaschi, R | 1 |
| Fragoso, Y | 1 |
| Al-Harbi, T | 1 |
| Turkoglu, R | 1 |
| Lechner-Scott, J | 1 |
| Laureys, G | 1 |
| Oreja-Guevara, C | 1 |
| Pucci, E | 1 |
| Sola, P | 1 |
| Ferraro, D | 1 |
| Altintas, A | 1 |
| Soysal, A | 1 |
| Vucic, S | 1 |
| Grand'Maison, F | 1 |
| Izquierdo, G | 1 |
| Eichau, S | 1 |
| Lugaresi, A | 1 |
| Onofrj, M | 1 |
| Trojano, M | 1 |
| Marriott, M | 1 |
| Butzkueven, H | 1 |
| Kister, I | 1 |
| Kalincik, T | 2 |
| Rojo, E | 1 |
| Casanova, MJ | 2 |
| Gisbert, JP | 4 |
| Schwier, NC | 2 |
| Cornelio, CK | 1 |
| Epperson, TM | 1 |
| Vakrakou, AG | 1 |
| Evangelopoulos, ME | 1 |
| Boutzios, G | 1 |
| Tzanetakos, D | 1 |
| Tzartos, J | 1 |
| Velonakis, G | 1 |
| Toulas, P | 1 |
| Anagnostouli, M | 1 |
| Andreadou, E | 1 |
| Koutsis, G | 1 |
| Stefanis, L | 1 |
| Fragoulis, GE | 1 |
| Kilidireas, C | 1 |
| Kawali, A | 1 |
| Bavaharan, B | 1 |
| Sanjay, S | 1 |
| Mohan, A | 1 |
| Mahendradas, P | 1 |
| Shetty, B | 1 |
| Williet, N | 2 |
| Boschetti, G | 2 |
| Phelip, JM | 2 |
| Del Tedesco, E | 2 |
| Berger, AE | 1 |
| Vedrines, P | 1 |
| Duru, G | 2 |
| Flourie, B | 3 |
| Paul, S | 2 |
| Papamichael, K | 2 |
| Cheifetz, AS | 1 |
| Irving, PM | 2 |
| Liu, Y | 1 |
| Zeng, Q | 1 |
| Zhu, L | 2 |
| Gao, J | 1 |
| Yang, F | 1 |
| Wang, K | 1 |
| Chen, D | 1 |
| Xia, C | 1 |
| Zhang, S | 1 |
| Shen, D | 1 |
| Yu, G | 1 |
| Li, ZG | 1 |
| Harada, S | 1 |
| Inatomi, Y | 1 |
| Nakajima, M | 1 |
| Yonehara, T | 1 |
| Poupart, J | 1 |
| Giovannelli, J | 1 |
| Deschamps, R | 1 |
| Audoin, B | 1 |
| Ciron, J | 1 |
| Maillart, E | 1 |
| Papeix, C | 1 |
| Collongues, N | 1 |
| Bourre, B | 1 |
| Cohen, M | 1 |
| Wiertlewski, S | 1 |
| Outteryck, O | 1 |
| Laplaud, D | 1 |
| Vukusic, S | 1 |
| Marignier, R | 2 |
| Zephir, H | 1 |
| Larkins, NG | 1 |
| Liu, ID | 1 |
| Willis, NS | 1 |
| Craig, JC | 2 |
| Hodson, EM | 1 |
| Erzin, Y | 1 |
| Şişman, G | 1 |
| Hatemi, İ | 1 |
| Baca, B | 1 |
| Hamzaoglu, İ | 1 |
| Dirican, A | 1 |
| Korman, U | 1 |
| Çelik, AF | 1 |
| Boube, M | 1 |
| Pariente, B | 2 |
| Minet-Quinard, R | 1 |
| Hruskova, Z | 1 |
| Miele, E | 1 |
| Benninga, MA | 1 |
| Broekaert, I | 1 |
| Dolinsek, J | 1 |
| Mas, E | 1 |
| Orel, R | 1 |
| Pienar, C | 1 |
| Ribes-Koninckx, C | 1 |
| Thomassen, RA | 1 |
| Thomson, M | 1 |
| Tzivinikos, C | 1 |
| Thapar, N | 1 |
| Balram, B | 1 |
| Lubov, J | 1 |
| Theoret, Y | 1 |
| Afif, W | 1 |
| Bitton, A | 1 |
| Wild, G | 1 |
| Lakatos, PL | 3 |
| Bessissow, T | 1 |
| Candia, R | 2 |
| Bravo-Soto, GA | 1 |
| Monrroy, H | 1 |
| Hernandez, C | 1 |
| Nguyen, GC | 2 |
| Snast, I | 1 |
| Spitzer, L | 1 |
| Hodak, E | 1 |
| Levi, A | 1 |
| Mimouni, D | 1 |
| Leshem, YA | 1 |
| Lee, MS | 1 |
| Yeh, YC | 1 |
| Tu, YK | 1 |
| Chan, TC | 1 |
| Zonozi, R | 1 |
| Wallace, ZS | 1 |
| Laliberte, K | 1 |
| Huizenga, NR | 1 |
| Rosenthal, JM | 1 |
| Rhee, EP | 1 |
| Cortazar, FB | 1 |
| Niles, JL | 1 |
| Luo, D | 1 |
| Wei, R | 1 |
| Chen, C | 1 |
| Ma, L | 1 |
| Dong, X | 1 |
| Zhang, E | 1 |
| Zhou, Y | 1 |
| Cui, Y | 1 |
| Fanouriakis, A | 1 |
| Tziolos, N | 1 |
| Bertsias, G | 1 |
| Boumpas, DT | 1 |
| de Sousa Magalhães, R | 1 |
| Xavier, S | 1 |
| Cúrdia Gonçalves, T | 1 |
| Dias de Castro, F | 1 |
| Rosa, B | 1 |
| Moreira, MJ | 1 |
| Cotter, J | 1 |
| Orlando, A | 1 |
| Mocciaro, F | 1 |
| Ventimiglia, M | 1 |
| Renna, S | 1 |
| Rispo, A | 1 |
| Scribano, ML | 1 |
| Testa, A | 1 |
| Aratari, A | 1 |
| Bossa, F | 1 |
| Angelucci, E | 1 |
| Onali, S | 1 |
| Cappello, M | 1 |
| Giunta, M | 1 |
| Scimeca, D | 1 |
| Macaluso, FS | 1 |
| Castiglione, F | 1 |
| Papi, C | 1 |
| Annese, V | 3 |
| Biancone, L | 1 |
| Kohn, A | 1 |
| Di Mitri, R | 1 |
| Cottone, M | 1 |
| Hegyi, PJ | 1 |
| Szakács, Z | 1 |
| Faluhelyi, N | 1 |
| Németh, BC | 1 |
| Bajor, J | 1 |
| Hegyi, P | 1 |
| Peretto, G | 1 |
| Barzaghi, F | 1 |
| Cicalese, MP | 1 |
| Di Resta, C | 1 |
| Slavich, M | 1 |
| Benedetti, S | 1 |
| Giangiobbe, S | 1 |
| Rizzo, S | 1 |
| Palmisano, A | 1 |
| Esposito, A | 1 |
| De Cobelli, F | 1 |
| Gulletta, S | 1 |
| Basso, C | 1 |
| Casari, G | 1 |
| Aiuti, A | 1 |
| Della Bella, P | 1 |
| Sala, S | 1 |
| Jayne, DRW | 1 |
| Schall, TJ | 1 |
| Bekker, P | 1 |
| Girgin, S | 1 |
| Yurumez, S | 1 |
| Omma, A | 1 |
| Celik, S | 1 |
| Cemal Icacan, O | 1 |
| Bes, C | 1 |
| Alpay-Kanitez, N | 1 |
| Gomes, ABAGR | 1 |
| Pitombeira, MS | 1 |
| Sato, DK | 1 |
| Callegaro, D | 2 |
| Apóstolos-Pereira, SL | 1 |
| Gómez-Medina, C | 1 |
| Capilla-Lozano, M | 1 |
| Ballester-Ferré, MP | 1 |
| Martí-Aguado, D | 1 |
| Crespo, A | 1 |
| Bosca-Watts, MM | 2 |
| Navarro-Cortés, P | 1 |
| Antón, R | 1 |
| Pascual-Moreno, I | 1 |
| Tosca Cuquerella, J | 1 |
| Mínguez Pérez, M | 1 |
| Manlay, L | 1 |
| Rubin, DT | 2 |
| Nie, N | 1 |
| Liu, Z | 4 |
| Kang, J | 1 |
| Li, L | 1 |
| Cao, G | 1 |
| Jorissen, C | 1 |
| Verstockt, B | 1 |
| Schils, N | 1 |
| Sabino, J | 1 |
| Ferrante, M | 3 |
| Vermeire, S | 4 |
| Pyo, JY | 1 |
| Lee, LE | 1 |
| Ahn, SS | 1 |
| Song, JJ | 1 |
| Park, YB | 1 |
| Lee, SW | 1 |
| Won, YB | 1 |
| Seo, SK | 1 |
| Cho, S | 1 |
| Choi, YS | 1 |
| Lee, BS | 1 |
| Yun, BH | 1 |
| Lockwood, DN | 1 |
| Darlong, J | 1 |
| Govindharaj, P | 1 |
| Kurian, R | 1 |
| Sundarrao, P | 1 |
| John, AS | 1 |
| Morishita, KA | 1 |
| Moorthy, LN | 1 |
| Lubieniecka, JM | 1 |
| Twilt, M | 1 |
| Yeung, RSM | 2 |
| Toth, MB | 1 |
| Shenoi, S | 1 |
| Ristic, G | 1 |
| Nielsen, SM | 1 |
| Luqmani, RA | 3 |
| Li, SC | 1 |
| Lee, T | 1 |
| Lawson, EF | 1 |
| Kostik, MM | 1 |
| Klein-Gitelman, M | 1 |
| Huber, AM | 1 |
| Hersh, AO | 1 |
| Foell, D | 1 |
| Elder, ME | 1 |
| Eberhard, BA | 1 |
| Dancey, P | 1 |
| Charuvanij, S | 1 |
| Benseler, SM | 1 |
| Cabral, DA | 1 |
| Fernandez-Bañares, F | 1 |
| Piqueras, M | 1 |
| Guagnozzi, D | 1 |
| Robles, V | 1 |
| Ruiz-Cerulla, A | 1 |
| Busquets, D | 1 |
| Arguedas, Y | 1 |
| Pérez-Aisa, A | 1 |
| Fernández-Salazar, L | 1 |
| Lucendo, AJ | 1 |
| Mohammadi, M | 1 |
| Shahram, F | 1 |
| Shams, H | 1 |
| Akhlaghi, M | 1 |
| Ashofteh, F | 1 |
| Davatchi, F | 1 |
| Ben Ghorbel, I | 1 |
| Belfeki, N | 1 |
| Baouendi, N | 1 |
| Ben Salem, T | 1 |
| Houman, MH | 1 |
| Stellmann, JP | 1 |
| Krumbholz, M | 1 |
| Friede, T | 1 |
| Gahlen, A | 1 |
| Borisow, N | 1 |
| Fischer, K | 1 |
| Hellwig, K | 1 |
| Pache, F | 1 |
| Ruprecht, K | 1 |
| Havla, J | 1 |
| Kümpfel, T | 1 |
| Aktas, O | 1 |
| Hartung, HP | 2 |
| Ringelstein, M | 1 |
| Geis, C | 1 |
| Kleinschnitz, C | 1 |
| Berthele, A | 1 |
| Hemmer, B | 1 |
| Angstwurm, K | 1 |
| Young, KL | 1 |
| Schuster, S | 1 |
| Stangel, M | 1 |
| Lauda, F | 1 |
| Tumani, H | 2 |
| Mayer, C | 1 |
| Zeltner, L | 1 |
| Ziemann, U | 1 |
| Linker, RA | 1 |
| Schwab, M | 2 |
| Marziniak, M | 1 |
| Then Bergh, F | 1 |
| Hofstadt-van Oy, U | 1 |
| Neuhaus, O | 1 |
| Zettl, U | 1 |
| Faiss, J | 1 |
| Wildemann, B | 1 |
| Paul, F | 1 |
| Jarius, S | 3 |
| Trebst, C | 1 |
| Kleiter, I | 1 |
| Osman, A | 1 |
| Galiatsatos, P | 1 |
| Bose, S | 1 |
| Danoff, S | 1 |
| Yap, DYH | 2 |
| Tang, C | 1 |
| Ma, MKM | 2 |
| Mok, MMY | 2 |
| Chan, GCW | 2 |
| Kwan, LPY | 2 |
| Chan, TM | 5 |
| Puéchal, X | 5 |
| Baron, G | 2 |
| Quémeneur, T | 3 |
| Néel, A | 2 |
| Agard, C | 2 |
| Lifermann, F | 2 |
| Liozon, E | 1 |
| Ruivard, M | 3 |
| Godmer, P | 2 |
| Limal, N | 3 |
| Mékinian, A | 1 |
| Papo, T | 1 |
| Ruppert, AM | 1 |
| Bourgarit, A | 1 |
| Bienvenu, B | 1 |
| Geffray, L | 2 |
| Saraux, JL | 2 |
| Diot, E | 2 |
| Crestani, B | 1 |
| Delbrel, X | 1 |
| Sailler, L | 1 |
| Cohen, P | 4 |
| Terrier, B | 3 |
| Groh, M | 1 |
| Le Jeunne, C | 2 |
| Mouthon, L | 4 |
| Ravaud, P | 3 |
| Guillevin, L | 6 |
| Kotha, S | 1 |
| Tritto, G | 1 |
| Wong, T | 1 |
| Berry, P | 1 |
| Yarur, AJ | 1 |
| Gondal, B | 1 |
| Hirsch, A | 1 |
| Christensen, B | 1 |
| Cohen, RD | 1 |
| Zhang, H | 1 |
| Zhou, M | 1 |
| Chen, J | 1 |
| Xing, C | 1 |
| Lin, H | 1 |
| Ni, Z | 1 |
| Fu, P | 1 |
| Liu, F | 1 |
| He, Y | 2 |
| Liu, J | 2 |
| Zeng, C | 1 |
| Guo, J | 1 |
| Chen, BL | 1 |
| Chen, ZH | 1 |
| Luo, XP | 1 |
| Zhang, SH | 1 |
| Feng, R | 1 |
| Zeng, ZR | 1 |
| Song, XM | 1 |
| Mao, R | 1 |
| Chen, MH | 1 |
| Arida, A | 1 |
| Fragiadaki, K | 1 |
| Pentazos, G | 1 |
| Laskari, K | 1 |
| Tektonidou, M | 1 |
| Markomichelakis, N | 1 |
| Purnak, T | 1 |
| Efe, C | 1 |
| Kav, T | 1 |
| Wahlin, S | 1 |
| Ozaslan, E | 1 |
| Jain, V | 1 |
| Srivastava, A | 1 |
| Yachha, SK | 1 |
| Kumari, N | 1 |
| Kathuria, R | 1 |
| Sarma, MS | 1 |
| Poddar, U | 1 |
| Krishnani, N | 1 |
| Hey, P | 1 |
| Lokan, J | 1 |
| Johnson, P | 1 |
| Gow, P | 1 |
| de Joode, AAE | 1 |
| Sanders, JSF | 1 |
| Guillevin, LP | 1 |
| Hiemstra, TF | 2 |
| Flossmann, O | 2 |
| Rasmussen, N | 3 |
| Westman, K | 2 |
| Jayne, DR | 4 |
| Stegeman, CA | 4 |
| Yang, P | 1 |
| Ye, Z | 1 |
| Du, L | 1 |
| Zhou, Q | 1 |
| Qi, J | 1 |
| Liang, L | 1 |
| Wu, L | 1 |
| Wang, C | 1 |
| Kijlstra, A | 1 |
| Bennji, SM | 1 |
| du Preez, L | 1 |
| Griffith-Richards, S | 1 |
| Smit, DP | 1 |
| Rigby, J | 1 |
| Koegelenberg, CFN | 1 |
| Irusen, EM | 1 |
| Allwood, BW | 1 |
| Han, ZM | 1 |
| Qiao, WG | 1 |
| Ai, XY | 1 |
| Li, AM | 1 |
| Chen, ZY | 1 |
| Feng, XC | 1 |
| Zhang, J | 1 |
| Wan, TM | 1 |
| Xu, ZM | 1 |
| Bai, Y | 1 |
| Li, MS | 1 |
| Liu, SD | 1 |
| Zhi, FC | 1 |
| Lee, HW | 2 |
| Moon, SH | 1 |
| Kim, MH | 1 |
| Cho, DH | 1 |
| Jun, JH | 1 |
| Nam, K | 1 |
| Song, TJ | 1 |
| Park, DH | 1 |
| Lee, SS | 1 |
| Seo, DW | 1 |
| Lee, SK | 1 |
| Mehra, S | 1 |
| Usdadiya, JB | 1 |
| Jain, VK | 1 |
| Misra, DP | 1 |
| Negi, VS | 1 |
| Dube, M | 1 |
| Sodani, A | 1 |
| Chouksey, D | 1 |
| Kang, B | 1 |
| Choi, SY | 1 |
| Choi, YO | 1 |
| Kim, K | 1 |
| Lee, JH | 3 |
| Ray, G | 1 |
| Jones, D | 1 |
| Manns, MP | 1 |
| Terracciano, L | 1 |
| Torbenson, M | 1 |
| Vierling, JM | 1 |
| Ordóñez Rubiano, MF | 1 |
| Arenas, CM | 1 |
| Chalela, JG | 1 |
| Perrodeau, É | 1 |
| Khouatra, C | 1 |
| Aumaître, O | 1 |
| Decaux, O | 1 |
| Desmurs-Clavel, H | 1 |
| Blanchard-Delaunay, C | 1 |
| Bonnotte, B | 2 |
| Carron, PL | 2 |
| Ducret, M | 1 |
| Hamidou, M | 1 |
| Lidove, O | 1 |
| Boyapati, RK | 1 |
| Torres, J | 2 |
| Palmela, C | 1 |
| Parker, CE | 1 |
| Silverberg, OM | 1 |
| Upadhyaya, SD | 1 |
| Nguyen, TM | 1 |
| Saku, A | 1 |
| Hiraguri, M | 1 |
| Ikeda, K | 1 |
| Kobayashi, Y | 1 |
| Kagami, SI | 1 |
| Kurasawa, K | 1 |
| Matsumura, R | 1 |
| Nakagomi, D | 1 |
| Sugiyama, T | 1 |
| Umibe, T | 1 |
| Watanabe, N | 1 |
| Nakajima, H | 1 |
| Tunnicliffe, DJ | 1 |
| Palmer, SC | 1 |
| Henderson, L | 1 |
| Masson, P | 1 |
| Tong, A | 1 |
| Singh-Grewal, D | 1 |
| Flanc, RS | 1 |
| Roberts, MA | 1 |
| Webster, AC | 1 |
| Strippoli, GF | 1 |
| Guo, Z | 2 |
| Cai, X | 1 |
| Liu, R | 1 |
| Gong, J | 2 |
| Li, Y | 2 |
| Cao, L | 2 |
| Zhu, W | 2 |
| Sparrow, M | 2 |
| Sokollik, C | 1 |
| McLin, VA | 1 |
| Vergani, D | 1 |
| Terziroli Beretta-Piccoli, B | 1 |
| Mieli-Vergani, G | 1 |
| Trivedi, PJ | 1 |
| Hubscher, SG | 1 |
| Heneghan, M | 1 |
| Hirschfield, GM | 2 |
| Van Driessche, B | 1 |
| Verloo, P | 1 |
| Herregods, N | 1 |
| Mondelaers, V | 1 |
| Dehoorne, J | 1 |
| Van Coster, R | 1 |
| Verhelst, H | 1 |
| Iborra, M | 1 |
| Herreras, J | 1 |
| Cortés, X | 1 |
| Trejo, G | 1 |
| Cerrillo, E | 1 |
| Hervás, D | 1 |
| Mínguez, M | 2 |
| Beltrán, B | 1 |
| Nos, P | 2 |
| Ballarin, J | 1 |
| Blockmans, DE | 1 |
| Brogan, P | 1 |
| Cid, MC | 1 |
| Dahlsveen, K | 1 |
| de Zoysa, J | 1 |
| Espigol-Frigolé, G | 1 |
| Vaglio, A | 1 |
| Walsh, M | 1 |
| Walsh, D | 1 |
| Deng, J | 2 |
| Xie, H | 2 |
| Luo, L | 1 |
| Castaño-González, PA | 1 |
| González, LA | 1 |
| Taxonera, C | 1 |
| López-Sanromán, A | 1 |
| Vera-Mendoza, I | 1 |
| Domènech, E | 3 |
| Ruiz, VV | 1 |
| Marín-Jiménez, I | 1 |
| Guardiola, J | 2 |
| Castro, L | 1 |
| Esteve, M | 1 |
| Iglesias, E | 1 |
| Ceballos, D | 1 |
| Martínez-Montiel, P | 1 |
| Echarri, A | 1 |
| Calvet, X | 1 |
| Barrio, J | 1 |
| Hinojosa, J | 1 |
| Martín-Arranz, MD | 1 |
| Márquez-Mosquera, L | 1 |
| Bermejo, F | 1 |
| Rimola, J | 1 |
| Alba, C | 1 |
| Pons, V | 1 |
| Romeo, AR | 1 |
| Segal, BM | 1 |
| Wislez, M | 1 |
| Cottin, V | 1 |
| Aouba, A | 1 |
| Cho, YT | 1 |
| Huang, YM | 2 |
| Wang, LF | 1 |
| Chu, CY | 1 |
| Saliba, C | 1 |
| Rabah, H | 1 |
| Nicolas, G | 1 |
| Emmanuel, N | 1 |
| Sleiman, A | 1 |
| Hashem, M | 1 |
| Hussein, R | 1 |
| El Masri, A | 1 |
| Abboud, R | 1 |
| Fawaz, M | 1 |
| Haidar Ahmad, H | 1 |
| Tan, L | 1 |
| Li, S | 1 |
| Yang, H | 1 |
| Zou, Q | 1 |
| Wan, J | 1 |
| Li, Q | 1 |
| Lee, JJY | 1 |
| Alsaleem, A | 1 |
| Chiang, GPK | 1 |
| Limenis, E | 1 |
| Sontichai, W | 1 |
| Akikusa, J | 1 |
| Laxer, RM | 1 |
| Panikar, V | 1 |
| Joshi, S | 1 |
| Vadgama, J | 1 |
| Kamat, T | 1 |
| Wagle, T | 1 |
| Nasilkar, N | 1 |
| Shah, N | 1 |
| Sheikh, S | 1 |
| Jain, C | 1 |
| Zhao, XY | 1 |
| Rakhda, MI | 1 |
| Wang, TI | 1 |
| Jia, JD | 1 |
| Bourrier, A | 1 |
| Seksik, P | 2 |
| Cosnes, J | 4 |
| Zhou, YQ | 1 |
| Mao, WQ | 1 |
| Zhang, XJ | 1 |
| Li, T | 1 |
| Chouchana, L | 1 |
| Roche, D | 1 |
| Jian, R | 1 |
| Beaune, P | 1 |
| Loriot, MA | 1 |
| Seo, P | 5 |
| Langford, CA | 7 |
| Hoffman, GS | 6 |
| Kallenberg, CG | 5 |
| St Clair, EW | 4 |
| Fessler, BJ | 2 |
| Ding, L | 4 |
| Viviano, L | 2 |
| Tchao, NK | 4 |
| Phippard, DJ | 1 |
| Asare, AL | 1 |
| Lim, N | 2 |
| Ikle, D | 4 |
| Jepson, B | 3 |
| Brunetta, P | 4 |
| Allen, NB | 2 |
| Fervenza, FC | 4 |
| Geetha, D | 3 |
| Keogh, K | 2 |
| Kissin, EY | 2 |
| Monach, PA | 4 |
| Peikert, T | 2 |
| Stegeman, C | 2 |
| Ytterberg, SR | 3 |
| Mueller, M | 1 |
| Sejismundo, LP | 1 |
| Mieras, K | 1 |
| Stone, JH | 4 |
| Rodríguez-Grau, Mdel C | 1 |
| Chaparro, M | 1 |
| Díaz, R | 1 |
| Sinha, A | 1 |
| Gulati, A | 1 |
| Saini, S | 1 |
| Blanc, C | 1 |
| Gupta, A | 3 |
| Gurjar, BS | 1 |
| Saini, H | 1 |
| Kotresh, ST | 1 |
| Ali, U | 1 |
| Bhatia, D | 1 |
| Ohri, A | 1 |
| Kumar, M | 1 |
| Agarwal, I | 1 |
| Gulati, S | 1 |
| Anand, K | 1 |
| Vijayakumar, M | 1 |
| Sinha, R | 1 |
| Sethi, S | 1 |
| Salmona, M | 1 |
| George, A | 2 |
| Bal, V | 1 |
| Singh, G | 1 |
| Dinda, AK | 1 |
| Hari, P | 1 |
| Rath, S | 1 |
| Dragon-Durey, MA | 1 |
| Bagga, A | 1 |
| Manousou, P | 3 |
| Cholongitas, E | 2 |
| Samonakis, D | 2 |
| Tsochatzis, E | 2 |
| Corbani, A | 1 |
| Dhillon, AP | 4 |
| Davidson, J | 1 |
| Rodríguez-Perálvarez, M | 1 |
| Patch, D | 3 |
| O'Beirne, J | 3 |
| Thorburn, D | 2 |
| Luong, T | 1 |
| Rolles, K | 3 |
| Davidson, B | 1 |
| McCormick, PA | 1 |
| Hayes, P | 2 |
| Burroughs, AK | 5 |
| Marie, I | 1 |
| Hatron, PY | 1 |
| Cherin, P | 1 |
| Vittecoq, O | 1 |
| Menard, JF | 1 |
| Jouen, F | 1 |
| Dominique, S | 1 |
| Cuthbertson, D | 1 |
| McAlear, CA | 2 |
| Krischer, JP | 1 |
| Magro, F | 1 |
| Santos-Antunes, J | 1 |
| Vilas-Boas, F | 1 |
| Rodrigues-Pinto, E | 1 |
| Coelho, R | 1 |
| Ribeiro, OS | 1 |
| Lopes, S | 1 |
| Macedo, G | 1 |
| Kim, SM | 1 |
| Park, J | 1 |
| Kim, SH | 3 |
| Park, SY | 1 |
| Kim, JY | 1 |
| Sung, JJ | 1 |
| Park, KS | 1 |
| Lee, KW | 2 |
| Mealy, MA | 1 |
| Wingerchuk, DM | 1 |
| Palace, J | 3 |
| Greenberg, BM | 1 |
| Levy, M | 1 |
| Zabana, Y | 1 |
| Mañosa, M | 1 |
| Cabré, E | 2 |
| Bernal, I | 2 |
| Marín, L | 1 |
| Lorenzo-Zúñiga, V | 1 |
| Moreno, V | 1 |
| Boix, J | 2 |
| Springer, J | 1 |
| Nutter, B | 1 |
| Villa-Forte, A | 1 |
| Elsone, L | 1 |
| Kitley, J | 1 |
| Luppe, S | 1 |
| Lythgoe, D | 1 |
| Mutch, K | 1 |
| Jacob, S | 2 |
| Brown, R | 1 |
| Moss, K | 1 |
| McNeillis, B | 1 |
| Goh, YY | 1 |
| Leite, MI | 2 |
| Robertson, N | 1 |
| Jacob, A | 1 |
| Nordstrom, E | 1 |
| Fischer, M | 1 |
| Haris, Á | 1 |
| Polner, K | 1 |
| Arányi, J | 1 |
| Braunitzer, H | 1 |
| Kaszás, I | 1 |
| Mucsi, I | 1 |
| Frivolt, K | 1 |
| Schwerd, T | 1 |
| Werkstetter, KJ | 1 |
| Schwarzer, A | 1 |
| Schatz, SB | 1 |
| Bufler, P | 1 |
| Koletzko, S | 1 |
| Chauvin, A | 1 |
| Le Thuaut, A | 1 |
| Belhassan, M | 1 |
| Le Baleur, Y | 1 |
| Mesli, F | 1 |
| Bastuji-Garin, S | 1 |
| Delchier, JC | 1 |
| Amiot, A | 1 |
| Heidari, P | 1 |
| Verdijk, RM | 1 |
| van den Bosch, WA | 1 |
| Paridaens, D | 1 |
| Thorell, SE | 1 |
| Gorodkin, R | 1 |
| Murray, D | 1 |
| Thachil, J | 1 |
| Miloslavsky, EM | 2 |
| Villarreal, M | 1 |
| Boyle, BM | 1 |
| Kappelman, MD | 1 |
| Colletti, RB | 1 |
| Baldassano, RN | 1 |
| Milov, DE | 1 |
| Crandall, WV | 1 |
| Lorenzetti, R | 1 |
| Zullo, A | 1 |
| Ridola, L | 1 |
| Diamanti, AP | 1 |
| Laganà, B | 1 |
| Gatta, L | 1 |
| Migliore, A | 1 |
| Armuzzi, A | 1 |
| Hassan, C | 2 |
| Bruzzese, V | 1 |
| Robb, PM | 1 |
| Sorrentino, D | 1 |
| Vester-Andersen, MK | 1 |
| Vind, I | 1 |
| Prosberg, MV | 1 |
| Bengtsson, BG | 1 |
| Blixt, T | 1 |
| Munkholm, P | 1 |
| Andersson, M | 2 |
| Jess, T | 1 |
| Bendtsen, F | 1 |
| Kuno, T | 1 |
| Tamura, Y | 1 |
| Ono, T | 1 |
| Murata, M | 2 |
| Kuwana, M | 1 |
| Satoh, T | 1 |
| Fukuda, K | 1 |
| Esmaili, N | 2 |
| Chams-Davatchi, C | 2 |
| Valikhani, M | 2 |
| Daneshpazhooh, M | 1 |
| Toosi, S | 1 |
| Karimi, A | 1 |
| Mortazavi, H | 1 |
| Croft, AP | 1 |
| Smith, SW | 1 |
| Carr, S | 1 |
| Youssouf, S | 1 |
| Salama, AD | 1 |
| Burns, A | 1 |
| Pusey, CD | 2 |
| Hamilton, P | 1 |
| Brown, N | 1 |
| Venning, M | 1 |
| Morgan, MD | 1 |
| Kennedy, NA | 1 |
| Kalla, R | 1 |
| Warner, B | 1 |
| Gambles, CJ | 1 |
| Musy, R | 1 |
| Reynolds, S | 1 |
| Dattani, R | 1 |
| Nayee, H | 1 |
| Felwick, R | 1 |
| Harris, R | 1 |
| Marriott, S | 1 |
| Senanayake, SM | 1 |
| Al-Hilou, H | 1 |
| Gaya, DR | 1 |
| Mansfield, J | 1 |
| Parkes, M | 1 |
| Ahmad, T | 1 |
| Cummings, JR | 1 |
| Arnott, ID | 1 |
| Lobo, AJ | 1 |
| Smith, M | 1 |
| Lindsay, JO | 1 |
| Lees, CW | 1 |
| Goh, KG | 1 |
| Ong, SG | 1 |
| Vidigal, FM | 1 |
| de Souza, GS | 1 |
| Chebli, LA | 1 |
| da Rocha Ribeiro, TC | 1 |
| Furtado, MC | 1 |
| Castro, AC | 1 |
| Pinto, AL | 1 |
| do Valle Pinheiro, B | 1 |
| de Lima Pace, FH | 1 |
| Machado de Oliveira, J | 1 |
| de Oliveira Zanini, KA | 1 |
| Gaburri, PD | 1 |
| Zanini, A | 1 |
| Ribeiro, LC | 1 |
| Chebli, JM | 1 |
| Wenzl, HH | 1 |
| Primas, C | 1 |
| Novacek, G | 3 |
| Teml, A | 2 |
| Öfferlbauer-Ernst, A | 1 |
| Högenauer, C | 1 |
| Vogelsang, H | 4 |
| Petritsch, W | 3 |
| Reinisch, W | 5 |
| Massacesi, L | 1 |
| Tramacere, I | 1 |
| Amoroso, S | 1 |
| Battaglia, MA | 1 |
| Benedetti, MD | 1 |
| Filippini, G | 1 |
| La Mantia, L | 1 |
| Repice, A | 1 |
| Solari, A | 1 |
| Tedeschi, G | 1 |
| Milanese, C | 2 |
| Arends, S | 1 |
| Berden, JH | 1 |
| Grootscholten, C | 1 |
| Derksen, RH | 1 |
| Berger, SP | 1 |
| de Sévaux, RG | 1 |
| Voskuyl, AE | 2 |
| Bijl, M | 1 |
| Zuo, L | 1 |
| Gu, L | 1 |
| Li, N | 1 |
| Li, J | 1 |
| De Cruz, P | 2 |
| Kamm, MA | 2 |
| Hamilton, AL | 2 |
| Ritchie, KJ | 2 |
| Krejany, EO | 2 |
| Gorelik, A | 2 |
| Liew, D | 2 |
| Prideaux, L | 2 |
| Lawrance, IC | 2 |
| Andrews, JM | 2 |
| Bampton, PA | 2 |
| Gibson, PR | 2 |
| Leong, RW | 3 |
| Florin, TH | 2 |
| Gearry, RB | 3 |
| Radford-Smith, G | 2 |
| Macrae, FA | 2 |
| Debinski, H | 2 |
| Selby, W | 2 |
| Kronborg, I | 2 |
| Johnston, MJ | 2 |
| Woods, R | 2 |
| Elliott, PR | 2 |
| Bell, SJ | 2 |
| Brown, SJ | 2 |
| Connell, WR | 2 |
| Desmond, PV | 2 |
| Mok, CC | 4 |
| Ying, KY | 2 |
| Yim, CW | 1 |
| Siu, YP | 2 |
| Tong, KH | 1 |
| To, CH | 1 |
| Ng, WL | 2 |
| Ataya, A | 1 |
| Faruqi, I | 1 |
| Salgado, JC | 1 |
| Pruitt, A | 1 |
| Balcer, L | 1 |
| Galetta, S | 1 |
| Markowitz, C | 1 |
| Dahodwala, N | 1 |
| Chen, SF | 1 |
| Wang, H | 1 |
| Li, ZY | 1 |
| Wang, SX | 1 |
| Yu, F | 1 |
| Zhao, MH | 1 |
| Chen, M | 1 |
| Villareal, M | 1 |
| Duricova, D | 1 |
| Archavlis, E | 1 |
| Rutgeerts, P | 4 |
| Bortlik, M | 1 |
| Mantzaris, G | 1 |
| Van Assche, G | 3 |
| Corrigan, M | 1 |
| Oo, YH | 1 |
| Adams, DH | 1 |
| Qiu, W | 2 |
| Kermode, AG | 1 |
| Li, R | 1 |
| Dai, Y | 1 |
| Wang, J | 2 |
| Zhong, X | 1 |
| Li, C | 1 |
| Lu, Z | 2 |
| Hu, X | 1 |
| Marzouk, S | 1 |
| Garbaa, S | 1 |
| Cherif, Y | 1 |
| Jallouli, M | 1 |
| Bahri, F | 1 |
| Bahloul, Z | 1 |
| Ampuero, J | 1 |
| Rojas-Feria, M | 1 |
| Castro-Fernández, M | 1 |
| Millán-Lorenzo, M | 1 |
| Guerrero-Jiménez, P | 1 |
| Romero-Gómez, M | 1 |
| Rotondo, C | 1 |
| Lopalco, G | 1 |
| Iannone, F | 1 |
| Vitale, A | 1 |
| Talarico, R | 1 |
| Galeazzi, M | 1 |
| Lapadula, G | 1 |
| Cantarini, L | 1 |
| Flamant, M | 1 |
| Cheon, JH | 6 |
| Lee, HJ | 2 |
| Park, SJ | 2 |
| Hong, SP | 3 |
| Kim, TI | 5 |
| Kim, WH | 5 |
| Lazaros, G | 1 |
| Brucato, A | 1 |
| Gaita, F | 1 |
| Jakobovits, S | 1 |
| Mejía-Vilet, JM | 1 |
| Córdova-Sánchez, BM | 1 |
| Arreola-Guerra, JM | 1 |
| Morales-Buenrostro, LE | 1 |
| Uribe-Uribe, NO | 1 |
| Correa-Rotter, R | 1 |
| Bollen, L | 1 |
| Vande Casteele, N | 1 |
| Ballet, V | 1 |
| Gils, A | 1 |
| Yamamura, M | 1 |
| Fujii, T | 1 |
| Takasaki, Y | 1 |
| Amano, K | 1 |
| Muso, E | 1 |
| Murakawa, Y | 1 |
| Arimura, Y | 1 |
| Makino, H | 1 |
| Szalmás, O | 1 |
| Nagy-Vince, M | 1 |
| Dankó, K | 1 |
| Farkas, F | 1 |
| Bouma, G | 2 |
| van Nieuwkerk, CM | 1 |
| Eliadou, E | 1 |
| Day, AS | 1 |
| Thompson-Fawcett, MW | 1 |
| Rowbotham, DS | 1 |
| Walmsley, R | 1 |
| Schultz, M | 1 |
| Inns, SJ | 1 |
| Andrew, NH | 1 |
| Kearney, D | 1 |
| Sladden, N | 1 |
| McKelvie, P | 1 |
| Wu, A | 1 |
| Sun, MT | 1 |
| McNab, A | 1 |
| Selva, D | 2 |
| Vazquez, V | 1 |
| Fayad, A | 1 |
| González, G | 1 |
| Smuclir Quevedo, A | 1 |
| Robaina Sindín, J | 1 |
| Goyal, V | 1 |
| Srivastava, AK | 1 |
| Shukla, G | 1 |
| Behari, M | 1 |
| Kim, JH | 3 |
| Park, Y | 1 |
| Lalueza, A | 1 |
| Ruiz, S | 1 |
| Villacampa, F | 1 |
| López, R | 1 |
| Zabia, E | 1 |
| Sarandeses, P | 1 |
| Hernández, AC | 1 |
| Herrero, JM | 1 |
| Lumbreras, C | 1 |
| Karstensen, JG | 1 |
| Săftoiu, A | 1 |
| Brynskov, J | 1 |
| Hendel, J | 1 |
| Ciocalteu, A | 1 |
| Klausen, P | 1 |
| Klausen, TW | 1 |
| Riis, LB | 1 |
| Vilmann, P | 1 |
| Copova, I | 2 |
| Zarubova, K | 2 |
| Nevoral, J | 1 |
| Begun, J | 1 |
| Puga, M | 1 |
| Carpio, D | 1 |
| Sampil, M | 1 |
| Zamora, MJ | 1 |
| Fernandez-Salgado, E | 1 |
| Adler, Y | 1 |
| Charron, P | 1 |
| Sanders, JS | 1 |
| de Joode, AA | 1 |
| DeSevaux, RG | 1 |
| Broekroelofs, J | 1 |
| van Paassen, P | 1 |
| Tervaert, JW | 4 |
| Karakoyun, M | 2 |
| Ecevit, CO | 1 |
| Kilicoglu, E | 1 |
| Aydogdu, S | 1 |
| Yagci, RV | 1 |
| Ozgenc, F | 2 |
| Fotis, L | 1 |
| Tuttle, PV | 1 |
| Baszis, KW | 1 |
| Pepmueller, PH | 1 |
| Moore, TL | 1 |
| White, AJ | 1 |
| Valenzuela, RM | 1 |
| Byrd, J | 1 |
| Kramer, GD | 1 |
| Palmer, CA | 1 |
| Osborn, AG | 1 |
| Digre, KB | 1 |
| Warner, JE | 1 |
| Sah, BP | 1 |
| Sharma, B | 1 |
| Iannuzzi, MC | 1 |
| Xu, Y | 1 |
| Ren, HT | 1 |
| Qiao, L | 1 |
| Zhang, Y | 1 |
| Fei, YY | 1 |
| Zhao, Y | 1 |
| Cui, LY | 1 |
| Lian, Z | 1 |
| Feng, H | 1 |
| Miao, X | 1 |
| Hyun, JW | 2 |
| Kim, G | 1 |
| Kim, Y | 1 |
| Jeong, IH | 1 |
| Kim, HJ | 2 |
| Lim, JY | 1 |
| Lim, YH | 1 |
| Choi, EH | 1 |
| Cuilleron, M | 1 |
| Jarlot, C | 1 |
| Sugimoto, M | 1 |
| Yokota, Y | 1 |
| Ban, H | 1 |
| Inatomi, O | 1 |
| Bamba, S | 1 |
| Kushima, R | 1 |
| Andoh, A | 1 |
| Kubota, K | 1 |
| Kamisawa, T | 1 |
| Okazaki, K | 1 |
| Kawa, S | 1 |
| Hirano, K | 1 |
| Hirooka, Y | 1 |
| Uchida, K | 1 |
| Shiomi, H | 1 |
| Ohara, H | 1 |
| Shimizu, K | 1 |
| Arakura, N | 1 |
| Kanno, A | 1 |
| Sakagami, J | 1 |
| Itoi, T | 1 |
| Ito, T | 1 |
| Ueki, T | 2 |
| Nishino, T | 1 |
| Inui, K | 1 |
| Mizuno, N | 1 |
| Yoshida, H | 1 |
| Sugiyama, M | 1 |
| Iwasaki, E | 1 |
| Irisawa, A | 1 |
| Shimosegawa, T | 1 |
| Takeyama, Y | 1 |
| Chiba, T | 1 |
| Hale, GM | 1 |
| Davies, ML | 1 |
| Joung, A | 1 |
| Park, EY | 1 |
| Joo, J | 1 |
| Liebscher, F | 1 |
| Pfammatter, T | 1 |
| Kolios, A | 1 |
| Greutmann, M | 1 |
| Franzen, D | 1 |
| Muratore, F | 1 |
| Pipitone, N | 1 |
| Salvarani, C | 1 |
| Chong, JH | 1 |
| Koh, MJA | 1 |
| Rouskova, B | 1 |
| Pos, L | 1 |
| Skaba, R | 1 |
| Gopaluni, S | 1 |
| Lewin, M | 1 |
| Vingerhoedt, NM | 1 |
| Janssen, S | 1 |
| Mravunac, M | 1 |
| Wauters, CA | 1 |
| Strobbe, LJ | 1 |
| Demircin, G | 1 |
| Oner, A | 1 |
| Erdoğan, O | 1 |
| Delibaş, A | 1 |
| Baysun, S | 1 |
| Bülbül, M | 1 |
| Bek, K | 1 |
| Oksal, A | 1 |
| Mossop, H | 1 |
| Davies, P | 1 |
| Murphy, MS | 1 |
| Cordero-Coma, M | 1 |
| Benito, MF | 1 |
| Hernández, AM | 1 |
| Antolín, SC | 1 |
| Ruíz, JM | 1 |
| Treton, X | 1 |
| Mary, JY | 3 |
| Duclos, B | 2 |
| Soule, JC | 2 |
| Lerebours, E | 2 |
| Lemann, M | 9 |
| Tabbara, KF | 1 |
| Al-Hemidan, AI | 1 |
| Aboul-Enein, F | 1 |
| Waters, P | 1 |
| Kuenz, B | 1 |
| Hauser, A | 1 |
| Berger, T | 1 |
| Lang, W | 1 |
| Reindl, M | 1 |
| Vincent, A | 2 |
| Kristoferitsch, W | 1 |
| Park, BJ | 1 |
| Lee, KJ | 1 |
| Hwang, JC | 1 |
| Sin, SJ | 1 |
| Chung, JY | 1 |
| Cho, SW | 1 |
| Kim, KO | 1 |
| Jang, BI | 2 |
| Wang, XL | 2 |
| Lu, JM | 2 |
| Yang, LJ | 1 |
| Lü, ZH | 2 |
| Dou, JT | 2 |
| Mu, YM | 2 |
| Pan, CY | 1 |
| Horakova, D | 3 |
| Dwyer, MG | 2 |
| Havrdova, E | 3 |
| Cox, JL | 2 |
| Dolezal, O | 3 |
| Bergsland, N | 2 |
| Rimes, B | 1 |
| Seidl, Z | 3 |
| Vaneckova, M | 3 |
| Zivadinov, R | 3 |
| Sandanayake, NS | 1 |
| Church, NI | 1 |
| Chapman, MH | 1 |
| Johnson, GJ | 1 |
| Dhar, DK | 1 |
| Amin, Z | 1 |
| Deheragoda, MG | 1 |
| Novelli, M | 1 |
| Winstanley, A | 1 |
| Rodriguez-Justo, M | 1 |
| Hatfield, AR | 1 |
| Pereira, SP | 1 |
| Webster, GJ | 1 |
| Mulay, AV | 1 |
| van Walraven, C | 1 |
| Knoll, GA | 1 |
| Usui, J | 1 |
| Yamagata, K | 1 |
| Leu, S | 1 |
| Sun, PK | 1 |
| Collyer, J | 1 |
| Smidt, A | 1 |
| Stika, CS | 1 |
| Schlosser, B | 1 |
| Mirowski, GW | 1 |
| Vanagunas, A | 1 |
| Buchman, AL | 1 |
| Chakour, R | 1 |
| Leimgruber, A | 1 |
| Bart, PA | 1 |
| Spertini, F | 1 |
| Sokol, H | 1 |
| Nion-Larmurier, I | 1 |
| Vienne, A | 1 |
| Beaugerie, L | 2 |
| Krasensky, J | 2 |
| Novakova, I | 1 |
| Ticha, V | 1 |
| Dusek, L | 1 |
| Houzvickova, E | 1 |
| Hussein, S | 1 |
| Svobodnik, A | 1 |
| McLeod, RS | 2 |
| Wolff, BG | 1 |
| Ross, S | 1 |
| Parkes, R | 1 |
| McKenzie, M | 1 |
| Deltenre, P | 1 |
| Ardizzone, S | 3 |
| Hanauer, SB | 1 |
| Herfarth, H | 1 |
| Cassinotti, A | 1 |
| Actis, GC | 2 |
| Duca, P | 1 |
| Massari, A | 1 |
| Colombo, E | 1 |
| Gai, E | 1 |
| D'Albasio, G | 2 |
| Manes, G | 1 |
| Travis, S | 2 |
| Porro, GB | 1 |
| Velayos, FS | 1 |
| Sandborn, WJ | 3 |
| Viazis, N | 1 |
| Vlachogiannakos, J | 1 |
| Georgiou, O | 1 |
| Rodias, M | 1 |
| Georgiadis, D | 1 |
| Papastamopoulos, V | 1 |
| Baraboutis, IG | 1 |
| Karamanolis, DG | 1 |
| Skoutelis, A | 1 |
| Moreira, T | 1 |
| Lago, P | 1 |
| Salgado, M | 1 |
| Pimentel, R | 1 |
| Arnold, DM | 1 |
| Nazi, I | 1 |
| Santos, A | 1 |
| Chan, H | 1 |
| Heddle, NM | 1 |
| Warkentin, TE | 1 |
| Kelton, JG | 1 |
| McCormick, A | 1 |
| Miyamoto, K | 1 |
| Kusunoki, S | 1 |
| Jung, YS | 1 |
| Park, JJ | 3 |
| Moon, CM | 1 |
| Kim, SW | 1 |
| Papay, P | 1 |
| Ho, E | 1 |
| Gratzer, C | 1 |
| Lissner, D | 1 |
| Herkner, H | 1 |
| Riss, S | 1 |
| Dejaco, C | 3 |
| Miehsler, W | 2 |
| Saida, T | 1 |
| Kil, JS | 1 |
| Han, AR | 1 |
| Kang, JY | 1 |
| Won, HJ | 1 |
| Jung, HY | 1 |
| Lim, HM | 1 |
| Gwak, GY | 1 |
| Choi, MS | 1 |
| Koh, KC | 1 |
| Paik, SW | 1 |
| Yoo, BC | 1 |
| Chung, MJ | 1 |
| Kim, SU | 1 |
| Kim, NK | 1 |
| Lee, YH | 1 |
| Woo, JH | 1 |
| Choi, SJ | 1 |
| Ji, JD | 1 |
| Song, GG | 1 |
| Murakami, Y | 1 |
| Matsui, T | 1 |
| Hirai, F | 1 |
| Takatsu, N | 1 |
| Takaki, Y | 1 |
| Nagahama, T | 1 |
| Hisabe, T | 1 |
| Beppu, T | 1 |
| Miyaoka, M | 1 |
| Maki, S | 1 |
| Takeichi, M | 1 |
| Nishimura, T | 1 |
| Yao, K | 1 |
| Tay, L | 1 |
| Duncan, E | 1 |
| Singhal, D | 1 |
| Al-Qunfoidi, R | 1 |
| Coghlan, D | 1 |
| Jaksic, W | 1 |
| Szabo, F | 1 |
| McRae, S | 1 |
| Lloyd, J | 1 |
| Oussalah, A | 1 |
| Chevaux, JB | 1 |
| Fay, R | 1 |
| Bigard, MA | 1 |
| Lakatos, L | 2 |
| Tursi, A | 1 |
| Brandimarte, G | 1 |
| Papa, A | 1 |
| Giglio, A | 1 |
| Elisei, W | 1 |
| Giorgetti, GM | 1 |
| Forti, G | 1 |
| Morini, S | 1 |
| Pistoia, MA | 1 |
| Modeo, ME | 1 |
| Rodino', S | 1 |
| D'Amico, T | 1 |
| Sebkova, L | 1 |
| Sacca', N | 1 |
| Di Giulio, E | 1 |
| Luzza, F | 1 |
| Imeneo, M | 1 |
| Larussa, T | 1 |
| Di Rosa, S | 1 |
| Danese, S | 1 |
| Rosien, U | 1 |
| Weiss, S | 1 |
| Layer, P | 1 |
| Jeon, EJ | 1 |
| Lee, KM | 2 |
| Jung, DY | 1 |
| Kim, TH | 2 |
| Ji, JS | 1 |
| Kim, HK | 1 |
| Choi, KY | 1 |
| Krumsiek, A | 1 |
| Poggemann, V | 1 |
| Wertzel, H | 1 |
| Achenbach, HJ | 1 |
| Kitayama, A | 1 |
| Misago, N | 1 |
| Okawa, T | 1 |
| Iwakiri, R | 1 |
| Narisawa, Y | 1 |
| McKiernan, PJ | 1 |
| Strassburg, CP | 1 |
| Naumovic, R | 1 |
| Jovanovic, D | 1 |
| Pavlovic, S | 1 |
| Stosovic, M | 1 |
| Marinkovic, J | 1 |
| Basta-Jovanovic, G | 1 |
| Lohse, AW | 1 |
| Gil, H | 1 |
| Shirai, T | 1 |
| Ishii, T | 1 |
| Tajima, Y | 1 |
| Fujii, H | 1 |
| Takasawa, N | 1 |
| Sato, H | 1 |
| Harigae, H | 1 |
| Maggiore, G | 2 |
| Sciveres, M | 1 |
| Fabre, M | 1 |
| Gori, L | 1 |
| Pacifico, L | 1 |
| Resti, M | 1 |
| Choulot, JJ | 1 |
| Jacquemin, E | 1 |
| Bernard, O | 2 |
| Bernard, P | 1 |
| Charneux, J | 1 |
| Kovács, J | 1 |
| Nagy, A | 1 |
| Szabó, A | 1 |
| Lorincz, M | 1 |
| Yang, G | 1 |
| Ba, J | 1 |
| Dou, J | 1 |
| Mu, Y | 1 |
| French, H | 1 |
| Mark Dalzell, A | 1 |
| Srinivasan, R | 1 |
| El-Matary, W | 1 |
| Manfredi, R | 1 |
| Frulloni, L | 1 |
| Mantovani, W | 1 |
| Bonatti, M | 1 |
| Graziani, R | 1 |
| Pozzi Mucelli, R | 1 |
| García Domínguez, JM | 1 |
| Martínez Ginés, ML | 1 |
| Martín-Barriga, ML | 1 |
| Guzmán-de-Villoria, J | 1 |
| Muñoz Blanco, JL | 1 |
| de Andrés Frutos, C | 1 |
| Yang, GQ | 1 |
| Gu, WJ | 1 |
| Du, J | 1 |
| Guo, QH | 1 |
| Ba, JM | 1 |
| El M'Kaddem, B | 1 |
| Clapuyt, P | 1 |
| de Bruycker, JJ | 1 |
| Lauwerys, B | 1 |
| Raftopoulos, C | 1 |
| Godfraind, C | 1 |
| Nassogne, MC | 1 |
| Costanzi, C | 1 |
| Matiello, M | 1 |
| Lucchinetti, CF | 1 |
| Weinshenker, BG | 1 |
| Pittock, SJ | 1 |
| Mandrekar, J | 1 |
| Thapa, P | 1 |
| McKeon, A | 1 |
| Kiss, LS | 1 |
| Szamosi, T | 1 |
| Molnár, T | 1 |
| Miheller, P | 1 |
| Vincze, A | 1 |
| Palatka, K | 1 |
| Bartha, Z | 1 |
| Gasztonyi, B | 1 |
| Salamon, A | 1 |
| Horváth, G | 1 |
| Tóth, GT | 1 |
| Farkas, K | 1 |
| Banai, J | 1 |
| Tulassay, Z | 1 |
| Nagy, F | 2 |
| Szenes, M | 1 |
| Lovász, BD | 1 |
| Végh, Z | 1 |
| Golovics, PA | 1 |
| Szathmári, M | 1 |
| Papp, M | 1 |
| Herrlinger, K | 2 |
| Stange, EF | 3 |
| Samonakis, DN | 2 |
| Germani, G | 1 |
| Hernandez-Da Mota, SE | 1 |
| Arellanes-Garcia, L | 1 |
| Recillas-Gispert, C | 1 |
| Cornejo-Ballesteros, H | 1 |
| Melgoza-del-Angel, C | 1 |
| Teran-Estrada, L | 1 |
| Sanchez-Gonzalez, R | 1 |
| Rudd, A | 1 |
| Dolianitis, C | 1 |
| Varigos, G | 1 |
| Howard, A | 1 |
| Yoshida, S | 1 |
| Takeuchi, T | 1 |
| Yoshikawa, A | 1 |
| Ozaki, T | 1 |
| Fujiki, Y | 1 |
| Hata, K | 1 |
| Makino, S | 1 |
| Hanafusa, T | 1 |
| Vafa, H | 1 |
| Demetter, P | 1 |
| Goyens, P | 1 |
| De Laet, C | 1 |
| Adler, M | 1 |
| Seck, SM | 1 |
| Brunet, P | 1 |
| Dhaliwal, HK | 1 |
| Anderson, R | 1 |
| Thornhill, EL | 1 |
| Schneider, S | 1 |
| McFarlane, E | 1 |
| Lennard, L | 1 |
| Kim, KJ | 1 |
| Han, BJ | 1 |
| Yang, SK | 2 |
| Na, SY | 1 |
| Park, SK | 1 |
| Boo, SJ | 1 |
| Park, SH | 1 |
| Yang, DH | 1 |
| Park, JH | 1 |
| Jeong, KW | 1 |
| Ye, BD | 2 |
| Byeon, JS | 1 |
| Myung, SJ | 1 |
| Kher, A | 1 |
| Kher, V | 1 |
| Le Guenno, G | 1 |
| Galicier, L | 1 |
| Uro-Coste, E | 1 |
| Petitcolin, V | 1 |
| Rieu, V | 1 |
| Ormerod, C | 1 |
| Sarkar, S | 1 |
| Woodcock, B | 1 |
| White, D | 1 |
| Lal, S | 1 |
| Tsuji, RK | 1 |
| Bittencourt, AG | 1 |
| Arai, MH | 1 |
| Santiago Gebrim, EM | 1 |
| van Gerven, NM | 1 |
| Verwer, BJ | 1 |
| Witte, BI | 1 |
| van Hoek, B | 1 |
| Coenraad, MJ | 1 |
| van Erpecum, KJ | 1 |
| Beuers, U | 1 |
| van Buuren, HR | 1 |
| de Man, RA | 1 |
| Drenth, JP | 1 |
| den Ouden, JW | 1 |
| Verdonk, RC | 1 |
| Koek, GH | 1 |
| Brouwer, JT | 1 |
| Guichelaar, MM | 1 |
| Mulder, CJ | 1 |
| van Nieuwkerk, KM | 1 |
| Minen, F | 1 |
| De Cunto, A | 1 |
| Martelossi, S | 2 |
| Ventura, A | 2 |
| Miettunen, PM | 1 |
| Pistorio, A | 1 |
| Palmisani, E | 1 |
| Ravelli, A | 1 |
| Silverman, E | 1 |
| Oliveira, S | 1 |
| Alessio, M | 1 |
| Cuttica, R | 1 |
| Mihaylova, D | 1 |
| Espada, G | 1 |
| Pasic, S | 1 |
| Insalaco, A | 1 |
| Ozen, S | 1 |
| Porras, O | 1 |
| Sztajnbok, F | 1 |
| Lazarevic, D | 1 |
| Martini, A | 1 |
| Ruperto, N | 1 |
| Feng, L | 1 |
| Huo, DM | 1 |
| Wu, QY | 1 |
| Liao, YH | 1 |
| Gustavsson, A | 1 |
| Magnuson, A | 1 |
| Blomberg, B | 1 |
| Halfvarson, J | 1 |
| Tysk, C | 1 |
| Gómez García, I | 1 |
| Sánchez Castaño, A | 1 |
| Romero Molina, M | 1 |
| Rubio Hidalgo, E | 1 |
| García Betancourth, N | 1 |
| Labra González, R | 1 |
| Sampietro Crespo, A | 1 |
| Álvarez Fernández, F | 1 |
| Flores Herrero, Á | 1 |
| Gómez Rodríguez, A | 1 |
| Sochatzis, ET | 1 |
| Isgro, G | 1 |
| Hall, A | 1 |
| Green, A | 1 |
| Calvaruso, V | 1 |
| Ma, GL | 1 |
| Gale, J | 1 |
| Burgess, G | 1 |
| Leandro, G | 2 |
| Angelberger, S | 1 |
| Schaeffeler, E | 1 |
| Shonova, O | 1 |
| Lukas, M | 1 |
| Bar-Meir, S | 1 |
| Dilger, K | 1 |
| Greinwald, R | 1 |
| Mueller, R | 1 |
| Herrlinger, KR | 1 |
| Jussila, A | 1 |
| Färkkilä, M | 1 |
| Järvinen, HJ | 1 |
| Fernández, O | 1 |
| Guerrero, M | 1 |
| Mayorga, C | 1 |
| Muñoz, L | 1 |
| Leán, A | 1 |
| Luque, G | 1 |
| Hervás, M | 1 |
| Fernández, V | 1 |
| Capdevila, A | 1 |
| de Ramón, E | 1 |
| Uehara, T | 1 |
| Nakaseko, C | 1 |
| Yokota, A | 1 |
| Saito, Y | 1 |
| Nishimura, M | 2 |
| Jungraithmayr, T | 1 |
| Staskewitz, A | 1 |
| Kirste, G | 1 |
| Böswald, M | 1 |
| Bulla, M | 1 |
| Burghard, R | 1 |
| Dippell, J | 1 |
| Greiner, C | 1 |
| Klare, B | 1 |
| Klaus, G | 1 |
| Leichter, H | 1 |
| Misselwitz, J | 1 |
| Patzer, L | 1 |
| Querfeld, U | 1 |
| Rascher, W | 1 |
| Tönshoff, B | 1 |
| Wiesel, M | 1 |
| Brandis, M | 1 |
| Zimmerhackl, LB | 1 |
| Sahu, DK | 1 |
| Rawoof, A | 1 |
| Sujatha, B | 1 |
| Hauer, HA | 1 |
| Bajema, IM | 1 |
| Van Houwelingen, HC | 1 |
| Ferrario, F | 1 |
| Noël, LH | 2 |
| Waldherr, R | 1 |
| Bruijn, JA | 1 |
| Hagen, EC | 2 |
| Garcia-Planella, E | 1 |
| Rosinach, M | 1 |
| Fluvià, L | 1 |
| Gassull, MA | 1 |
| Benabdallah, L | 1 |
| Rerolle, JP | 1 |
| Peraldi, MN | 1 |
| Bruneel, MF | 1 |
| Morelon, E | 1 |
| Kreis, H | 1 |
| Purvin, V | 1 |
| Ranson, N | 1 |
| Kawasaki, A | 1 |
| Fleig, WE | 1 |
| Hoffmann, J | 1 |
| Zeitz, M | 1 |
| Buhr, HJ | 1 |
| Kroesen, AJ | 1 |
| Ganten, M | 1 |
| Encke, J | 1 |
| Flosdorff, P | 1 |
| Grüber-Hoffmann, B | 1 |
| Erb, G | 1 |
| Hansmann, J | 1 |
| Aviña-Zubieta, JA | 1 |
| Galindo-Rodrìguez, G | 1 |
| Robledo, I | 1 |
| Vela-Ojeda, J | 1 |
| Vadillo-Buenfil, M | 1 |
| Rosas-Cabral, A | 1 |
| Salazar-Exaire, D | 1 |
| Czaja, AJ | 8 |
| Carpenter, HA | 1 |
| Rammert, Ch | 1 |
| Kullak-Ublick, GA | 1 |
| Umemoto, N | 1 |
| Demitsu, T | 1 |
| Toda, S | 1 |
| Ohsawa, M | 1 |
| Noguchi, T | 1 |
| Kakurai, M | 1 |
| Yamada, T | 1 |
| Suzuki, M | 1 |
| Nakagawa, H | 1 |
| Komai, A | 1 |
| Hashimoto, T | 1 |
| Andrassy, K | 1 |
| Bacon, P | 1 |
| Dadoniené, J | 1 |
| Ekstrand, A | 1 |
| Gaskin, G | 1 |
| Gregorini, G | 1 |
| de Groot, K | 1 |
| Gross, W | 1 |
| Mirapeix, E | 1 |
| Pettersson, E | 1 |
| Siegert, C | 1 |
| Sinico, A | 1 |
| Pariente, A | 2 |
| Shums, Z | 1 |
| Binder, WL | 1 |
| Lewis, SJ | 1 |
| Nelson, VJ | 1 |
| Norman, GL | 1 |
| Bonaz, B | 1 |
| Boitard, J | 1 |
| Marteau, P | 1 |
| Coffin, B | 1 |
| Belaiche, J | 1 |
| Cadiot, G | 1 |
| Metman, EH | 1 |
| Cortot, A | 1 |
| Pascual, J | 1 |
| Segoloni, G | 1 |
| Gonzalez Molina, M | 1 |
| del Castillo, D | 1 |
| Capdevila, L | 1 |
| Arias, M | 1 |
| Garcia, J | 1 |
| Ortuño, J | 1 |
| Johansen, TL | 1 |
| Kromann-Andersen, H | 1 |
| Hohlfeld, R | 2 |
| Voltz, R | 1 |
| Harrer, M | 1 |
| Waldhoer, T | 1 |
| Zekry, A | 1 |
| Gleeson, M | 1 |
| Guney, S | 1 |
| McCaughan, GW | 1 |
| Kolyvanos Naumann, U | 1 |
| Käser, L | 1 |
| Vetter, W | 1 |
| Contreras, G | 1 |
| Pardo, V | 1 |
| Leclercq, B | 1 |
| Lenz, O | 1 |
| Tozman, E | 1 |
| O'Nan, P | 1 |
| Roth, D | 1 |
| Kaplan, M | 1 |
| Mutlu, EA | 1 |
| Jakate, S | 1 |
| Bruninga, K | 1 |
| Losurdo, J | 2 |
| Keshavarzian, A | 1 |
| Lagget, M | 1 |
| Rizzetto, M | 1 |
| Fadda, M | 1 |
| Palmo, A | 1 |
| Pinna-Pintor, M | 1 |
| Morino, F | 1 |
| Kohnen, EM | 1 |
| Pansdorf, Y | 1 |
| Zubcov, A | 1 |
| Slot, MC | 1 |
| Boomsma, MM | 1 |
| Kühbacher, T | 1 |
| Schreiber, S | 2 |
| Fölsch, UR | 1 |
| Vilien, M | 1 |
| Dahlerup, JF | 1 |
| Munck, LK | 1 |
| Nørregaard, P | 1 |
| Grønbaek, K | 1 |
| Fallingborg, J | 1 |
| Farhey, Y | 1 |
| Hess, E | 1 |
| Delmont, E | 1 |
| Chanalet, S | 1 |
| Bourg, V | 1 |
| Soriani, MH | 1 |
| Chatel, M | 1 |
| Lebrun, C | 1 |
| Sornay-Soares, C | 1 |
| Job-Deslandre, C | 1 |
| Kahan, A | 1 |
| Tang, S | 1 |
| Leung, CY | 1 |
| Wong, RW | 4 |
| Lau, CS | 5 |
| Reissmann, A | 1 |
| Bischoff, SC | 1 |
| Fleig, W | 1 |
| Dignass, AU | 1 |
| Schölmerich, J | 2 |
| Heim, MH | 1 |
| Alves, A | 1 |
| Panis, Y | 1 |
| Joly, F | 1 |
| Pocard, M | 1 |
| Lavergne-Slove, A | 1 |
| Valleur, P | 2 |
| Mayo, JM | 1 |
| Colmenarejo, MB | 1 |
| Vaquerizo, PJ | 1 |
| Gutierrez, MV | 1 |
| Kornberg, A | 1 |
| Küpper, B | 1 |
| Tannapfel, A | 1 |
| Hommann, M | 1 |
| Scheele, J | 1 |
| Sarmiento, E | 1 |
| Fernàndez-Yáñez, J | 1 |
| Muñoz, P | 1 |
| Palomo, J | 1 |
| Rodríguez-Molina, JJ | 1 |
| Bermejo, J | 1 |
| Catalan, P | 1 |
| Bouza, E | 1 |
| Fernández-Cruz, E | 1 |
| Carbone, J | 1 |
| Molmenti, EP | 2 |
| Malagó, M | 1 |
| Rumbo, C | 1 |
| Shneider, BL | 1 |
| Emre, SH | 1 |
| Filipponi, F | 1 |
| Callea, F | 1 |
| Salizzoni, M | 1 |
| Grazi, GL | 1 |
| Fassati, LR | 2 |
| Rossi, M | 1 |
| Risaliti, A | 1 |
| Burra, P | 1 |
| Agnes, S | 1 |
| De Carlis, L | 1 |
| Valente, U | 1 |
| Ferrara, R | 1 |
| Pisati, R | 1 |
| Kennedy, ED | 1 |
| Urbach, DR | 1 |
| Krahn, MD | 1 |
| Steinhart, AH | 2 |
| Cohen, Z | 1 |
| Etienney, I | 1 |
| Gendre, JP | 1 |
| Matuchansky, C | 3 |
| Modigliani, R | 5 |
| Rambaud, JC | 4 |
| Tse, KC | 1 |
| Tang, CS | 2 |
| Mok, MY | 2 |
| Li, FK | 2 |
| Féray, C | 1 |
| Triantos, CK | 1 |
| Thalheimer, U | 1 |
| Quaglia, A | 1 |
| Teixeira, R | 1 |
| Papatheodoridis, GV | 1 |
| Sabin, CA | 1 |
| Rolando, N | 1 |
| Davies, S | 1 |
| Griffiths, P | 1 |
| Emery, V | 1 |
| Patch, DW | 1 |
| Davidson, BR | 1 |
| Lo, Y | 1 |
| Wong, WS | 1 |
| Vetter, C | 1 |
| Muzi, F | 1 |
| Orlando, G | 2 |
| Ielpo, B | 1 |
| Anselmo, A | 1 |
| Sabato Ceraldi, S | 1 |
| de Liguori Carino, N | 1 |
| de'Liguori Carino, N | 1 |
| Manzia, T | 1 |
| D'Andria, D | 1 |
| Tariciotti, L | 1 |
| Angelico, M | 2 |
| Tisone, G | 2 |
| Henderson, RD | 1 |
| Sandroni, P | 1 |
| Wijdicks, EF | 1 |
| Bacal, F | 2 |
| Silva, CP | 1 |
| Bocchi, EA | 2 |
| Pires, PV | 1 |
| Moreira, LF | 1 |
| Issa, VS | 1 |
| Moreira, SA | 1 |
| das Dores Cruz, F | 1 |
| Strabelli, T | 1 |
| Stolf, NA | 2 |
| Ramires, JA | 1 |
| Tan, P | 1 |
| Marotta, P | 1 |
| Ghent, C | 1 |
| Adams, P | 1 |
| Seela, S | 1 |
| Sheela, H | 1 |
| Boyer, JL | 1 |
| Barthel, HR | 1 |
| Gille, T | 1 |
| Halbsguth, A | 1 |
| Kramer, M | 1 |
| Aries, PM | 1 |
| Reinhold-Keller, E | 2 |
| Shoari, M | 1 |
| Katz, BJ | 1 |
| Hellmich, B | 1 |
| Lamprecht, P | 1 |
| Gross, WL | 2 |
| Green, CJ | 1 |
| Mee, AS | 1 |
| Rose, E | 1 |
| Wever, S | 1 |
| Zilliken, D | 1 |
| Linse, R | 1 |
| Haustein, UF | 1 |
| Bröcker, EB | 1 |
| Brueck, M | 1 |
| Runde, T | 1 |
| Rauber, K | 1 |
| Kramer, W | 1 |
| Lichtenstein, GR | 1 |
| Abreu, MT | 1 |
| Cohen, R | 1 |
| Tremaine, W | 1 |
| Moroni, G | 1 |
| Gallelli, B | 1 |
| Banfi, G | 2 |
| Sandri, S | 1 |
| Messa, P | 1 |
| Ponticelli, C | 2 |
| Vianna, RN | 1 |
| Ozdal, PC | 1 |
| Deschênes, J | 1 |
| Burnier, MN | 1 |
| Banerjee, S | 1 |
| Rahhal, R | 1 |
| Bishop, WP | 1 |
| Myrelid, P | 1 |
| Svärm, S | 1 |
| Andersson, P | 1 |
| Bodemar, G | 1 |
| Olaison, G | 1 |
| Miyake, Y | 2 |
| Iwasaki, Y | 1 |
| Terada, R | 1 |
| Okamaoto, R | 1 |
| Ikeda, H | 1 |
| Makino, Y | 1 |
| Kobashi, H | 1 |
| Takaguchi, K | 1 |
| Sakaguchi, K | 2 |
| Shiratori, Y | 1 |
| García-Gómez, PJ | 1 |
| Belzunce, A | 1 |
| Salinas Alamán, A | 1 |
| Heras, H | 1 |
| Sádaba, LM | 1 |
| Vahid, B | 1 |
| Marik, PE | 1 |
| Boura, P | 1 |
| Tselios, K | 1 |
| Kamali, S | 1 |
| Skendros, P | 1 |
| Sarantopoulos, A | 1 |
| Topouzis, F | 1 |
| Ramirez-Ortiz, MA | 1 |
| Vasquez-Resendis, A | 1 |
| Guilpain, P | 1 |
| Hattori, M | 1 |
| Olszewska, M | 1 |
| Kolacinska-Strasz, Z | 1 |
| Sulej, J | 1 |
| Labecka, H | 1 |
| Cwikla, J | 1 |
| Natorska, U | 1 |
| Blaszczyk, M | 1 |
| Hogan, AC | 1 |
| McAvoy, CE | 1 |
| Dick, AD | 1 |
| Lee, RW | 1 |
| Reale, LD | 1 |
| Besa, EC | 1 |
| Sunkad, M | 1 |
| Le Page, E | 1 |
| Leray, E | 1 |
| Taurin, G | 1 |
| Coustans, M | 1 |
| Chaperon, J | 1 |
| Morrissey, SP | 1 |
| Edan, G | 1 |
| Netzer, P | 1 |
| Gschossmann, JM | 1 |
| Straumann, A | 1 |
| Sendensky, A | 1 |
| Weimann, R | 1 |
| Schoepfer, AM | 1 |
| Sachdev, N | 1 |
| Gupta, V | 1 |
| Singh, R | 1 |
| Scheja, A | 1 |
| Hesselstrand, R | 1 |
| Wildt, M | 1 |
| Akesson, A | 1 |
| Rodríguez-Moranta, F | 1 |
| Soriano-Izquierdo, A | 1 |
| Al-Chalabi, T | 1 |
| Underhill, JA | 1 |
| Portmann, BC | 1 |
| McFarlane, IG | 3 |
| Heneghan, MA | 1 |
| Beissert, S | 1 |
| Werfel, T | 1 |
| Frieling, U | 1 |
| Böhm, M | 1 |
| Sticherling, M | 1 |
| Stadler, R | 1 |
| Zillikens, D | 1 |
| Rzany, B | 1 |
| Hunzelmann, N | 1 |
| Meurer, M | 1 |
| Gollnick, H | 1 |
| Ruzicka, T | 1 |
| Pillekamp, H | 1 |
| Junghans, V | 1 |
| Bonsmann, G | 1 |
| Luger, TA | 1 |
| Irani, SR | 1 |
| Rajabally, YA | 1 |
| Grubneac, A | 1 |
| Walters, RJ | 1 |
| Yazaki, M | 1 |
| Clover, L | 1 |
| Ribi, C | 1 |
| Mahr, A | 1 |
| Arène, JP | 1 |
| Lauque, D | 1 |
| Letellier, P | 1 |
| Delaval, P | 1 |
| Cordier, JF | 1 |
| Depla, JA | 1 |
| Van Calster, J | 1 |
| Shah, JA | 1 |
| Edwards, CM | 1 |
| Probert, CS | 1 |
| Reddy, D | 1 |
| Murphy, SJ | 1 |
| Kane, SV | 1 |
| Present, DH | 1 |
| Kornbluth, AA | 1 |
| Stocco, G | 1 |
| Malusa', N | 1 |
| Marino, S | 1 |
| Decorti, G | 1 |
| Bartoli, F | 1 |
| Kavusi, S | 1 |
| Hallaji, Z | 1 |
| Ghandi, N | 1 |
| Farahani, F | 1 |
| Lajevardi, V | 1 |
| Antel, JP | 1 |
| Singleton, JW | 4 |
| Morettini, A | 1 |
| Scartabelli, S | 1 |
| Bechi, P | 1 |
| Bartolozzi, C | 1 |
| Taddei, GL | 1 |
| Bartoletti, L | 1 |
| Allamani, A | 1 |
| Ewe, K | 1 |
| Karbach, U | 1 |
| Bender, SW | 1 |
| Posselt, HG | 1 |
| Waag, KL | 1 |
| Auer, IO | 1 |
| Hegarty, JE | 1 |
| McSorley, CG | 1 |
| McFarlane, BM | 1 |
| Williams, R | 4 |
| Hauser, SL | 1 |
| Fosburg, M | 1 |
| Kevy, S | 1 |
| Weiner, HL | 1 |
| James, SP | 1 |
| Hoofnagle, JH | 1 |
| Strober, W | 1 |
| Jones, EA | 1 |
| Blyth, WA | 1 |
| Harbour, DA | 1 |
| Hill, TJ | 1 |
| Calne, R | 2 |
| Kotulová, D | 1 |
| Stefanovic, J | 1 |
| Neuberger, J | 1 |
| Portmann, B | 1 |
| Ellison, GW | 3 |
| Myers, LW | 2 |
| Mickey, MR | 1 |
| Frane, MV | 1 |
| Tourtellotte, WW | 1 |
| Spina, CA | 1 |
| Fahey, JL | 1 |
| Hind, CR | 1 |
| Winearls, CG | 1 |
| Lockwood, CM | 3 |
| Rees, AJ | 3 |
| Pepys, MB | 1 |
| Marchiori, PE | 1 |
| Scaff, M | 1 |
| Zambon, AA | 1 |
| de Assis, JL | 1 |
| Aimard, G | 1 |
| Confavreux, C | 1 |
| Ventre, JJ | 1 |
| Guillot, M | 1 |
| Devic, M | 1 |
| Pinching, AJ | 1 |
| Pussell, BA | 1 |
| Sweny, P | 1 |
| Evans, DJ | 1 |
| Bowley, N | 1 |
| Peters, DK | 2 |
| Manns, M | 1 |
| Meyer zum Büschenfelde, KH | 2 |
| Dienes, HP | 1 |
| Dormeyer, HH | 1 |
| Lever, WF | 2 |
| Schaumburg-Lever, G | 2 |
| Witte, AS | 1 |
| Cornblath, DR | 1 |
| Parry, GJ | 1 |
| Lisak, RP | 1 |
| Schatz, NJ | 1 |
| Dosa, S | 1 |
| Cairns, SA | 1 |
| Mallick, NP | 1 |
| Lawler, W | 1 |
| Williams, G | 1 |
| Lehner, T | 1 |
| Adinolfi, M | 1 |
| Steinman, TI | 1 |
| Jaffe, BF | 1 |
| Monaco, AP | 1 |
| Wolff, SM | 2 |
| Fauci, AS | 2 |
| Feldhoff, CM | 1 |
| Balfour, HH | 1 |
| Simmons, RL | 1 |
| Najarian, JS | 2 |
| Mauer, SM | 1 |
| James, MP | 1 |
| Herdson, PB | 1 |
| Gavin, JB | 1 |
| Knight, SC | 1 |
| Harding, B | 1 |
| Burman, S | 1 |
| Mertin, J | 2 |
| Picozzi, VJ | 1 |
| Roeske, WR | 1 |
| Creger, WP | 1 |
| Latysh, VN | 1 |
| Rozhok, EI | 1 |
| Jones, RR | 1 |
| Ammon, HV | 1 |
| Summerskill, WH | 3 |
| Kartasheva, VI | 1 |
| Carter, B | 1 |
| Harrison, R | 1 |
| Lunt, GG | 1 |
| Behan, PO | 2 |
| Simpson, JA | 2 |
| Lemmens, HP | 1 |
| Langrehr, JM | 1 |
| Blumhardt, G | 2 |
| Lohmann, R | 1 |
| Knoop, M | 1 |
| Verschl, J | 1 |
| Schattenfroh, N | 1 |
| Neuhaus, R | 2 |
| Hopf, U | 3 |
| Bechstein, WO | 2 |
| Ozerova, LV | 1 |
| Gross, V | 1 |
| Andus, T | 1 |
| Chan, GL | 1 |
| Weinstein, SS | 1 |
| Vijayanagar, RR | 1 |
| Chryssomallis, F | 1 |
| Dimitriades, A | 1 |
| Chaidemenos, GC | 1 |
| Panagiotides, D | 1 |
| Karakatsanis, G | 1 |
| Johnson, PJ | 1 |
| Woodle, ES | 1 |
| So, S | 1 |
| Jendrisak, MD | 1 |
| Perdrizet, GA | 1 |
| White, HM | 1 |
| Marsh, JW | 1 |
| Jackson, LD | 1 |
| Song, E | 1 |
| Farthing, PM | 1 |
| Maragou, P | 1 |
| Coates, M | 1 |
| Tatnall, F | 1 |
| Leigh, IM | 2 |
| Williams, DM | 1 |
| Miller, BW | 1 |
| Brennan, DC | 1 |
| Korenblat, PE | 1 |
| Goss, JA | 1 |
| Flye, MW | 1 |
| Kalra, PA | 1 |
| Wood, GN | 1 |
| O'Donoghue, DJ | 1 |
| Mamtora, H | 1 |
| Routledge, R | 1 |
| Armstrong, G | 1 |
| Sinnott, PJ | 1 |
| Jos, V | 1 |
| Johnson, RW | 1 |
| Waldek, S | 1 |
| Agaliotis, DP | 1 |
| Papenhausen, PR | 1 |
| Moscinski, LC | 1 |
| Elfenbein, GJ | 1 |
| Flechtner, KM | 1 |
| Baum, K | 1 |
| Stark, ME | 1 |
| Tremaine, WJ | 2 |
| Gordon, M | 2 |
| Adu, D | 2 |
| Greaves, I | 2 |
| Richards, N | 2 |
| Michael, J | 2 |
| Emery, P | 2 |
| Bacon, PA | 2 |
| Howie, AJ | 1 |
| Khan, GA | 1 |
| Glicklich, DG | 1 |
| Iskaros, BF | 1 |
| Posner, L | 1 |
| Bialasiewicz, AA | 1 |
| Förster, W | 1 |
| Radig, H | 1 |
| Hüttenbrink, KB | 1 |
| Grewe, S | 1 |
| Busse, H | 1 |
| Yagyu, K | 1 |
| Takeshita, M | 1 |
| Otsuka, T | 1 |
| Kubota, H | 1 |
| Furuse, A | 1 |
| van Breda Vriesman, PJ | 1 |
| Hirose, M | 1 |
| Sano, T | 1 |
| Takahashi, Y | 1 |
| Okamoto, Y | 1 |
| Ushiroguchi, Y | 1 |
| Watanabe, T | 1 |
| Ninomiya, T | 1 |
| Kuroda, Y | 1 |
| Purvin, VA | 1 |
| Chioran, G | 1 |
| Chemtob, A | 1 |
| Malka, D | 1 |
| Lévy, P | 1 |
| Lévy, H | 1 |
| Ponsot, P | 1 |
| Bernades, P | 1 |
| Hughes, RA | 2 |
| Berrebi, W | 1 |
| Chaussade, S | 1 |
| Bruhl, AL | 1 |
| Hautefeuille, P | 1 |
| Couturier, D | 1 |
| Sawyer, MD | 1 |
| Mayoral, JL | 2 |
| Gillingham, KJ | 1 |
| Kramer, MA | 2 |
| Dunn, DL | 2 |
| Wang, KK | 1 |
| Shiels, MT | 1 |
| Katzmann, JA | 1 |
| Aoki, M | 1 |
| Miura, A | 1 |
| Sato, I | 1 |
| Suzuki, C | 1 |
| Schofield, JK | 1 |
| Tatnall, FM | 1 |
| Becker, CC | 1 |
| Gidal, BE | 1 |
| Fleming, JO | 1 |
| Scemama, G | 1 |
| Taï, R | 1 |
| Alloway, RR | 1 |
| Russell, WC | 1 |
| Gaber, LW | 1 |
| Amiri, MH | 1 |
| Vera, SR | 1 |
| Gaber, AO | 1 |
| Birck, R | 1 |
| Braun, C | 1 |
| Back, W | 1 |
| Gottstein, T | 1 |
| Rohmeiss, P | 1 |
| Manegold, BC | 1 |
| Strauch, M | 1 |
| Gretz, N | 1 |
| Bellotti, G | 1 |
| Mocelin, AO | 1 |
| Uip, D | 1 |
| Higuchi, ML | 1 |
| Amato-Neto, V | 1 |
| Fiorelli, A | 1 |
| Jatene, AD | 1 |
| Pileggi, F | 1 |
| Han, DJ | 2 |
| Yoon, HS | 1 |
| Lee, HM | 1 |
| Wagoner, LE | 1 |
| Taylor, DO | 1 |
| Olsen, SL | 1 |
| Bristow, MR | 1 |
| O'Connell, JB | 1 |
| Hammond, EH | 1 |
| Lappe, DL | 1 |
| Renlund, DG | 1 |
| Cariem, AK | 1 |
| Arendse, M | 1 |
| Cruse, P | 1 |
| Rayner, B | 1 |
| Vazquez, MC | 1 |
| Sabbatiello, R | 1 |
| Schiavelli, R | 1 |
| Maiolo, E | 1 |
| Jacob, N | 1 |
| Pattin, M | 1 |
| Rearte, A | 1 |
| Abboud, P | 1 |
| Messing, B | 2 |
| Quéreux, C | 1 |
| Napoléone, C | 1 |
| Zeitoun, P | 1 |
| Wahl, P | 1 |
| Bell, WR | 1 |
| Koop, I | 1 |
| Geboes, K | 1 |
| Ponette, E | 1 |
| Penninckx, F | 1 |
| ten Wolde, S | 1 |
| Hermans, J | 1 |
| Breedveld, FC | 1 |
| Dijkmans, BA | 1 |
| Guttmann, RD | 1 |
| Flemming, C | 1 |
| Newell, KA | 1 |
| Alonso, EM | 1 |
| Kelly, SM | 1 |
| Rubin, CM | 1 |
| Thistlethwaite, JR | 1 |
| Whitington, PF | 1 |
| Cantarovich, M | 1 |
| Latter, DA | 1 |
| Loertscher, R | 1 |
| Nau, R | 1 |
| Hinterleitner, TA | 1 |
| Aichbichler, B | 1 |
| Fickert, P | 1 |
| Ranner, G | 1 |
| Krejs, GJ | 1 |
| Ghandour, FZ | 1 |
| Knauss, TC | 1 |
| Mulligan, DC | 1 |
| Schulak, JA | 1 |
| Hricik, DE | 1 |
| Luketic, VA | 1 |
| Gomez, DA | 1 |
| Sanyal, AJ | 1 |
| Shiffman, ML | 1 |
| Bakr, MA | 1 |
| Sobh, M | 1 |
| el-Agroudy, A | 1 |
| Sally, S | 1 |
| Fouda, MA | 1 |
| el-Mekresh, M | 1 |
| Moustafa, F | 1 |
| el-Baz, M | 1 |
| Wafa, E | 1 |
| Ghoneim, MA | 1 |
| Takao, T | 1 |
| Hatori, M | 1 |
| Ichimaru, N | 1 |
| Honda, M | 1 |
| Nonomura, N | 1 |
| Matsumiya, K | 1 |
| Kokado, Y | 1 |
| Takahara, S | 1 |
| Okuyama, A | 1 |
| Miyamoto, M | 1 |
| Yokoyama, K | 1 |
| Imai, E | 1 |
| Kyo, M | 1 |
| Molteni, P | 1 |
| Imbesi, V | 1 |
| Bollani, S | 1 |
| Bianchi Porro, G | 1 |
| Molteni, F | 1 |
| Cavazzuti, M | 1 |
| Merelli, E | 1 |
| Tassone, G | 1 |
| Mavilla, L | 1 |
| Andrade, SG | 1 |
| Carneiro Filho, A | 1 |
| de Souza, AJ | 1 |
| de Lima, ES | 1 |
| Andrade, ZA | 1 |
| Kaatz, M | 1 |
| Görnig, M | 1 |
| Bocker, T | 1 |
| Zouboulis, CC | 1 |
| Wollina, U | 1 |
| Hagendorff, A | 1 |
| Hümmelgen, M | 1 |
| Omran, H | 1 |
| Pizzulli, L | 1 |
| Zirbes, M | 1 |
| Bierhoff, E | 1 |
| Sommer, T | 1 |
| Pfeifer, U | 1 |
| Kirchhoff, PG | 1 |
| Nitsch, J | 1 |
| Lüderitz, B | 1 |
| Berenguer, M | 1 |
| Prieto, M | 1 |
| Córdoba, J | 1 |
| Rayón, JM | 1 |
| Carrasco, D | 1 |
| Olaso, V | 1 |
| San-Juan, F | 1 |
| Gobernado, M | 1 |
| Mir, J | 1 |
| Berenguer, J | 1 |
| Ghobrial, RM | 1 |
| Colquhoun, S | 1 |
| Rosen, H | 1 |
| Hollis, P | 1 |
| Ponthieux, S | 1 |
| Pakrasi, A | 1 |
| Farmer, DG | 1 |
| Markman, JF | 1 |
| Markowitz, J | 1 |
| Drazan, K | 1 |
| Yersiz, H | 1 |
| Singer, J | 1 |
| Stribling, R | 1 |
| Arnout, W | 1 |
| Holt, CD | 1 |
| Goss, J | 1 |
| Imagawa, D | 1 |
| Seu, P | 1 |
| Goldstein, LI | 1 |
| Shackleton, CR | 1 |
| Martin, P | 1 |
| Busuttil, RW | 1 |
| Sabeel, A | 1 |
| Qunibi, W | 1 |
| Caccamo, L | 1 |
| Rossi, G | 1 |
| Gridelli, B | 1 |
| Maggi, U | 1 |
| Reggiani, P | 1 |
| Colledan, M | 1 |
| O'Hair, DP | 1 |
| Cantu, E | 1 |
| McGregor, C | 1 |
| Jorgensen, B | 1 |
| Gerow-Smith, R | 1 |
| Galantowicz, ME | 1 |
| Schulman, LL | 1 |
| Mandler, RN | 1 |
| Ahmed, W | 1 |
| Dencoff, JE | 1 |
| Gasché, C | 1 |
| Moser, G | 1 |
| Tillinger, W | 1 |
| Gangl, A | 1 |
| Besnard, M | 1 |
| Jaby, O | 1 |
| Mougenot, JF | 1 |
| Ferkdadji, L | 1 |
| Debrun, A | 1 |
| Faure, C | 1 |
| Delagausie, P | 1 |
| Peuchmaur, M | 1 |
| Aigrain, Y | 1 |
| Navarro, J | 1 |
| Cézard, JP | 1 |
| Stratton, JD | 1 |
| Farrington, K | 1 |
| Vandeputte, L | 1 |
| Greenwood, AJ | 1 |
| Stanford, MR | 1 |
| Graham, EM | 1 |
| Klein, M | 1 |
| Radhakrishnan, J | 1 |
| Appel, G | 1 |
| Börnke, C | 1 |
| Przuntek, H | 1 |
| Postert, T | 1 |
| Schwechheimer, K | 1 |
| Büttner, T | 1 |
| Gajdos, P | 1 |
| Shteyngarts, AR | 1 |
| Warner, MR | 1 |
| Camisa, C | 1 |
| Velicia, MR | 1 |
| González, JM | 1 |
| Fernández, P | 1 |
| Remacha, B | 1 |
| Martín, MA | 1 |
| Sánchez, G | 1 |
| Goyeneche, ML | 1 |
| Caro-Paton, A | 1 |
| van Vonderen, MG | 1 |
| ter Maaten, JC | 1 |
| van der Valk, P | 1 |
| Hoorntje, SJ | 1 |
| Gans, RO | 1 |
| Cohen, JA | 1 |
| Carter, JL | 1 |
| Kinkel, RP | 1 |
| Schwid, SR | 1 |
| Sucker, C | 1 |
| Djawari, J | 1 |
| Kim, PS | 1 |
| Zlatanic, J | 1 |
| Korelitz, BI | 1 |
| Gleim, GW | 1 |
| Lowry, PW | 1 |
| Weaver, AL | 1 |
| Cazzato, G | 1 |
| Antonello, RM | 1 |
| Zorzon, M | 1 |
| Torre, P | 1 |
| Moretti, R | 1 |
| Bragadin, LM | 1 |
| De Masi, R | 1 |
| Nasuelli, D | 1 |
| Zouhair, K | 1 |
| el Ouazzani, T | 1 |
| Azzouzi, S | 1 |
| Sqalli, S | 1 |
| Lakhdar, H | 1 |
| Stamenkovic, SA | 1 |
| Alphonso, N | 1 |
| Rice, P | 1 |
| Madden, BP | 1 |
| Laria, G | 1 |
| Pisani, F | 1 |
| Palmieri, GP | 1 |
| Bellanova, G | 1 |
| Torri, E | 1 |
| Buonomo, O | 1 |
| Casciani, CU | 1 |
| Waiser, J | 1 |
| Schötschel, R | 1 |
| Budde, K | 1 |
| Neumayer, HH | 1 |
| Stegmayr, BG | 1 |
| Gothefors, L | 1 |
| Malmer, B | 1 |
| Müller Wiefel, DE | 1 |
| Nilsson, K | 1 |
| Sundelin, B | 1 |
| Choi, IJ | 1 |
| Kim, JS | 1 |
| Cha, SD | 1 |
| Jung, HC | 1 |
| Park, JG | 1 |
| Song, IS | 1 |
| Kim, CY | 1 |
| Hiraoka, M | 1 |
| Tsukahara, H | 1 |
| Hori, C | 1 |
| Ohshima, Y | 1 |
| Momoi, T | 1 |
| Seo, A | 1 |
| Mayumi, M | 1 |
| Fang, GX | 1 |
| Ji, YL | 1 |
| Wong, AK | 1 |
| Tong, MK | 1 |
| Chan, KW | 3 |
| Lai, KN | 1 |
| Madden, RL | 1 |
| Mulhern, JG | 1 |
| Benedetto, BJ | 1 |
| O'Shea, MH | 1 |
| Germain, MJ | 1 |
| Braden, GL | 1 |
| O'Shaughnessy, J | 1 |
| Lipkowitz, GS | 1 |
| Suzuki, K | 1 |
| Tanabe, K | 1 |
| Tokumoto, T | 1 |
| Shimizu, T | 1 |
| Ishikawa, N | 1 |
| Yagisawa, T | 1 |
| Honda, K | 1 |
| Nihei, H | 1 |
| Toma, H | 1 |
| Kim, SC | 1 |
| Kang, CH | 1 |
| Kim, SK | 1 |
| Jang, HJ | 1 |
| Jung, JG | 1 |
| Belmont, HM | 1 |
| Kaklamani, VG | 1 |
| Kaklamanis, PG | 1 |
| Stange, K | 1 |
| Damaschke, HJ | 1 |
| Berwing, K | 1 |
| Dolman, PJ | 1 |
| Rootman, J | 1 |
| Folkmane, I | 1 |
| Chapenko, S | 1 |
| Amerika, D | 1 |
| Bicans, J | 1 |
| Murovska, M | 1 |
| Rosentals, R | 1 |
| Forni, A | 1 |
| Faggian, G | 1 |
| Luciani, GB | 1 |
| Lamascese, N | 1 |
| Mazzucco, A | 1 |
| Lamasciese, N | 1 |
| Rutgeerts, PJ | 1 |
| Schmitt, WH | 1 |
| Ho, CT | 2 |
| Kwan, TH | 1 |
| Au, TC | 1 |
| McGeown, MG | 1 |
| Douglas, JF | 1 |
| Middleton, D | 1 |
| Allan, DS | 1 |
| Kovacs, MJ | 1 |
| Clark, WF | 1 |
| Cuillerier, E | 1 |
| Allez, M | 1 |
| Campbell, S | 2 |
| Ghosh, S | 2 |
| Al-Khalidi, JA | 1 |
| Takenami, T | 1 |
| Miyashita, M | 1 |
| Terao, M | 1 |
| Fujiwara, A | 1 |
| Tsuji, T | 1 |
| Akpek, EK | 1 |
| Baltatzis, S | 1 |
| Yang, J | 1 |
| Foster, CS | 2 |
| Kingstone, K | 1 |
| Fraser, AG | 1 |
| Orchard, TR | 1 |
| Jewell, DP | 1 |
| Netto, GJ | 1 |
| Murray, NG | 1 |
| Smith, DM | 1 |
| Molmenti, H | 1 |
| Crippin, JS | 1 |
| Hoover, TC | 1 |
| Jung, G | 1 |
| Marubashi, S | 1 |
| Sanchez, EQ | 1 |
| Gogel, B | 1 |
| Levy, MF | 1 |
| Goldstein, RM | 1 |
| Fasola, CG | 2 |
| Gonwa, TA | 1 |
| Klintmalm, GB | 1 |
| Watkinson, G | 1 |
| Allan, R | 1 |
| Steinberg, DM | 1 |
| Williams, JA | 2 |
| Cooke, WT | 2 |
| Katz, P | 1 |
| Haynes, BF | 1 |
| Winship, DH | 1 |
| Summers, RW | 2 |
| Best, WR | 2 |
| Becktel, JM | 2 |
| Lenk, LF | 1 |
| Kern, F | 2 |
| Switz, DM | 1 |
| Sessions, JT | 1 |
| Goldberg, HI | 1 |
| Caruthers, SB | 1 |
| Nelson, JA | 1 |
| Brooke, BN | 1 |
| Cave, DR | 1 |
| King, DW | 1 |
| Hamilton, JD | 1 |
| Chambers, RA | 1 |
| Wynn-Williams, A | 1 |
| Dölle, W | 1 |
| Herfarth, C | 1 |
| van Ypersele de Strihou, C | 1 |
| Pirson, Y | 1 |
| O'Donoghue, DP | 1 |
| Dawson, AM | 2 |
| Powell-Tuck, J | 1 |
| Bown, RL | 1 |
| Lennard-Jones, JE | 2 |
| Shakir, RA | 1 |
| Burnett, AK | 1 |
| Allan, TL | 1 |
| Haase, G | 1 |
| Lovschall, S | 1 |
| Friedman, HM | 1 |
| Grossman, RA | 1 |
| Plotkin, SA | 1 |
| Perloff, LJ | 1 |
| Barker, CF | 1 |
| Blank, H | 1 |
| Farmer, RG | 1 |
| Ahmed, AR | 1 |
| Maize, JC | 1 |
| Provost, TT | 1 |
| Hjort, EF | 1 |
| Grupe, WE | 1 |
| Eichholtz, W | 1 |
| Konen, W | 1 |
| Mies, R | 1 |
| Lang, R | 1 |
| Rai, GS | 1 |
| Wilkinson, R | 1 |
| Elliott, RW | 1 |
| Uldall, PR | 1 |
| Taylor, RM | 1 |
| Deltz, E | 1 |
| Hantschmann, N | 1 |
| Barratt, TM | 1 |
| Cameron, JS | 2 |
| Chantler, C | 1 |
| Counahan, R | 1 |
| Ogg, CS | 1 |
| Soothill, JF | 1 |
| Dobek, E | 1 |
| Zaleska, T | 1 |
| Eckhardt, R | 1 |
| Krieg, H | 1 |
| Pedersen, FK | 1 |
| Petersen, EA | 1 |
| Rosenberg, JL | 1 |
| Levin, B | 1 |
| Wall, AJ | 1 |
| Kirsner, JB | 1 |
| Lusins, JO | 1 |
| Szilagyi, PA | 1 |
| Kunz, F | 1 |
| Dienstl, F | 1 |
| Hörtnagl, H | 1 |
| Holzknecht, F | 1 |
| Lederer, B | 1 |
| Trainin, EB | 1 |
| Boichis, H | 1 |
| Spitzer, A | 1 |
| Edelmann, CM | 1 |
| Greifer, I | 1 |
| Cendrowski, WS | 1 |
| Kuijten, RH | 1 |
| Donckerwolcke, RA | 1 |
| Tiddens, HA | 1 |
| Goldstein, F | 1 |
| Ruder, H | 1 |
| Thurn, C | 1 |
| Guggenbichler, JP | 1 |
| Lauzurica, R | 1 |
| Bonet, J | 1 |
| Vaquero, M | 1 |
| Torguet, P | 1 |
| Serra, A | 1 |
| Borrás, M | 1 |
| Caralps, A | 2 |
| Venning, VA | 1 |
| Wojnarowska, F | 1 |
| Hawthorne, AB | 1 |
| Logan, RF | 1 |
| Hawkey, CJ | 1 |
| Foster, PN | 1 |
| Axon, AT | 1 |
| Swarbrick, ET | 1 |
| Scott, BB | 1 |
| Yudkin, PL | 1 |
| Ghezzi, A | 1 |
| Goodkin, DE | 2 |
| McPherson, K | 1 |
| Chofflon, M | 1 |
| Juillard, C | 1 |
| Gauthier, G | 1 |
| Grau, GE | 1 |
| Neuhaus, P | 1 |
| Lobeck, H | 1 |
| König, V | 1 |
| Küther, S | 1 |
| Bauditz, J | 1 |
| Steffen, R | 1 |
| Loeffler, CM | 1 |
| Orrom, WJ | 1 |
| Matas, AJ | 1 |
| Neumann, R | 1 |
| Tauber, J | 1 |
| Hooper, PL | 1 |
| Kaplan, HJ | 1 |
| Müllges, W | 1 |
| Ringelstein, EB | 1 |
| Sommer, C | 1 |
| Biniek, R | 1 |
| Glöckner, WM | 1 |
| Goodman, DJ | 1 |
| Walker, RG | 1 |
| Birchall, IE | 1 |
| d'Apice, AJ | 1 |
| Powell, HR | 1 |
| Kincaid-Smith, P | 1 |
| Bailly, RC | 1 |
| Teetzen, ML | 1 |
| Hertsgaard, D | 1 |
| Beatty, WW | 1 |
| Kong, G | 1 |
| Madden, B | 1 |
| Spyrou, N | 1 |
| Pomerance, A | 1 |
| Mitchell, A | 1 |
| Yacoub, M | 1 |
| Yamazaki, Y | 1 |
| Fukushima, T | 1 |
| Sugita, A | 1 |
| Takemura, H | 1 |
| Tsuchiya, S | 1 |
| Leone, MR | 1 |
| Barry, JM | 1 |
| Alexander, SR | 1 |
| Melvin, T | 1 |
| Striegel, J | 1 |
| Reller, K | 1 |
| Henell, KR | 1 |
| Kimball, J | 1 |
| Funnell, MB | 1 |
| Goldstein, G | 1 |
| Colturi, C | 1 |
| Montagnino, G | 1 |
| Litzenberger, J | 1 |
| Bittner, K | 1 |
| Becker, T | 1 |
| Huffmann, G | 1 |
| Le Quintrec, JL | 1 |
| Menkès, CJ | 1 |
| Amor, B | 1 |
| Quiquandon, I | 1 |
| Fenaux, P | 1 |
| Caulier, MT | 1 |
| Pagniez, D | 1 |
| Huart, JJ | 1 |
| Bauters, F | 1 |
| Rakela, J | 1 |
| Hay, JE | 1 |
| Moore, SB | 1 |
| Baker, JP | 1 |
| Brzezinski, A | 1 |
| Prokipchuk, EJ | 1 |
| Bonhomme, P | 1 |
| Bitoun, A | 1 |
| Freedman, BI | 1 |
| Graves, JW | 1 |
| Burkart, JM | 1 |
| Callahan, MF | 1 |
| Tell, GS | 1 |
| Heise, ER | 1 |
| Adams, PL | 1 |
| Norris, PG | 1 |
| Hawk, JL | 1 |
| Nagy, G | 1 |
| Prónay, G | 1 |
| Ujszászy, L | 1 |
| Brunner, G | 1 |
| Miller, JP | 1 |
| Griñó, JM | 1 |
| Carreras, L | 1 |
| Nogués, R | 1 |
| Castelao, AM | 1 |
| Romero, R | 1 |
| Carreras, M | 1 |
| Alsina, J | 1 |
| Kappos, L | 1 |
| Firkin, FC | 1 |
| Maher, D | 1 |
| Leimenstoll, G | 1 |
| Zabel, P | 1 |
| Schoel, R | 1 |
| Müller-Hermelink, HK | 1 |
| Niedermayer, W | 1 |
| Michels, M | 1 |
| Heininger, K | 1 |
| Besinger, UA | 1 |
| Toyka, KV | 1 |
| Seidenbaum, M | 1 |
| David, M | 1 |
| Sandbank, M | 1 |
| Assan, R | 1 |
| Feutren, G | 1 |
| Sirmai, J | 1 |
| Smith, AY | 1 |
| Van Buren, CT | 1 |
| Lewis, RM | 1 |
| Kerman, RH | 1 |
| Welsh, M | 1 |
| Kahan, BD | 1 |
| West, CD | 1 |
| Landsberg, K | 1 |
| Bear, RA | 1 |
| Callen, JP | 1 |
| af Ekenstam, E | 1 |
| Scherpbier, HJ | 1 |
| Oosterhuis, HJ | 1 |
| Aberer, W | 1 |
| Wolff-Schreiner, EC | 1 |
| Stingl, G | 1 |
| Wolff, K | 1 |
| Moake, JL | 1 |
| Rudy, CK | 1 |
| Troll, JH | 1 |
| Schafer, AI | 1 |
| Weinstein, MJ | 1 |
| Colannino, NM | 1 |
| Hong, SL | 1 |
| Homberg, JC | 1 |
| Hadchouel, M | 1 |
| Alvarez, F | 1 |
| Hadchouel, P | 1 |
| Odièvre, M | 1 |
| Alagille, D | 1 |
| Cade, R | 1 |
| Mars, D | 1 |
| Privette, M | 1 |
| Thompson, R | 1 |
| Croker, B | 1 |
| Peterson, J | 1 |
| Campbell, K | 1 |
| Achurra Castillo, AF | 1 |
| Bulgín, O | 1 |
| López, RI | 1 |
| Benítez, R | 1 |
| Llerena, JM | 1 |
| Villarreal, V | 1 |
| Sandoval, E | 1 |
| Hall, S | 1 |
| McCormick, JL | 1 |
| Greipp, PR | 1 |
| Michet, CJ | 1 |
| McKenna, CH | 1 |
| Cogan, E | 1 |
| Fastrez, R | 1 |
| Tremolada, F | 1 |
| Realdi, G | 1 |
| Noventa, F | 1 |
| Antona, C | 1 |
| Ruol, A | 1 |
| Korman, MG | 1 |
| Hofmann, AF | 1 |
| Lurati, M | 1 |
| Mertens, HG | 1 |
| Kampf, D | 1 |
| Baethke, R | 1 |
| McDonald, J | 1 |
| Murphy, AV | 1 |
| Arneil, GC | 1 |
| Baumann, W | 1 |
| Fahrländer, H | 1 |
| Shalev, E | 1 |
| Asamer, H | 1 |
| Aizawa, Y | 1 |
| Komeji, S | 1 |
| Irimajiri, S | 1 |
| Abe, T | 1 |
| Honma, M | 1 |
| Olbing, H | 1 |
| Dioguardi, N | 1 |
| Degeorges, M | 1 |
| Passa, P | 1 |
| Varin, G | 1 |
| Bläker, F | 1 |
| Schäfer, KH | 1 |
| Hurley, RM | 1 |
| Steinberg, RH | 1 |
| Patriquin, H | 1 |
| Drummond, KN | 1 |
| Nethercott, J | 1 |
| Lester, RS | 1 |
| Mackay, IR | 1 |
| Mathews, JD | 1 |
| Toh, BH | 1 |
| Baker, HW | 1 |
| Walker, I | 1 |
| Alarcón-Segovia, D | 1 |
| Fishbein, E | 1 |
| Díaz-Jouanen, E | 1 |
| Thomson, TJ | 1 |
| Seigler, HF | 1 |
| Gunnells, JC | 1 |
| Robinson, RR | 1 |
| Ward, FE | 1 |
| Amos, DB | 1 |
| Rowlands, DT | 1 |
| Burkholder, PM | 1 |
| Klein, WJ | 1 |
| Stickel, DL | 1 |
| Smith, MG | 1 |
| Mahon, FB | 1 |
| Malek, GH | 1 |
| Uehling, DT | 1 |
| Papp, JP | 1 |
| Watson, DW | 1 |
| Bull, FE | 1 |
| Goligher, JC | 1 |
| de Dombal, FT | 1 |
| Burton, I | 1 |
| Weitgasser, H | 1 |
| Swinburn, WR | 1 |
| Liversedge, LA | 1 |
| Bourdinière, J | 1 |
| Jezéquel, J | 1 |
| de Labarthe, B | 1 |
| Ramée, MP | 1 |
| Bourguet, J | 1 |
| Higaki, T | 1 |
| Makker, SP | 1 |
| Heymann, W | 1 |
| Willoughby, JM | 1 |
| Beckett, J | 1 |
| Becker, K | 1 |
| Müller-Wieland, K | 1 |
| Wallensten, S | 1 |
| Persson, S | 1 |
| Stögmann, W | 1 |
| Haas, P | 1 |
| Leibetseder, F | 1 |
| Thurner, J | 1 |
| Cerný, M | 1 |
| Tekgöz, E | 1 |
| Çolak, S | 1 |
| Çinar, M | 1 |
| Yilmaz, S | 1 |
| Naimark, D | 1 |
| Sander, B | 1 |
| Hacohen, Y | 1 |
| Wong, YY | 1 |
| Lechner, C | 1 |
| Jurynczyk, M | 1 |
| Wright, S | 1 |
| Konuskan, B | 1 |
| Kalser, J | 1 |
| Poulat, AL | 1 |
| Maurey, H | 1 |
| Ganelin-Cohen, E | 1 |
| Wassmer, E | 1 |
| Hemingway, C | 1 |
| Forsyth, R | 1 |
| Hennes, EM | 1 |
| Ciccarelli, O | 1 |
| Anlar, B | 1 |
| Hintzen, R | 1 |
| Baumann, M | 1 |
| Rostásy, K | 1 |
| Neuteboom, R | 1 |
| Deiva, K | 1 |
| Lim, M | 1 |
| Bohn Thomsen, S | 1 |
| Kiszka-Kanowitz, M | 1 |
| Theede, K | 1 |
| Gluud, LL | 1 |
| Mertz Nielsen, A | 1 |
| Ecevit, Ç | 1 |
| Hekimci, H | 1 |
| Kıran Taşçı, E | 1 |
| Erdemir, G | 1 |
| Shin, SJ | 1 |
| Choi, CH | 1 |
| Kim, YH | 1 |
| Lee, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Impaired Functional Reserve of Adrenal Cortex May Associate With difficult-to Treat RA: Can a Disturbed Cortisol Circadian Rhythm Serve as a Predictor of Difficult-to-treat RA?[NCT05671627] | 50 participants (Anticipated) | Observational | 2022-02-02 | Recruiting | |||
| Weaning of Immunosuppression in Nephritis of Lupus[NCT01284725] | Phase 3 | 100 participants (Actual) | Interventional | 2011-01-31 | Active, not recruiting | ||
| Optimization of Glucocorticoid Taper Strategies for Maintenance Therapy of Systemic Lupus Erythematosus Associated Immune Thrombocytopenia (SLE-ITP)[NCT05506033] | 120 participants (Anticipated) | Interventional | 2022-08-15 | Enrolling by invitation | |||
| A Randomized, Double-Blind, Active-Controlled, Phase 3 Study to Evaluate the Safety and Efficacy of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis Treated Concomitantly With Rituximab or Cyclophosphamide/Azathioprine[NCT02994927] | Phase 3 | 331 participants (Actual) | Interventional | 2017-03-15 | Completed | ||
| Low-dose IL-2 Treatment on Behcet's Disease[NCT04065672] | Phase 2 | 15 participants (Anticipated) | Interventional | 2019-11-12 | Recruiting | ||
| Evaluation of a New Treatment Strategy for Patients With Microscopic Polyangiitis, Polyarteritis Nodosa or Eosinophilic Granulomatosis With Polyangiitis (Churg Strauss Syndrome) Without Poor Prognosis Factors[NCT00647166] | Phase 3 | 114 participants (Actual) | Interventional | 2008-05-31 | Completed | ||
| Effectiveness of Mycophenolate Mofetil Combined With Tacrolimus for Steroid Tapering in Systemic Lupus Erythematosus: A Prospective, Random Control, Open-label, Single Center Clinical Trial[NCT05916781] | Phase 4 | 220 participants (Anticipated) | Interventional | 2023-07-01 | Recruiting | ||
| Efficacy of Lower Dose Prednisolone in the Induction of Remission of Lupus Nephritis[NCT04146220] | Phase 4 | 32 participants (Actual) | Interventional | 2018-07-16 | Completed | ||
| Comparison of Intravenous Low Dose Versus High Dose Cyclophosphamide as Induction Therapy in the Treatment of Proliferative Lupus Nephritis[NCT02645565] | Phase 4 | 75 participants (Actual) | Interventional | 2015-12-31 | Completed | ||
| MAINtenance of Remission Using RITuximab in Systemic ANCA-associated Vasculitis[NCT00748644] | Phase 3 | 117 participants (Actual) | Interventional | 2008-10-31 | Completed | ||
| Induction Therapy for Lupus Nephritis With no Added Oral Steroids: An Open Label Randomised Multicentre Controlled Trial Comparing Oral Corticosteroids Plus Mycophenolate Mofetil (MMF) Versus Obinutuzumab and MMF[NCT04702256] | Phase 3 | 196 participants (Anticipated) | Interventional | 2021-12-09 | Recruiting | ||
| A Randomised Clinical Trial of Mycophenolate Mofetil Versus Cyclophosphamide for Remission Induction in ANCA Associated Vasculitis.[NCT00414128] | Phase 2/Phase 3 | 140 participants (Actual) | Interventional | 2007-03-31 | Completed | ||
| Rituximab for the Otolaryngologic Manifestations of Granulomatosis With Polyangiitis[NCT02626845] | Phase 4 | 3 participants (Actual) | Interventional | 2015-12-31 | Terminated (stopped due to Slow recruitment) | ||
| Rituximab Therapy for the Induction of Remission and Tolerance in ANCA-Associated Vasculitis (ITN021AI)[NCT00104299] | Phase 2/Phase 3 | 197 participants (Actual) | Interventional | 2005-01-31 | Completed | ||
| Maintenance of ANCA Vasculitis Remission by Intermittent Rituximab Dosing Based on B-cell Reconstitution vs a Serologic ANCA Flare[NCT02749292] | Phase 4 | 115 participants (Actual) | Interventional | 2016-06-30 | Terminated (stopped due to Due to the coronavirus disease 2019 (COVID-19) pandemic and the deleterious impact of rituximab on vaccination efficacy, the trial was concluded before reaching the target enrollment of 200.) | ||
| Efficacy and Safety of Rituximab in the Treatment of Good Prognosis Microscopic Polyangiitis[NCT03920722] | Phase 3 | 8 participants (Actual) | Interventional | 2020-10-24 | Active, not recruiting | ||
| Salvage Therapy for Patients With Inadequate Response to Standard of Care Therapy in Granulomatosis With Polyangiitis[NCT04871191] | Phase 2 | 42 participants (Anticipated) | Interventional | 2023-03-31 | Not yet recruiting | ||
| A Multi-Center, Open-label Pilot Study of Abatacept (CTLA4-Ig) in the Treatment of Mild Relapsing Wegener's Granulomatosis[NCT00468208] | Phase 1/Phase 2 | 20 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| Anti-TNF Discontinuation in Patients With Inflammatory Bowel Disease: Multicentre, Prospective, Randomized Clinical Trial and Economic Evaluation[NCT02994836] | Phase 4 | 139 participants (Actual) | Interventional | 2017-04-21 | Completed | ||
| "Post-Operative Crohn's Disease Endoscopic Recurrence POCER Study: Endoscopic Guided Therapeutic Intervention & Determination of Cause"[NCT00989560] | Phase 3 | 175 participants (Actual) | Interventional | 2009-08-31 | Completed | ||
| To Compare the Efficacy of Tacrolimus and Mycophenolate Mofetil for the Initial Therapy of Active Lupus Nephritis[NCT00371319] | Phase 4 | 150 participants (Actual) | Interventional | 2005-09-30 | Completed | ||
| Azathioprine in the Prevention of Ileal Crohn's Disease Postoperative Recurrence: Systematic Versus Endoscopic-directed Treatment. A Multi-center, Randomized, Clinical Practice Evaluation Study.[NCT02247258] | Phase 2 | 63 participants (Actual) | Interventional | 2005-10-31 | Terminated (stopped due to Slow recruitment) | ||
| Post-Operative Crohn's Disease Outcome in Children (The POPCORN Trial): a Prospective Comparative Non-interventional Open Study[NCT03681652] | 100 participants (Anticipated) | Observational | 2019-02-11 | Recruiting | |||
| Confocal Laser Endomicroscopy Findings in Patients With Proctosigmoiditis Before and After Initiation of Treatment[NCT01684514] | 29 participants (Actual) | Interventional | 2012-10-31 | Completed | |||
| Prevention of Relapses in PR3-ANCA-associated Vasculitis, a Tailored Approach[NCT00128895] | Phase 4 | 131 participants (Actual) | Interventional | 2003-06-30 | Terminated | ||
| An International, Open Label, Randomised Controlled Trial Comparing Rituximab With Azathioprine as Maintenance Therapy in Relapsing ANCA-associated Vasculitis[NCT01697267] | Phase 3 | 188 participants (Actual) | Interventional | 2013-04-30 | Completed | ||
| Assessment of Lesion Activity Analysis in the Avonex- Steroid Azathioprine (ASA) Study[NCT01628315] | 159 participants (Actual) | Observational | 2009-03-31 | Completed | |||
| MeSenteric SpAring Versus High Ligation Ileocolic Resection for the Prevention of REcurrent Crohn's DiseaSe (SPARES)[NCT04578392] | 181 participants (Anticipated) | Interventional | 2020-07-28 | Recruiting | |||
| A Randomized, Controlled, Open-label Study to Investigate the Impact of Disease Activity and Nutrition Treat on Postoperative Recurrence and Complications After Bowel Resection for Crohn's Disease[NCT01540942] | 91 participants (Actual) | Interventional | 2011-11-30 | Completed | |||
| A Randomized, Controlled, Open-label Study to Assess the Efficacy of T2 Versus Azathioprine for the Maintenance of Clinical and Endoscopic Remission in Subjects With Crohn's Disease After Surgical Resection[NCT01015391] | 100 participants (Anticipated) | Interventional | 2009-11-30 | Recruiting | |||
| Prospective Multicenter Randomized Comparative Study of the Treatment of de Novo Stenosis in Crohn's Disease. Endoscopic Treatment (Self-expanding Metal Prosthesis/Ballon Dilation) vc Surgical Resection (ENDOCIR STUDY)[NCT04330846] | 40 participants (Anticipated) | Interventional | 2022-11-29 | Recruiting | |||
| "A Phase 1b/2 Study to Demonstrate the Safety and Efficacy of EXE-346 Live Biotherapeutic to Reduce High Bowel Movement Frequency in Subjects With an Ileal Pouch-Anal Anastomosis (PROF). The PROF Study."[NCT05938465] | Phase 1/Phase 2 | 50 participants (Anticipated) | Interventional | 2023-10-11 | Recruiting | ||
| Comparison of Annual Relapse Rate, Expanded Disability Status Scale, and Side Effects Between Azathioprine and Rituximab in Patients With Neuromyelitis Optica Spectrum Disorders[NCT03002038] | Phase 2/Phase 3 | 86 participants (Actual) | Interventional | 2015-09-30 | Completed | ||
| Multicenter, Nationwide, Observational, Retrospective and Prospective Study Based on the Development of a Autoimmune Hepatitis Patient's Database Linked to a Biological Sample Storage[NCT06078098] | 10,000 participants (Anticipated) | Observational [Patient Registry] | 2023-03-29 | Recruiting | |||
| A Prospective Cross-over Study Comparing the Effect of Sirolimus Versus Mycophenolate on Viral Load in Liver Transplant Recipients With Recurrent Chronic HCV Infection[NCT01134952] | Phase 4 | 11 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| A Randomized, Multicenter Study to Assess the Efficacy on Diseases Activity of Enteric-coated Mycophenolate Sodium Versus Continuation of Azathioprine in Patients With Systemic Lupus Erythematosus on Azathioprine Maintenance Therapy.[NCT00504244] | Phase 3 | 12 participants (Actual) | Interventional | 2007-07-31 | Terminated (stopped due to Insufficient recruitment) | ||
| Five-Year Single-Blind, Phase III Effectiveness Randomised Actively Controlled Clinical Trial in New Onset Juvenile Systemic Lupus Erythematosus Nephritis: Oral Cyclophosphamide Versus High Dose Intravenous Cyclophosphamide Versus Intermediate Dose Intrav[NCT00336414] | Phase 3 | 0 participants (Actual) | Interventional | 2006-06-30 | Withdrawn (stopped due to the study is withdrawn due to low and unexpected enrollment rate) | ||
| CYCLONES - CYClophosphamide LOw Dose and No Extra Steroid[NCT03492255] | 49 participants (Actual) | Interventional | 2018-04-12 | Terminated (stopped due to Significative difference between percentage of renal response (primary outcome) between the two study arms.) | |||
| Risk-stratified Randomized Controlled Trial in Paediatric Crohn Disease:Methotrexate vs Azathioprine or Adalimumab for Maintaining Remission in Patients at Low or High Risk for Aggressive Disease Course, respectively-a Treatment Strategy[NCT02852694] | Phase 4 | 312 participants (Anticipated) | Interventional | 2017-02-28 | Recruiting | ||
| Assessment of Disease Activity in Ulcerative Colitis by Endoscopic Ultrasound[NCT01852760] | 60 participants (Actual) | Observational | 2013-09-30 | Completed | |||
| A Randomised Trial of Prednisone and Tamoxifen in Patients With Idiopathic Retroperitoneal Fibrosis[NCT00440349] | Phase 2 | 38 participants | Interventional | 2000-10-31 | Active, not recruiting | ||
| A Comparison of Oral Methylprednisolone Plus Azathioprine or Mycophenolate Mofetil for the Treatment of Bullous Pemphigoid[NCT00431119] | Phase 2 | 70 participants | Interventional | 1997-10-31 | Completed | ||
| CHUSPAN SCS BP Treatment of Churg-Strauss Syndrome Without Poor-Prognosis Factors: a Prospective Randomized Study in 72 Patients.[NCT00399399] | Phase 4 | 72 participants | Interventional | 1996-07-31 | Active, not recruiting | ||
| Counseling to Optimize Medication Adherence in Expectant Mothers With Inflammatory Bowel Disease (COACH-IBD)[NCT03091309] | 220 participants (Anticipated) | Interventional | 2017-10-01 | Recruiting | |||
| Continuous Positive Airway Pressure for Fatigue Treatment in Patients With Multiple Sclerosis and Obstructive Sleep Apnea[NCT01563900] | 0 participants (Actual) | Interventional | 2012-02-29 | Withdrawn (stopped due to Was unable to recruit subjects) | |||
| Cyclophosphamide Versus Methotrexate for Remission Maintenance in Systemic Necrotizing Vasculitides. A Randomized Controlled Trial.[NCT00751517] | Phase 2 | 0 participants | Interventional | Active, not recruiting | |||
| Comparison of Maintenance Treatment by Ribavirin to a Placebo, After an Initial One-year Treatment With Pegylated Interferon-α2a - Ribavirin Association in Hepatitis C Viral Recurrence After Liver Transplantation[NCT00151580] | Phase 3 | 200 participants (Actual) | Interventional | 2002-02-28 | Completed | ||
| Rituximab in the Treatment of Patients With Bullous Pemphigoid[NCT00286325] | Phase 1/Phase 2 | 8 participants (Actual) | Interventional | 2005-03-31 | Completed | ||
| Hypnotherapy for Prevention of Relapse in Ulcerative Colitis: a Randomised, Single-blind, Controlled Clinical Trial[NCT00553163] | 26 participants (Actual) | Interventional | 2007-10-31 | Terminated (stopped due to Unable to recruit sufficient numbers of patinets in the time available) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"BVAS=Birmingham Vasculitis Activity Score;~A relapse was defined as occurrence of at least one major item in the BVAS, or three or more minor items in the BVAS, or one or two minor items in the BVAS recorded at two consecutive visits, after:~having achieved remission at Week 26 (BVAS=0 and no glucocorticoids for ANCA-associated vasculitis within 4 weeks) or~having achieved BVAS=0 at any time during the treatment period~The BVAS form is divided into 9 organ-based systems, with each section including symptoms/signs that are typical of that particular organ involvement in systemic vasculitis. The clinician only scores features believed to be due to active vasculitis. Completion of the form provides a numerical score, which ranges from 0 (best health) to 63 (worst health)." (NCT02994927)
Timeframe: From day 1 throughout the study period (day 421/week 60)
| Intervention | Participants (Count of Participants) |
|---|---|
| Prednisone Group | 33 |
| Avacopan Group | 16 |
"Clinical significance was assessed by the individual reading of the ECGs~ECG=Electrocardiogram" (NCT02994927)
Timeframe: From day 1 throughout the study period (day 421/week 60)
| Intervention | Participants (Count of Participants) |
|---|---|
| Prednisone Group | 8 |
| Avacopan Group | 12 |
"AC=Adjudication Committee; BVAS=Birmingham Vasculitis Activity Score;~The BVAS form is divided into 9 organ-based systems, with each section including symptoms/signs that are typical of that particular organ involvement in systemic vasculitis. The clinician only scores features believed to be due to active vasculitis. Completion of the form provides a numerical score, which ranges from 0 (best health) to 63 (worst health)." (NCT02994927)
Timeframe: Week 4
| Intervention | percentage of participants (Number) |
|---|---|
| Prednisone Group | 68.9 |
| Avacopan Group | 62.7 |
"Disease remission at Week 26 was defined as:~Achieving a BVAS of 0 as determined by the Adjudication Committee;~No administration of glucocorticoids given for ANCA-associated vasculitis within 4 weeks prior to Week 26;~No BVAS >0 during the 4 weeks prior to Week 26 (if collected for an unscheduled assessment)." (NCT02994927)
Timeframe: Week 26
| Intervention | percentage of participants (Number) |
|---|---|
| Prednisone Group | 70.1 |
| Avacopan Group | 72.3 |
"Sustained remission at Week 52 was defined as:~Disease remission at Week 26 as defined above;~Disease remission at Week 52 defined as a BVAS of 0 at Week 52 as determined by the Adjudication Committee and no administration of glucocorticoids for treatment of ANCA-associated vasculitis within 4 weeks prior to Week 52;~No disease relapse between Week 26 and Week 52 as determined by the Adjudication Committee." (NCT02994927)
Timeframe: Week 52
| Intervention | percentage of participants (Number) |
|---|---|
| Prednisone Group | 54.9 |
| Avacopan Group | 65.7 |
"The median time to relapse was not estimable because of small number of relapsed subjects.~A relapse was defined as occurrence of at least one major item in the BVAS, or three or more minor items in the BVAS, or one or two minor items in the BVAS recorded at two consecutive visits, after:~having achieved remission at Week 26 (BVAS=0 and no glucocorticoids for ANCA-associated vasculitis within 4 weeks) or~having achieved BVAS=0 at any time during the treatment period~The Birmingham Vasculitis Activity Score (BVAS) form is divided into 9 organ-based systems, with each section including symptoms/signs that are typical of that particular organ involvement in systemic vasculitis. The clinician only scores features believed to be due to active vasculitis. Completion of the form provides a numerical score, which ranges from 0 (best health) to 63 (worst health)." (NCT02994927)
Timeframe: Week 52
| Intervention | percentage of participants (Number) |
|---|---|
| Prednisone Group | 21.0 |
| Avacopan Group | 10.1 |
"The median time to relapse was not estimable because of small number of relapsed subjects.~A relapse was defined as occurrence of at least one major item in the BVAS, or three or more minor items in the BVAS, or one or two minor items in the BVAS recorded at two consecutive visits, after:~having achieved remission at Week 26 (BVAS=0 and no glucocorticoids for ANCA-associated vasculitis within 4 weeks) or~having achieved BVAS=0 at any time during the treatment period~ANCA=anti-neutrophil cytoplasmic autoantibody; BVAS=Birmingham Vasculitis Activity Score; The BVAS form is divided into 9 organ-based systems, with each section including symptoms/signs that are typical of that particular organ involvement in systemic vasculitis. The clinician only scores features believed to be due to active vasculitis. Completion of the form provides a numerical score, which ranges from 0 (best health) to 63 (worst health)." (NCT02994927)
Timeframe: Week 52
| Intervention | percentage of participants (Number) |
|---|---|
| Prednisone Group | 12.2 |
| Avacopan Group | 7.5 |
"WBC=White Blood Cell~TEAE=Treatment-Emergent Adverse Event" (NCT02994927)
Timeframe: From day 1 throughout the study period (day 421/week 60)
| Intervention | Participants (Count of Participants) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Any Treatment-Emergent Infection | Any Serious Treatment-Emergent Infection | Any Severe Treatment-Emergent Infection | Any Treatment-Emergent Infection Leading to Study Withdrawal | Any Treatment-Emergent Life-threatening Infection | Any Treatment-Emergent Infection Leading to Death | Any TEAE Associated with Hepatic Abnormalities | Any TEAE Associated with Low WBC Counts | Any TEAE Associated with hypersensitivity | |
| Avacopan Group | 113 | 22 | 12 | 4 | 1 | 1 | 22 | 31 | 68 |
| Prednisone Group | 124 | 25 | 10 | 5 | 2 | 2 | 19 | 39 | 70 |
(NCT02994927)
Timeframe: Baseline, Week 26 and 52
| Intervention | 10^3 cells/μL (Mean) | |||||
|---|---|---|---|---|---|---|
| Leukocytes (Week 26) | Leukocytes (Week 52) | Neutrophils (Week 26) | Neutrophils (Week 52) | Lymphocytes (Week 26) | Lymphocytes (Week 52) | |
| Avacopan Group | -5.94 | -5.62 | -5.24 | -4.95 | -0.84 | -0.82 |
| Prednisone Group | -5.69 | -5.54 | -5.10 | -4.89 | -0.62 | -0.67 |
(NCT02994927)
Timeframe: Baseline, Week 26 and 52
| Intervention | 10^9 cells/L (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Eosinophils (Week 26) | Eosinophils (Week 52) | Basophils (Week 26) | Basophils (Week 52) | Monocytes (Week 26) | Monocytes (Week 52) | Platelets (Week 26) | Platelets (Week 52) | |
| Avacopan Group | 0.07 | 0.07 | -0.00 | -0.01 | -0.04 | -0.01 | -77.1 | -73.8 |
| Prednisone Group | 0.07 | 0.05 | -0.01 | -0.01 | 0.01 | 0.01 | -73.9 | -75.5 |
(NCT02994927)
Timeframe: Baseline, Week 26 and 52
| Intervention | 10^12 cells/L (Mean) | |
|---|---|---|
| Erythrocytes (Week 26) | Erythrocytes (Week 52) | |
| Avacopan Group | 0.252 | 0.279 |
| Prednisone Group | 0.226 | 0.244 |
(NCT02994927)
Timeframe: Baseline, Week 26 and 52
| Intervention | g/dL (Mean) | |
|---|---|---|
| Hemoglobin (Week 26) | Hemoglobin (Week 52) | |
| Avacopan Group | 1.10 | 1.27 |
| Prednisone Group | 1.07 | 1.20 |
(NCT02994927)
Timeframe: Baseline, Week 26 and 52
| Intervention | percentage of red blood cells (Mean) | |
|---|---|---|
| Hematocrit (Week 26) | Hematocrit (Week 52) | |
| Avacopan Group | 2.7 | 3.2 |
| Prednisone Group | 2.6 | 3.0 |
(NCT02994927)
Timeframe: Baseline, Week 26 and 52
| Intervention | U/L (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Lactate Dehydrogenase (Week 26) | Lactate Dehydrogenase (Week 52) | Alkaline Phosphatase (Week 26) | Alkaline Phosphatase (Week 52) | Creatine Kinase (Week 26) | Creatine Kinase (Week 52) | Alanine Aminotransferase (Week 26) | Alanine Aminotransferase (Week 52) | Aspartate Aminotransferase (Week 26) | Aspartate Aminotransferase (Week 52) | |
| Avacopan Group | -6.1 | -10.7 | -3.9 | -4.0 | 76.8 | 76.3 | -6.1 | -7.2 | 2.5 | 2.0 |
| Prednisone Group | 2.3 | -8.6 | -0.6 | 0.8 | 47.6 | 57.6 | -6.8 | -8.2 | 1.9 | 0.5 |
(NCT02994927)
Timeframe: Baseline, Week 26 and 52
| Intervention | mg/dL (Mean) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Creatinine (Week 26) | Creatinine (Week 52) | Urea Nitrogen (Week 26) | Urea Nitrogen (Week 52) | Protein (Week 26) | Protein (Week 52) | Cholesterol (Week 26) | Cholesterol (Week 52) | LDL Cholesterol (Week 26) | LDL Cholesterol (Week 52) | Bilirubin (Week 26) | Bilirubin (Week 52) | |
| Avacopan Group | -0.195 | -0.244 | -11.0 | -11.9 | 220 | 250 | 7.4 | 9.3 | 12.0 | 11.9 | 0.078 | 0.057 |
| Prednisone Group | -0.105 | -0.200 | -9.4 | -7.8 | 50 | 160 | 19.0 | 13.8 | 22.7 | 21.7 | 0.065 | 0.053 |
(NCT02994927)
Timeframe: Baseline, Week 26 and 52
| Intervention | mmHg (Mean) | |||
|---|---|---|---|---|
| Systolic Blood Pressure (Week 26) | Systolic Blood Pressure (Week 52) | Diastolic Blood Pressure (Week 26) | Diastolic Blood Pressure (Week 52) | |
| Avacopan Group | -2.6 | -1.0 | 0.5 | 1.4 |
| Prednisone Group | -2.5 | -2.4 | 2.7 | 1.4 |
(NCT02994927)
Timeframe: Baseline, Week 26 and 52
| Intervention | beats/min (Mean) | |
|---|---|---|
| Pulse Rate (Week 26) | Pulse Rate (Week 52) | |
| Avacopan Group | 0.9 | -0.3 |
| Prednisone Group | 2.2 | -1.3 |
(NCT02994927)
Timeframe: Baseline, Week 26 and 52
| Intervention | degree Celsius (Mean) | |
|---|---|---|
| Temperature (Week 26) | Temperature (Week 52) | |
| Avacopan Group | -0.11 | -0.11 |
| Prednisone Group | -0.03 | 0.04 |
(NCT02994927)
Timeframe: Baseline, Week 26 and 52
| Intervention | kilogram(s) (Mean) | |
|---|---|---|
| Weight (Week 26) | Weight (Week 52) | |
| Avacopan Group | 1.93 | 2.59 |
| Prednisone Group | 3.33 | 3.27 |
BMI=Body Mass Index (NCT02994927)
Timeframe: Baseline, Week 26 and 52
| Intervention | kilogram(s)/ square meter (Mean) | |
|---|---|---|
| BMI (Week 26) | BMI (Week 52) | |
| Avacopan Group | 0.67 | 0.94 |
| Prednisone Group | 1.13 | 1.12 |
"SF-36v2: Measure of health- related quality of life (Medical Outcomes Survey Short Form-36 version 2)~EQ-5D-5L: EuroQuality of Life-5 Domains-5 Levels~The SF-36v2 component scores and the EQ-5D-5L VAS score range from 0 (worst health) to 100 (best health). The EQ-5D-5L Index Score ranges from 0 (worst health) to 1 (best health)." (NCT02994927)
Timeframe: Baseline, Week 26 and 52
| Intervention | Change from baseline (Least Squares Mean) | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SF-36v2: Physical Component Score (Week 26) | SF-36v2: Physical Component Score (Week 52) | SF-36v2: Physical Functioning (Week 26) | SF-36v2: Physical Functioning (Week 52) | SF-36v2: Role Physical (Week 26) | SF-36v2: Role Physical (Week 52) | SF-36v2: Bodily Pain (Week 26) | SF-36v2: Bodily Pain (Week 52) | SF-36v2: General Health Perception (Week 26) | SF-36v2: General Health Perception (Week 52) | SF-36v2: Mental Component Score (Week 26) | SF-36v2: Mental Component Score (Week 52) | SF-36v2: Mental Health (Week 26) | SF-36v2: Mental Health (Week 52) | SF-36v2: Role Emotional (Week 26) | SF-36v2: Role Emotional (Week 52) | SF-36v2: Social Functioning (Week 26) | SF-36v2: Social Functioning (Week 52) | SF-36v2: Vitality (Week 26) | SF-36v2: Vitality (Week 52) | EQ-5D-5L VAS Score (Week 26) | EQ-5D-5L VAS Score (Week 52) | EQ-5D-5L Index Score (Week 26) | EQ-5D-5L Index Score (Week 52) | |
| Avacopan Group | 4.445 | 4.980 | 7.31 | 9.55 | 16.78 | 17.12 | 14.75 | 16.12 | 3.12 | 5.84 | 4.849 | 6.394 | 8.29 | 10.89 | 7.32 | 9.38 | 14.50 | 18.06 | 12.03 | 14.36 | 9.1 | 13.0 | 0.0229 | 0.0474 |
| Prednisone Group | 1.344 | 2.626 | 1.88 | 4.82 | 7.52 | 12.27 | 9.82 | 11.87 | -2.89 | -0.17 | 3.271 | 4.694 | 6.84 | 9.66 | 1.40 | 4.14 | 11.09 | 13.56 | 6.42 | 10.48 | 5.5 | 7.1 | -0.0010 | -0.0038 |
VDI=Vasculitis Damage Index; The VDI is comprised of 64 items of damage, grouped into 11 organ-based systems or categorizations. Damage is defined as the presence of non-healing scars and does not give any indication of current disease activity. Damage is also defined as having been present or currently present for at least 3 months. Completion of the form provides a numerical score, which ranges from 0 (best health) to 64 (worst health). (NCT02994927)
Timeframe: Baseline, Week 26 and 52
| Intervention | score on a scale (Least Squares Mean) | |
|---|---|---|
| Week 26 | Week 52 | |
| Avacopan Group | 1.06 | 1.17 |
| Prednisone Group | 0.97 | 1.15 |
"GTI-CWS=Glucocorticoid Toxicity Index Cumulative Worsening Score;~GTI-AIS=Glucocorticoid Toxicity Index Aggregate Improvement Score;~The Glucocorticoid Toxicity Index (GTI) was developed to score glucocorticoid toxicity. The GTI includes: the Cumulative Worsening Score (CWS) that captures cumulative toxicity, both permanent and transient, over the course of time (serves as a cumulative record of toxicity); and the Aggregate Improvement Score that captures both improvement and worsening of toxicity over time (serves as a record of both improving and worsening toxicity). Both scores range from 0 (best health) to 100 (worst health)." (NCT02994927)
Timeframe: Baseline, Week 13 and 26
| Intervention | Glucocorticoid Toxicity Index (Least Squares Mean) | |||
|---|---|---|---|---|
| GTI-CWS (Week 13) | GTI-CWS (Week 26) | GTI-AIS (Week 13) | GTI-AIS (Week 26) | |
| Avacopan Group | 25.7 | 39.7 | 9.9 | 11.2 |
| Prednisone Group | 36.6 | 56.6 | 23.2 | 23.4 |
"BVAS=Birmingham Vasculitis Activity Score~UACR=Urinary albumin:creatinine ratio" (NCT02994927)
Timeframe: Baseline, Week 4, 26 and 52
| Intervention | Percentage change (Least Squares Mean) | ||
|---|---|---|---|
| Week 4 | Week 26 | Week 52 | |
| Avacopan Group | -40 | -63 | -74 |
| Prednisone Group | 0 | -70 | -77 |
"Change from baseline in kidney function, as measured by eGFR (based on the MDRD equation), was measured in subjects with renal disease based on the BVAS renal component.~eGFR=estimated glomerular filtration rate~BVAS=Birmingham Vasculitis Activity Score~MDRD=Modification of Diet in Renal Disease" (NCT02994927)
Timeframe: Baseline, Week 26 and 52
| Intervention | Change in eGFR (mL/min/1.73 m^2) (Least Squares Mean) | |
|---|---|---|
| Week 26 | Week 52 | |
| Avacopan Group | 5.8 | 7.3 |
| Prednisone Group | 2.9 | 4.1 |
"BVAS=Birmingham Vasculitis Activity Score~MCP-1=monocyte chemoattractant protein-1" (NCT02994927)
Timeframe: Baseline, Week 26 and 52
| Intervention | Percentage change (Least Squares Mean) | |
|---|---|---|
| Week 26 | Week 52 | |
| Avacopan Group | -67 | -73 |
| Prednisone Group | -64 | -71 |
AE=Adverse Event (NCT02994927)
Timeframe: From day 1 throughout the study period (day 421/week 60)
| Intervention | Participants (Count of Participants) | ||||||
|---|---|---|---|---|---|---|---|
| Relationship of avacopan/placebo to an AE | Relationship of glucocorticoid use to an AE | Relationship of cyclophosphamide IV use to an AE | Relationship of oral cyclophosphamide use to an AE | Relationship of rituximab use to an AE | Relationship of azathioprine use to an AE | Relationship of mycophenolate use to an AE | |
| Avacopan Group | 100 | 107 | 31 | 8 | 50 | 28 | 6 |
| Prednisone Group | 103 | 131 | 30 | 4 | 61 | 35 | 9 |
"AEs=Adverse events~SAEs=Serious adverse events~TEAE=Treatment-emergent adverse event" (NCT02994927)
Timeframe: From day 1 throughout the study period (day 421/week 60)
| Intervention | Number (Number) | ||||
|---|---|---|---|---|---|
| Number of subjects with at least one TEAE | Number of TEAEs | Number of subjects with SAEs | Number of SAEs | Subjects with TEAE leading to discontinuation | |
| Avacopan Group | 164 | 1779 | 70 | 116 | 27 |
| Prednisone Group | 161 | 2139 | 74 | 166 | 28 |
A Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG) score of 0 with prednisone taper successfully completed at six months. The BVAS/WG is a validated disease activity index. The BVAS/WG is designed to document new or worsening clinically active vasculitis and consists of a set of items divided into nine organ based systems. BVAS/WG scores range from 0 to 63, with higher scores indicating more active disease. (NCT00104299)
Timeframe: 6 months post-randomization
| Intervention | Participants (Number) |
|---|---|
| Rituximab | 63 |
| Control Group | 52 |
"The 2-sided 95% CI of the percentage of participants who have a Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG)[1] of 0 and have successfully completed the glucocorticoid taper by 6 months post-randomization and the 2-sided 95% CI of the difference between two arms for assessing the superiority of rituximab to control~[1] The BVAS/WG is a disease activity index designed to document new or worsening clinically active vasculitis consisting of items divided into 9 organ based systems. BVAS/WG scores range from 0 to 63, with higher scores indicating more active disease" (NCT00104299)
Timeframe: 6 months post-randomization
| Intervention | participants (Number) |
|---|---|
| Rituximab | 62 |
| Control Group | 51 |
Number of subjects according to originally received treatment that experienced a serious adverse event through 18 months post-randomization or prior to being censored from analyses due to crossover, switching to open-label treatment, or best medical judgment for censor. Events are categorized by coded system organ classes (SOC). Within each SOC, a participant was counted once if the participant reported one or more events coded to that SOC. (NCT00104299)
Timeframe: Randomization to censor at Crossover, Open-label or Best Medical Judgment (up to 18 months post-randomization)
| Intervention | participants (Number) | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Participants with at least one SAE | Blood and Lymphatic System Disorders | Cardiac Disorders | Eye Disorders | Gastrointestinal Disorders | General Disorders and Administration Site | Immune System Disorders | Infections and Infestations | Injury, Poisoning, and Procedural Complications | Investigations | Metabolism and Nutrition Disorders | Musculoskeletal and Connective Tissue Disorders | Neoplasms Benign, Malignant, and Unspecified | Nervous System Disorders | Pregnancy, Puerperium, and Perinatal Conditions | Psychiatric Disorders | Renal and Urinary Disorders | Respiratory, Thoracic, and Mediastinal Disorders | Vascular Disorders | |
| Control Group | 37 | 5 | 2 | 1 | 1 | 3 | 2 | 12 | 0 | 0 | 2 | 3 | 2 | 0 | 0 | 1 | 3 | 8 | 7 |
| Rituximab | 42 | 4 | 2 | 1 | 4 | 5 | 2 | 12 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 4 | 8 | 1 |
The adverse event rate for the following events considered related to vasculitis: Death; Grade 2 or higher leukopenia or thrombocytopenia; Grade 3 or higher infections; Hemorrhagic cystitis (grade 2 or lower needs confirmation by cytoscopy); Malignancy; Venous thromboembolic event (deep venous thrombosis or pulmonary embolism); Hospitalization resulting either from the disease or from a complication due to study treatment; Infusion reactions (within 24 hours of infusion) that result in the cessation of further infusions (including cytokine release allergic reaction); Cerebrovascular accident (NCT00104299)
Timeframe: Through common close-out (defined as 18 months after the last participant is enrolled in the trial)
| Intervention | participants (Number) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Death | Grade 2 or Higher Leukopenia | Grade 2 or Higher Thrombocytopenia | Grade 3 or Higher Infections | Hemorrhagic Cystitis (Grade 2 or Lower) | Malignancy | Venous Thromboembolic Event | Hospitalization Resulting from the Disease | Cerebrovascular Accident (CVA) | Infusion Reactions Leading to Infusion Disc. | |
| Control Group | 2 | 23 | 1 | 16 | 1 | 2 | 8 | 7 | 1 | 0 |
| Rituximab | 2 | 7 | 4 | 18 | 2 | 5 | 6 | 16 | 1 | 1 |
"Duration of complete remission is defined as a Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG)[1] of 0 and a completing taper of Prednisone to the first flare, BVAS/WG score of greater than 0, or an increase in Prednisone dosing.~[1] The BVAS/WG is a disease activity index designed to document new or worsening clinically active vasculitis consisting of items divided into 9 organ based systems. BVAS/WG scores range from 0 to 63, with higher scores indicating more active disease" (NCT00104299)
Timeframe: 18 months post-randomization
| Intervention | Days (Number) | ||
|---|---|---|---|
| 25% Quartile (95%CI) | 50% Quartile (95%CI) | 75% Quartile (95%CI) | |
| Control Group | 230 | NA | NA |
| Rituximab | 243 | NA | NA |
Duration of remission is defined as a Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG)[1] of 0 and a completing taper of glucocorticoid by 6 months post-randomization to the first flare, BVAS/WG score of greater than 0, or an increase in Prednisone dosing. (NCT00104299)
Timeframe: 18 months post-randomization
| Intervention | Days (Number) | ||
|---|---|---|---|
| 25% Quartile (95%CI) | 50% Quartile (95%CI) | 75% Quartile (95%CI) | |
| Control Group | 168 | NA | NA |
| Rituximab | 246 | NA | NA |
"Time to complete remission is defined as the number of days from baseline visit (Visit 1) to a Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG)[1] of 0 and completing taper of glucocorticoid by 6 months post-randomization.~[1] The BVAS/WG is a disease activity index designed to document new or worsening clinically active vasculitis consisting of items divided into 9 organ based systems. BVAS/WG scores range from 0 to 63, with higher scores indicating more active disease" (NCT00104299)
Timeframe: 18 months post-randomization
| Intervention | Days (Number) | ||
|---|---|---|---|
| 25% Quartile (95%CI) | 50% Quartile (95%CI) | 75% Quartile (95%CI) | |
| Control Group | 177 | 183 | 266 |
| Rituximab | 176 | 180 | 189 |
"Time to complete remission is defined as the number of days from baseline visit (Visit 1) to a Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG)[1] of 0.~[1] The BVAS/WG is a disease activity index designed to document new or worsening clinically active vasculitis consisting of items divided into 9 organ based systems. BVAS/WG scores range from 0 to 63, with higher scores indicating more active disease" (NCT00104299)
Timeframe: 18 months post-randomization
| Intervention | Days (Number) | ||
|---|---|---|---|
| 25% Quartile (95%CI) | 50% Quartile (95%CI) | 75% Quartile (95%CI) | |
| Control Group | 29 | 43 | 112 |
| Rituximab | 30 | 57 | 119 |
Number of disease relapse added with the number of SAE in each group (NCT02749292)
Timeframe: Median follow-up period of 4.1 years (IQR, 2.5 - 5.0)
| Intervention | Number of events (Number) |
|---|---|
| B Cell Reconstitution | 27 |
| Serologic ANCA Flare | 36 |
The rituximab utilization was measured in how many times a subject received Rituximab throughout the study which was then averaged for all subjects in each treatment arm, including those who did not receive any infusion. (NCT02749292)
Timeframe: Median follow-up period of 4.1 years (IQR, 2.5 - 5.0)
| Intervention | Infusions per subject (Mean) |
|---|---|
| B Cell Reconstitution | 3.6 |
| Serologic ANCA Flare | 0.5 |
The Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG ) is a form with 34 predefined items grouped into 9 organ systems. The items are clinical features observed in patients with active ANCA vasculitis. Each item has a specified weight of either 3 or 1, depending on whether it reflects major or minor disease activity. The total BVAS/WG score is the weighted sum of individual manifestations that are present and believed to be due to active ANCA vasculitis. Higher scores reflect more active disease. BVAS/WG scores range from 0 to 64. (NCT02749292)
Timeframe: Median follow-up period of 4.1 years (IQR, 2.5 - 5.0)
| Intervention | number of events (Number) |
|---|---|
| B Cell Reconstitution | 4 |
| Serologic ANCA Flare | 7 |
Number of patients with serious adverse events (SAEs), including all episodes of late onset neutropenia (LON). SAE are defined in the Serious adverse event section. Serious adverse events were reported over the entire study period (5.5 years) (NCT02749292)
Timeframe: Median follow-up period of 4.1 years (IQR, 2.5 - 5.0)
| Intervention | Participants (Count of Participants) |
|---|---|
| B Cell Reconstitution | 15 |
| Serologic ANCA Flare | 14 |
Hypogammaglobulinemia defined as an IgG < 250mg/dL (NCT02749292)
Timeframe: Median follow-up period of 4.1 years (IQR, 2.5 - 5.0)
| Intervention | Participants (Count of Participants) |
|---|---|
| B Cell Reconstitution | 1 |
| Serologic ANCA Flare | 0 |
number of deaths throughout the study. (NCT02749292)
Timeframe: 5.5 years
| Intervention | number of deaths (Number) |
|---|---|
| B Cell Reconstitution | 2 |
| Serologic ANCA Flare | 0 |
The Short Form (36) Health Survey is a 36-item, patient-reported survey of patient health. The SF-36 is a measure of health status and is commonly used in health economics as a variable in the quality-adjusted life year calculation to determine the cost-effectiveness of a health treatment. The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability. (NCT02749292)
Timeframe: Assessed throughout the study period, every 6 months unless such time point was not reached or was missed by the patient. Median follow-up period is of 4.1 years (IQR, 2.5 - 5.0)
| Intervention | score on a scale (Mean) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Physical functioning at 6 months | Role functioning/physical at 6 months | Role functioning/emotional at 6 months | Energy/fatigue at 6 months | Emotional well-being at 6 months | Social functioning at 6 months | Pain at 6 months | General health at 6 months | Physical functioning at 36 months | Role functioning/physical at 36 months | Role functioning/emotional at 36 months | Energy/fatigue at 36 months | Emotional well-being at 36 months | Social functioning at 36 months | Pain at 36 months | General health at 36 months | Physical functioning at 12 months | Role functioning/physical at 12 months | Role functioning/emotional at 12 months | Energy/ fatigue at 12 months | Emotional well-being at 12 months | Social functioning at 12 months | Pain at 12 months | General health at 12 months | Physical functioning at 18 months | Role functioning/physical at 18 months | Role functioning/emotional at 18 months | Energy/fatigue at 18 months | Emotional well-being at 18 months | Social functioning at 18 months | Pain at 18 months | General health at 18 months | Physical functioning at 24 months | Role functioning/physical at 24 months | Role functioning/emotional at 24 months | Energy/fatigue at 24 months | Emotional well-being at 24 months | Social functioning at 24 months | Pain at 24 months | General health at 24 months | Physical functioning at 30 months | Role functioning/physical at 30 months | Role functioning/emotional at 30 months | Energy/fatigue at 30 months | Emotional well-being at 30 months | Social functioning at 30 months | Pain at 30 months | General health at 30 months | Physical functioning at 42 months | Role functioning/physical at 42 months | Role functioning/emotional at 42 months | Energy/fatigue at 42 months | Emotional well-being at 42 months | Social functioning at 42 months | Pain at 42 months | General health at 42 months | Physical functioning at 48 months | Role functioning/physical at 48 months | Role functioning/emotional at 48 months | Energy/fatigue at 48 months | Emotional well-being at 48 months | Social functioning at 48 months | Pain at 48 months | General health at 48 months | Physical functioning at 60 months | Role functioning/physical at 60 months | Role functioning/emotional at 60 months | Energy/fatigue at 60 months | Emotional well-being at 60 months | Social functioning at 60 months | Pain at 60 months | General health at 60 months | |
| Serologic ANCA Flare | 82 | 65 | 75 | 67 | 81 | 88 | 82 | 63 | 88 | 79 | 82 | 73 | 84 | 95 | 87 | 70 | 82 | 63 | 68 | 65 | 81 | 86 | 80 | 63 | 82 | 62 | 74 | 68 | 81 | 92 | 82 | 67 | 88 | 71 | 80 | 76 | 85 | 94 | 82 | 70 | 88 | 72 | 80 | 72 | 84 | 94 | 83 | 70 | 82 | 60 | 76 | 70 | 85 | 87 | 82 | 63 | 95 | 100 | 100 | 75 | 85 | 100 | 80 | 75 | 92 | 100 | 89 | 71 | 83 | 92 | 83 | 70 |
The Short Form (36) Health Survey is a 36-item, patient-reported survey of patient health. The SF-36 is a measure of health status and is commonly used in health economics as a variable in the quality-adjusted life year calculation to determine the cost-effectiveness of a health treatment. The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability. (NCT02749292)
Timeframe: Assessed throughout the study period, every 6 months unless such time point was not reached or was missed by the patient. Median follow-up period is of 4.1 years (IQR, 2.5 - 5.0)
| Intervention | score on a scale (Mean) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Physical functioning at 6 months | Role functioning/physical at 6 months | Role functioning/emotional at 6 months | Energy/fatigue at 6 months | Emotional well-being at 6 months | Social functioning at 6 months | Pain at 6 months | General health at 6 months | Physical functioning at 36 months | Role functioning/physical at 36 months | Role functioning/emotional at 36 months | Energy/fatigue at 36 months | Emotional well-being at 36 months | Social functioning at 36 months | Pain at 36 months | General health at 36 months | Physical functioning at 12 months | Role functioning/physical at 12 months | Role functioning/emotional at 12 months | Energy/ fatigue at 12 months | Emotional well-being at 12 months | Social functioning at 12 months | Pain at 12 months | General health at 12 months | Physical functioning at 18 months | Role functioning/physical at 18 months | Role functioning/emotional at 18 months | Energy/fatigue at 18 months | Emotional well-being at 18 months | Social functioning at 18 months | Pain at 18 months | General health at 18 months | Physical functioning at 24 months | Role functioning/physical at 24 months | Role functioning/emotional at 24 months | Energy/fatigue at 24 months | Emotional well-being at 24 months | Social functioning at 24 months | Pain at 24 months | General health at 24 months | Physical functioning at 30 months | Role functioning/physical at 30 months | Role functioning/emotional at 30 months | Energy/fatigue at 30 months | Emotional well-being at 30 months | Social functioning at 30 months | Pain at 30 months | General health at 30 months | Physical functioning at 42 months | Role functioning/physical at 42 months | Role functioning/emotional at 42 months | Energy/fatigue at 42 months | Emotional well-being at 42 months | Social functioning at 42 months | Pain at 42 months | General health at 42 months | Physical functioning at 48 months | Role functioning/physical at 48 months | Role functioning/emotional at 48 months | Energy/fatigue at 48 months | Emotional well-being at 48 months | Social functioning at 48 months | Pain at 48 months | General health at 48 months | Physical functioning at 54 months | Role functioning/physical at 54 months | Role functioning/emotional at 54 months | Energy/fatigue at 54 months | Emotional well-being at 54 months | Social functioning at 54 months | Pain at 54 months | General health at 54 months | Physical functioning at 60 months | Role functioning/physical at 60 months | Role functioning/emotional at 60 months | Energy/fatigue at 60 months | Emotional well-being at 60 months | Social functioning at 60 months | Pain at 60 months | General health at 60 months | |
| B Cell Reconstitution | 84 | 66 | 79 | 65 | 83 | 89 | 79 | 66 | 74 | 50 | 65 | 58 | 76 | 83 | 69 | 60 | 79 | 61 | 82 | 65 | 86 | 92 | 81 | 66 | 83 | 70 | 88 | 69 | 85 | 96 | 84 | 68 | 83 | 71 | 84 | 68 | 82 | 91 | 81 | 69 | 85 | 74 | 87 | 64 | 81 | 90 | 86 | 60 | 76 | 58 | 67 | 60 | 77 | 85 | 83 | 59 | 65 | 67 | 67 | 52 | 73 | 65 | 70 | 61 | 88 | 50 | 67 | 67 | 84 | 84 | 81 | 59 | 72 | 33 | 100 | 48 | 82 | 63 | 53 | 58 |
Number of infections mild and severe, whether they were treated or not with antibiotics (NCT02749292)
Timeframe: Median follow-up period of 4.1 years (IQR, 2.5 - 5.0)
| Intervention | number of events (Number) | |
|---|---|---|
| Serious Adverse Events- Infections | Adverse Events- Infections | |
| B Cell Reconstitution | 12 | 72 |
| Serologic ANCA Flare | 6 | 59 |
Relapses recording period was from 6/1/2016 to 12/31/2021. The outcome was reported as the number of participants with disease relapse who had either positive ANCA titers specific for myeloperoxidase (MPO-ANCA) or proteinase 3 (PR3-ANCA). The Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG ) is a form with 34 predefined items grouped into 9 organ systems. The items are clinical features observed in patients with active ANCA vasculitis. Each item has a specified weight of either 3 or 1, depending on whether it reflects major or minor disease activity. The total BVAS/WG score is the weighted sum of individual manifestations that are present and believed to be due to active ANCA vasculitis. Higher scores reflect more active disease. BVAS/WG scores range from 0 to 64. (NCT02749292)
Timeframe: Median follow-up period of 4.1 years (IQR, 2.5 - 5.0)
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| PR3 | MPO | |
| B Cell Reconstitution | 1 | 4 |
| Serologic ANCA Flare | 7 | 7 |
The Vasculitis Damage Index (VDI) is a validated formal assessment tool in ANCA-associated vasculitis clinical trials. The VDI distinguishes vasculitis-induced chronic damage from active inflammation or persistent disease. Each item represents a disease manifestation and is given a score (of 1) if present for at least 3 months. Neither the cause of damage (vasculitis vs treatment) nor an ongoing activity are taken into consideration. The VDI includes 64 items categorized into 11 groups (by organ system) and the scored items are summed to give a total score ranging from 0 to 64. A higher score means more accrued damage. (NCT02749292)
Timeframe: 3 years starting at inclusion
| Intervention | score on a scale (Mean) | |
|---|---|---|
| VDI at inclusion | VDI at 3 years | |
| B Cell Reconstitution | 1.27 | 1.42 |
| Serologic ANCA Flare | 1.07 | 1.08 |
"Disease improvement was measured by a reduction in the Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG).~The BVAS/WG is a validated disease activity index. The BVAS/WG is designed to document new or worsening clinically active vasculitis and consists of a set of items divided into nine organ based systems. BVAS/WG scores range from 0 to 63." (NCT00468208)
Timeframe: Measured monthly until common closing or early termination, up to 3 years and 4 months.
| Intervention | participants (Number) |
|---|---|
| Open-label Abatacept | 18 |
"Disease relapse was measured by a rise in the Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG) of greater than or equal to 1 after achieving remission.~The BVAS/WG is a validated disease activity index. The BVAS/WG is designed to document new or worsening clinically active vasculitis and consists of a set of items divided into nine organ based systems. BVAS/WG scores range from 0 to 63." (NCT00468208)
Timeframe: Measured monthly until common closing or early termination, up to 3 years and 4 months.
| Intervention | participants (Number) |
|---|---|
| Open-label Abatacept | 3 |
"Disease remission was measured by a Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG) of 0.~The BVAS/WG is a validated disease activity index. The BVAS/WG is designed to document new or worsening clinically active vasculitis and consists of a set of items divided into nine organ based systems. BVAS/WG scores range from 0 to 63." (NCT00468208)
Timeframe: Measured monthly until common closing or early termination,up to 3 years and 4 months.
| Intervention | participants (Number) |
|---|---|
| Open-label Abatacept | 16 |
The number of subjects that reached the common closing date. (NCT00468208)
Timeframe: Number assessed at the time of common closing, up to 3 years and 4 months.
| Intervention | participants (Number) |
|---|---|
| Open-label Abatacept | 14 |
"This study examined the safety profile of this agent when used in Wegener's granulomatosis. Information was gathered on all adverse events with specific events being identified in the protocol for analysis that included the following:~Infection~Infusion reactions~Cytopenias~Transaminase elevation~Skin reactions~GI side effects~Malignancy~All adverse events were reportable for this study." (NCT00468208)
Timeframe: Measured continuously from the screening visit through to the 6 month post-treatment study visit, up to 3 years and 4 months.
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| Serious adverse events | Non-serious adverse events | Infection | Infusion related (systemic) | Infusion related( intravenous site reaction) | Cytopenia | |
| Open-label Abatacept | 7 | 16 | 14 | 1 | 1 | 4 |
The 36-Item Short Form Health Survey (SF-36) is a set of generic, coherent, and easily administered quality-of-life measures. Scores for the scale range from 0-100 and transformed to have a mean of 50 and SD of 10 in the reference population, with higher scores indicating a better Health-related Quality of Life. (NCT01697267)
Timeframe: 12 months
| Intervention | score on a scale (Mean) |
|---|---|
| Rituximab Maintenance | 50.8 |
| Azathioprine Maintenance | 51.9 |
The 36-Item Short Form Health Survey (SF-36) is a set of generic, coherent, and easily administered quality-of-life measures. Scores for the scale range from 0-100 and transformed to have a mean of 50 and SD of 10 in the reference population, with higher scores indicating a better Health-related Quality of Life. (NCT01697267)
Timeframe: 24 months
| Intervention | score on a scale (Mean) |
|---|---|
| Rituximab Maintenance | 51.9 |
| Azathioprine Maintenance | 53.5 |
The 36-Item Short Form Health Survey (SF-36) is a set of generic, coherent, and easily administered quality-of-life measures. Scores for the scale range from 0-100 and transformed to have a mean of 50 and SD of 10 in the reference population, with higher scores indicating a better Health-related Quality of Life. (NCT01697267)
Timeframe: 36 months
| Intervention | score on a scale (Mean) |
|---|---|
| Rituximab Maintenance | 52.3 |
| Azathioprine Maintenance | 51.8 |
The 36-Item Short Form Health Survey (SF-36) is a set of generic, coherent, and easily administered quality-of-life measures. Scores for the scale range from 0-100 and transformed to have a mean of 50 and SD of 10 in the reference population, with higher scores indicating a better Health-related Quality of Life. (NCT01697267)
Timeframe: 4 months
| Intervention | score on a scale (Mean) |
|---|---|
| Rituximab Maintenance | 51.8 |
| Azathioprine Maintenance | 51.0 |
The 36-Item Short Form Health Survey (SF-36) is a set of generic, coherent, and easily administered quality-of-life measures. Scores for the scale range from 0-100 and transformed to have a mean of 50 and SD of 10 in the reference population, with higher scores indicating a better Health-related Quality of Life. (NCT01697267)
Timeframe: 48 months
| Intervention | score on a scale (Mean) |
|---|---|
| Rituximab Maintenance | 50.9 |
| Azathioprine Maintenance | 53.9 |
The 36-Item Short Form Health Survey (SF-36) is a set of generic, coherent, and easily administered quality-of-life measures. Scores for the scale range from 0-100 and transformed to have a mean of 50 and SD of 10 in the reference population, with higher scores indicating a better Health-related Quality of Life. (NCT01697267)
Timeframe: 12 months
| Intervention | score on a scale (Mean) |
|---|---|
| Rituximab Maintenance | 38.2 |
| Azathioprine Maintenance | 34.6 |
The 36-Item Short Form Health Survey (SF-36) is a set of generic, coherent, and easily administered quality-of-life measures. Scores for the scale range from 0-100 and transformed to have a mean of 50 and SD of 10 in the reference population, with higher scores indicating a better Health-related Quality of Life. (NCT01697267)
Timeframe: 24 months
| Intervention | score on a scale (Mean) |
|---|---|
| Rituximab Maintenance | 36.7 |
| Azathioprine Maintenance | 35.6 |
The 36-Item Short Form Health Survey (SF-36) is a set of generic, coherent, and easily administered quality-of-life measures. Scores for the scale range from 0-100 and transformed to have a mean of 50 and SD of 10 in the reference population, with higher scores indicating a better Health-related Quality of Life. (NCT01697267)
Timeframe: 36 months
| Intervention | score on a scale (Mean) |
|---|---|
| Rituximab Maintenance | 34.6 |
| Azathioprine Maintenance | 33.8 |
The 36-Item Short Form Health Survey (SF-36) is a set of generic, coherent, and easily administered quality-of-life measures. Scores for the scale range from 0-100 and transformed to have a mean of 50 and SD of 10 in the reference population, with higher scores indicating a better Health-related Quality of Life. (NCT01697267)
Timeframe: 4 months
| Intervention | score on a scale (Mean) |
|---|---|
| Rituximab Maintenance | 36.7 |
| Azathioprine Maintenance | 36.1 |
The 36-Item Short Form Health Survey (SF-36) is a set of generic, coherent, and easily administered quality-of-life measures. Scores for the scale range from 0-100 and transformed to have a mean of 50 and SD of 10 in the reference population, with higher scores indicating a better Health-related Quality of Life. (NCT01697267)
Timeframe: 48 months
| Intervention | score on a scale (Mean) |
|---|---|
| Rituximab Maintenance | 35.8 |
| Azathioprine Maintenance | 35.0 |
Infection (treated with intravenous or oral antibiotics) rates (NCT01697267)
Timeframe: Up to 4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Rituximab Maintenance | 54 |
| Azathioprine Maintenance | 62 |
Severe adverse event (SAE) rate (NCT01697267)
Timeframe: Up to 48 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rituximab Maintenance | 37 |
| Azathioprine Maintenance | 48 |
Cumulative accrual of damage as measured by the combined damage assessment score (CDA). Each persistent or new occurrence of damage is given a score of 1. The cumulative accrual of damage is obtained by summing across the different types of damage to get an overall score (max score = 64). (NCT01697267)
Timeframe: data in Rows represent the change from randomization (month 4) to months 12, 24, 36, and 48.
| Intervention | score on a scale (Mean) | |||
|---|---|---|---|---|
| Randomisation to month 12 | Randomisation to month 24 | Randomisation to month 36 | Randomisation to month 48 | |
| Azathioprine Maintenance | 0.337 | 0.533 | 0.899 | 1.38 |
| Rituximab Maintenance | 0.275 | 0.571 | 0.676 | 1.09 |
Cumulative glucocorticoid (GC) exposure during the trial. The trial had a common close out date when the final patient reached month 36 in the trial. Patients were followed until month 48 or the common close out date, whichever happened sooner. Therefore, follow up varied between 36 and 48 months. Cumulative glucocorticoid exposure is presented as a dose in mg for during the treatment period (up to month 24) and across the whole trial (until month 48 or common close out when the final patient reached month 36). (NCT01697267)
Timeframe: Up to 48 months
| Intervention | mg (Mean) | |
|---|---|---|
| Overall (randomisation to end of trial) | Maintenance treatment period (randomisation to month 24) | |
| Azathioprine Maintenance | 4780 | 2426 |
| Rituximab Maintenance | 3717 | 2184 |
Proportion of patients who maintain remission at 24 and 48 months (NCT01697267)
Timeframe: 24 and 48 months
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Month 24 | Month 48 | |
| Azathioprine Maintenance | 70 | 44 |
| Rituximab Maintenance | 73 | 54 |
The primary efficacy outcome measure of the trial is relapse-free survival, where a relapse is either major or minor. The primary analysis will be a Cox regression model adjusted for the stratification factors (ANCA type, relapse severity and prednisone induction regimen) for the difference in the distribution of relapse-free survival between the rituximab arm and the azathioprine (control) arm (two-sided at α-level of 5%). (NCT01697267)
Timeframe: Any patients who have not relapsed at up to a maximum of 4 years will be censored.
| Intervention | participants (Number) | ||
|---|---|---|---|
| Total number of patients with a relapse | Total number of patients with a relapse during treatment | Total number of patients with a relapse post treatment | |
| Azathioprine Maintenance | 60 | 32 | 28 |
| Rituximab Maintenance | 38 | 13 | 25 |
adverse drug reactions will be observed closely and reported during the intervention. We will compare the number of adverse drug reactions in two groups. Also, adverse drug reactions will be described by details in each group. (NCT03002038)
Timeframe: one year
| Intervention | Participants (Count of Participants) |
|---|---|
| Azathioprine | 3 |
| Rituximab | 4 |
annual relapse rate will be measured in the baseline (according to patients' history in the last year) and after 12 months of intervention. (NCT03002038)
Timeframe: one year
| Intervention | Number of relapses (Mean) | |
|---|---|---|
| Baseline | Outcome | |
| Azathioprine | 1 | 0.51 |
| Rituximab | 1.30 | 0.21 |
"expanded disability status scale will be measured in the baseline and after 12 months of intervention.~Expanded disability status scale (EDSS) is a measure of disability for patients. The score ranges from 0-10, with 0 showing normal neurological exam and 10 showing death due to the disabling disease. Thus, higher scores represent more profound levels of disability." (NCT03002038)
Timeframe: one year
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Baseline | Outcome | |
| Azathioprine | 2.40 | 1.95 |
| Rituximab | 3.55 | 2.56 |
Percent change determined 3 months after switch from MMF to SRL (NCT01134952)
Timeframe: 3 month
| Intervention | percent change (Mean) |
|---|---|
| MMF SRL Switch | 9 |
Percent change determined 3 months after switch from MMF to SRL (NCT01134952)
Timeframe: 3 month
| Intervention | percent change (Mean) |
|---|---|
| MMF SRL Switch | 13.8 |
Percent change determined 3 months after switch from MMF to SRL (NCT01134952)
Timeframe: 3 month
| Intervention | percent change (Mean) |
|---|---|
| MMF SRL Switch | -6.0 |
Percent change determined 3 months after switch from MMF to SRL (NCT01134952)
Timeframe: 3 month
| Intervention | percent change (Mean) |
|---|---|
| MMF SRL Switch | 1.2 |
Percent change determined 3 months after switch from MMF to SRL (NCT01134952)
Timeframe: 3 month
| Intervention | percent change (Mean) |
|---|---|
| MMF SRL Switch | -2.7 |
Percent change in HCV load determined 3 months after switch from MMF to SRL. (NCT01134952)
Timeframe: 3 month
| Intervention | percent change (Mean) |
|---|---|
| MMF SRL Switch | 15 |
Percent change determined 3 months after switch from MMF to SRL (NCT01134952)
Timeframe: 3 month
| Intervention | percent change (Mean) |
|---|---|
| MMF SRL Switch | -8.5 |
Percent change determined 3 months after switch from MMF to SRL (NCT01134952)
Timeframe: 3 month
| Intervention | percent change (Mean) |
|---|---|
| MMF SRL Switch | 23 |
Percent change determined 3 months after switch from MMF to SRL (NCT01134952)
Timeframe: 3 month
| Intervention | percent change (Mean) |
|---|---|
| MMF SRL Switch | 23 |
Percent change in HCV load determined 3 months after switch from SRL to MMF (NCT01134952)
Timeframe: 3 month
| Intervention | percent change (Mean) |
|---|---|
| MMF SRL Switch | -47 |
(NCT01134952)
Timeframe: 3 month
| Intervention | ng/ml (Mean) |
|---|---|
| MMF SRL Switch | 7.2 |
Peripheral blood B cell number at week 24 compared to B cell number at week 0 (NCT00286325)
Timeframe: Week 0 and at 24 weeks
| Intervention | B cells per microliter (Median) |
|---|---|
| Treated | 3.99 |
IgG antibodies against BP 180 measured in units (by ELISA) for each participant at week 0 compared to value at week 24, (NCT00286325)
Timeframe: Week 0 and at 24 weeks
| Intervention | Elisa Units (Median) |
|---|---|
| Treated | 40.5 |
The first study visit in which patient reported and was confirmed to have no new blister or lesion formation . (NCT00286325)
Timeframe: 1 year
| Intervention | Days (Median) |
|---|---|
| Treated | 57 |
Subject systemic corticosteroid dosage at week 24 was 25% of starting dose or 10 mg/day of prednisone or less (NCT00286325)
Timeframe: 24 weeks
| Intervention | participants (Number) |
|---|---|
| Treated | 7 |
The primary safety endpoint is the occurrence of treatment emergent adverse events including infections, infusion reactions and disease progression. These were determined by clinical evaluation and laboratory questions. Disease progression is defined as development of new blisters despite therapy. These are reported as the number of participants with a study related SAE. (NCT00286325)
Timeframe: 1 year
| Intervention | participants (Number) | ||
|---|---|---|---|
| Treatment emergent adverse events | Infusion reactions | Disease Progression | |
| Treated | 0 | 0 | 1 |
Measure of anxiety, HADS Hospital anxiety and depression scale. HADS questionnaire consists of a 14 question validated questionnaire, developed to measure anxiety and depression in the hospital setting. Each item is answered by the patient on a four point (0-3) response category so the possible scores range from 0 (minimum) to 21 (maximum) for anxiety and 0 (minimum) to 21 (maximum) for depression. Higher scores indicate worse outcome, (NCT00553163)
Timeframe: 13 weeks
| Intervention | score on a scale (Median) |
|---|---|
| UC Patients Given Gut-focussed Hpynotherapy | 7 |
| UC Patients Given Control Educational Sessions | 10 |
Measure of depression. Each item is answered by the patient on a four point (0-3) response category so the possible scores range from 0 to 21 for anxiety and 0 to 21 for depression. Each item is answered by the patient on a four point (0-3) response category so the possible scores range from 0 (minimum) to 21 (maximum) for anxiety and (minimum) to 21 (maximum) for depression. Higher scores worse outcome. (NCT00553163)
Timeframe: 13 weeks
| Intervention | units on a scale (Median) |
|---|---|
| UC Patients Given Gut-focussed Hypnotherapy | 1.5 |
| UC Patients Given Control Educational Sessions | 4 |
IBDQ (standard measure of IBD patients' Quality of life (QoL) (Irvine et al 1982 approx). The IBDQ is a validated and reliable tool to measure of health-related quality of life in adult patients with IBD. The questionnaire consists of 32 questions scored in four domains: bowel symptoms, emotional health, systemic systems and social function. Scores range from 1 (poorest QoL) to 7 (best QoL). Higher scores indicate better QoL. Lowest score 7, highest score 224. (NCT00553163)
Timeframe: 13 weeks
| Intervention | units on a scale (Median) |
|---|---|
| UC Patients Given Gut-focussed Hypnotherapy | 195 |
| UC Patients Given Control Educational Sessions | 192 |
Measure of recent psychological stress. THE PSQ R consists of a 30 question questionnaires: recent, in which the statements used apply to the last month in which used statements apply to the last two years (Appendix 1.3). The score for both recent and general stress levels were stated as the PSQ index ranging from 0 (non-stressed) to 0.99 (highly stressed). Higher scores indicate worse outcome. (NCT00553163)
Timeframe: 13 weeks
| Intervention | units on a scale (Median) |
|---|---|
| UC Patients Given Gut-focussed Hypnotherapy | 0.3 |
| UC Patients Given Control Educational Sessions | 0.4 |
The number of patients suffering a relapse was compared between the two treatment groups, and was the primary outcome parameter of this study. (NCT00553163)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| UC Patients Given Gut-focussed Hypnotherapy | 8 |
| UC Patients Given Control Educational Sessions | 7 |
100 reviews available for azathioprine and Recrudescence
| Article | Year |
|---|---|
Effectiveness and tolerability of different therapies in preventive treatment of MOG-IgG-associated disorder: A network meta-analysis.
Topics: Azathioprine; Bayes Theorem; Demyelinating Autoimmune Diseases, CNS; Humans; Immunoglobulins, Intrav | 2022 |
A meta-analysis on efficacy and safety of rituximab for neuromyelitis optica spectrum disorders.
Topics: Antibodies; Azathioprine; Humans; Neuromyelitis Optica; Recurrence; Rituximab | 2022 |
Systematic review and meta-analysis for 2023 clinical practice guidelines of the Japan Research Committee of the Ministry of Health, Labour, and Welfare for Intractable Vasculitis for the management of ANCA-associated vasculitis.
Topics: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Antineutrophil Cytoplasmic; | 2023 |
Autoimmune Pancreatitis: From Pathogenesis to Treatment.
Topics: Adrenal Cortex Hormones; Autoimmune Diseases; Autoimmune Pancreatitis; Azathioprine; Biological Prod | 2022 |
Different monoclonal antibodies and immunosuppressants administration in patients with neuromyelitis optica spectrum disorder: a Bayesian network meta-analysis.
Topics: Adrenal Cortex Hormones; Antibodies, Monoclonal; Azathioprine; Bayes Theorem; Humans; Immunosuppress | 2023 |
New Developments in the Management of Recurrent Pericarditis.
Topics: Adrenal Cortex Hormones; Azathioprine; Colchicine; Humans; Immunoglobulins, Intravenous; Pericarditi | 2023 |
Relapsing autoimmune inner ear disease with significant response to methotrexate and azathioprine combination therapy: A case report and mini literature review.
Topics: Adrenal Cortex Hormones; Adult; Autoimmune Diseases; Azathioprine; Female; Hearing Loss, Sensorineur | 2023 |
Efficacy and safety of immunosuppressive agents for adults with lupus nephritis: a systematic review and network meta-analysis.
Topics: Adult; Azathioprine; Bone Marrow Diseases; Cyclophosphamide; Glucocorticoids; Herpes Zoster; Humans; | 2023 |
Glucocorticoids and steroid sparing medications monotherapies or in combination for IgG4-RD: a systematic review and network meta-analysis.
Topics: Antirheumatic Agents; Azathioprine; Cyclophosphamide; Cyclosporine; Drug Therapy, Combination; Gluco | 2020 |
Treatment of microscopic colitis: the role of budesonide and new alternatives for refractory patients.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Antidiarrheals; Antimetabolites; Azathioprine; Bi | 2020 |
Managing acute and recurrent idiopathic pericarditis.
Topics: Acute Disease; Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Azathiopri | 2020 |
Recurrent myelitis and asymptomatic hypophysitis in IgG4-related disease: case-based review.
Topics: Adolescent; Asymptomatic Diseases; Autoimmune Hypophysitis; Azathioprine; Cervical Vertebrae; Female | 2020 |
[A suspected case of Hashimoto encephalopathy with frequent relapses despite multiple courses of immunotherapy].
Topics: Autoantibodies; Azathioprine; Biomarkers; Hashimoto Disease; Humans; Immunotherapy; Male; Methylpred | 2020 |
Non-corticosteroid immunosuppressive medications for steroid-sensitive nephrotic syndrome in children.
Topics: Adolescent; Alkylating Agents; Azathioprine; Child; Child, Preschool; Chlorambucil; Cyclophosphamide | 2020 |
Colonoscopy-guided therapy for the prevention of post-operative recurrence of Crohn's disease.
Topics: Adalimumab; Adult; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Asymptomatic Dise | 2020 |
Network meta-analysis-based comparison of first-line steroid-sparing adjuvants in the treatment of pemphigus vulgaris and pemphigus foliaceus.
Topics: Azathioprine; Cyclophosphamide; Cyclosporine; Drug Therapy, Combination; Humans; Immunologic Factors | 2021 |
Efficacy and safety of azathioprine for neuromyelitis optica spectrum disorders: A meta-analysis of real-world studies.
Topics: Azathioprine; China; Humans; Immunosuppressive Agents; Neuromyelitis Optica; Recurrence | 2020 |
Update οn the diagnosis and management of systemic lupus erythematosus.
Topics: Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal, Humanized; Autoantibodies; Azathioprine; Calc | 2021 |
Withdrawal of immunosuppressant or biologic therapy for patients with quiescent Crohn's disease.
Topics: Adult; Azathioprine; Combined Modality Therapy; Crohn Disease; Feasibility Studies; Gastrointestinal | 2018 |
Immunosuppressive treatment for proliferative lupus nephritis.
Topics: Adult; Azathioprine; Calcineurin; Child; Cyclophosphamide; Female; Glucocorticoids; Humans; Immunosu | 2018 |
Juvenile autoimmune hepatitis: A comprehensive review.
Topics: Adolescent; Adult; Autoantibodies; Azathioprine; Child; Cholangitis, Sclerosing; Disease Management; | 2018 |
Grand round: Autoimmune hepatitis.
Topics: Adolescent; Adult; Anti-Inflammatory Agents; Azathioprine; Clinical Decision-Making; Complementary T | 2019 |
Stopping immunosuppressive treatment in autoimmune hepatitis (AIH): Is it justified (and in whom and when)?
Topics: Azathioprine; Hepatitis, Autoimmune; Humans; Immunosuppressive Agents; Patient Selection; Prednisolo | 2019 |
Maintenance therapy for lupus nephritis with mycophenolate mofetil or azathioprine. A meta-analysis
.
Topics: Azathioprine; Creatinine; Disease Progression; Humans; Immunosuppressive Agents; Kidney Failure, Chr | 2019 |
Treatment of neuromyelitis optica spectrum disorders.
Topics: Azathioprine; Comorbidity; Diagnosis, Differential; Humans; Immunosuppressive Agents; Lymphocyte Dep | 2019 |
Efficacy and acceptability of immunosuppressive agents for pediatric frequently-relapsing and steroid-dependent nephrotic syndrome: A network meta-analysis of randomized controlled trials.
Topics: Adolescent; Azathioprine; Child; Child, Preschool; Chlorambucil; Cyclophosphamide; Cyclosporine; Dru | 2019 |
Hallmark trials in ANCA-associated vasculitis (AAV) for the pediatric rheumatologist.
Topics: Adult; Anti-Inflammatory Agents; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Azathio | 2019 |
L44. Management of relapses in vasculitis.
Topics: Anti-Inflammatory Agents; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Mo | 2013 |
Immunoglobulin G4-associated de novo autoimmune hepatitis after liver transplantation for chronic hepatitis B- and C-related cirrhosis and hepatocellular carcinoma: a case report with literature review.
Topics: Antiviral Agents; Azathioprine; Carcinoma, Hepatocellular; Coinfection; Drug Therapy, Combination; H | 2013 |
Is there still a room for azathioprine monotherapy in inflammatory bowel disease?
Topics: Antibodies, Monoclonal; Azathioprine; Drug Therapy, Combination; Humans; Immunosuppressive Agents; I | 2013 |
Higher risk of tuberculosis reactivation when anti-TNF is combined with immunosuppressive agents: a systematic review of randomized controlled trials.
Topics: Adalimumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Azathioprine; Certolizumab Pe | 2014 |
Autoimmune hepatitis: an approach to disease understanding and management.
Topics: Azathioprine; Glucocorticoids; Hepatitis, Autoimmune; Humans; Immunosuppressive Agents; Liver Transp | 2015 |
Mucocutaneous Involvement in Behçet's Disease: How Systemic Treatment Has Changed in the Last Decades and Future Perspectives.
Topics: Anti-Bacterial Agents; Azathioprine; Behcet Syndrome; Colchicine; Dapsone; Humans; Interferon-alpha; | 2015 |
Recurrent pericarditis: new and emerging therapeutic options.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Aspirin; Azathioprine; Colchicine; Gl | 2016 |
Recurrent Pericarditis: Modern Approach in 2016.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Azathioprine; Colchicine; Drug Therapy, Combinatio | 2016 |
Efficacy of additional treatment with azathioprine in a patient with prednisolone-dependent gastric sarcoidosis.
Topics: Administration, Oral; Adult; Azathioprine; Biopsy; Drug Administration Schedule; Drug Therapy, Combi | 2016 |
Treatment of Adults with Idiopathic Recurrent Pericarditis: Novel Use of Immunotherapy.
Topics: Adult; Azathioprine; Glucocorticoids; Humans; Immunoglobulins, Intravenous; Immunosuppressive Agents | 2017 |
Standard and biological treatment in large vessel vasculitis: guidelines and current approaches.
Topics: Animals; Antibodies, Monoclonal; Azathioprine; Biological Therapy; Clinical Trials as Topic; Giant C | 2017 |
Non-topical management of recalcitrant paediatric atopic dermatitis.
Topics: Azathioprine; Child; Cyclosporine; Dermatitis, Atopic; Dermatologic Agents; Humans; Immunosuppressiv | 2017 |
[Wegener's granulomatosis and microscopic polyangiitis].
Topics: Adrenal Cortex Hormones; Adult; Age Factors; Aged; Antibodies, Antineutrophil Cytoplasmic; Azathiopr | 2008 |
[Treatment of systemic vasculitides].
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Antiviral Agents; Azathioprine; Ch | 2008 |
Immunosuppression in inflammatory bowel disease: traditional, biological or both?
Topics: Adjuvants, Immunologic; Antibodies, Monoclonal; Azathioprine; Biological Products; Colitis, Ulcerati | 2009 |
Azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in Crohn's disease: a meta-analysis.
Topics: Azathioprine; Crohn Disease; Humans; Immunosuppressive Agents; Mercaptopurine; Recurrence | 2009 |
Azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in Crohn's disease: a meta-analysis.
Topics: Azathioprine; Crohn Disease; Humans; Immunosuppressive Agents; Mercaptopurine; Recurrence | 2009 |
Azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in Crohn's disease: a meta-analysis.
Topics: Azathioprine; Crohn Disease; Humans; Immunosuppressive Agents; Mercaptopurine; Recurrence | 2009 |
Azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in Crohn's disease: a meta-analysis.
Topics: Azathioprine; Crohn Disease; Humans; Immunosuppressive Agents; Mercaptopurine; Recurrence | 2009 |
[Treatment of NMO].
Topics: Acute-Phase Reaction; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Azathioprine; | 2009 |
Induction and maintenance therapy for lupus nephritis: a systematic review and meta-analysis.
Topics: Azathioprine; Bias; Cyclophosphamide; Humans; Immunosuppressive Agents; Lupus Nephritis; Mycophenoli | 2010 |
Twelve years of experience of acquired hemophilia A: trials and tribulations in South Australia.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Auto | 2009 |
[Postoperative recurrence of Crohn's disease, and its prevention].
Topics: Anti-Infective Agents; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Colonoscopy; Crohn Dis | 2010 |
Autoimmune hepatitis.
Topics: Animals; Azathioprine; Budesonide; Diagnosis, Differential; Drug Therapy, Combination; Genetic Predi | 2010 |
[Bullous pemphigoid: a review].
Topics: Aged; Azathioprine; Clobetasol; Combined Modality Therapy; Dapsone; Dose-Response Relationship, Drug | 2011 |
Relapse rate following azathioprine withdrawal in maintaining remission for Crohn's disease: a meta-analysis.
Topics: Azathioprine; Crohn Disease; Humans; Immunosuppressive Agents; Randomized Controlled Trials as Topic | 2011 |
Immunosuppression and HCV recurrence after liver transplantation.
Topics: Azathioprine; Cyclosporine; Graft Survival; Hepatitis C; Humans; Immunosuppressive Agents; Liver Tra | 2012 |
Immunotherapy in renal diseases.
Topics: Adrenal Cortex Hormones; Antibodies, Monoclonal, Murine-Derived; Azathioprine; Cyclophosphamide; Cyc | 2012 |
Mycophenolate mofetil versus azathioprine as maintenance therapy for lupus nephritis: a meta-analysis.
Topics: Adolescent; Adult; Aged; Azathioprine; Child; Disease Progression; Female; Humans; Immunosuppressive | 2013 |
Retroperitoneal fibrosis: single-centre experience from 1992 to 2010, current status of knowledge and review of the international literature.
Topics: Adrenal Cortex Hormones; Adult; Aged; Azathioprine; Disease Management; Drug Therapy, Combination; F | 2013 |
[Can the postoperative relapse of Crohn disease be influenced?].
Topics: Anti-Infective Agents; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Clinical Trials as Top | 2001 |
[Conservative therapy of inflammatory bowel diseases].
Topics: Acute Disease; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Chro | 2002 |
[Management of ulcerative colitis].
Topics: Administration, Oral; Adrenal Cortex Hormones; Aminosalicylic Acids; Anemia; Anti-Inflammatory Agent | 2003 |
[Auto-immune hepatitis: therapeutic management].
Topics: Anti-Inflammatory Agents; Antimetabolites; Azathioprine; Calcineurin Inhibitors; Cyclophosphamide; C | 2003 |
[Diagnosis and treatment of multiple sclerosis. Update, 2003].
Topics: Acute Disease; Adjuvants, Immunologic; Analgesics; Anti-Inflammatory Agents; Antibodies, Monoclonal; | 2003 |
[Wegener's granulomatosis (morbus Wegener)].
Topics: Adult; Anti-Infective Agents; Anti-Inflammatory Agents; Azathioprine; Cyclophosphamide; Diagnosis, D | 2003 |
Ulcerative colitis: conservative management and long-term effects.
Topics: Administration, Oral; Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, | 2004 |
[Autoimmune hepatitis].
Topics: Anti-Inflammatory Agents; Azathioprine; Diagnosis, Differential; Drug Therapy, Combination; Female; | 2004 |
Advances in the therapy of Wegener's granulomatosis.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Azathioprine; Cyclophosphamide; Etan | 2006 |
American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease.
Topics: Adrenal Cortex Hormones; Antibodies, Monoclonal; Azathioprine; Calcineurin Inhibitors; Cyclosporine; | 2006 |
[Microscopic polyangiitis].
Topics: Adrenal Cortex Hormones; Age Factors; Antibodies, Antineutrophil Cytoplasmic; Azathioprine; Biologic | 2007 |
Rituximab in autoimmune pancytopenia: a case report and review of literature.
Topics: Adult; Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived | 2007 |
[Current status of treatment of inflammatory bowel disease].
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, H | 2007 |
Plasmapheresis, lymphocytapheresis, and immunosuppressive drug therapy in multiple sclerosis.
Topics: Acute Disease; Adrenocorticotropic Hormone; Adult; Antilymphocyte Serum; Azathioprine; Cell Separati | 1982 |
[Sarcoidosis: diagnosis, clinical aspects, course and therapy].
Topics: Azathioprine; Beclomethasone; Diagnosis, Differential; Glucocorticoids; Humans; Immunosuppressive Ag | 1995 |
[Crohn disease: prevention and drug therapy].
Topics: Aminosalicylic Acids; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Azathioprin | 1995 |
Common variable immunodeficiency in a renal transplant patient with severe recurrent bacterial infection: a case report and review of the literature.
Topics: Adolescent; Azathioprine; Common Variable Immunodeficiency; Humans; Immunoglobulins, Intravenous; Im | 1995 |
Maintenance of symptomatic remission in patients with Crohn's disease.
Topics: Adrenal Cortex Hormones; Aminosalicylic Acids; Azathioprine; Clinical Trials as Topic; Crohn Disease | 1993 |
Immunotherapy for multiple sclerosis.
Topics: Azathioprine; Cyclophosphamide; Cyclosporine; Female; Forecasting; Humans; Immunotherapy; Interferon | 1994 |
Immunotherapy in multiple sclerosis, Part 1.
Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Adult; Azathioprine; Clinical Trials as Topic; | 1995 |
[Chronic recurrent subileus due to Strongyloides stercoralis infection under immunosuppressive therapy].
Topics: Adult; Animals; Azathioprine; Chronic Disease; Diagnosis, Differential; Drug Therapy, Combination; D | 1996 |
Cyclosporine treatment of glomerular diseases.
Topics: Autoimmune Diseases; Azathioprine; Cyclosporine; Drug Combinations; Glomerulonephritis; Glomerulonep | 1999 |
Lupus erythematosus associated with erythema multiforme: does Rowell's syndrome exist?
Topics: Adult; Azathioprine; Cathartics; Dermatologic Agents; Diagnosis, Differential; Erythema Multiforme; | 1999 |
[Acute azathioprine-induced pancreatitis in a female patient with Crohn's disease].
Topics: Acute Disease; Adult; Azathioprine; Crohn Disease; Female; Humans; Immunosuppressive Agents; Pancrea | 1999 |
Therapy of relapsing multiple sclerosis. Treatment approaches for nonresponders.
Topics: Anti-Inflammatory Agents; Azathioprine; Cyclophosphamide; Humans; Immunoglobulins, Intravenous; Immu | 1999 |
[Treatment of multiple sclerosis. The present and the future. Study Group on Diagnosis and Therapy of Multiple Sclerosis].
Topics: Adjuvants, Immunologic; Adrenal Cortex Hormones; Azathioprine; Clinical Trials as Topic; Forecasting | 1999 |
[Use of immunosuppressors in chronic inflammatory intestinal diseases].
Topics: Azathioprine; Humans; Immunosuppressive Agents; Inflammatory Bowel Diseases; Mercaptopurine; Methotr | 1999 |
Initial management of proliferative lupus nephritis: to cytotoxic or not to cytotoxic?
Topics: Adrenal Cortex Hormones; Antineoplastic Agents; Azathioprine; Clinical Trials as Topic; Cyclophospha | 1999 |
Conventional treatment of Crohn's disease: objectives and outcomes.
Topics: Aminosalicylic Acids; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Azathioprin | 2001 |
Frequently relapsing thrombotic thrombocytopenic purpura treated with cytotoxic immunosuppressive therapy.
Topics: Adult; Azathioprine; Cyclophosphamide; Female; Humans; Immunosuppressive Agents; Middle Aged; Platel | 2001 |
Current concepts in the diagnosis, pathogenesis, and treatment of autoimmune hepatitis.
Topics: Age Distribution; Anti-Inflammatory Agents; Azathioprine; Causality; Drug Therapy, Combination; Euro | 2001 |
The management of ulcerative colitis.
Topics: Azathioprine; Colitis, Ulcerative; Cromolyn Sodium; Humans; Hydrocortisone; Prednisolone; Recurrence | 1976 |
A review of systemic nonspecific immunosuppressive treatment of multiple sclerosis.
Topics: Adrenocorticotropic Hormone; Azathioprine; Clinical Trials as Topic; Cyclophosphamide; Drug Therapy, | 1978 |
The protean manifestations of Crohn's disease.
Topics: Adolescent; Adrenocorticotropic Hormone; Adult; Arthritis; Azathioprine; Child; Colectomy; Colitis, | 1975 |
Chronic hepatitis. To treat or not to treat?
Topics: Adrenal Cortex Hormones; Adult; Azathioprine; Chronic Disease; Hepatitis; Hepatitis B; Humans; Middl | 1978 |
Maintenance treatment for Crohn's disease: has the time arrived?
Topics: Aminosalicylic Acids; Azathioprine; Crohn Disease; Drug Administration Schedule; Drug Therapy, Combi | 1992 |
Overview of azathioprine treatment in multiple sclerosis.
Topics: Azathioprine; Disability Evaluation; Follow-Up Studies; Humans; Meta-Analysis as Topic; Multiple Scl | 1991 |
[Immunotherapy of chronic Guillain-Barré syndrome with high dose IgG and cyclosporin A. Case report, review of the literature and perspectives].
Topics: Aged; Azathioprine; Chronic Disease; Cyclosporins; Dose-Response Relationship, Drug; Drug Therapy, C | 1991 |
Ligneous conjunctivitis.
Topics: Azathioprine; Child; Conjunctivitis; Humans; Middle Aged; Recurrence | 1990 |
The medical, nutritional and surgical treatment of fistulae in Crohn's disease.
Topics: Adult; Azathioprine; Colonic Diseases; Combined Modality Therapy; Crohn Disease; Enteral Nutrition; | 1990 |
Inflammatory bowel disease in pregnancy: a review.
Topics: Abortion, Spontaneous; Adrenal Cortex Hormones; Azathioprine; Colitis, Ulcerative; Crohn Disease; Fe | 1986 |
[Therapy of lupus-nephritis using corticosteroids and immunosuppressive agents].
Topics: Adrenal Cortex Hormones; Antibodies, Antinuclear; Azathioprine; Beta-Globulins; Chlorambucil; Cyclop | 1974 |
Advances in gastroenterology.
Topics: Adrenal Cortex Hormones; Azathioprine; Chronic Disease; Colitis, Ulcerative; Diet; Disaccharides; Du | 1972 |
Crohn's disease, with special reference to surgical management.
Topics: Abdomen; Anus Diseases; Azathioprine; Barium Sulfate; Colitis, Ulcerative; Crohn Disease; Diagnosis, | 1972 |
The place of surgery in Crohn's disease.
Topics: Abscess; Acute Disease; Anemia; Appendectomy; Azathioprine; Colectomy; Colonic Diseases; Crohn Disea | 1971 |
Immunosuppressant agents in the treatment of glomerulonephritis. 2. Cytotoxic drugs.
Topics: Adult; Anti-Glomerular Basement Membrane Disease; Antilymphocyte Serum; Antineoplastic Agents; Azath | 1971 |
93 trials available for azathioprine and Recrudescence
| Article | Year |
|---|---|
Weaning of maintenance immunosuppressive therapy in lupus nephritis (WIN-Lupus): results of a multicentre randomised controlled trial.
Topics: Azathioprine; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Lupus Erythematosus, Syst | 2022 |
Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial.
Topics: Adult; Azathioprine; Crohn Disease; Humans; Immunosuppressive Agents; Infliximab; Recurrence; Tumor | 2023 |
Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: an international randomised controlled trial.
Topics: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Antineutrophil Cytoplasmic; | 2023 |
Azathioprine as an adjuvant therapy in severe Graves' disease: a randomized controlled open-label clinical trial.
Topics: Antibodies; Antithyroid Agents; Azathioprine; Carbimazole; Graves Disease; Humans; Propranolol; Recu | 2023 |
In relapsing AAV with rituximab-induced remission, maintenance rituximab vs. azathioprine reduced relapse at ≥32 mo.
Topics: Azathioprine; Chronic Disease; Cyclophosphamide; Humans; Immunosuppressive Agents; Recurrence; Remis | 2023 |
Oral Curcumin No More Effective Than Placebo in Preventing Recurrence of Crohn's Disease After Surgery in a Randomized Controlled Trial.
Topics: Azathioprine; Crohn Disease; Curcumin; Humans; Quality of Life; Recurrence; Treatment Outcome | 2020 |
Addition of azathioprine to the switch of anti-TNF in patients with IBD in clinical relapse with undetectable anti-TNF trough levels and antidrug antibodies: a prospective randomised trial.
Topics: Adalimumab; Adult; Anti-Inflammatory Agents; Azathioprine; Crohn Disease; Drug Therapy, Combination; | 2020 |
Variation of faecal calprotectin level within the first three months after bowel resection is predictive of endoscopic postoperative recurrence in Crohn's disease.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Biomarkers; Colectomy; Crohn Disease; | 2020 |
Azathioprine for prevention of clinical recurrence in Crohn's disease patients with severe endoscopic recurrence: an IG-IBD randomized double-blind trial.
Topics: Azathioprine; Crohn Disease; Double-Blind Method; Humans; Mesalamine; Recurrence | 2020 |
Avacopan for the Treatment of ANCA-Associated Vasculitis.
Topics: Administration, Oral; Aniline Compounds; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; | 2021 |
AZALEP a randomized controlled trial of azathioprine to treat leprosy nerve damage and Type 1 reactions in India: Main findings.
Topics: Administration, Oral; Adolescent; Adult; Azathioprine; Drug Therapy, Combination; Female; Humans; Im | 2017 |
High-dose intravenous steroid pulse therapy in ocular involvement of Behcet's disease: a pilot double-blind controlled study.
Topics: Administration, Intravenous; Adult; Azathioprine; Behcet Syndrome; Cyclophosphamide; Double-Blind Me | 2017 |
Adding Azathioprine to Remission-Induction Glucocorticoids for Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss), Microscopic Polyangiitis, or Polyarteritis Nodosa Without Poor Prognosis Factors: A Randomized, Controlled Trial.
Topics: Adult; Aged; Asthma; Azathioprine; Churg-Strauss Syndrome; Disease Progression; Double-Blind Method; | 2017 |
Comparing the efficacy of low-dose vs high-dose cyclophosphamide regimen as induction therapy in the treatment of proliferative lupus nephritis: a single center study.
Topics: Administration, Intravenous; Azathioprine; Cyclophosphamide; Drug Administration Schedule; Drug Ther | 2018 |
Comparing the efficacy of low-dose vs high-dose cyclophosphamide regimen as induction therapy in the treatment of proliferative lupus nephritis: a single center study.
Topics: Administration, Intravenous; Azathioprine; Cyclophosphamide; Drug Administration Schedule; Drug Ther | 2018 |
Comparing the efficacy of low-dose vs high-dose cyclophosphamide regimen as induction therapy in the treatment of proliferative lupus nephritis: a single center study.
Topics: Administration, Intravenous; Azathioprine; Cyclophosphamide; Drug Administration Schedule; Drug Ther | 2018 |
Comparing the efficacy of low-dose vs high-dose cyclophosphamide regimen as induction therapy in the treatment of proliferative lupus nephritis: a single center study.
Topics: Administration, Intravenous; Azathioprine; Cyclophosphamide; Drug Administration Schedule; Drug Ther | 2018 |
Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides.
Topics: Adult; Aged; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Antineutrophil | 2018 |
Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial.
Topics: Adolescent; Adult; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Azathioprine; Child; | 2019 |
Quality of life during one year of postoperative prophylactic drug therapy after intestinal resection in Crohn's patients: Results of the APPRECIA trial.
Topics: Adalimumab; Adult; Azathioprine; Crohn Disease; Endoscopes, Gastrointestinal; Female; Humans; Immuno | 2019 |
[Effects of shugan jianpi gusui recipe on multiple sclerosis recurrence: a primary report].
Topics: Adrenal Cortex Hormones; Adult; Azathioprine; Drugs, Chinese Herbal; gamma-Globulins; Humans; Middle | 2013 |
Efficacy of remission-induction regimens for ANCA-associated vasculitis.
Topics: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Monoclonal, Murine-Derived; | 2013 |
Efficacy of remission-induction regimens for ANCA-associated vasculitis.
Topics: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Monoclonal, Murine-Derived; | 2013 |
Efficacy of remission-induction regimens for ANCA-associated vasculitis.
Topics: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Monoclonal, Murine-Derived; | 2013 |
Efficacy of remission-induction regimens for ANCA-associated vasculitis.
Topics: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Monoclonal, Murine-Derived; | 2013 |
Efficacy of remission-induction regimens for ANCA-associated vasculitis.
Topics: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Monoclonal, Murine-Derived; | 2013 |
Efficacy of remission-induction regimens for ANCA-associated vasculitis.
Topics: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Monoclonal, Murine-Derived; | 2013 |
Efficacy of remission-induction regimens for ANCA-associated vasculitis.
Topics: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Monoclonal, Murine-Derived; | 2013 |
Efficacy of remission-induction regimens for ANCA-associated vasculitis.
Topics: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Monoclonal, Murine-Derived; | 2013 |
Efficacy of remission-induction regimens for ANCA-associated vasculitis.
Topics: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Monoclonal, Murine-Derived; | 2013 |
Efficacy of remission-induction regimens for ANCA-associated vasculitis.
Topics: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Monoclonal, Murine-Derived; | 2013 |
Efficacy of remission-induction regimens for ANCA-associated vasculitis.
Topics: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Monoclonal, Murine-Derived; | 2013 |
Efficacy of remission-induction regimens for ANCA-associated vasculitis.
Topics: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Monoclonal, Murine-Derived; | 2013 |
Efficacy of remission-induction regimens for ANCA-associated vasculitis.
Topics: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Monoclonal, Murine-Derived; | 2013 |
Efficacy of remission-induction regimens for ANCA-associated vasculitis.
Topics: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Monoclonal, Murine-Derived; | 2013 |
Efficacy of remission-induction regimens for ANCA-associated vasculitis.
Topics: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Monoclonal, Murine-Derived; | 2013 |
Efficacy of remission-induction regimens for ANCA-associated vasculitis.
Topics: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Monoclonal, Murine-Derived; | 2013 |
Reduced fibrosis in recurrent HCV with tacrolimus, azathioprine and steroids versus tacrolimus: randomised trial long term outcomes.
Topics: Anti-Inflammatory Agents; Azathioprine; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Hum | 2014 |
Rituximab for the treatment of relapses in antineutrophil cytoplasmic antibody-associated vasculitis.
Topics: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Monoclonal, Murine-Derived; | 2014 |
Assessment of the therapeutic benefit of oral prednisolone and common adjuvant therapy in stage II of randomized controlled trial study for management of pemphigus vulgaris.
Topics: Administration, Oral; Adult; Azathioprine; Chemotherapy, Adjuvant; Cyclophosphamide; Drug Therapy, C | 2014 |
Azathioprine is more effective than mesalazine at preventing recurrent bowel obstruction in patients with ileocecal Crohn's disease.
Topics: Adult; Azathioprine; Crohn Disease; Demography; Female; Humans; Ileocecal Valve; Intestinal Obstruct | 2014 |
Withdrawal of long-term maintenance treatment with azathioprine tends to increase relapse risk in patients with Crohn's disease.
Topics: Adult; Anti-Inflammatory Agents; Austria; Azathioprine; Crohn Disease; Double-Blind Method; Drug Adm | 2015 |
Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement.
Topics: Adult; Aged; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Monoclonal, Mur | 2015 |
Azathioprine versus beta interferons for relapsing-remitting multiple sclerosis: a multicentre randomized non-inferiority trial.
Topics: Adult; Azathioprine; Female; Follow-Up Studies; Humans; Immunologic Factors; Immunosuppressive Agent | 2014 |
Tripterygium wilfordii Hook. f. versus azathioprine for prevention of postoperative recurrence in patients with Crohn's disease: a randomized clinical trial.
Topics: Adult; Azathioprine; Crohn Disease; Female; Humans; Immunosuppressive Agents; Male; Phytotherapy; Po | 2015 |
Crohn's disease management after intestinal resection: a randomised trial.
Topics: Adalimumab; Adult; Antibodies, Monoclonal, Humanized; Azathioprine; Colonoscopy; Crohn Disease; Fema | 2015 |
Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomised controlled trial and long-term follow-up.
Topics: Adult; Anti-Inflammatory Agents; Azathioprine; Creatinine; Disease Progression; Drug Therapy, Combin | 2016 |
Outcomes of nonsevere relapses in antineutrophil cytoplasmic antibody-associated vasculitis treated with glucocorticoids.
Topics: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Monoclonal, Murine-Derived; | 2015 |
Systematic versus Endoscopy-driven Treatment with Azathioprine to Prevent Postoperative Ileal Crohn's Disease Recurrence.
Topics: Adult; Anastomosis, Surgical; Azathioprine; Clinical Decision-Making; Colon; Colonoscopy; Crohn Dise | 2015 |
Efficacy of thiopurines and adalimumab in preventing Crohn's disease recurrence in high-risk patients - a POCER study analysis.
Topics: Adalimumab; Adult; Aged; Azathioprine; Colonoscopy; Crohn Disease; Drug Therapy, Combination; Female | 2015 |
Different responses to treatment across classified diseases and severities in Japanese patients with microscopic polyangiitis and granulomatosis with polyangiitis: a nationwide prospective inception cohort study.
Topics: Aged; Aged, 80 and over; Azathioprine; Cyclophosphamide; Disease-Free Survival; Drug Therapy, Combin | 2015 |
Extended versus standard azathioprine maintenance therapy in newly diagnosed proteinase-3 anti-neutrophil cytoplasmic antibody-associated vasculitis patients who remain cytoplasmic anti-neutrophil cytoplasmic antibody-positive after induction of remission
Topics: Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Anti-Neutrophil Cytoplasmic Antibody-Associ | 2016 |
Endoscopic Recurrence 6 Months After Ileocecal Resection in Children With Crohn Disease Treated With Azathioprine.
Topics: Adalimumab; Adolescent; Anti-Inflammatory Agents; Azathioprine; Cecum; Child; Child, Preschool; Colo | 2017 |
Rituximab versus azathioprine as therapy for maintenance of remission for anti-neutrophil cytoplasm antibody-associated vasculitis (RITAZAREM): study protocol for a randomized controlled trial.
Topics: Administration, Intravenous; Administration, Oral; Anti-Neutrophil Cytoplasmic Antibody-Associated V | 2017 |
Azathioprine withdrawal in patients with Crohn's disease maintained on prolonged remission: a high risk of relapse.
Topics: Adult; Azathioprine; C-Reactive Protein; Cohort Studies; Crohn Disease; Female; Follow-Up Studies; H | 2009 |
Gray matter atrophy and disability progression in patients with early relapsing-remitting multiple sclerosis: a 5-year longitudinal study.
Topics: Adult; Atrophy; Azathioprine; Brain; Cerebral Ventricles; Disease Progression; Drug Therapy, Combina | 2009 |
Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis.
Topics: Administration, Oral; Adrenal Cortex Hormones; Atrophy; Azathioprine; Brain; Disability Evaluation; | 2009 |
Recurrence of Crohn's disease after ileocolic resection is not affected by anastomotic type: results of a multicenter, randomized, controlled trial.
Topics: Adult; Anastomosis, Surgical; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Colon; Crohn Di | 2009 |
Recurrence of Crohn's disease after ileocolic resection is not affected by anastomotic type: results of a multicenter, randomized, controlled trial.
Topics: Adult; Anastomosis, Surgical; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Colon; Crohn Di | 2009 |
Recurrence of Crohn's disease after ileocolic resection is not affected by anastomotic type: results of a multicenter, randomized, controlled trial.
Topics: Adult; Anastomosis, Surgical; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Colon; Crohn Di | 2009 |
Recurrence of Crohn's disease after ileocolic resection is not affected by anastomotic type: results of a multicenter, randomized, controlled trial.
Topics: Adult; Anastomosis, Surgical; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Colon; Crohn Di | 2009 |
Combination immunosuppressant therapy for patients with chronic refractory immune thrombocytopenic purpura.
Topics: Azathioprine; Chronic Disease; Cyclosporine; Drug Therapy, Combination; Female; Humans; Immunosuppre | 2010 |
Outcome of recurrent hepatitis C virus after liver transplantation in a randomized trial of tacrolimus monotherapy versus triple therapy.
Topics: Adolescent; Adult; Aged; Azathioprine; Biopsy; Child; Drug Therapy, Combination; Female; Graft Rejec | 2009 |
Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study.
Topics: Adult; Azathioprine; Bifidobacterium; Colitis, Ulcerative; Combined Modality Therapy; Double-Blind M | 2010 |
Cyclosporine versus azathioprine therapy in high-risk idiopathic membranous nephropathy patients: A 3-year prospective study.
Topics: Adult; Azathioprine; Cyclosporine; Female; Follow-Up Studies; Glomerulonephritis, Membranous; Humans | 2011 |
Interferon, azathioprine and corticosteroids in multiple sclerosis: 6-year follow-up of the ASA cohort.
Topics: Adjuvants, Immunologic; Adolescent; Adrenal Cortex Hormones; Adult; Azathioprine; Brain; Cohort Stud | 2012 |
Determinants of outcome in ANCA-associated glomerulonephritis: a prospective clinico-histopathological analysis of 96 patients.
Topics: Antibodies, Antineutrophil Cytoplasmic; Azathioprine; Biopsy; Cyclophosphamide; Glomerular Filtratio | 2002 |
A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies.
Topics: Adult; Aged; Antibodies, Antineutrophil Cytoplasmic; Azathioprine; Cyclophosphamide; Drug Therapy, C | 2003 |
A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies.
Topics: Adult; Aged; Antibodies, Antineutrophil Cytoplasmic; Azathioprine; Cyclophosphamide; Drug Therapy, C | 2003 |
A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies.
Topics: Adult; Aged; Antibodies, Antineutrophil Cytoplasmic; Azathioprine; Cyclophosphamide; Drug Therapy, C | 2003 |
A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies.
Topics: Adult; Aged; Antibodies, Antineutrophil Cytoplasmic; Azathioprine; Cyclophosphamide; Drug Therapy, C | 2003 |
Comparison between a two-drug regimen with tacrolimus and steroids and a triple one with azathioprine in kidney transplantation: results of a European trial with 3-year follow up.
Topics: Acute Disease; Adrenal Cortex Hormones; Azathioprine; Chronic Disease; Creatinine; Drug Therapy, Com | 2003 |
Antibiotics and azathioprine for the treatment of perianal fistulas in Crohn's disease.
Topics: Adjuvants, Immunologic; Adolescent; Adult; Aged; Anti-Bacterial Agents; Anus Diseases; Azathioprine; | 2003 |
Sequential therapies for proliferative lupus nephritis.
Topics: Adult; Amenorrhea; Azathioprine; Cyclophosphamide; Drug Administration Schedule; Drug Therapy, Combi | 2004 |
Sequential therapies for proliferative lupus nephritis.
Topics: Adult; Amenorrhea; Azathioprine; Cyclophosphamide; Drug Administration Schedule; Drug Therapy, Combi | 2004 |
Sequential therapies for proliferative lupus nephritis.
Topics: Adult; Amenorrhea; Azathioprine; Cyclophosphamide; Drug Administration Schedule; Drug Therapy, Combi | 2004 |
Sequential therapies for proliferative lupus nephritis.
Topics: Adult; Amenorrhea; Azathioprine; Cyclophosphamide; Drug Administration Schedule; Drug Therapy, Combi | 2004 |
Sequential therapies for proliferative lupus nephritis.
Topics: Adult; Amenorrhea; Azathioprine; Cyclophosphamide; Drug Administration Schedule; Drug Therapy, Combi | 2004 |
Sequential therapies for proliferative lupus nephritis.
Topics: Adult; Amenorrhea; Azathioprine; Cyclophosphamide; Drug Administration Schedule; Drug Therapy, Combi | 2004 |
Sequential therapies for proliferative lupus nephritis.
Topics: Adult; Amenorrhea; Azathioprine; Cyclophosphamide; Drug Administration Schedule; Drug Therapy, Combi | 2004 |
Sequential therapies for proliferative lupus nephritis.
Topics: Adult; Amenorrhea; Azathioprine; Cyclophosphamide; Drug Administration Schedule; Drug Therapy, Combi | 2004 |
Sequential therapies for proliferative lupus nephritis.
Topics: Adult; Amenorrhea; Azathioprine; Cyclophosphamide; Drug Administration Schedule; Drug Therapy, Combi | 2004 |
Positive classic antineutrophil cytoplasmic antibody (C-ANCA) titer at switch to azathioprine therapy associated with relapse in proteinase 3-related vasculitis.
Topics: Adult; Aged; Antibodies, Antineutrophil Cytoplasmic; Azathioprine; Cyclophosphamide; Disease-Free Su | 2004 |
Randomized controlled azathioprine withdrawal after more than two years treatment in Crohn's disease: increased relapse rate the following year.
Topics: Adult; Aged; Azathioprine; Crohn Disease; Disease-Free Survival; Dose-Response Relationship, Drug; H | 2004 |
Impact of mycophenolate mofetil versus azathioprine on early recurrence of hepatitis C after liver transplantation.
Topics: Adult; Azathioprine; Cyclosporine; Female; Fibrosis; Graft Rejection; Hepatitis C; Humans; Immunosup | 2005 |
Hypogammaglobulinemia after heart transplantation: use of intravenous immunoglobulin replacement therapy in relapsing CMV disease.
Topics: Agammaglobulinemia; Antilymphocyte Serum; Antiviral Agents; Azathioprine; Cyclosporine; Cytomegalovi | 2005 |
Double-blind comparison of hepatitis C histological recurrence Rate in HCV+ Liver transplant recipients given basiliximab + steroids or basiliximab + placebo, in addition to cyclosporine and azathioprine.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antibodies, Monoclonal; Azathioprine; Basiliximab; Cyclosporin | 2004 |
Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis.
Topics: Adult; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Cyclophospha | 2005 |
A randomized, double-blind, controlled withdrawal trial in Crohn's disease patients in long-term remission on azathioprine.
Topics: Adult; Azathioprine; Biomarkers; C-Reactive Protein; Crohn Disease; Double-Blind Method; Female; Hum | 2005 |
Intravenous dexamethasone-cyclophosphamide pulse therapy in comparison with oral methylprednisolone-azathioprine therapy in patients with pemphigus: results of a multicenter prospectively randomized study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Azathioprine; Cyclop | 2005 |
Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients.
Topics: Adult; Antineoplastic Agents; Antiviral Agents; Azathioprine; Brain; Demography; Disability Evaluati | 2008 |
A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of bullous pemphigoid.
Topics: Administration, Oral; Adrenal Cortex Hormones; Aged; Aged, 80 and over; Azathioprine; Dose-Response | 2007 |
Treatment of Churg-Strauss syndrome without poor-prognosis factors: a multicenter, prospective, randomized, open-label study of seventy-two patients.
Topics: Administration, Oral; Adult; Aged; Azathioprine; Churg-Strauss Syndrome; Cyclophosphamide; Disease-F | 2008 |
[Current status of drug therapy of chronic inflammatory intestinal diseases].
Topics: Azathioprine; Clinical Trials as Topic; Colitis, Ulcerative; Cromolyn Sodium; Double-Blind Method; D | 1983 |
Therapeutic trials in multiple sclerosis: azathioprine.
Topics: Adult; Azathioprine; Clinical Trials as Topic; Drug Therapy, Combination; Female; Humans; Male; Meth | 1984 |
Cell number requirements for lymphocyte stimulation in vitro: changes during the course of multiple sclerosis and the effects of immunosuppression.
Topics: Adult; Azathioprine; Cells, Cultured; Clinical Trials as Topic; Humans; Immunosuppressive Agents; Le | 1981 |
Steroid-pulse therapy in pemphigus vulgaris long term follow-up.
Topics: Administration, Oral; Adolescent; Adult; Autoantibodies; Azathioprine; Cyclophosphamide; Drug Therap | 1995 |
Azathioprine for long-term maintenance of remission in autoimmune hepatitis.
Topics: Adolescent; Adult; Aged; Arthralgia; Autoimmune Diseases; Azathioprine; Disease-Free Survival; Femal | 1995 |
Treatment of recurrent cytomegalovirus disease in patients receiving solid organ transplants.
Topics: Acyclovir; Azathioprine; Cyclosporine; Cytomegalovirus Infections; Drug Tolerance; Ganciclovir; Graf | 1993 |
Oral pulse prednisone therapy after relapse of severe autoimmune chronic active hepatitis. A prospective randomized treatment trial evaluating clinical, biochemical, and lymphocyte subset responses.
Topics: Administration, Oral; Adult; Autoimmune Diseases; Azathioprine; Drug Administration Schedule; Drug T | 1993 |
Conversion from cyclosporine to tacrolimus in kidney, kidney/pancreas, and pancreas alone transplant recipients: the Memphis experience.
Topics: Adolescent; Adult; Amylases; Antilymphocyte Serum; Azathioprine; Creatinine; Cyclosporine; Drug Ther | 1996 |
Preliminary experience with mycophenolate mofetil used after lung transplantation.
Topics: Azathioprine; Female; Graft Rejection; Humans; Immunosuppressive Agents; Lung Transplantation; Male; | 1998 |
Devic's neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine.
Topics: Adult; Aged; Anti-Inflammatory Agents; Azathioprine; Disability Evaluation; Female; Humans; Immunosu | 1998 |
Combination therapy with oral tacrolimus (FK506) and azathioprine or 6-mercaptopurine for treatment-refractory Crohn's disease perianal fistulae.
Topics: Administration, Oral; Adolescent; Adult; Azathioprine; Crohn Disease; Drug Therapy, Combination; Fem | 1999 |
Efficacy of long-term azathioprine for relapsing nephrotic syndrome.
Topics: Adolescent; Adult; Age of Onset; Azathioprine; Child; Child, Preschool; Female; Follow-Up Studies; G | 2000 |
Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group.
Topics: Adult; Azathioprine; Cyclophosphamide; Drug Therapy, Combination; Female; Glucocorticoids; Humans; I | 2000 |
beta-herpesvirus activation after kidney transplantation with mycophenolate mofetil-based maintenance immunosuppression.
Topics: Adult; Azathioprine; Cyclosporine; Cytomegalovirus; Cytomegalovirus Infections; Drug Therapy, Combin | 2001 |
Treatment of diffuse proliferative lupus glomerulonephritis: a comparison of two cyclophosphamide-containing regimens.
Topics: Administration, Oral; Adolescent; Adult; Azathioprine; Biopsy; Cyclophosphamide; Drug Therapy, Combi | 2001 |
Relevance of thiopurine methyltransferase activity in inflammatory bowel disease patients maintained on low-dose azathioprine.
Topics: Adolescent; Adult; Aged; Azathioprine; Biomarkers; Female; Humans; Immunosuppressive Agents; Inflamm | 2002 |
Outcome and prognostic indicators of diffuse proliferative lupus glomerulonephritis treated with sequential oral cyclophosphamide and azathioprine.
Topics: Administration, Oral; Adult; Azathioprine; Cohort Studies; Cyclophosphamide; Female; Humans; Immunos | 2002 |
National Cooperative Crohn's Disease Study: study design and conduct of the study.
Topics: Azathioprine; Clinical Trials as Topic; Crohn Disease; Double-Blind Method; Drug Therapy, Combinatio | 1979 |
National Cooperative Crohn's Disease Study: results of drug treatment.
Topics: Adult; Azathioprine; Clinical Trials as Topic; Crohn Disease; Double-Blind Method; Female; Follow-Up | 1979 |
[Indications for surgical and conservative therapy of Crohn's disease].
Topics: Acute Disease; Azathioprine; Chronic Disease; Clinical Trials as Topic; Crohn Disease; Humans; Intes | 1977 |
Double-blind withdrawal trial of azathioprine as maintenance treatment for Crohn's disease.
Topics: Adult; Aged; Azathioprine; Clinical Trials as Topic; Crohn Disease; Double-Blind Method; Drug Evalua | 1978 |
A review of systemic nonspecific immunosuppressive treatment of multiple sclerosis.
Topics: Adrenocorticotropic Hormone; Azathioprine; Clinical Trials as Topic; Cyclophosphamide; Drug Therapy, | 1978 |
A controlled trial of azathioprine in Crohn's disease.
Topics: Adolescent; Adult; Azathioprine; Clinical Trials as Topic; Crohn Disease; Female; Humans; Male; Midd | 1975 |
Randomised controlled trial of azathioprine withdrawal in ulcerative colitis.
Topics: Azathioprine; Chronic Disease; Colitis, Ulcerative; Double-Blind Method; Humans; Long-Term Care; Rec | 1992 |
The efficacy of azathioprine in relapsing-remitting multiple sclerosis.
Topics: Adolescent; Adult; Aged; Azathioprine; Disability Evaluation; Humans; Middle Aged; Multiple Sclerosi | 1991 |
[Severe psoriatic rheumatism. Treatment with azathioprine. Report of 11 cases].
Topics: Adult; Arthritis, Psoriatic; Azathioprine; Drug Evaluation; Female; Follow-Up Studies; Humans; Male; | 1990 |
The impact of different immunosuppressant regimens on recurrent glomerulonephritis.
Topics: Adult; Azathioprine; Biopsy; Clinical Trials as Topic; Cyclosporins; Female; Follow-Up Studies; Glom | 1989 |
Clinical trials of immunosuppression and immunomodulation in multiple sclerosis.
Topics: Adjuvants, Immunologic; Azathioprine; Brain; Clinical Trials as Topic; Cyclophosphamide; Cyclosporin | 1988 |
Cyclosporine trials in diabetes: updated results of the French experience.
Topics: Autoimmune Diseases; Azathioprine; C-Peptide; Clinical Trials as Topic; Cyclosporins; Diabetes Melli | 1988 |
[Basis of the immunosuppressive therapy of ulcerative colitis in childhood].
Topics: Adolescent; Adrenal Cortex Hormones; Azathioprine; Child; Clinical Trials as Topic; Colitis, Ulcerat | 1972 |
Azathioprine treatment in Crohn's disease.
Topics: Adolescent; Adult; Azathioprine; Body Weight; Clinical Trials as Topic; Crohn Disease; Diarrhea; Fem | 1974 |
A double-blind trial of azathioprine in Crohn's disease.
Topics: Azathioprine; Clinical Trials as Topic; Crohn Disease; Humans; Placebos; Prednisolone; Recurrence | 1971 |
481 other studies available for azathioprine and Recrudescence
| Article | Year |
|---|---|
Discontinuation of Azathioprine could be considered in pediatric patients with Crohn's disease who have sustained clinical and deep remission.
Topics: Adolescent; Azathioprine; Child; Crohn Disease; Female; Gastrointestinal Agents; Humans; Infliximab; | 2022 |
Vogt-Koyanagi-Harada Relapse after COVID-19 Vaccination.
Topics: Adrenal Cortex Hormones; Azathioprine; Chronic Disease; COVID-19; COVID-19 Vaccines; Female; Humans; | 2022 |
Mycophenolate mofetil or tacrolimus compared with azathioprine in long-term maintenance treatment for active lupus nephritis.
Topics: Azathioprine; Humans; Immunosuppressive Agents; Lupus Nephritis; Mycophenolic Acid; Recurrence; Tacr | 2022 |
The efficacy and safety of mycophenolate mofetil in Thai neuromyelitis optica spectrum disorder patients.
Topics: Azathioprine; Humans; Mycophenolic Acid; Neuromyelitis Optica; Recurrence; Retrospective Studies; Th | 2022 |
Impaired adrenal cortex reserve in patients with rheumatic and musculoskeletal diseases who relapse upon tapering of low glucocorticoid dose.
Topics: Adrenal Cortex; Adrenal Cortex Hormones; Adrenal Insufficiency; Antirheumatic Agents; Arthritis, Rhe | 2022 |
Relapse rates after withdrawal of thiopurines in patients with inflammatory bowel disease.
Topics: Azathioprine; Colitis, Ulcerative; Crohn Disease; Humans; Immunologic Factors; Immunosuppressive Age | 2022 |
The description of neuromyelitis optica spectrum disorder: Patient registry in Yangtze River Delta area of China.
Topics: Antibodies, Antinuclear; Aquaporin 4; Autoantibodies; Azathioprine; Female; Humans; Iodide Peroxidas | 2022 |
Prediction of thiopurine failure in pediatric Crohn's disease: pediatric IBD Porto group of ESPGHAN.
Topics: Azathioprine; Child; Crohn Disease; Humans; Immunosuppressive Agents; Prospective Studies; Recurrenc | 2023 |
Therapeutic Response in Pediatric Neuromyelitis Optica Spectrum Disorder.
Topics: Aquaporin 4; Autoantibodies; Azathioprine; Enzyme Inhibitors; Female; Humans; Immunoglobulin G; Immu | 2023 |
Therapeutic Response in Pediatric Neuromyelitis Optica Spectrum Disorder.
Topics: Aquaporin 4; Autoantibodies; Azathioprine; Enzyme Inhibitors; Female; Humans; Immunoglobulin G; Immu | 2023 |
Therapeutic Response in Pediatric Neuromyelitis Optica Spectrum Disorder.
Topics: Aquaporin 4; Autoantibodies; Azathioprine; Enzyme Inhibitors; Female; Humans; Immunoglobulin G; Immu | 2023 |
Therapeutic Response in Pediatric Neuromyelitis Optica Spectrum Disorder.
Topics: Aquaporin 4; Autoantibodies; Azathioprine; Enzyme Inhibitors; Female; Humans; Immunoglobulin G; Immu | 2023 |
Azathioprine Withdrawal Is Cost-Effective in Patients with Crohn's Disease in Remission on Infliximab and Azathioprine.
Topics: Azathioprine; Child, Preschool; Cost-Benefit Analysis; Crohn Disease; Humans; Immunosuppressive Agen | 2023 |
Azathioprine Withdrawal Is Cost-Effective in Patients with Crohn's Disease in Remission on Infliximab and Azathioprine.
Topics: Azathioprine; Child, Preschool; Cost-Benefit Analysis; Crohn Disease; Humans; Immunosuppressive Agen | 2023 |
Azathioprine Withdrawal Is Cost-Effective in Patients with Crohn's Disease in Remission on Infliximab and Azathioprine.
Topics: Azathioprine; Child, Preschool; Cost-Benefit Analysis; Crohn Disease; Humans; Immunosuppressive Agen | 2023 |
Azathioprine Withdrawal Is Cost-Effective in Patients with Crohn's Disease in Remission on Infliximab and Azathioprine.
Topics: Azathioprine; Child, Preschool; Cost-Benefit Analysis; Crohn Disease; Humans; Immunosuppressive Agen | 2023 |
A comparison of the efficacy of tocilizumab versus azathioprine for neuromyelitis optica spectrum disorder: A study protocol for systematic review and meta-analysis.
Topics: Azathioprine; Humans; Meta-Analysis as Topic; Neuromyelitis Optica; Recurrence; Systematic Reviews a | 2023 |
Effectiveness of rituximab versus oral immunosuppressive therapies in neuromyelitis optica spectrum disorder in a racially diverse cohort of subjects: A single-center retrospective study.
Topics: Aquaporin 4; Azathioprine; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Mycophenolic | 2023 |
What predicts the recurrence in ıdiopathic granulomatous mastitis?
Topics: Abscess; Adult; Aged; Azathioprine; Cross-Sectional Studies; Female; Granulomatous Mastitis; Humans; | 2023 |
Long-term Outcome of Autoimmune Hepatitis: Consecutive Patient Cohort and Data on the Second Twenty Years.
Topics: Azathioprine; Disease Progression; Hepatitis, Autoimmune; Humans; Immunosuppressive Agents; Recurren | 2023 |
Efficacy of vedolizumab in granulomatous cheilitis refractory to TNFα inhibitors.
Topics: Antibodies, Monoclonal, Humanized; Azathioprine; Crohn Disease; Drug Resistance; Female; Humans; Inf | 2019 |
Clinical course of acute deep vein thrombosis of the legs in Behçet's syndrome.
Topics: Adult; Azathioprine; Behcet Syndrome; Cyclophosphamide; Cyclosporine; Disease Progression; Female; F | 2020 |
Prevalence and predictors of flare after immunosuppressant discontinuation in patients with systemic lupus erythematosus in remission.
Topics: Adult; Antimalarials; Antirheumatic Agents; Azathioprine; Cyclosporine; Deprescriptions; Female; Hum | 2020 |
Intratympanic infliximab is a safe and effective rescue therapy for refractory immune-mediated hearing loss.
Topics: Administration, Oral; Adult; Aged; Auditory Threshold; Azathioprine; Chronic Disease; Female; Hearin | 2020 |
Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorder.
Topics: Adult; Age Factors; Aquaporin 4; Azathioprine; Disease Progression; Female; Follow-Up Studies; Human | 2020 |
A Long-Term Follow-up of Retinal Vasculitis - Do They Develop Systemic Disease?
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Azathioprine; Colitis, Ulcerative; Cyclosporine; Dru | 2020 |
New role for azathioprine in case of switching anti-TNFs in IBD.
Topics: Azathioprine; Colitis, Ulcerative; Humans; Infliximab; Prospective Studies; Recurrence; Tumor Necros | 2020 |
Relapse predictors and serologically unstable condition of IgG4-related disease: a large Chinese cohort.
Topics: Adult; Age Factors; Azathioprine; Biomarkers; Cyclophosphamide; Drug Therapy, Combination; Female; G | 2020 |
Evaluation of efficacy and tolerability of first-line therapies in NMOSD.
Topics: Adult; Antibodies; Aquaporin 4; Azathioprine; Female; Humans; Immunosuppressive Agents; Male; Middle | 2020 |
Predictors of endoscopic recurrence in resected patients with Crohn's disease in a long-term follow-up cohort: History of multiple previous resections and residual synchronous disease in the remnant intestine.
Topics: Adult; Azathioprine; Colectomy; Colon; Colonoscopy; Crohn Disease; Female; Follow-Up Studies; Humans | 2020 |
Treatment of Granulomatosis with Polyangiitis and Microscopic Polyangiitis: Should Type of ANCA Guide the Treatment?
Topics: Antibodies, Antineutrophil Cytoplasmic; Azathioprine; Cyclophosphamide; Granulomatosis with Polyangi | 2020 |
Safety of Thiopurine Use in Paediatric Gastrointestinal Disease.
Topics: Azathioprine; Child; Crohn Disease; Gastrointestinal Agents; Humans; Immunologic Factors; Immunosupp | 2020 |
Poor Drug Sustainability in Inflammatory Bowel Disease Patients in Clinical Remission on Thiopurine Monotherapy.
Topics: Adult; Anti-Inflammatory Agents; Azathioprine; Colitis, Ulcerative; Crohn Disease; Female; Gastroint | 2021 |
Treatment of Pemphigus Vulgaris and Foliaceus with Adjuvant Rituximab Compared to Immunosuppression Alone: Real-Life Experience.
Topics: Adult; Azathioprine; Drug Therapy, Combination; Female; Humans; Immunosuppressive Agents; Male; Midd | 2021 |
Incidence, Clinical Features, and Outcomes of Late-Onset Neutropenia From Rituximab for Autoimmune Disease.
Topics: Adult; Aged; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Asymptomatic Diseases; Auto | 2021 |
Does Perianal Disease Influence the Efficacy of Combination Therapy in Crohn's Disease?
Topics: Adult; Anal Canal; Anus Diseases; Azathioprine; Crohn Disease; Drug Therapy, Combination; Endoscopy, | 2021 |
Recurrent acute pancreatitis induced by 5-ASA and azathioprine in ulcerative colitis.
Topics: Acute Disease; Adult; Azathioprine; Colitis, Ulcerative; Humans; Male; Mesalamine; Pancreatitis; Rec | 2020 |
Immunosuppressive therapy in childhood-onset arrhythmogenic inflammatory cardiomyopathy.
Topics: Arrhythmogenic Right Ventricular Dysplasia; Azathioprine; Biomarkers; Child; Echocardiography; Elect | 2021 |
Comparison of relapse rates in Behçet's disease with venous involvement on different doses of azathioprine therapy, a retrospective observational study.
Topics: Adult; Azathioprine; Behcet Syndrome; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; P | 2021 |
Long-term safety of azathioprine for treatment of neuromyelitis optica spectrum disorders.
Topics: Adult; Aquaporin 4; Azathioprine; Brazil; Female; Humans; Male; Neuromyelitis Optica; Recurrence; Re | 2021 |
Thiopurine adherence: a high prevalence with low impact on UC outcomes.
Topics: Adult; Azathioprine; Colitis, Ulcerative; Female; Humans; Male; Mercaptopurine; Prevalence; Recurren | 2022 |
Ustekinumab is more effective than azathioprine to prevent endoscopic postoperative recurrence in Crohn's disease.
Topics: Adult; Antibodies, Monoclonal, Humanized; Azathioprine; Control Groups; Crohn Disease; Female; Gastr | 2021 |
Multifocal pleural capillary hemangioma: a rare cause of hemorrhagic pleural effusion-case report.
Topics: Administration, Oral; Adult; Azathioprine; Biopsy; Female; Hemangioma, Capillary; Hemothorax; Humans | 2021 |
Long-term clinical outcome after thiopurine discontinuation in elderly IBD patients.
Topics: Aged; Azathioprine; Humans; Immunosuppressive Agents; Inflammatory Bowel Diseases; Recurrence; Retro | 2021 |
Efficacy of tacrolimus as maintenance therapy after cyclophosphamide for treating antineutrophil cytoplasmic antibody-associated vasculitis.
Topics: Adult; Aged; Aged, 80 and over; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Azathiop | 2021 |
Vulvar Crohn's disease in an adolescent diagnosed after unsuccessful surgical treatment.
Topics: Adolescent; Azathioprine; Crohn Disease; Female; Humans; Recurrence; Vulvar Diseases | 2021 |
Early Outcomes in Children With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
Topics: Adolescent; Adrenal Cortex Hormones; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Aza | 2017 |
Collagenous colitis: Requirement for high-dose budesonide as maintenance treatment.
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Budesonide; Colitis | 2017 |
Granulomatosis with polyangiitis in Tunisia.
Topics: Adult; Anti-Bacterial Agents; Antibodies, Antineutrophil Cytoplasmic; Azathioprine; Biomarkers; Cycl | 2017 |
Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response.
Topics: Adult; Aquaporin 4; Autoantibodies; Azathioprine; Cohort Studies; Female; Follow-Up Studies; Germany | 2017 |
Rheumatoid arthritis causing diffuse alveolar haemorrhage: a novel therapeutic approach.
Topics: Adult; Arthritis, Rheumatoid; Azathioprine; Diagnosis, Differential; Drug Administration Schedule; F | 2017 |
Longterm Data on Disease Flares in Patients with Proliferative Lupus Nephritis in Recent Years.
Topics: Adult; Azathioprine; Disease Progression; Disease-Free Survival; Female; Humans; Immunosuppressive A | 2017 |
IgG4-related disease: long-term natural history and management of a relapsing multisystem disease entity.
Topics: Autoimmune Diseases; Azathioprine; Diagnosis, Differential; Hepatitis, Autoimmune; Humans; Immunoglo | 2017 |
Higher Thioguanine Nucleotide Metabolite Levels are Associated With Better Long-term Outcomes in Patients With Inflammatory Bowel Diseases.
Topics: Adult; Anti-Inflammatory Agents; Azathioprine; Biomarkers; Colitis, Ulcerative; Crohn Disease; Diges | 2018 |
Multitarget Therapy for Maintenance Treatment of Lupus Nephritis.
Topics: Adolescent; Adult; Aged; Azathioprine; China; Cyclophosphamide; Drug Therapy, Combination; Female; H | 2017 |
Thiopurines prevented surgical recurrence in patients with Crohn's disease after intestinal resection: Strategy based on risk stratification.
Topics: Adolescent; Adult; Aged; Azathioprine; Cohort Studies; Colectomy; Crohn Disease; Female; Follow-Up S | 2018 |
Brief Report: Drug-Free Long-Term Remission in Severe Behçet's Disease Following Withdrawal of Successful Anti-Tumor Necrosis Factor Treatment.
Topics: Adult; Aged; Azathioprine; Behcet Syndrome; Female; Humans; Immunosuppressive Agents; Longitudinal S | 2017 |
Treatment Response and Outcome with Two Different Prednisolone Regimens in Autoimmune Hepatitis.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents; Azathioprine; Drug Administration Schedule; Drug | 2017 |
Autoimmune acute liver failure and seronegative autoimmune liver disease in children: Are they different from classical disease?
Topics: Adolescent; Alanine Transaminase; Ascites; Aspartate Aminotransferases; Autoantibodies; Autoimmune D | 2017 |
Efficacy of oral vancomycin in recurrent primary sclerosing cholangitis following liver transplantation.
Topics: Adult; Anti-Bacterial Agents; Azathioprine; Cholangitis, Sclerosing; Ciprofloxacin; Drug Therapy, Co | 2017 |
Long term azathioprine maintenance therapy in ANCA-associated vasculitis: combined results of long-term follow-up data.
Topics: Adult; Aged; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Antineutrophil | 2017 |
Novel treatment regimen of Vogt-Koyanagi-Harada disease with a reduced dose of corticosteroids combined with immunosuppressive agents.
Topics: Acute Disease; Azathioprine; Cyclophosphamide; Cyclosporine; Drug Therapy, Combination; Fluorescein | 2018 |
Recurrent Pulmonary Aneurysms: Hughes-Stovin Syndrome on the Spectrum of Behçet Disease.
Topics: Administration, Oral; Adult; Aneurysm; Azathioprine; Behcet Syndrome; Computed Tomography Angiograph | 2017 |
Impact of capsule endoscopy on prevention of postoperative recurrence of Crohn's disease.
Topics: Adult; Antirheumatic Agents; Asymptomatic Diseases; Azathioprine; Capsule Endoscopy; Cohort Studies; | 2018 |
Relapse rate and predictors of relapse in a large single center cohort of type 1 autoimmune pancreatitis: long-term follow-up results after steroid therapy with short-duration maintenance treatment.
Topics: Aged; Anti-Inflammatory Agents; Autoimmune Diseases; Azathioprine; Bile Duct Diseases; Calculi; Exoc | 2018 |
Outcome of Myasthenia gravis treated with high-dose prednisolone and azathioprine: A single centre ambispective study from India.
Topics: Adult; Aged; Azathioprine; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Myasthenia | 2017 |
Subtherapeutic Infliximab Trough Levels and Complete Mucosal Healing Are Associated With Sustained Clinical Remission After Infliximab Cessation in Paediatric-onset Crohn's Disease Patients Treated With Combined Immunosuppressive Therapy.
Topics: Adolescent; Azathioprine; Crohn Disease; Drug Therapy, Combination; Female; Follow-Up Studies; Gastr | 2018 |
Preemptive immunosuppressive treatment for asymptomatic serological reactivation may reduce renal flares in patients with lupus nephritis: a cohort study.
Topics: Adult; Azathioprine; Disease Progression; Female; Glomerular Filtration Rate; Humans; Immunosuppress | 2019 |
Long-term maintenance treatment of ulcerative colitis in eastern India: a 15-year follow-up.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Colitis, Ulcerative; | 2018 |
Unmet needs and new models for future trials in autoimmune hepatitis.
Topics: Adrenal Cortex Hormones; Adult; Azathioprine; Biomarkers; Child; Disease Progression; Hepatitis, Aut | 2018 |
UVA-1 phototherapy for the management of atopic dermatitis: a large retrospective study conducted in a low-middle income country.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Azathioprine; Colombia; Dermatitis, Atopic; Develo | 2018 |
Longterm Outcomes of 188 Japanese Patients with Eosinophilic Granulomatosis with Polyangiitis.
Topics: Aged; Azathioprine; Churg-Strauss Syndrome; Eosinophils; Female; Humans; Immunosuppressive Agents; J | 2018 |
Immediate prophylactic vs endoscopic or symptomatic-driven azathioprine treatment to prevent surgical recurrence after intestinal resection for Crohn's disease.
Topics: Azathioprine; Colectomy; Colonoscopy; Crohn Disease; Databases, Factual; Female; Follow-Up Studies; | 2018 |
Positioning biologics-A case-based discussion: Vedolizumab.
Topics: Adult; Antibodies, Monoclonal, Humanized; Azathioprine; Biosimilar Pharmaceuticals; Crohn Disease; F | 2018 |
Recurrent arterial ischemic stroke with good response to mycophenolate mofetil.
Topics: Azathioprine; Child; Cyclophosphamide; Drug Therapy, Combination; Humans; Immunosuppressive Agents; | 2019 |
Withdrawal of Azathioprine in Inflammatory Bowel Disease Patients Who Sustain Remission: New Risk Factors for Relapse.
Topics: Adrenal Cortex Hormones; Adult; Aged; Azathioprine; Colitis, Ulcerative; Crohn Disease; Drug Adminis | 2019 |
Recurrent Abdominal Pain in Systemic Lupus Erythematosus: Concurrent Lupus Enteritis and Lupus Cystitis.
Topics: Abdominal Pain; Adult; Azathioprine; Cyclophosphamide; Cystitis; Enteritis; Female; Humans; Immunosu | 2019 |
Non-severe eosinophilic granulomatosis with polyangiitis: long-term outcomes after remission-induction trial.
Topics: Adult; Aged; Asthma; Azathioprine; Churg-Strauss Syndrome; Disease Progression; Disease-Free Surviva | 2019 |
Maintenance therapy with azathioprine prolonged duration of remission for pemphigus patients who received rituximab as first-line or add-on therapy.
Topics: Adult; Aged; Azathioprine; Drug Therapy, Combination; Female; Humans; Immunosuppressive Agents; Logi | 2020 |
Recurrent Asymptomatic Sigmoid Diverticular Perforation in a Patient with Pemphigus Vulgaris on Immunosuppressive Therapy: A Case Report.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Diverticulum, Colon; Humans; Immunosuppressiv | 2019 |
Autoimmune Hypoglycemia Relapse on Glucocorticoids, Effectively Treated with Azathioprine.
Topics: Autoimmune Diseases; Azathioprine; Glucocorticoids; Humans; Hypoglycemia; Immunosuppressive Agents; | 2018 |
Poor response to thiopurine in inflammatory bowel disease: how to overcome therapeutic resistance?
Topics: Adalimumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Azathioprine; Colitis, Ulcera | 2013 |
[Infliximab in the treatment of refractory gastroduodenal Crohn's disease].
Topics: Adult; Anti-Bacterial Agents; Antibodies, Monoclonal; Azathioprine; Crohn Disease; Drug Resistance; | 2014 |
Prompt plasma exchanges and immunosuppressive treatment improves the outcomes of anti-factor H autoantibody-associated hemolytic uremic syndrome in children.
Topics: Age Factors; Antibodies, Monoclonal, Murine-Derived; Autoantibodies; Azathioprine; Biomarkers; Blood | 2014 |
Functional outcome and prognostic factors in anti-Jo1 patients with antisynthetase syndrome.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Antinuclear; Azathioprine; Female; Follow-Up | 2013 |
An open-label trial of abatacept (CTLA4-IG) in non-severe relapsing granulomatosis with polyangiitis (Wegener's).
Topics: Abatacept; Adolescent; Adult; Aged; Anti-Inflammatory Agents; Azathioprine; Cohort Studies; Drug The | 2014 |
An open-label trial of abatacept (CTLA4-IG) in non-severe relapsing granulomatosis with polyangiitis (Wegener's).
Topics: Abatacept; Adolescent; Adult; Aged; Anti-Inflammatory Agents; Azathioprine; Cohort Studies; Drug The | 2014 |
An open-label trial of abatacept (CTLA4-IG) in non-severe relapsing granulomatosis with polyangiitis (Wegener's).
Topics: Abatacept; Adolescent; Adult; Aged; Anti-Inflammatory Agents; Azathioprine; Cohort Studies; Drug The | 2014 |
An open-label trial of abatacept (CTLA4-IG) in non-severe relapsing granulomatosis with polyangiitis (Wegener's).
Topics: Abatacept; Adolescent; Adult; Aged; Anti-Inflammatory Agents; Azathioprine; Cohort Studies; Drug The | 2014 |
Crohn's disease outcome in patients under azathioprine: a tertiary referral center experience.
Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Azathioprine; Co | 2014 |
Factors associated with the time to next attack in neuromyelitis optica: accelerated failure time models with random effects.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Aquaporin 4; Autoantibodies; Azathi | 2013 |
Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Azathioprine; Child; Child, Prescho | 2014 |
Addition of mesalazine for subclinical post-surgical endoscopic recurrence of Crohn's disease despite preventive thiopurine therapy: A case-control study.
Topics: Adolescent; Adult; Azathioprine; Case-Control Studies; Crohn Disease; Drug Therapy, Combination; End | 2014 |
Granulomatosis with polyangiitis (Wegener's): impact of maintenance therapy duration.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Azathioprine; Child; Drug Administration Schedule; Femal | 2014 |
Long-term efficacy, tolerability and retention rate of azathioprine in 103 aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder patients: a multicentre retrospective observational study from the UK.
Topics: Adult; Aged; Aquaporin 4; Azathioprine; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; | 2014 |
The great masquerader: Behcet's disease.
Topics: Abdominal Pain; Adrenal Cortex Hormones; Adult; Azathioprine; Behcet Syndrome; Crohn Disease; Cyclop | 2014 |
Clinical outcomes of ANCA-associated vasculitis in elderly patients.
Topics: Age Factors; Aged; Anti-Inflammatory Agents; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculi | 2014 |
Repeated exclusive enteral nutrition in the treatment of paediatric Crohn's disease: predictors of efficacy and outcome.
Topics: Adolescent; Azathioprine; Child; Crohn Disease; Enteral Nutrition; Female; Genotype; Humans; Immunos | 2014 |
Infliximab as a bridge to remission maintained by antimetabolite therapy in Crohn's disease: A retrospective study.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antimetabolites; Azathioprin | 2014 |
Biopsy-proven recurrence of unilateral IgG4-related orbital inflammation after 20 years.
Topics: Administration, Oral; Adult; Azathioprine; Biopsy; Drug Therapy, Combination; Female; Glucocorticoid | 2014 |
Behcet's disease and refractory thrombosis.
Topics: Anticoagulants; Azathioprine; Behcet Syndrome; Drug Therapy, Combination; Female; Humans; Immunosupp | 2015 |
Routine use of thiopurines in maintaining remission in pediatric Crohn's disease.
Topics: Adolescent; Age Factors; Anti-Inflammatory Agents; Azathioprine; Child; Crohn Disease; Drug Monitori | 2014 |
Long-term prevention of postoperative Crohn's disease recurrence with azathioprine: the wolf in the sheep clothing.
Topics: Azathioprine; Colonoscopy; Crohn Disease; Humans; Male; Middle Aged; Postoperative Period; Recurrenc | 2015 |
Hospitalisation, surgical and medical recurrence rates in inflammatory bowel disease 2003-2011—a Danish population-based cohort study.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Azathioprine; Child; Child, Preschool; Coho | 2014 |
Recurrent right atrial thrombosis due to Behçet disease.
Topics: Anticoagulants; Azathioprine; Behcet Syndrome; Disease Progression; Heart Atria; Heart Diseases; Hum | 2014 |
Successful outcome of pregnancy in patients with anti-neutrophil cytoplasm antibody-associated small vessel vasculitis.
Topics: Abortion, Spontaneous; Adolescent; Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Azathio | 2015 |
Thiopurine withdrawal during sustained clinical remission in inflammatory bowel disease: relapse and recapture rates, with predictive factors in 237 patients.
Topics: Adult; Azathioprine; C-Reactive Protein; Colitis, Ulcerative; Crohn Disease; Female; Humans; Immunos | 2014 |
Recurrent spontaneous subdural hematoma secondary to immune thrombocytopenia in a patient with overlap syndrome.
Topics: Anti-Inflammatory Agents; Azathioprine; Cyclophosphamide; Female; Hematoma, Subdural; Humans; Immuno | 2015 |
Induction therapy with short-term high-dose intravenous cyclophosphamide followed by mycophenolate mofetil in proliferative lupus nephritis.
Topics: Administration, Intravenous; Adult; Anti-Inflammatory Agents; Azathioprine; Cyclophosphamide; Drug T | 2014 |
A 41-year-old woman with shortness of breath and history of rash and recurrent laryngeal edema.
Topics: Adult; Azathioprine; Complement System Proteins; Disease Progression; Dyspnea; Female; Glucocorticoi | 2015 |
Analysis of the treatment of neuromyelitis optica.
Topics: Adolescent; Adult; Aged; Azathioprine; Child; Cyclophosphamide; Female; Follow-Up Studies; Humans; I | 2015 |
Clinicopathologic characteristics and outcomes of renal thrombotic microangiopathy in anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis.
Topics: ADAM Proteins; ADAMTS13 Protein; Adrenal Cortex Hormones; Adult; Aged; Anti-Inflammatory Agents; Ant | 2015 |
Azathioprine plus corticosteroid treatment in Chinese patients with neuromyelitis optica.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Anti-Inflammatory Agents; Asian People; Azathiopri | 2015 |
[Recurrent lupus enteritis improved by Azathioprine].
Topics: Adult; Azathioprine; Enteritis; Female; Humans; Immunosuppressive Agents; Lupus Erythematosus, Syste | 2015 |
Remission maintained by monotherapy after biological + immunosuppressive combination for Crohn's disease in clinical practice.
Topics: Adolescent; Adult; Age Factors; Azathioprine; Biomarkers; C-Reactive Protein; Crohn Disease; Drug Th | 2016 |
Could therapeutic drug monitoring of anti-TNF-α be useful to consider a de-escalation of treatment?
Topics: Azathioprine; Drug Monitoring; Humans; Immunologic Factors; Inflammatory Bowel Diseases; Infliximab; | 2015 |
Postoperative Effects of Thiopurines in Patients with Intestinal Behçet's Disease.
Topics: Adolescent; Adult; Aged; Aminosalicylic Acids; Azathioprine; Behcet Syndrome; Female; Humans; Immuno | 2015 |
Renal flare prediction and prognosis in lupus nephritis Hispanic patients.
Topics: Adolescent; Adult; Azathioprine; Biomarkers; Chi-Square Distribution; Creatinine; Disease Progressio | 2016 |
Thromboembolism as an important complication of inflammatory bowel disease.
Topics: Adalimumab; Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; C | 2016 |
[Clinical features of patients with juvenile and adult dermatomyositis].
Topics: Adolescent; Adult; Azathioprine; Child; Child, Preschool; Cyclosporine; Dermatomyositis; Female; Fol | 2015 |
Treatment Withdrawal in Autoimmune Hepatitis.
Topics: Azathioprine; Glucocorticoids; Hepatitis, Autoimmune; Humans; Immunosuppressive Agents; Recurrence; | 2015 |
New Zealand Society of Gastroenterology Guidelines for the Management of Refractory Ulcerative Colitis.
Topics: Adalimumab; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antibodies, Monoclonal, | 2015 |
Idiopathic Dacryoadenitis: Clinical Features, Histopathology, and Treatment Outcomes.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Azathioprine; Biopsy; Child; Dacryocystitis; Drug Resist | 2016 |
[Clinical practice guideline for ANCA-associated vasculitis with renal involvement].
Topics: Adult; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antibodies, Antineutrophil Cytopl | 2015 |
Remission And relapse of myasthenia gravis on long-term azathioprine: An ambispective study.
Topics: Adult; Analysis of Variance; Azathioprine; Cohort Studies; Female; Humans; Immunosuppressive Agents; | 2016 |
Effect of mucosal healing (Mayo 0) on clinical relapse in patients with ulcerative colitis in clinical remission.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; C | 2016 |
Recurrent Aortitis Associated With IgG4-Related Disease.
Topics: Aortitis; Autoimmune Hypophysitis; Azathioprine; Humans; Male; Middle Aged; Recurrence | 2016 |
Confocal laser endomicroscopy in ulcerative colitis: a longitudinal study of endomicroscopic changes and response to medical therapy (with videos).
Topics: Adrenal Cortex Hormones; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Case-Co | 2016 |
Time to Relapse in Children with Crohn's Disease Treated with Azathioprine and Nutritional Therapy or Corticosteroids.
Topics: Adolescent; Adrenal Cortex Hormones; Azathioprine; Child; Crohn Disease; Enteral Nutrition; Humans; | 2016 |
Inflammatory bowel disease in the clinic: Escalation and de-escalation of therapy: A longitudinal case-based discussion.
Topics: Adolescent; Azathioprine; Crohn Disease; Drug Substitution; Drug Therapy, Combination; Enteral Nutri | 2016 |
Ocular Toxoplasmosis Reactivation in a Patient With Inflammatory Bowel Disease Under Treatment With Azathioprine.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Chorioretinitis; Colitis, Ulcerative; | 2016 |
Autoimmune hepatitis and long-term disease course in children in Turkey, a single-center experience.
Topics: Adolescent; Age of Onset; Autoantibodies; Azathioprine; Biomarkers; Child; Drug Therapy, Combination | 2016 |
Azathioprine therapy for steroid-resistant Henoch-Schönlein purpura: a report of 6 cases.
Topics: Azathioprine; Child; Female; Glucocorticoids; Humans; IgA Vasculitis; Immunosuppressive Agents; Male | 2016 |
An 82-Year-Old Man With Diplopia.
Topics: Aged, 80 and over; Azathioprine; Carcinoma, Squamous Cell; Cranial Nerve Neoplasms; Diplopia; Drug T | 2016 |
Isolated extraocular orbital mass: a rare presentation of sarcoidosis.
Topics: Aged; Azathioprine; Biopsy; Diplopia; Drug Administration Schedule; Drug Therapy, Combination; Eyeli | 2016 |
Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and cyclophosphamide among patients with neuromyelitis optica spectrum disorder: A prospective cohort study.
Topics: Adult; Azathioprine; Cyclophosphamide; Disability Evaluation; Female; Humans; Immunosuppressive Agen | 2016 |
Comparisons of the efficacy and tolerability of mycophenolate mofetil and azathioprine as treatments for neuromyelitis optica and neuromyelitis optica spectrum disorder.
Topics: Adult; Azathioprine; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Mycophenolic Acid; | 2017 |
Severe Relapse After Cessation of Immunosuppressive Therapy in a Patient With Neuromyelitis Optica Spectrum Disorder.
Topics: Adult; Aquaporin 4; Autoantibodies; Azathioprine; Female; Humans; Immunosuppressive Agents; Medicati | 2016 |
Acute-onset chronic inflammatory demyelinating polyneuropathy in hantavirus and hepatitis B virus coinfection: A case report.
Topics: Acute Disease; Adult; Azathioprine; Carrier State; Coinfection; Exercise Therapy; Follow-Up Studies; | 2016 |
Development and Internal Validation of a Model Using Fecal Calprotectin in Combination with Infliximab Trough Levels to Predict Clinical Relapse in Crohn's Disease.
Topics: Adult; Azathioprine; C-Reactive Protein; Crohn Disease; Feces; Female; Gastrointestinal Agents; Huma | 2017 |
Low-dose maintenance steroid treatment could reduce the relapse rate in patients with type 1 autoimmune pancreatitis: a long-term Japanese multicenter analysis of 510 patients.
Topics: Aged; Anti-Inflammatory Agents; Autoimmune Diseases; Azathioprine; Female; Humans; Immunosuppressive | 2017 |
Predictors of response to first-line immunosuppressive therapy in neuromyelitis optica spectrum disorders.
Topics: Adult; Age of Onset; Azathioprine; Drug Substitution; Female; Humans; Immunosuppressive Agents; Male | 2017 |
Takayasu's Arteritis with Isolated Pulmonary Artery Involvement in a Middle-Aged Asian Woman with Hepatitis B and Latent Tuberculosis Infection.
Topics: Angiography, Digital Subtraction; Antitubercular Agents; Antiviral Agents; Azathioprine; Female; Flu | 2017 |
[Granulomatous lobular mastitis: a benign abnormality that mimics malignancy].
Topics: Adult; Anti-Inflammatory Agents; Azathioprine; Breast Neoplasms; Cytodiagnosis; Diagnosis, Different | 2008 |
Maintaining remission in a patient with vasculitis.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Azathioprine; Cyclophosphamid | 2008 |
Long-term efficacy and safety of quadruple therapy in childhood diffuse proliferative lupus nephritis.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Azathioprine; Biopsy, Needle; Chi-Square | 2008 |
Predicting the need for azathioprine at first presentation in children with inflammatory bowel disease.
Topics: Azathioprine; Child; Child, Preschool; Cohort Studies; Colitis, Ulcerative; Crohn Disease; Factor An | 2008 |
Serpiginous choroiditis.
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Choroiditis; Cyclosporine; Drug Ther | 2008 |
Infliximab effects compared to conventional therapy in the management of retinal vasculitis in Behçet disease.
Topics: Adolescent; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Behcet Syndrome; | 2008 |
Antibody to aquaporin-4 in the long-term course of neuromyelitis optica.
Topics: Adolescent; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD19; A | 2008 |
[Relapse rates of ulcerative colitis in remission and factors related to relapse].
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antimetabolites; Azathioprine; Chronic Disease | 2008 |
[Relapse of ulcerative colitis in remission].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antimetabolites; Azathioprine; Chronic Disease; Colitis, Ul | 2008 |
A case of relapsed autoimmune hypothalamitis successfully treated with methylprednisolone and azathioprine.
Topics: Aged; Anti-Inflammatory Agents; Autoimmune Diseases; Azathioprine; Diabetes Insipidus; Female; Human | 2008 |
Presentation and management of post-treatment relapse in autoimmune pancreatitis/immunoglobulin G4-associated cholangitis.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Autoimmune Diseases; Azathioprine; Cholang | 2009 |
Impact of immunosuppressive medication on the risk of renal allograft failure due to recurrent glomerulonephritis.
Topics: Adult; Azathioprine; Cyclosporine; Female; Glomerulonephritis; Hepatitis B Surface Antigens; Histoco | 2009 |
[Present status and future perspective of RPGN in Japan].
Topics: Adrenal Cortex Hormones; Azathioprine; Blood Component Removal; Cyclophosphamide; Disease Progressio | 2009 |
Clinical spectrum of vulva metastatic Crohn's disease.
Topics: Adult; Antibodies, Monoclonal; Azathioprine; Colon; Colonoscopy; Crohn Disease; Disease Progression; | 2009 |
[Therapeutic strategies in idiopatic inflammatory myopathies].
Topics: Adolescent; Age Factors; Anti-Inflammatory Agents; Autoantibodies; Azathioprine; Biopsy; Dermatomyos | 2009 |
Current smoking, not duration of remission, delays Crohn's disease relapse following azathioprine withdrawal.
Topics: Azathioprine; Crohn Disease; Female; Humans; Immunosuppressive Agents; Male; Recurrence; Remission I | 2010 |
Maintenance treatment with azathioprine in ulcerative colitis: outcome and predictive factors after drug withdrawal.
Topics: Adult; Analysis of Variance; Azathioprine; Cohort Studies; Colitis, Ulcerative; Dose-Response Relati | 2009 |
Use of azathioprine and 6MP in postoperative Crohn's: changing natural history or just along for the ride?
Topics: Azathioprine; Crohn Disease; Humans; Immunosuppressive Agents; Mercaptopurine; Recurrence | 2009 |
Course of inflammatory bowel disease in patients infected with human immunodeficiency virus.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antiretroviral Therapy, Highly Active; Azathioprine; | 2010 |
Epstein-Barr virus and parvovirus B19 coinfection in a Crohn's disease patient under azathioprine.
Topics: Antibodies, Monoclonal; Azathioprine; Crohn Disease; Epstein-Barr Virus Infections; Fluconazole; Gra | 2010 |
Intermittent plasmapheresis prevents recurrence in neuromyelitis optica.
Topics: Anti-Inflammatory Agents; Azathioprine; Combined Modality Therapy; Cyclophosphamide; Female; Humans; | 2009 |
Correlation of genotypes for thiopurine methyltransferase and inosine triphosphate pyrophosphatase with long-term clinical outcomes in Korean patients with inflammatory bowel diseases during treatment with thiopurine drugs.
Topics: Asian People; Azathioprine; Gene Frequency; Genotype; Humans; Inflammatory Bowel Diseases; Mercaptop | 2010 |
The impact of thiopurines on the risk of surgical recurrence in patients with Crohn's disease after first intestinal surgery.
Topics: Adolescent; Adult; Age Distribution; Azathioprine; Cohort Studies; Colectomy; Crohn Disease; Female; | 2010 |
Long-term treatment outcomes for autoimmune hepatitis in Korea.
Topics: Adolescent; Adult; Aged; Azathioprine; Disease-Free Survival; Drug Therapy, Combination; Female; Hep | 2010 |
Response rates to medical treatments and long-term clinical outcomes of nonsurgical patients with intestinal Behçet disease.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Azathiopr | 2010 |
Efficacy of azathioprine in mild or moderate relapse in Crohn's disease: clinical and endoscopic evaluation.
Topics: Adult; Azathioprine; Crohn Disease; Endoscopy, Gastrointestinal; Erythrocyte Indices; Female; Humans | 2010 |
Predictors of infliximab failure after azathioprine withdrawal in Crohn's disease treated with combination therapy.
Topics: Adolescent; Adult; Antibodies, Monoclonal; Azathioprine; Cohort Studies; Confidence Intervals; Crohn | 2010 |
[Azathioprine: live long without probation?].
Topics: Adult; Azathioprine; C-Reactive Protein; Cohort Studies; Crohn Disease; Female; Follow-Up Studies; H | 2010 |
[Clinical characteristics of 17 cases of eosinophilic gastroenteritis].
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Azathioprine; Child; Child, Preschool; Diagnosis, | 2010 |
[Recurrent hemoptysis in a 29-year old woman].
Topics: Adult; Anemia; Anti-Inflammatory Agents; Azathioprine; Biopsy; Bronchoscopy; Combined Modality Thera | 2010 |
Pyodermatitis-pyostomatitis vegetans after subtotal colectomy for ulcerative colitis.
Topics: Azathioprine; Colectomy; Colitis, Ulcerative; Colonoscopy; Cyclosporine; Diagnosis, Differential; Fe | 2010 |
Long-term care following paediatric liver transplantation.
Topics: Azathioprine; Calcineurin Inhibitors; Child; Continuity of Patient Care; Glucocorticoids; Graft Reje | 2011 |
Reactivation of autoimmune hepatitis during budesonide monotherapy, and response to standard treatment.
Topics: Alanine Transaminase; Aspartate Aminotransferases; Azathioprine; Budesonide; Female; Glucocorticoids | 2011 |
Thrombotic microangiopathy presenting with a considerable accumulation of ascites: a case report.
Topics: Ascites; Azathioprine; Blood Transfusion; Cyclophosphamide; Humans; Immunosuppressive Agents; Kidney | 2011 |
Giant cell hepatitis with autoimmune hemolytic anemia in early childhood: long-term outcome in 16 children.
Topics: Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal, Murine-Derived; Azathioprine; Bilirubin; Coom | 2011 |
[To grow up with Crohn's disease].
Topics: Adolescent; Adrenal Cortex Hormones; Age of Onset; Anti-Inflammatory Agents; Azathioprine; Child; Cr | 2011 |
Spontaneous pregnancy in a patient with a relapse of lymphocytic hypophysitis successfully treated with azathioprine and glucocorticoids.
Topics: Adult; Anti-Inflammatory Agents; Azathioprine; Female; Humans; Inflammation; Pituitary Diseases; Pre | 2011 |
Autoimmune pancreatitis: pancreatic and extrapancreatic MR imaging-MR cholangiopancreatography findings at diagnosis, after steroid therapy, and at recurrence.
Topics: Adult; Aged; Autoimmune Diseases; Azathioprine; Cholangiopancreatography, Magnetic Resonance; Contra | 2011 |
[Recurrent acute rhombencephalomyelitis in an adult or neuromyelitis optica? Presentation of a case].
Topics: Azathioprine; Brain Stem; Corticosterone; Encephalitis; Female; Humans; Immunoglobulins, Intravenous | 2012 |
Recurrent autoimmune hypophysitis successfully treated with glucocorticoids plus azathioprine: a report of three cases.
Topics: Adult; Aged; Anti-Inflammatory Agents; Autoimmune Diseases; Azathioprine; Drug Therapy, Combination; | 2011 |
Primary cerebral arteritis in a young girl: an unusual cause of acute recurrent neurological deterioration.
Topics: Acute Disease; Antibodies, Monoclonal, Murine-Derived; Ataxia; Azathioprine; Brain; Cerebral Arterie | 2012 |
Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Azathioprine; Child; Female; Follow-Up Studies; Humans; | 2011 |
[Predictors of efficacy, mucosal healing and dose intensification during the first year of adalimumab therapy in patients with luminal and fistulizing Crohn's disease. National data from Hungary].
Topics: Adalimumab; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humaniz | 2011 |
[Biologicals first-line in chronic inflammatory bowel disease? No].
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Biological Products; Cost-Benefit An | 2011 |
Lupus relapse presented as frosted branch retinal angiitis: case report.
Topics: Adolescent; Azathioprine; Female; Humans; Immunosuppressive Agents; Lupus Vasculitis, Central Nervou | 2011 |
Outcome predictors for thiopurine maintenance therapy in patients with Crohn's disease.
Topics: Adult; Age Factors; Azathioprine; Biomarkers; C-Reactive Protein; Crohn Disease; Dose-Response Relat | 2012 |
A case of multicentric reticulohistiocytosis responsive to azathioprine in a patient with no underlying malignancy.
Topics: Antitubercular Agents; Azathioprine; Histiocytosis, Non-Langerhans-Cell; Humans; Immunosuppressive A | 2011 |
Good response to infliximab in a patient with deep vein thrombosis associated with Behçet disease.
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Azathioprine; Behcet Syndrome; Cyclosporine; Drug Resi | 2012 |
Autoimmune hepatitis with anti SLA antibodies.
Topics: Autoantibodies; Autoantigens; Azathioprine; Hepatitis, Autoimmune; Humans; Immunosuppressive Agents; | 2011 |
Clinical features and outcomes of ANCA-associated renal vasculitis.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Anti-Neutrophil Cytoplasmic Antibody-Associated V | 2012 |
Clinical significance of azathioprine metabolites for the maintenance of remission in autoimmune hepatitis.
Topics: Administration, Oral; Adult; Aged; Alanine Transaminase; Azathioprine; Cohort Studies; Confidence In | 2012 |
Risk factors and outcome of acute severe lower gastrointestinal bleeding in Crohn's disease.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non- | 2012 |
Successful treatment with azathioprine of relapsing Rosai-Dorfman disease of the central nervous system.
Topics: Azathioprine; Central Nervous System Diseases; Comorbidity; Crohn Disease; Follow-Up Studies; Histio | 2012 |
Gastric ulcers and swollen kidneys: a rare diagnosis complicating Crohn's disease.
Topics: Abdominal Pain; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Azathioprine; | 2010 |
Cochleovestibular nerve involvement in multifocal fibrosclerosis.
Topics: Azathioprine; Biopsy; Diagnosis, Differential; Disease Progression; Female; Glucocorticoids; Humans; | 2012 |
Relapse is almost universal after withdrawal of immunosuppressive medication in patients with autoimmune hepatitis in remission.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Azathioprine; Child; Female; Follow-Up Studies; He | 2013 |
Acute and recurrent pancreatitis in children: exploring etiological factors.
Topics: Adolescent; Azathioprine; Biliary Tract; Biliary Tract Diseases; Carrier Proteins; Child; Child, Pre | 2012 |
Therapeutic approaches for the treatment of renal disease in juvenile systemic lupus erythematosus: an international multicentre PRINTO study.
Topics: Adolescent; Age of Onset; Azathioprine; Cohort Studies; Cyclophosphamide; Drug Therapy, Combination; | 2013 |
Smoking is a risk factor for recurrence of intestinal stricture after endoscopic dilation in Crohn's disease.
Topics: Adult; Azathioprine; Crohn Disease; Endoscopy; Female; Humans; Immunosuppressive Agents; Intestinal | 2013 |
Digital image analysis of collagen assessment of progression of fibrosis in recurrent HCV after liver transplantation.
Topics: Adolescent; Adult; Aged; Azathioprine; Biopsy; Cohort Studies; Collagen; Disease Progression; Female | 2013 |
Mucosal improvement in patients with moderate to severe postoperative endoscopic recurrence of Crohn's disease and azathioprine metabolite levels.
Topics: Adolescent; Adult; Aged; Azathioprine; Biomarkers; Crohn Disease; Drug Administration Schedule; Drug | 2013 |
Combination therapy with interferon beta-1b and azathioprine in secondary progressive multiple sclerosis. A two-year pilot study.
Topics: Adjuvants, Immunologic; Adult; Azathioprine; Disease Progression; Drug Therapy, Combination; Female; | 2002 |
A successful second unrelated BMT (UBMT) from a different unrelated donor to treat ALL that relapsed after the initial UBMT.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Azathioprine; Bone Marrow Trans | 2002 |
Prevalence of arterial hypertension and its morbidity in children and adolescents 3 years after renal transplantation with mycophenolate mofetil-based immunosuppression.
Topics: Adolescent; Antihypertensive Agents; Azathioprine; Child; Cyclosporine; Graft Rejection; Humans; Hyp | 2002 |
Macular serpiginous choroiditis.
Topics: Adolescent; Adult; Anti-Inflammatory Agents; Azathioprine; Choroid; Choroiditis; Diagnosis, Differen | 2002 |
Azathioprine without oral ciclosporin in the long-term maintenance of remission induced by intravenous ciclosporin in severe, steroid-refractory ulcerative colitis.
Topics: Administration, Oral; Adult; Azathioprine; Colectomy; Colitis, Ulcerative; Cyclosporine; Drug Resist | 2002 |
An unusual recurrence of crescentic nephritis after renal transplantation for IgA nephropathy.
Topics: Azathioprine; Drug Administration Schedule; Female; Glomerulonephritis; Glomerulonephritis, IGA; Gra | 2002 |
Idiopathic recurrent neuroretinitis: effects of long-term immunosuppression.
Topics: Adult; Azathioprine; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Immunosuppression | 2003 |
[Maintaining a remission].
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti | 2003 |
[Chronically active Crohn's disease].
Topics: Adult; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Az | 2003 |
[Surgery -- fistulas].
Topics: Abdominal Abscess; Adrenal Cortex Hormones; Anti-Bacterial Agents; Antibodies, Monoclonal; Azathiopr | 2003 |
[Follow up of Crohn's disease under therapy with hydro-MRI].
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Anti-Bacterial Agents; Anti-Infective Agents; Azathiopri | 2003 |
Long-term effectiveness of danazol corticosteroids and cytotoxic drugs in the treatment of hematologic manifestations of systemic lupus erythematosus.
Topics: Adult; Anemia, Hemolytic; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Azathio | 2003 |
Histological features associated with relapse after corticosteroid withdrawal in type 1 autoimmune hepatitis.
Topics: Adrenal Cortex Hormones; Adult; Azathioprine; Biopsy; Female; Follow-Up Studies; Hepatitis, Autoimmu | 2003 |
A case of nonscarring subepidermal blistering disease associated with autoantibodies reactive with both type VII collagen and laminin 5.
Topics: Adult; Autoantibodies; Azathioprine; Betamethasone; Biopsy, Needle; Collagen Type VII; Drug Therapy, | 2003 |
Treatment of ANCA-associated vasculitis.
Topics: Antibodies, Antineutrophil Cytoplasmic; Azathioprine; Cyclophosphamide; Humans; Immunosuppressive Ag | 2003 |
Frequency and significance of antibodies to chromatin in autoimmune hepatitis.
Topics: Adolescent; Adult; Aged; Autoantibodies; Azathioprine; Chromatin; Drug Therapy, Combination; Female; | 2003 |
Tioguanine in patients with Crohn's disease intolerant or resistant to azathioprine/mercaptopurine.
Topics: Adult; Antimetabolites; Azathioprine; Crohn Disease; Drug Resistance; Female; Humans; Male; Mercapto | 2003 |
[Picture of the month: recurrent pancreatitis].
Topics: Acute Disease; Adult; Azathioprine; Diagnosis, Differential; Humans; Male; Pancreatitis; Radiography | 2003 |
[Treatment of patients with Wegener's granulomatosis or ANCA-associated vasculitis].
Topics: Antibodies, Antineutrophil Cytoplasmic; Azathioprine; Cyclophosphamide; Drug Therapy, Combination; G | 2003 |
A prospective cross-over study comparing the effect of mycophenolate versus azathioprine on allograft function and viral load in liver transplant recipients with recurrent chronic HCV infection.
Topics: Azathioprine; Creatinine; Cross-Over Studies; Cyclosporine; Female; Hepatitis C; Humans; Immunosuppr | 2004 |
Endoscopy in eosinophilic esophagitis: "feline" esophagus and perforation risk.
Topics: Adult; Anti-Inflammatory Agents; Azathioprine; Biomarkers; Biopsy; Budesonide; Catheterization; Degl | 2003 |
Long-term efficacy of oral microemulsion cyclosporin for refractory ulcerative colitis.
Topics: Administration, Oral; Azathioprine; Colitis, Ulcerative; Cyclosporine; Emulsions; Female; Humans; Im | 2004 |
[Recurrent uveitis with bilateral exudative retinal detachment. 10-year-old boy with bilaterally impaired vision and eye pain. Vogt-Koyanagi-Harada syndrome].
Topics: Azathioprine; Child; Diagnosis, Differential; Dose-Response Relationship, Drug; Drug Therapy, Combin | 2004 |
Sequential therapies for proliferative lupus nephritis.
Topics: Azathioprine; Cyclophosphamide; Humans; Immunosuppressive Agents; Lupus Nephritis; Mycophenolic Acid | 2004 |
[Treatment of progressive multiple sclerosis with monthly pulsed cyclophosphamide-methylprednisolone: predictive factors of treatment response].
Topics: Adjuvants, Immunologic; Adult; Azathioprine; Brain; Cyclophosphamide; Demography; Drug Therapy, Comb | 2004 |
Joint lavage for treating recurrent knee involvement in patients with juvenile idiopathic arthritis.
Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Juvenile; Azathioprine; Child | 2004 |
Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis.
Topics: Adult; Azathioprine; Biopsy; Complement C3; Creatinine; Cyclophosphamide; Female; Humans; Kidney; Ki | 2004 |
[Ulcerative colitis. Acute episode].
Topics: Acute Disease; Administration, Oral; Adrenal Cortex Hormones; Aminosalicylic Acids; Anti-Inflammator | 2004 |
[Ulcerative colitis. Chronic active course].
Topics: Administration, Oral; Adult; Age Factors; Anti-Infective Agents; Azathioprine; Child; Chronic Diseas | 2004 |
Could immunosuppressive drugs reduce recurrence rate after second resection for Crohn disease?
Topics: Adult; Azathioprine; Colon; Crohn Disease; Female; Gastrointestinal Agents; Humans; Ileum; Immunosup | 2004 |
Hypersensitivity reaction to azathioprine in a patient with ulcerative colitis. Infrequent manifestations.
Topics: Adult; Azathioprine; Colitis, Ulcerative; Diagnosis, Differential; Drug Hypersensitivity; Fever; Hum | 2004 |
Utility of azathioprine metabolite measurements in post-transplant recurrent autoimmune and immune-mediated hepatitis.
Topics: Azathioprine; Hepatitis, Autoimmune; Humans; Immunosuppressive Agents; Kidney Transplantation; Monit | 2004 |
Utility of azathioprine metabolite measurements in post-transplant recurrent autoimmune and immune-mediated hepatitis.
Topics: Adolescent; Azathioprine; Child; Female; Hepatitis, Autoimmune; Humans; Immunosuppressive Agents; Ki | 2004 |
Azathioprine or ileocolic resection for steroid-dependent terminal ileal Crohn's disease? A Markov analysis.
Topics: Adult; Anti-Inflammatory Agents; Azathioprine; Cohort Studies; Colectomy; Combined Modality Therapy; | 2004 |
Crohn's disease over 20 years after diagnosis in a referral population.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Age Factors; Anti-Inflammatory Agents, Non-Steroidal; Az | 2004 |
Steroid and azathoprine maintenance as the best regimen during recurrent hepatitis C?
Topics: Age Factors; Azathioprine; Glucocorticoids; Hepatitis C; Humans; Immunosuppressive Agents; Liver Tra | 2005 |
Immunosuppression and donor age with respect to severity of HCV recurrence after liver transplantation.
Topics: Adult; Age Factors; Aged; Azathioprine; Cyclosporine; Drug Therapy, Combination; Female; Glucocortic | 2005 |
Tuberculosis in systemic lupus erythematosus in an endemic area and the role of isoniazid prophylaxis during corticosteroid therapy.
Topics: Adult; Antibiotic Prophylaxis; Antitubercular Agents; Azathioprine; Endemic Diseases; Female; Glucoc | 2005 |
[Chronic inflammatory bowel diseases. Recurrence prevention = carcinoma prevention?].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Cholangitis, Sclerosing; Colitis, Ulcerative; | 2005 |
Amantadine monotherapy is ineffective in the treatment of hepatitis C virus recurrence in the post-liver transplantation setting.
Topics: Amantadine; Antiviral Agents; Azathioprine; Cyclosporine; Female; Hepatitis C; Humans; Immunosuppres | 2005 |
Chronic inflammatory demyelinating polyneuropathy and respiratory failure.
Topics: Aged; Azathioprine; Biopsy; Coma; Cyclophosphamide; Electromyography; Female; Follow-Up Studies; Hum | 2005 |
Mychophenolate mofetil increased chagas disease reactivation in heart transplanted patients: comparison between two different protocols.
Topics: Adolescent; Adult; Aged; Azathioprine; Chagas Cardiomyopathy; Dose-Response Relationship, Drug; Fema | 2005 |
Early treatment response predicts the need for liver transplantation in autoimmune hepatitis.
Topics: Adult; Azathioprine; Canada; Drug Therapy, Combination; Endpoint Determination; Female; Hepatitis, A | 2005 |
Autoimmune hepatitis type 1: safety and efficacy of prolonged medical therapy.
Topics: Adult; Aged; Aged, 80 and over; Alanine Transaminase; Azathioprine; Drug Therapy, Combination; Femal | 2005 |
Successful treatment with adalimumab in infliximab-resistant Crohn's disease.
Topics: Adalimumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Azathioprine; Crohn Disease; | 2005 |
[Symmetric polyarthritis in a patient with Churg-Strauss syndrome].
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Arthritis; Azathioprine; Churg-Strauss Syndrome; Cyclo | 2005 |
Recurrent neuroretinitis in an adolescent with ulcerative colitis.
Topics: Adolescent; Azathioprine; Colitis, Ulcerative; Colonoscopy; Drug Therapy, Combination; Humans; Immun | 2005 |
Re-introduction of azathioprine in previously intolerant patients.
Topics: Adult; Aged; Azathioprine; Colitis, Ulcerative; Crohn Disease; Drug Administration Schedule; Female; | 2006 |
[Fibrinogen-guided thrombolysis with urokinase of a portal and mesenterial venous thrombosis during an acute episode of ulcerative colitis].
Topics: Adult; Anti-Inflammatory Agents; Azathioprine; Colitis, Ulcerative; Diarrhea; Drug Therapy, Combinat | 2006 |
Long-term outcome of idiopathic retroperitoneal fibrosis treated with surgical and/or medical approaches.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Azathioprine; Female; Follow-Up Studies; Glucocorticoi | 2006 |
Combination of azathioprine and corticosteroids in the treatment of serpiginous choroiditis.
Topics: Azathioprine; Choroiditis; Drug Therapy, Combination; Female; Fluorescein Angiography; Follow-Up Stu | 2006 |
Azathioprine monotherapy for maintenance of remission in pediatric patients with autoimmune hepatitis.
Topics: Adolescent; Adrenal Cortex Hormones; Alanine Transaminase; Antibodies, Antinuclear; Aspartate Aminot | 2006 |
Azathioprine as a postoperative prophylaxis reduces symptoms in aggressive Crohn's disease.
Topics: Adolescent; Adult; Aged; Azathioprine; Crohn Disease; Female; Humans; Male; Mercaptopurine; Middle A | 2006 |
Persistent elevation of serum alanine aminotransferase levels leads to poor survival and hepatocellular carcinoma development in type 1 autoimmune hepatitis.
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Anti-Inflammatory Agents; Azathioprine; Carcinoma, He | 2006 |
[Bilateral recurrent autoimmune optical neuropathy in childhood].
Topics: Autoimmune Diseases; Azathioprine; Child; Female; Humans; Immunosuppressive Agents; Optic Neuritis; | 2006 |
Recurrent episodes of dermatomyositis-associated pneumonitis masquerading as hypersensitivity pneumonitis.
Topics: Adult; Alveolitis, Extrinsic Allergic; Azathioprine; Biopsy; Dermatomyositis; Diagnosis, Differentia | 2006 |
Concurrent relapsing central nervous system and ocular involvement in a case of life-threatening Adamantiades-Behçet Disease (ABD).
Topics: Acute Disease; Adrenal Cortex Hormones; Adult; Azathioprine; Behcet Syndrome; Cyclophosphamide; Cycl | 2006 |
Isolated bilateral posterior scleritis after eye trauma.
Topics: Azathioprine; Child; Conjunctiva; Drug Therapy, Combination; Eye Injuries; Eyelids; Female; Fluoresc | 2007 |
[Recent advances in therapy for nephrotic syndrome in children].
Topics: Anti-Inflammatory Agents; Azathioprine; Child; Chlorambucil; Cyclophosphamide; Drug Administration S | 2007 |
Efficacy and safety of cyclophosphamide, azathioprine, and cyclosporine (ciclosporin) as adjuvant drugs in pemphigus vulgaris.
Topics: Adolescent; Adult; Aged; Azathioprine; Child; Cyclophosphamide; Cyclosporine; Drug Therapy, Combinat | 2007 |
Long-term efficacy and tolerance of tacrolimus for the treatment of uveitis.
Topics: Adolescent; Adult; Azathioprine; Child; Cyclosporine; Female; Follow-Up Studies; Humans; Immunosuppr | 2007 |
Ref: Role of azathioprine in preventing recurrence of ENL in a patient--article by K K Verma et al. Lepr Rev (2006) 77: 225-229.
Topics: Azathioprine; Erythema Nodosum; Humans; Leprostatic Agents; Leprosy, Lepromatous; Recurrence | 2007 |
Corticosteroid-dependent eosinophilic oesophagitis: azathioprine and 6-mercaptopurine can induce and maintain long-term remission.
Topics: Adult; Anti-Inflammatory Agents; Azathioprine; Eosinophilia; Esophagitis; Esophagoscopy; Female; Glu | 2007 |
Posterior segment recurrences in Vogt-Koyanagi-Harada disease.
Topics: Adult; Azathioprine; Drug Therapy, Combination; Female; Fluorescein Angiography; Glucocorticoids; Hu | 2008 |
Relapse of skin thickening after discontinuation or decrease of azathioprine therapy in a patient with diffuse cutaneous systemic sclerosis.
Topics: Aged; Azathioprine; Biopsy, Needle; Dose-Response Relationship, Drug; Drug Administration Schedule; | 2007 |
Impact of gender on the long-term outcome and survival of patients with autoimmune hepatitis.
Topics: Adult; Age of Onset; Analysis of Variance; Anti-Inflammatory Agents; Autoantibodies; Azathioprine; E | 2008 |
Hypothermia in VGKC antibody-associated limbic encephalitis.
Topics: Aged; Atrophy; Autoantibodies; Azathioprine; Cyclosporine; Dominance, Cerebral; Epilepsy, Temporal L | 2008 |
Serpiginous choroiditis treated in a stepladder approach.
Topics: Azathioprine; Choroiditis; Drug Administration Schedule; Drug Therapy, Combination; Folic Acid; Huma | 2007 |
Should azathioprine and 5-aminosalicylates be coprescribed in inflammatory bowel disease?: an audit of adverse events and outcome.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Dose-Response Relationship, Drug; Drug Intera | 2008 |
Relapses of inflammatory bowel disease during pregnancy: in-hospital management and birth outcomes.
Topics: Adult; Apgar Score; Azathioprine; Case-Control Studies; Cesarean Section; Colectomy; Colitis, Ulcera | 2008 |
Interruption of mesalamine and reduction of the blood concentration of the active metabolites of azathioprine: possible causes of ulcerative colitis relapse.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Child, Preschool; Colitis, Ulcerative; Drug I | 2008 |
Impact of smoking on pemphigus.
Topics: Adult; Azathioprine; Case-Control Studies; Female; Humans; Immunosuppressive Agents; Iran; Male; Mid | 2008 |
Clinical spectrum of multiple sclerosis.
Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Adult; Age Factors; Azathioprine; Brain Diseas | 1983 |
Medical therapy of inflammatory bowel disease.
Topics: Acute Disease; Adjuvants, Immunologic; Anus Diseases; Azathioprine; Colitis, Ulcerative; Crohn Disea | 1980 |
[Evaluation of the results of radical surgical treatment of Crohn disease as related to a diversified postoperative treatment].
Topics: Azathioprine; Crohn Disease; Follow-Up Studies; Humans; Postoperative Care; Postoperative Complicati | 1981 |
[Crohn disease and ulcerative colitis - current status: internal medicine aspects].
Topics: Adrenal Cortex Hormones; Azathioprine; Colitis, Ulcerative; Crohn Disease; Diagnosis, Differential; | 1981 |
[Treatment of Crohn disease in childhood].
Topics: Adolescent; Azathioprine; Child; Child Development; Colectomy; Crohn Disease; Dose-Response Relation | 1982 |
Antibodies to liver-specific protein predict outcome of treatment withdrawal in autoimmune chronic active hepatitis.
Topics: Adolescent; Adult; Aged; Autoantibodies; Autoimmune Diseases; Azathioprine; Clinical Enzyme Tests; F | 1984 |
NIH conference: Primary biliary cirrhosis: a model autoimmune disease.
Topics: Antibody Formation; Autoimmune Diseases; Azathioprine; Bile Ducts, Intrahepatic; Cholestasis; Humans | 1983 |
Effect of immunosuppression on recurrent herpes simplex in mice.
Topics: Animals; Antilymphocyte Serum; Azathioprine; Erythema; Female; Herpes Simplex; Hypersensitivity, Del | 1980 |
Hepatic transplantation.
Topics: Azathioprine; Carcinoma, Hepatocellular; Cyclosporins; Graft Rejection; Humans; Immunosuppression Th | 1980 |
Phagocytic capacity of human leukocytes preincubated with Imuran and prednisone.
Topics: Azathioprine; Bacterial Infections; Blood Bactericidal Activity; Candida albicans; Humans; Immune To | 1983 |
Recurrence of autoimmune chronic active hepatitis following orthotopic liver grafting.
Topics: Adult; Autoimmune Diseases; Azathioprine; Cyclosporins; Female; Hepatitis, Chronic; Humans; Liver Tr | 1984 |
Objective monitoring of activity in Wegener's granulomatosis by measurement of serum C-reactive protein concentration.
Topics: Adolescent; Adult; Aged; Azathioprine; Blood Sedimentation; C-Reactive Protein; Cyclophosphamide; Dr | 1984 |
[Recurrent polyradiculoneuritis: report of 2 cases].
Topics: Adolescent; Adult; Azathioprine; Cyclophosphamide; Female; HLA Antigens; Humans; Immunity; Male; Pol | 1983 |
[Study of 213 cases of multiple sclerosis treated with azathioprine from 1967- to 1982].
Topics: Azathioprine; Humans; Multiple Sclerosis; Prospective Studies; Recurrence | 1983 |
Wegener's granulomatosis: observations on 18 patients with severe renal disease.
Topics: Adrenal Cortex Hormones; Adult; Aged; Azathioprine; Cyclophosphamide; Female; Granulomatosis with Po | 1983 |
[Chronic active hepatitis: recurrence after long-term immunosuppressive therapy in spite of normal liver histology].
Topics: Adult; Alkaline Phosphatase; Autoantibodies; Azathioprine; Female; Hepatitis, Chronic; Humans; Immun | 1983 |
Treatment of pemphigus vulgaris. Results obtained in 84 patients between 1961 and 1982.
Topics: Azathioprine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Pemphigus; Predni | 1984 |
Azathioprine in the treatment of myasthenia gravis.
Topics: Adult; Aged; Azathioprine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Huma | 1984 |
Relapsing Henoch-Schönlein syndrome with renal involvement in a patient with an IgA monoclonal gammopathy. A study of the results of immunosuppressant and cytotoxic therapy.
Topics: Adult; Antineoplastic Agents; Azathioprine; Bence Jones Protein; Biopsy; Female; Humans; Hypergammag | 1980 |
Acute phase proteins, C9, factor B, and lysozyme in recurrent oral ulceration and Behçet's syndrome.
Topics: Azathioprine; Behcet Syndrome; Blood Proteins; C-Reactive Protein; Complement C9; Complement Factor | 1980 |
Recurrence of Wegener's granulomatosis after kidney transplantation. Successful re-induction of remission with cyclophosphamide.
Topics: Adult; Azathioprine; Cyclophosphamide; Granulomatosis with Polyangiitis; Humans; Immunosuppression T | 1980 |
Varicella in children with renal transplants.
Topics: Adolescent; Azathioprine; Chickenpox; Child; Child, Preschool; Female; Humans; Immunosuppression The | 1981 |
Recurrence of antiglomerular basement membrane glomerulonephritis in sheep renal allografts.
Topics: Animals; Azathioprine; Basement Membrane; Glomerulonephritis; Kidney; Kidney Transplantation; Male; | 1981 |
Treatment and prognosis in antibasement membrane antibody-mediated nephritis.
Topics: Adolescent; Adult; Aged; Autoantibodies; Azathioprine; Basement Membrane; Child; Child, Preschool; C | 1982 |
Fate of therapy failures in adult idiopathic thrombocytopenic purpura.
Topics: Adolescent; Adult; Aged; Azathioprine; Child; Cyclophosphamide; Drug Therapy, Combination; Evaluatio | 1980 |
[Importance of determining histamine and the histaminopexic index in bronchial asthma during imuran therapy].
Topics: Adult; Asthma; Azathioprine; Female; Histamine; Humans; Immunosuppressive Agents; Male; Middle Aged; | 1981 |
Azathioprine therapy in the management of persistent erythema multiforme.
Topics: Adult; Azathioprine; Erythema Multiforme; Female; Humans; Male; Recurrence | 1981 |
Clinical features and prognosis of severe chronic active liver disease (CALD) after corticosteroid-induced remission.
Topics: Azathioprine; Biopsy; Chronic Disease; Drug Therapy, Combination; Follow-Up Studies; Hepatic Encepha | 1980 |
[Comparative effectiveness of different therapeutic regimens in lupus nephritis in children and adolescents].
Topics: Adolescent; Azathioprine; Child; Child, Preschool; Dipyridamole; Drug Therapy, Combination; Evaluati | 1980 |
Anti-acetylcholine receptor antibody titres in the sera of myasthenia patients treated with plasma exchange combined with immunosuppressive therapy.
Topics: Acetylcholine; Adult; Aged; Antibodies; Azathioprine; Female; Humans; Immunosuppression Therapy; Mal | 1980 |
Outcome following orthotopic liver transplantation in HBsAg-positive patients using short- or long-term immunoprophylaxis.
Topics: Antibodies, Monoclonal; Antilymphocyte Serum; Azathioprine; Cyclosporine; Drug Administration Schedu | 1994 |
Treatment of recalcitrant cardiac allograft rejection with methotrexate. Cardiac Transplant Team.
Topics: Administration, Oral; Azathioprine; Bacterial Infections; Case-Control Studies; Combined Modality Th | 1995 |
Recurrent rejection following FK 506 rescue therapy for acute hepatic allograft rejection.
Topics: Adrenal Cortex Hormones; Alanine Transaminase; Azathioprine; Bilirubin; Cyclosporine; Drug Therapy, | 1993 |
Cyclosporin in the treatment of corticosteroid resistant autoimmune chronic active hepatitis.
Topics: Adolescent; Azathioprine; Cyclosporine; Drug Administration Schedule; Drug Resistance, Multiple; Hep | 1995 |
Characteristics of the oral lesions in patients with cutaneous recurrent erythema multiforme.
Topics: Adolescent; Adult; Aged; Azathioprine; Erythema Multiforme; Female; Humans; Male; Middle Aged; Mouth | 1995 |
Complete regression of recurrent diffuse malignant lymphoma after withdrawal of cyclosporin A in a renal transplant recipient.
Topics: Azathioprine; Cyclosporine; Drug Therapy, Combination; Female; Humans; Immunosuppression Therapy; Ki | 1994 |
Case report of spontaneous remission of cytogenetic relapse of chronic myelogenous leukemia suggestive of progression to blast crisis after allogeneic bone marrow transplantation.
Topics: Adult; Azathioprine; Blast Crisis; Bone Marrow Transplantation; Female; Graft vs Host Disease; Human | 1995 |
Mixed connective tissue disease: recurrent episodes of optic neuropathy and transverse myelopathy. Successful treatment with plasmapheresis.
Topics: Adult; Azathioprine; Female; Humans; Magnetic Resonance Imaging; Mixed Connective Tissue Disease; My | 1994 |
Necrotizing vasculitis--relapse despite cytotoxic therapy.
Topics: Adult; Aged; Arteritis; Azathioprine; Cyclophosphamide; Female; Granulomatosis with Polyangiitis; Hu | 1993 |
Relapses in patients with a systemic vasculitis.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Antineutrophil Cytoplasmic; Autoantibodies; Azathioprine | 1993 |
Relapsing polychondritis occurring de novo in a renal transplant patient.
Topics: Azathioprine; Cyclosporine; Humans; Kidney Transplantation; Male; Middle Aged; Polychondritis, Relap | 1994 |
[Syngeneic transplantation of nasal mucosa and azathioprine medication for therapy of cicatricial ocular mucous membrane pemphigoid. Study of 9 patients with 11 eyes].
Topics: Aged; Aged, 80 and over; Azathioprine; Combined Modality Therapy; Conjunctivitis; Female; Follow-Up | 1994 |
Reactivation of latent cytomegalovirus in allografts: comparison of lung graft and kidney graft in rats.
Topics: Animals; Azathioprine; Cyclosporine; Cytomegalovirus Infections; Drug Therapy, Combination; Graft Re | 1994 |
Immunoblastic lymphadenopathy in a five-month-old girl: successful treatment with immunosuppressants.
Topics: Azathioprine; Cyclophosphamide; Cyclosporine; Drug Therapy, Combination; Female; Humans; Immunoblast | 1994 |
Recurrent neuroretinitis.
Topics: Adult; Azathioprine; Female; Follow-Up Studies; Fundus Oculi; Glucocorticoids; Humans; Male; Optic D | 1994 |
[Pharyngeal dysphagia and polymyositis].
Topics: Aged; Azathioprine; Deglutition Disorders; Enteral Nutrition; Female; Humans; Pharyngeal Diseases; P | 1993 |
Treatment of Crohn's disease recurrence after ileoanal anastomosis by azathioprine.
Topics: Adolescent; Adult; Anal Canal; Anastomosis, Surgical; Azathioprine; Crohn Disease; Female; Humans; I | 1993 |
[A case of repeated pyoderma gangrenosum with myelodysplastic syndrome].
Topics: Adult; Azathioprine; Humans; Male; Myelodysplastic Syndromes; Prednisolone; Pyoderma Gangrenosum; Re | 1993 |
Recurrent erythema multiforme: clinical features and treatment in a large series of patients.
Topics: Acyclovir; Administration, Oral; Adolescent; Adult; Aged; Azathioprine; Child; Child, Preschool; Chr | 1993 |
Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine.
Topics: Adolescent; Adult; Age Factors; Azathioprine; Crohn Disease; Female; Follow-Up Studies; Humans; Immu | 1996 |
Heart transplantation for chronic Chagas' heart disease.
Topics: Actuarial Analysis; Adolescent; Adult; Azathioprine; Cause of Death; Chagas Cardiomyopathy; Child; C | 1996 |
Accelerated acute rejection in renal allograft.
Topics: Acute Disease; Age Factors; Azathioprine; Cadaver; Cyclosporine; Female; Graft Rejection; Graft Surv | 1996 |
Cyclophosphamide in cardiac transplant recipients with frequent rejection: a six-year retrospective review.
Topics: Azathioprine; Cyclophosphamide; Female; Graft Rejection; Heart Transplantation; Humans; Immunosuppre | 1996 |
A 34-year-old man with recurrent melaena after renal transplantation.
Topics: Adult; Azathioprine; Diagnosis, Differential; Gastrointestinal Hemorrhage; Humans; Immunosuppressive | 1996 |
Chagas disease and transplantation.
Topics: Adult; Antilymphocyte Serum; Argentina; Azathioprine; Cadaver; Chagas Disease; Child; Cyclosporine; | 1996 |
[Crohn's disease and pregnancy. Two case reports].
Topics: Adult; Azathioprine; Cesarean Section; Crohn Disease; Female; Humans; Immunosuppressive Agents; Nutr | 1996 |
Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome relapse: frequency, pathogenesis, and meaning.
Topics: Adrenal Cortex Hormones; Adult; Azathioprine; Blood Transfusion; Female; Hematocrit; Hemoglobins; He | 1997 |
[Prevention of Crohn disease recurrence with azathioprine--for whom, how long?].
Topics: Azathioprine; Crohn Disease; Follow-Up Studies; Humans; Immunosuppressive Agents; Long-Term Care; Me | 1997 |
Healing of severe recurrent ileitis with azathioprine therapy in patients with Crohn's disease.
Topics: Adult; Azathioprine; Crohn Disease; Endoscopy; Female; Humans; Ileitis; Ileum; Immunosuppressive Age | 1997 |
Effect of resumption of second line drugs in patients with rheumatoid arthritis that flared up after treatment discontinuation.
Topics: Acute Disease; Aged; Antimalarials; Antirheumatic Agents; Arthritis, Rheumatoid; Azathioprine; Femal | 1997 |
Sequential biological immunosuppression. Induction therapy with rabbit antithymocyte globulin.
Topics: Actuarial Analysis; Adult; Animals; Antilymphocyte Serum; Azathioprine; Cadaver; Cohort Studies; Cre | 1997 |
Association between liver transplantation for Langerhans cell histiocytosis, rejection, and development of posttransplant lymphoproliferative disease in children.
Topics: Adolescent; Age Factors; Antiviral Agents; Azathioprine; Child; Child, Preschool; Cyclosporine; Foll | 1997 |
Treatment of steroid-resistant and recurrent acute cardiac transplant rejection with a short course of antibody therapy.
Topics: Acute Disease; Antilymphocyte Serum; Arteriosclerosis; Azathioprine; Bacterial Infections; Biopsy; C | 1997 |
[Myasthenic crisis caused by azathioprine-induced fever].
Topics: Aged; Azathioprine; Critical Care; Drug Hypersensitivity; Drug Therapy, Combination; Fever; Humans; | 1997 |
Combination of cyclosporine, azathioprine and prednisolone for perianal fistulas in Crohn's disease.
Topics: Adult; Azathioprine; Crohn Disease; Cyclosporine; Dose-Response Relationship, Drug; Drug Administrat | 1997 |
Influence of steroid withdrawal on proteinuria in renal allograft recipients.
Topics: Acute Disease; Analysis of Variance; Anti-Inflammatory Agents; Azathioprine; Chi-Square Distribution | 1997 |
An atypical presentation for primary sclerosing cholangitis.
Topics: Adrenal Cortex Hormones; Adult; Autoimmune Diseases; Azathioprine; Cholangiography; Cholangitis, Scl | 1997 |
Study of malignancy among Egyptian kidney transplant recipients.
Topics: Azathioprine; Cyclosporine; Egypt; Female; Graft Survival; Humans; Immunosuppressive Agents; Inciden | 1997 |
[A case of recurrent IgA nephropathy following renal transplantation under tacrolimus (FK506)].
Topics: Adult; Azathioprine; Drug Administration Schedule; Female; Glomerulonephritis, IGA; Graft Rejection; | 1997 |
Azathioprine in steroid-resistant and steroid-dependent ulcerative colitis.
Topics: Adolescent; Adult; Aged; Azathioprine; Colitis, Ulcerative; Drug Resistance; Drug Therapy, Combinati | 1997 |
Lesion load quantification in serial MR of early relapsing multiple sclerosis patients in azathioprine treatment. A retrospective study.
Topics: Adult; Azathioprine; Female; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Male; Mul | 1997 |
Influence of treatment with immunosuppressive drugs in mice chronically infected with Trypanosoma cruzi.
Topics: Animals; Antibodies, Helminth; Azathioprine; Betamethasone; Brain; Chagas Disease; Chronic Disease; | 1997 |
[Late manifestation of a fatal Behçet's disease with cardiac involvement and lethal outcome].
Topics: Aged; Anti-Inflammatory Agents; Azathioprine; Behcet Syndrome; Cardiomyopathy, Dilated; Cyclosporine | 1998 |
[Löffler fibroblastic endocarditis in the thrombotic stages in isolated right ventricular tissue eosinophilia].
Topics: Adult; Anti-Inflammatory Agents; Azathioprine; Biopsy; Cortisone; Diagnosis, Differential; Drug Ther | 1998 |
Early development of chronic active hepatitis in recurrent hepatitis C virus infection after liver transplantation: association with treatment of rejection.
Topics: Alanine Transaminase; Azathioprine; Cyclosporine; Drug Therapy, Combination; Female; Genome, Viral; | 1998 |
Retransplantation for recurrent hepatitis C following tacrolimus or cyclosporine immunosuppression.
Topics: Azathioprine; Cyclosporine; Drug Therapy, Combination; Follow-Up Studies; Hepatitis C; Humans; Immun | 1998 |
Recurrent Kaposi's sarcoma in a renal transplant recipient maintained on minimum doses of immunosuppression.
Topics: Azathioprine; Cyclosporine; Humans; Immunosuppressive Agents; Kidney Transplantation; Male; Middle A | 1998 |
High-rate hepatitis and low-rate rejection induced late morbidity and mortality in long-term follow-up after liver transplantation.
Topics: Adolescent; Adult; Azathioprine; Child; Child, Preschool; Cyclosporine; Drug Therapy, Combination; F | 1998 |
[Cyclosporin A therapy in steroid-refractory patients with chronic inflammatory bowel diseases].
Topics: Administration, Oral; Azathioprine; Colitis, Ulcerative; Crohn Disease; Cyclosporine; Drug Administr | 1998 |
Postoperative outcome of Crohn's disease in 30 children.
Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Child; Crohn Disease; Fema | 1998 |
Relapse of vasculitis, sepsis, or azathioprine allergy?
Topics: Adult; Aged; Azathioprine; Drug Hypersensitivity; Female; Humans; Immunosuppressive Agents; Male; Re | 1998 |
Methotrexate in refractory Crohn's disease.
Topics: Adolescent; Adult; Azathioprine; Crohn Disease; Drug Administration Schedule; Drug Resistance; Femal | 1999 |
The role of azathioprine in the management of retinal vasculitis.
Topics: Adolescent; Adult; Aged; Azathioprine; Drug Administration Schedule; Drug Therapy, Combination; Fema | 1998 |
Atypical multiple sclerosis presenting as chronic-progressive encephalomyelitis with polyneuritis and recurrent aseptic meningitis.
Topics: Ataxia; Autoimmune Diseases; Azathioprine; Biopsy; Brain; Encephalomyelitis; Gliosis; Humans; Immuno | 1999 |
[Treatment of myasthenia: role of corticoids and immunosuppressive agents].
Topics: Acute Disease; Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Azathioprine; Cyclosporins; | 1999 |
[Myositis in the presence of slightly elevated creatine kinase values].
Topics: Adult; Azathioprine; Biopsy; Creatine Kinase; Diagnosis, Differential; Humans; Male; Middle Aged; Mu | 1999 |
[Recurrent episodes of ulcerative gingivostomatitis associated with cyclic neutropenia].
Topics: Adrenal Cortex Hormones; Adult; Azathioprine; Dapsone; Gingivitis, Necrotizing Ulcerative; Humans; M | 1999 |
Optimum duration of treatment with 6-mercaptopurine for Crohn's disease.
Topics: Adjuvants, Immunologic; Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory A | 1999 |
[Herpetic superinfection of pemphigus: 6 cases].
Topics: Acyclovir; Adrenal Cortex Hormones; Adult; Aged; Antiviral Agents; Azathioprine; Cyclophosphamide; F | 1999 |
Recurrence of hepatitis B after single lung transplantation.
Topics: Adult; Azathioprine; Female; Hepatitis B Antibodies; Hepatitis B, Chronic; Humans; Immunosuppression | 1999 |
Effect of steroids amount on hepatitis C recurrence following orthtopic liver transplantation.
Topics: Azathioprine; Cyclosporine; Drug Therapy, Combination; Female; Follow-Up Studies; Graft Rejection; H | 1999 |
Reactivation of tuberculosis after conversion from azathioprine to mycophenolate mofetil 16 years after renal transplantation.
Topics: Azathioprine; Humans; Immunosuppressive Agents; Kidney Transplantation; Male; Middle Aged; Mycopheno | 2000 |
Wegener granulomatosis in children and young adults. A case study of ten patients.
Topics: Adolescent; Adult; Antigen-Antibody Reactions; Azathioprine; Child; Cyclophosphamide; Disease Progre | 2000 |
Long-term clinical course and prognostic factors in intestinal Behçet's disease.
Topics: Adolescent; Adult; Azathioprine; Behcet Syndrome; Colectomy; Colonic Diseases; Colonoscopy; Combined | 2000 |
Completely reversed acute rejection is not a significant risk factor for the development of chronic rejection in renal allograft recipients.
Topics: Acute Disease; Adrenal Cortex Hormones; Aged; Azathioprine; Chronic Disease; Cyclosporine; Drug Ther | 2000 |
Effect of tacrolimus in renal transplant recipients with immunoglobulin-A nephropathy.
Topics: Adult; Azathioprine; Drug Therapy, Combination; Female; Follow-Up Studies; Glomerulonephritis, IGA; | 2000 |
Impact of heavy proteinuria (>1 g/d) following renal transplantation.
Topics: Adolescent; Adult; Angiotensin-Converting Enzyme Inhibitors; Azathioprine; Biomarkers; Child; Cyclos | 2000 |
Treatment of Behçet's disease--an update.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Behcet Syndrome; Chl | 2001 |
[Secondary immunologically-caused myocarditis, pericarditis and exudative pleuritis due to meningococcal meningitis].
Topics: Adolescent; Anti-Inflammatory Agents; Anticoagulants; Azathioprine; Diuretics, Osmotic; Echocardiogr | 2001 |
Orbital granulomatous giant cell myositis: a case report and review.
Topics: Anti-Inflammatory Agents; Azathioprine; Biopsy; Drug Therapy, Combination; Female; Humans; Immunosup | 2000 |
Acute cardiac ongoing rejection: comparison between different strategies.
Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Azathioprine; Cyclosporine; Drug Admin | 2001 |
Azathioprine toxicity mimicking a relapse of Wegener's granulomatosis.
Topics: Azathioprine; Diagnosis, Differential; Granulomatosis with Polyangiitis; Humans; Male; Middle Aged; | 2001 |
One thousand renal transplants at Belfast City Hospital: post-graft neoplasia 1968-1999, comparing azathioprine only with cyclosporin-based regimes in a single centre.
Topics: Azathioprine; Cyclosporine; Female; Hospitals, Urban; Humans; Immunosuppressive Agents; Ireland; Kid | 2000 |
Azathioprine for prevention of postoperative recurrence in Crohn's disease.
Topics: Azathioprine; Crohn Disease; Humans; Recurrence | 2001 |
Azathioprine for prevention of postoperative recurrence in Crohn's disease: a retrospective study.
Topics: Adolescent; Adult; Azathioprine; Colectomy; Crohn Disease; Female; Humans; Immunosuppressive Agents; | 2001 |
Effective maintenance of inflammatory bowel disease remission by azathioprine does not require concurrent 5-aminosalicylate therapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Azathioprine; Colitis, Ulcerative; Crohn Disease; Drug T | 2001 |
Therapeutic effects of azathioprine in combination with low-dose prednisolone in patients with intractable autoimmune hepatitis type 1.
Topics: Adult; Anti-Inflammatory Agents; Azathioprine; Dose-Response Relationship, Drug; Drug Therapy, Combi | 2001 |
Long-term immunosuppressive treatment of serpiginous choroiditis.
Topics: Adult; Aged; Azathioprine; Choroiditis; Cyclophosphamide; Cyclosporine; Drug Therapy, Combination; F | 2001 |
The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review.
Topics: Adult; Aged; Azathioprine; Colitis, Ulcerative; Crohn Disease; Female; Humans; Immunosuppressive Age | 2002 |
Incidence and recurrence of autoimmune/alloimmune hepatitis in liver transplant recipients.
Topics: Adult; Azathioprine; Cyclophosphamide; Female; Graft Rejection; Graft Survival; Hepatitis, Autoimmun | 2002 |
Inflammatory bowel diseases 1977.
Topics: Azathioprine; Colitis, Ulcerative; Crohn Disease; Cromolyn Sodium; Diet; Eye Diseases; Humans; Joint | 1977 |
Crohn's disease involving the colon: an audit of clinical management.
Topics: Adolescent; Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Adult; Aged; Azathioprine; Child; | 1977 |
Crohn's disease of the colon.
Topics: Adrenal Cortex Hormones; Adult; Aminosalicylic Acids; Azathioprine; Colectomy; Colitis, Ulcerative; | 1979 |
Cyclophosphamide therapy of severe systemic necrotizing vasculitis.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Azathioprine; Cyclophosphamide; Female; Humans; Male; Mi | 1979 |
Radiographic findings of the National Cooperative Crohn's Disease Study.
Topics: Adult; Age Factors; Azathioprine; Colon; Crohn Disease; Duodenum; Female; Humans; Ileum; Intestinal | 1979 |
Place of azathioprine for Crohn's disease.
Topics: Adrenal Cortex Hormones; Azathioprine; Crohn Disease; Drug Evaluation; Follow-Up Studies; Humans; Re | 1976 |
Role of gluten, prednisone, and azathioprine in non-responsive coeliac disease.
Topics: Administration, Oral; Azathioprine; Celiac Disease; Drug Therapy, Combination; Female; Glutens; Huma | 1976 |
Immunosuppressive therapy for chronic active hepatitis.
Topics: Azathioprine; Chronic Disease; Cyclophosphamide; Drug Evaluation; Hepatitis B; Humans; Recurrence | 1978 |
Plasma-exchange combined with immunosuppressive therapy in myasthenia gravis.
Topics: Adult; Aged; Azathioprine; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myasthenia Gravis; | 1979 |
[Azathioprine in the treatment of temporal arteritis and polymyalgia rheumatica].
Topics: Aged; Azathioprine; Back Pain; Drug Evaluation; Drug Therapy, Combination; Female; Fractures, Sponta | 1977 |
Relapse of pneumonia caused by cytomegalovirus in two recipients of renal transplants.
Topics: Adolescent; Adult; Azathioprine; Cytomegalovirus; Cytomegalovirus Infections; Graft Rejection; Human | 1979 |
Herpetism.
Topics: Azathioprine; Female; Herpesviridae Infections; Humans; Idoxuridine; Recurrence; Vidarabine | 1979 |
Bullous pemphigoid. Clinical and immunologic follow-up after successful therapy.
Topics: Adult; Aged; Azathioprine; Basement Membrane; Complement C3; Drug Therapy, Combination; Female; Fluo | 1977 |
Continued experimental study on the pathogenesis of sporadic bacteriuria in the rat.
Topics: Animals; Azathioprine; Bacteriuria; Escherichia coli; Escherichia coli Infections; Female; Hepatecto | 1979 |
Relapsing nephrotic syndrome in childhood.
Topics: Adolescent; Azathioprine; Cyclophosphamide; Humans; Male; Nephrotic Syndrome; Prednisone; Recurrence | 1979 |
[Immunosuppressive treatment of Behçet's disease (author's transl)].
Topics: Azathioprine; Behcet Syndrome; Cortisone; Drug Evaluation; Humans; Immunosuppressive Agents; Recurre | 1977 |
The effect of recurrent early homograft rejection on subsequent patient and renal graft survival.
Topics: Acute Disease; Azathioprine; Cadaver; Drug Administration Schedule; Graft Rejection; Humans; Kidney | 1976 |
[Results of surgical treatment of Crohn's enterocolitis granulomatosa (author's transl)].
Topics: Adolescent; Adult; Azathioprine; Cecum; Colon, Sigmoid; Crohn Disease; Follow-Up Studies; Humans; Il | 1976 |
Controlled trial of azathioprine in treatment of steroid-responsive nephrotic syndrome of childhood.
Topics: Azathioprine; Child; Child, Preschool; Humans; Nephrotic Syndrome; Prednisolone; Recurrence | 1977 |
[Posttraumatic recurrent pericarditis].
Topics: Accidents, Traffic; Adult; Azathioprine; Humans; Male; Pericarditis; Recurrence | 1977 |
Immunosuppressants and prednisone in pemphigus vulgaris: therapeutic results obtained in 63 patients between 1961 and 1975.
Topics: Adult; Aged; Azathioprine; Cyclophosphamide; Drug Therapy, Combination; Female; Humans; Immunosuppre | 1977 |
[Course studies in patients with Crohn's disease after surgery or immunosuppressive therapy].
Topics: Azathioprine; Crohn Disease; Humans; Immunosuppression Therapy; Immunotherapy; Recurrence | 1976 |
Varicella followed by glomerulonephritis. Treatment with corticosteroids and azathioprine resulting in recurrence of varicella.
Topics: Azathioprine; Chickenpox; Child, Preschool; Exanthema; Gastrointestinal Hemorrhage; Glomerulonephrit | 1975 |
Clinical features of chorea associated with systemic lupus erythematosus.
Topics: Adult; Azathioprine; Blood Sedimentation; Chlorpromazine; Chorea; Female; Haloperidol; Humans; Lupus | 1975 |
[Lactacidaemia and disseminated intravascular coagulation associated with phenformin medication (author's transl)].
Topics: Acidosis; Azathioprine; Chronic Disease; Diabetes Complications; Diabetes Mellitus; Disseminated Int | 1975 |
Late nonresponsiveness to steroids in children with the nephrotic syndrome.
Topics: Azathioprine; Child; Child, Preschool; Cyclophosphamide; Drug Resistance; Female; Humans; Infant; Ma | 1975 |
Pilot-study on large-dose alternate-day steroid therapy in multiple sclerosis.
Topics: Adolescent; Adult; Azathioprine; Dexamethasone; Dose-Response Relationship, Drug; Drug Administratio | 1975 |
[Therapy of nephrotic syndrome in childhood].
Topics: Adolescent; Age Factors; Azathioprine; Biopsy; Child; Child, Preschool; Cyclophosphamide; Humans; In | 1976 |
Adherence of E. coli to uroepithelia in children and adolescents after renal transplantation.
Topics: Adolescent; Azathioprine; Bacterial Adhesion; Child; Epithelium; Escherichia coli; Escherichia coli | 1992 |
Recurrence of membranous lupus glomerulonephritis two months after a renal cadaver transplant.
Topics: Adult; Azathioprine; Cyclosporine; Humans; Immunosuppression Therapy; Kidney Transplantation; Lupus | 1992 |
Lack of predictive factors for the clinical course of bullous pemphigoid.
Topics: Aged; Aged, 80 and over; Autoimmune Diseases; Azathioprine; Dapsone; Drug Therapy, Combination; Fema | 1992 |
Correlation between in vitro cytokine production and clinical evolution of multiple sclerosis patients.
Topics: Azathioprine; Cells, Cultured; Cyclophosphamide; Cytokines; Humans; Immunoradiometric Assay; Interfe | 1991 |
Follow-up of recurrent hepatitis B and delta infection in liver allograft recipients after treatment with recombinant interferon-alpha.
Topics: Adrenal Cortex Hormones; Adult; Azathioprine; Cyclosporine; Female; Hepatitis B; Hepatitis B virus; | 1991 |
Diagnosis and treatment of cytomegalovirus disease in transplant patients based on gastrointestinal tract manifestations.
Topics: Abdominal Pain; Adult; Antilymphocyte Serum; Azathioprine; Bacterial Infections; Cyclosporins; Cytom | 1991 |
Remission and recurrence after withdrawal of therapy for ocular cicatricial pemphigoid.
Topics: Adult; Aged; Aged, 80 and over; Azathioprine; Cyclophosphamide; Dapsone; Female; Follow-Up Studies; | 1991 |
Triple agent immunosuppression in serpiginous choroiditis.
Topics: Adult; Azathioprine; Choroiditis; Cyclosporins; Drug Synergism; Drug Therapy, Combination; Female; F | 1991 |
Recurrent haemolytic uraemic syndrome in a transplant recipient on orthoclone (OKT 3).
Topics: Antibodies, Monoclonal; Azathioprine; Child; Drug Therapy, Combination; Hemolytic-Uremic Syndrome; H | 1991 |
Response of recurrent giant cell myocarditis in a transplanted heart to intensive immunosuppression.
Topics: Adult; Azathioprine; Biopsy; Cyclosporins; Granuloma, Giant Cell; Heart Failure; Heart Transplantati | 1991 |
Monoclonal antibody OKT3 therapy in pediatric kidney transplant recipients.
Topics: Acetaminophen; Adolescent; Antibodies, Anti-Idiotypic; Antibodies, Monoclonal; Antigens, CD; Antigen | 1990 |
The recurrence of focal segmental glomerulosclerosis in kidney transplant patients treated with cyclosporine.
Topics: Adolescent; Adult; Age Factors; Azathioprine; Child; Child, Preschool; Cyclosporins; Female; Glomeru | 1990 |
[Effectiveness of various forms of immunosuppressive therapy in chronic idiopathic polyneuritis. A case report].
Topics: Azathioprine; Combined Modality Therapy; Cyclosporins; Female; Humans; Immunoglobulin G; Immunosuppr | 1990 |
Re-evaluation of the role of azathioprine in the treatment of adult chronic idiopathic thrombocytopenic purpura: a report on 53 cases.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Azathioprine; Chronic Disease; Combined Modality Therapy | 1990 |
Clinical and prognostic implications of HLA B8 in corticosteroid-treated severe autoimmune chronic active hepatitis.
Topics: Adult; Age Factors; Autoimmune Diseases; Azathioprine; Chronic Disease; Drug Combinations; Female; F | 1990 |
Azathioprine therapy in chronic ulcerative colitis.
Topics: Adolescent; Adult; Azathioprine; Colitis, Ulcerative; Female; Humans; Immunosuppressive Agents; Male | 1990 |
Low-dose corticosteroid therapy after multiple relapses of severe HBsAg-negative chronic active hepatitis.
Topics: Azathioprine; Chronic Disease; Dose-Response Relationship, Drug; Drug Combinations; Hepatitis; Hepat | 1990 |
[Treatment of Crohn's disease with azathioprine or 6-mercaptopurine. Retrospective study of 126 cases].
Topics: Actuarial Analysis; Adolescent; Adrenal Cortex Hormones; Adult; Aged; Azathioprine; Crohn Disease; F | 1990 |
Successful treatment of severe polymorphous light eruption with azathioprine.
Topics: Azathioprine; Erythema; Female; Humans; Middle Aged; Photosensitivity Disorders; Pruritus; PUVA Ther | 1989 |
[Therapeutic experience with ulcerative colitis and Crohn disease].
Topics: Adrenal Cortex Hormones; Azathioprine; Colitis, Ulcerative; Crohn Disease; Drug Combinations; Drug T | 1985 |
Relapse after azathioprine withdrawal in autoimmune chronic active hepatitis.
Topics: Autoimmune Diseases; Azathioprine; Hepatitis, Chronic; Humans; Recurrence | 1985 |
Apparent recurrence of hemolytic uremic syndrome in azathioprine-treated allograft recipients.
Topics: Adult; Azathioprine; Female; Graft Rejection; Hemolytic-Uremic Syndrome; Humans; Kidney Failure, Chr | 1988 |
Cytotoxic immunosuppressive drug treatment strategy in pure red cell aplasia.
Topics: Aged; Azathioprine; Combined Modality Therapy; Cyclophosphamide; Female; Hemoglobins; Humans; Male; | 1988 |
[Recurrences of extracapillary glomerulonephritis in 2 kidney grafts in the same patient].
Topics: Adult; Antilymphocyte Serum; Azathioprine; Cortisone; Glomerulonephritis; Graft Rejection; Humans; K | 1985 |
Myasthenia gravis: discontinuation of long-term azathioprine.
Topics: Azathioprine; Follow-Up Studies; Humans; Myasthenia Gravis; Recurrence | 1988 |
The course and prognosis of pemphigus. A review of 115 patients.
Topics: Adult; Age Factors; Azathioprine; Cause of Death; Drug Therapy, Combination; Female; Follow-Up Studi | 1988 |
The outcome of repeat cadaveric kidney transplants in recipients managed with cyclosporine.
Topics: ABO Blood-Group System; Azathioprine; Blood Transfusion; Cadaver; Cyclosporins; Graft Rejection; HLA | 1988 |
Childhood membranoproliferative glomerulonephritis: an approach to management.
Topics: Aspirin; Azathioprine; Child; Cyclophosphamide; Dipyridamole; Drug Administration Schedule; Drug The | 1986 |
Severe condylomata acuminata in a renal transplant recipient.
Topics: Adult; Azathioprine; Condylomata Acuminata; Cyclosporins; Humans; Immunosuppressive Agents; Kidney T | 1986 |
Cutaneous leukocytoclastic vasculitis: clinical experience in 44 patients.
Topics: Adrenal Cortex Hormones; Adult; Aged; Azathioprine; Chronic Disease; Colchicine; Drug Evaluation; Dr | 1987 |
Factors influencing the relapse risk at steroid dose reduction in myasthenia gravis.
Topics: Azathioprine; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Myasthenia Gravis; | 1987 |
Azathioprine in the treatment of pemphigus vulgaris. A long-term follow-up.
Topics: Aged; Autoantibodies; Azathioprine; Drug Therapy, Combination; Female; Follow-Up Studies; Glucocorti | 1987 |
Therapy of chronic relapsing thrombotic thrombocytopenic purpura with prednisone and azathioprine.
Topics: Azathioprine; Chronic Disease; Drug Therapy, Combination; Female; Humans; Middle Aged; Prednisone; P | 1985 |
Liver disease associated with anti-liver-kidney microsome antibody in children.
Topics: Adolescent; Autoantibodies; Autoimmune Diseases; Azathioprine; Child; Child, Preschool; Female; Hepa | 1986 |
Effect of long-term azathioprine administration in adults with minimal-change glomerulonephritis and nephrotic syndrome resistant to corticosteroids.
Topics: Adolescent; Adult; Aged; Azathioprine; Child; Child, Preschool; Creatinine; Drug Resistance; Female; | 1986 |
[Polymyositis and dermatomyositis in the metropolitan hospital complex of the Panama Department of Social Security. 1973. Clinical review and effects of treatment].
Topics: Adolescent; Adult; Aged; Azathioprine; Child; Dermatomyositis; Female; Humans; Male; Methotrexate; M | 1985 |
Splenectomy does not cure the thrombocytopenia of systemic lupus erythematosus.
Topics: Adult; Aged; Autoimmune Diseases; Azathioprine; Female; Humans; Immunosuppressive Agents; Lupus Eryt | 1985 |
Azathioprine. An alternative treatment for recurrent idiopathic retroperitoneal fibrosis.
Topics: Azathioprine; Blood Sedimentation; Creatinine; Humans; Hydronephrosis; Male; Middle Aged; Prednisone | 1985 |
[Experience with immunosuppressive therapy of active chronic hepatitis using long-term multiple corticoids].
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Azathioprine; Drug Therapy, Combination; Female; H | 1985 |
Treatment of Crohn's disease.
Topics: Adrenal Cortex Hormones; Azathioprine; Crohn Disease; Fistula; Humans; Recurrence | 1971 |
Assessment of activity in chronic active liver disease. Serum bile acids compared with conventional tests and histology.
Topics: Adolescent; Adult; Aged; Alkaline Phosphatase; Aspartate Aminotransferases; Azathioprine; Bilirubin; | 1974 |
[Immunosuppression of severe dermatomyositis with cytostatic drugs and thymectomy (author's transl)].
Topics: Adrenal Cortex Hormones; Adult; Azathioprine; Chronic Disease; Dactinomycin; Dermatomyositis; Female | 1974 |
Long-term assessment of cyclophosphamide therapy for nephrosis in children.
Topics: Adolescent; Age Factors; Alopecia; Azathioprine; Child; Child, Preschool; Cyclophosphamide; Cystitis | 1974 |
[Diagnosis, therapy and clinical course in chronic active hepatitis in childhood with special reference to immunological findings (author's transl)].
Topics: Adolescent; Adrenal Cortex Hormones; Age Factors; Azathioprine; Chemical and Drug Induced Liver Inju | 1974 |
[Regional enteritis (Crohn's disease). A follow-up and comparative study of 182 patients (author's transl)].
Topics: Adolescent; Adult; Age Factors; Aged; Azathioprine; Child; Child, Preschool; Crohn Disease; Erythema | 1974 |
[Successes and failures of immunosuppressive therapy in nephropathies].
Topics: Adult; Anti-Glomerular Basement Membrane Disease; Azathioprine; Chronic Disease; Cortisone; Cyclopho | 1974 |
[Effective use of azathioprine in a case of polyarteritis nodosa with recurrent intestinal perforation: a distinction between polyarteritis nodosa and allergic granulomatous angiitis].
Topics: Adult; Arteritis; Azathioprine; Diagnosis, Differential; Granuloma; Humans; Intestinal Perforation; | 1974 |
[Hazard-adapted therapy of acquired idiopathic nephrotic syndromes in children].
Topics: Adrenal Cortex Hormones; Azathioprine; Child; Cyclophosphamide; Female; Glomerulonephritis; Humans; | 1973 |
[The treatment of chronic hepatitis (author's transl)].
Topics: Adrenal Cortex Hormones; Antimetabolites; Azathioprine; Chloroquine; Chronic Disease; Hepatitis; Hum | 1974 |
[Dressler's syndrome relapsing during corticotherapy but cured with immunosuppressive agents].
Topics: Azathioprine; Humans; Indomethacin; Male; Middle Aged; Myocardial Infarction; Pericarditis; Pleurisy | 1972 |
A vascular necrosis of the femoral head in childhood systemic lupus erythematosus.
Topics: Adolescent; Azathioprine; Child; Corticosterone; Female; Femur Head; Femur Head Necrosis; Glomerulon | 1974 |
Azathioprine therapy in incomplete Behcet syndrome.
Topics: Adult; Azathioprine; Behcet Syndrome; Female; Humans; Mouth Mucosa; Prednisone; Recurrence; Skin; St | 1974 |
A sequential trial comparing cyclophosphamide and azathioprine as adjuncts in the treatment of systemic lupus erythematosus.
Topics: Azathioprine; Cyclophosphamide; Drug Therapy, Combination; Female; Hospitalization; Humans; Lupus Er | 1974 |
Presence of hepatitis-associated antigen in systemic lupus erythematosus.
Topics: Adrenal Cortex Hormones; Agammaglobulinemia; Antibodies, Antinuclear; Azathioprine; Bacterial Infect | 1972 |
Renal transplantation between HL-A identical donor-recipient pairs. Functional and morphological evaluation.
Topics: Adult; Azathioprine; Biopsy; Blood Group Antigens; Blood Urea Nitrogen; Creatinine; Evaluation Studi | 1972 |
Liver transplantation: a clinical and immunological appraisal.
Topics: Adult; Animals; Autoantibodies; Azathioprine; Biliary Fistula; Cell Migration Inhibition; Complement | 1972 |
Urinary tract infection after renal transplantation.
Topics: Adolescent; Adult; Ampicillin; Azathioprine; Bacteriuria; Cadaver; Female; Glomerulonephritis; Human | 1973 |
[Experiences with an ambulatory immunosuppressive therapy of generalized psoriasis].
Topics: Administration, Oral; Adult; Age Factors; Azathioprine; Chronic Disease; Female; Humans; Immunosuppr | 1972 |
Long-term treatment of multiple sclerosis with azathioprine.
Topics: Azathioprine; Blood Cell Count; Blood Urea Nitrogen; Brain Stem; Cerebellum; Evaluation Studies as T | 1973 |
[Wegener's granulomatosis in otological form. (Diagnosis and evolution during immunodepressive treatment)].
Topics: Azathioprine; Betamethasone; Cortisone; Cyclophosphamide; Deafness; Ear Diseases; Eye Manifestations | 1973 |
[Studies on experimental ocular toxoplasmosis. Studies on reinfection following intraocular inoculation of Toxoplasma gondii by azathioprine (Imura) administration in rabbits (author's transl)].
Topics: Animals; Azathioprine; Rabbits; Recurrence; Toxoplasmosis, Ocular | 1973 |
The idiopathic nephrotic syndrome of childhood. A clinical reevaluation of 148 cases.
Topics: Adolescent; Antistreptolysin; Azathioprine; Bacteriuria; Blood Urea Nitrogen; Child; Child, Preschoo | 1974 |
[Outlines for the use of immunosuppressive therapy in chronic aggressive hepatitis].
Topics: Azathioprine; Chronic Disease; Cortisone; Hepatitis; Hepatitis B virus; Immunoglobulin A; Immunoglob | 1972 |
[Recommendations for immunosuppressive therapy in ulcerative colitis].
Topics: Adrenal Cortex Hormones; Azathioprine; Colitis, Ulcerative; Drug Resistance; Evaluation Studies as T | 1972 |
Azathioprine therapy for Crohn's disease.
Topics: Adolescent; Adult; Azathioprine; Colon; Crohn Disease; Female; Humans; Ileum; Male; Middle Aged; Rec | 1972 |
[Experiences in the treatment of dermatomyositis with immunosuppressiva].
Topics: Azathioprine; Child; Child, Preschool; Chlorambucil; Dermatomyositis; Drug Resistance; Drug Toleranc | 1972 |
[Liver autoantibodies in benign recurrent intrahepatic biliary stasis (Tygstrup's syndrome)].
Topics: Adult; Autoantibodies; Azathioprine; Cholestasis; Chronic Disease; Female; Follow-Up Studies; Humans | 1972 |
Crohn's disease and immunosuppressive therapy.
Topics: Animals; Azathioprine; Crohn Disease; Humans; Mice; Prednisolone; Recurrence | 1972 |
[Therapy of endogenous intraocular inflammation with azathioprine].
Topics: Adrenal Cortex Hormones; Adult; Aged; Azathioprine; Chronic Disease; Drug Synergism; Female; Humans; | 1971 |
Treatment of idiopathic granulomatous mastitis and factors related with disease recurrence
Topics: Adult; Breast; Female; Granulomatous Mastitis; Humans; Immunosuppressive Agents; Mercaptopurine; Met | 2020 |
Cost-utility Analysis: Thiopurines Plus Endoscopy-guided Biological Step-up Therapy is the Optimal Management of Postoperative Crohn's Disease.
Topics: Adult; Biological Therapy; Canada; Cost-Benefit Analysis; Crohn Disease; Decision Support Techniques | 2017 |
Disease Course and Treatment Responses in Children With Relapsing Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.
Topics: Autoantibodies; Cohort Studies; Disability Evaluation; Europe; Female; Humans; Immunologic Factors; | 2018 |
Optimized thiopurine therapy before withdrawal of anti-tumour necrosis factor-α in patients with Crohn's disease.
Topics: Adalimumab; Adult; Crohn Disease; Feces; Female; Gastrointestinal Agents; Humans; Immunosuppressive | 2018 |
Positioning biological agents: Session two summary.
Topics: Adult; Antibodies, Monoclonal, Humanized; Crohn Disease; Digestive System Surgical Procedures; Femal | 2018 |
Efficacy and safety of long-term thiopurine maintenance treatment for ulcerative colitis in Turkey: A single-center experience.
Topics: Adolescent; Child; Colitis, Ulcerative; Female; Humans; Immunosuppressive Agents; Induction Chemothe | 2018 |
[Guidelines for the management of Crohn's disease].
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Budesonide; Crohn | 2012 |